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Nicole Zangrilli Hoh, RN, PhD 
University of Pittsburgh, 2008
 
 
Background: Mortality and morbidity of patients following traumatic brain injury (TBI) 
remains extremely high. TBI sets into motion a cascade of apoptotic events that includes bcl-2, 
which inhibits apoptosis.  Patients with higher levels of bcl-2 protein after TBI appear to have 
smaller areas of ischemia and better functional outcomes as measured by Glasgow Outcome 
Scores (GOS).  
Purpose: The purpose of this study was to examine the relationship between BCL-2 genotypes 
in patients with severe TBI and global functional outcomes, cognitive-behavioral outcomes, 
mortality, and biological/clinical data.   
Methods: This pilot study was an ancillary study that examined biological/clinical markers in 
TBI patients and global functional and cognitive-behavioral outcomes after severe TBI (n=230). 
Nuclear DNA was extracted from CSF or blood. Based on HapMap, the DNA was analyzed for 
the genotypes of 17 high priority tagging single nucleotide polymorphisms (tSNPs) with a minor 
allele frequency ≥0.3 via TaqMan® allele discrimination. Biological/clinical data (bcl-2 protein 
levels, neurometabolites (lactate, pyruvate, and lactate pyruvate (LP) ratio) and cerebral blood 
flow (CBF) were analyzed following the first five to six (protein only) days post injury. 
Mortality and global functional outcomes [GOS & Disability Rating Scale (DRS)], analyzed at 3, 
6, 12, and 24 months. The cognitive behavioral outcomes [Neurobehavioral Rating Scale –
Revised (NRS-R), Trails A, and Trails B] were analyzed at 3, 6, and 12 months post injury. 
 iv 
Statistical analysis for BCL-2’s relationship with neuropsychological outcomes and biological/ 
clinical data overtime utilized was mixed modeling, (mortality utilized generalized mixed 
modeling).  
Results: There were 3 tSNPs of particular interest: Rs1801018: homozygous variant (GG) 
significant associated with decreased mortality (p=0.0055; OR=5.01), higher GOS (p=0.0004), 
lower DRS (p=0.0002), lower Global CBF (p=0.0031), [presence of the variant allele (G)] lower 
LP ratios (p=0.024); all better outcomes. Rs17756073: presence of variant allele (G) was 
associated with higher NRS-R (p=0.0331) and longer Trails B times (p=0.0516); both poorer 
outcomes. Rs7236090: homozygous wild type (CC) was associated with lower bcl-2 protein 
concentrations when analyzed without outliers (p=0.0056); the literature associates this with poor 
outcomes. 
Conclusion: BCL-2 genotypes had a significant relationship with global functional outcomes, 
cognitive behavioral outcomes, bcl-2 protein concentrations, neurometabolites, and CBF.  
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1.0  INTRODUCTION 
1.1 FACTS AND FIGURES 
There are 1.4 million people in the United States (U.S.) who seek medical treatment each 
year for a new traumatic brain injury (TBI) (Langlois, Rutland-Brown, & Thomas, 2006). Of 
these 51,000 will die and 235,000 are hospitalized due to their injuries. An estimated 1.1 million 
are treated and released from the emergency room) (Langlois et al., 2006). There are countless 
others who sustain a TBI, but never seek medical attention. As a consequence of TBI, 5.3 million 
Americans live with long-term or life long disabilities (125,000 new cases added each year) 
(Thurman, Alverson, Dunn, Guerri, &  Sniezek, 1999). The high risk groups are males between 
the ages of 15-24 and people 75 years of age or older (Langlois et al., 2006; National Institute of 
Neurological Disorders and Stroke [NINDS], 2008). African  American’s have the highest death 
rate from TBI (Langlois et al., 2006). The leading causes of TBI are related to falls (28%), motor 
vehicle- traffic crashes (20%), being stuck by/against events (19%), and assaults (11%) (Langlois 
et al., 2006). Blast related injuries are the leading cause of TBI’s in active military personnel 
(Langlois et al., 2006). 
One year post injury, 40% of people who were hospitalized for TBI report having at least 
one unmet need for continued services (Corrigan, Whiteneck, & Mellick, 2004). These needs are 
largely in the neuropsychological domain; memory and problem solving, managing stress and 
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emotions, controlling temper and employment/ job skills issues (Corrigan et al., 2004). 
Outpatient neuropsychological rehabilitation is most often not covered under health care 
insurance (Brain Injury Association of America [BIAA], 2007). 
1.2 PRIMARY VERSUS SECONDARY INJURY 
There are two types of injury that occur with TBI. First, the primary injury produces 
direct mechanical damage injury that results in contusion, blood clots, and fractures (Zhang, 
Chen, Jenkins, Kochanek,  & Clark, 2005). Second, a cascade of injury results from the response 
to the primary injury that can produce secondary injury such as ischemia, edema, anoxia, 
oxidative stress, and cytotoxins that damage cell membranes and disrupts the integrity of the 
blood brain barrier and walls of the cerebral vessels (Lovasik, Kerr, & Alexander, 2001; Marion, 
2001; Ng et al., 2000; Nicoll, Roberts, & Graham, 1995; Zhang et al., 2005). These cellular level 
injuries result in vasogenic edema and hyperemia which contribute to the increase of intracranial 
pressure (ICP), which is associated with poor outcomes (Lovasik, et al., 2001; Marion, 2001). 
Prevention is the only way to “treat” primary injuries (Bullock et al, 1996; Lovasik, et al., 2001; 
Marion, 2001) and impacting secondary injury is the best approach to improving outcomes. The 
ability to decrease such secondary injury is dependent on improving understanding of the 
complex, interrelated physiologic processes that produce secondary injury after TBI.   
 There are two common forms of secondary injury neuronal death following TBI: 
necrosis and apoptosis (Zhang et al., 2005). There are distinct morphological and biochemical 
and differences between these two forms of cell death. In short, necrosis is an unnatural death 
and does not require any energy expenditure. There is total lysis of the cell membrane which 
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results in a significant inflammatory response which is a hallmark of necrosis (Leppert, 2006). In 
contrast, apoptosis is programmed cell death.  It is process characterized by an orderly 
genetically encoded suicide program that requires energy. It is associated with the shrinking and 
condensation of the nucleus along with bleb formation on the cell membranes surface without 
loss of membrane integrity. A hallmark of apoptosis is phagocytosis which secrets cytokines that 
inhibits inflammation (Leppert, 2006; Fadok et al., 1992). 
1.3 BCL-2 
Bcl-2 (B-cell lymphoma 2) is an oncogene protein that inhibits apoptosis. Overexpression 
of bcl-2 protein in the central nervous system can prevent apoptosis in the presence of neurons 
that respond to nerve growth factor. Bcl-2 protein has been shown to limit anti-apoptotic effects 
in neurons that respond to ciliary growth factor (Graham, Chen & Clark, 2000). Damage to the 
mitochondria from cellular events related to the physical injury results in the release of apoptosis 
promoters (bax and bad), survival promoters (bcl-x and bcl-2) or a ratio of both (Graham et al., 
2000). Research indicates that patients with higher levels of bcl-2 protein, in there cerebrospinal 
fluid (CSF) or cerebral tissues, are likely to have better functional outcomes because less cell 
death occurs (Clark et al., 1999; Clark et al., 2000; Ng et al., 2000; Nathoo et al., 2004). Viable 
neuronal tissue should be preserved due to the cellular survival benefit of bcl-2 protein (Clark et 
al., 1999; Clark et al., 2000; Ng et al., 2000; Nathoo et al., 2004). The relationship between BCL-
2 genotypes and biological/ clinical variables and outcomes after TBI have not been reported in 
the literature.  
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1.4 APOPTOSIS 
TBI sets into motion a cascade of apoptotic events and the bcl-2 oncogene family has 
been shown to play a key role in programmed cell death, apoptosis- cellular suicide (Bredesen et 
al., 2000; Garcia, Martinou, Tsujimoto, & Martinou, 1992; Hockenbery, Nunez, Milliman,  
Schreiber, & Korsmeyer,  1990; Kane et al., 1993; Mah et al., 1993; Myers et al., 1995; Nunez et 
al., 1990). After TBI, apoptosis can occur with in the site of injury and in distant regions days to 
weeks after the trauma.  
There are two classic pathways of apoptosis; cysteine-dependent aspartate-specific 
protease “caspase” dependent and “caspase” independent apoptosis. A role of thirds is speculated 
to describe the types of cell death after TBI; one third is related to caspase dependent apoptosis, 
one third is associated with  caspase independent cell death, and the last thirds is attributed to 
necrosis (Zhang et al., 2005). The Bcl-2 family regulates apoptosis/cell death or survival by 
regulating the permeability of the mitochondrial outer membrane and permeability transition 
pore (mPTP) formation. 
 
1.4.1 Caspase Dependent Pathways 
There are two branches of caspase dependent pathways; extrinsic and intrinsic. These two 
branches describe whether the apoptosis initiation is initiated by intracellular or intracellular 
signals. 
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1.4.1.1 Extrinsic Pathway 
Extracellular signals, which initiate the extrinsic pathway, may include hormones, growth 
factors, nitric oxide, or cytokines. They are extrinsic because they cross the plasma membrane or 
transduce to effect a response. These signals may positively or negatively induce apoptosis 
(Mohamad et al., 2005). TNF is a cytokine produced mainly by activated macrophages and is the 
major extrinsic mediator of apoptosis. Most cells in the human body have two receptors for TNF: 
TNF-R1 ad TNF-R2. Binding to the TNF-R1 receptor can indirectly lead to the activation of 
transcription factors that are involved with cell survival. Following TNF-R1 activation a balance 
between pro-apoptotic and anti-apoptotic members of the bcl-2 family is established (Mohamad 
et al., 2005). 
1.4.1.2 Intrinsic Pathway 
Intracellular apoptotic signaling is a response initiated by a cell in response to stress; 
glucocorticoids, heat, radiation, nutrient deprivation, viral infection, and hypoxia.  The initiation 
of the intrinsic pathway of caspase dependent apoptosis is triggered by stress on the cellular 
organelle (i.e. mitochondria, ER). In a healthy cell, the outer membranes of the mitochondria 
express the protein bcl-2 on the surface. Bcl-2 is bound to a protein Apaf-1. Internal damage in 
the cell causes bcl-2 to release Apaf-1 which results in cytochrome c leaking from the 
mitochondria into the cytosol. The release of cytochrome c and Apaf-1 bind to molecules of 
caspase-9.  The resulting complex of cytochrome c, Apaf-1, caspase -9, and ATP is called the 
apoptosome (Liu et al., 1996).  As apoptosomes aggregate in the cytosol, caspase-9 cleaves and 
activates other caspases, especially caspase 3. The sequential activation of one caspase by 
another creates an expanding cascade of proteolytic activity which leads to digestion of structural 
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protein in the cytoplasm, degradation of chromosomal DNA, and phagocytosis of the cell 
(Fiskum et al., 2000; Kluck, Bossy-Wetzel, Green, & Newmeyer, 1997; Yang, J. et al., 1997).   
1.4.2 Caspase Independent Pathway 
Bcl-2 is at the heart of the caspase independent apoptosis cascade because of its integral 
role in inhibiting mitochondrial membrane permeability (Tanaka, 2005). When bcl-2 is inhibited, 
mitochondrial membrane pores are allowed to open.  This event in turn allows for apoptosis via 
the direct release or the indirect activation of mitochondrial and nuclear  proteins (i.e.  with 
apoptosis inducing Factor [AIF], endonuclease G [Endo G], ploy(ADP-ribose) polymerase 
[PARP] and p53.) These activators of apoptosis are independent of caspase cascades. 
1.5 PURPOSE 
The purpose of this study was to examine the relationship between BCL-2 genotypes in 
patients with severe TBI and global functional outcomes, cognitive-behavioral outcomes, 
mortality, and clinical data.  In addition, demographic factors, extent of injury, apolipoprotein E 
(APOE) genotypes, documentation of adverse events in the field, and participation in a 
hypothermia protocol were examined as potential mediating variables. 
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1.6 SPECIFIC AIMS AND RESEARCH QUESTIONS 
The Specific Aims and the Research Questions (RQ) to be answered by this study 
were: 
1. Specific Aim 1: Compare the relationship between BCL-2 genotype and global functional 
outcomes, cognitive-behavioral outcomes, and mortality attained by patients who have sustained 
a severe TBI. 
RQ1. Is there a relationship between BCL-2 genotype and global functional outcomes (GOS and 
DRS,), cognitive-behavioral outcomes (NRS-R, Trails A, and Trails B), and mortality attained 
by patients who have sustained a severe TBI?  
2. Specific Aims 2: Compare the relationship between BCL-2 genotype and biological/ clinical 
data.  
RQ2. Is there a relationship between BCL-2 genotype and biological/ clinical data (bcl-2 protein, 
neurometabolites [lactate, pyruvate, and lactate pyruvate (LP) ratio], and CBF [right hemisphere, 
left hemisphere, and global]) in patients who have sustained a severe TBI? 
1.7 DEFINITION OF TERMS 
1.7.1 Independent Variables 
1.7.1.1  BCL-2 Genotypes 
BCL-2 genotype was determined from DNA extracted from CSF or blood using TaqMan 
technology (the generic terms of XX, YY, or XY [heterozygous]). 
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1.7.1.2  Dichotomized BCL-2 Genotypes 
BCL-2 was dichotomized based on the frequency of the genotype in the database which 
was being analyzed (i.e. mortality, Trails A, bcl-2 protein, neurometabolite, etc.).  Therefore, the 
homozygous genotype with the least frequency was combined with the heterozygotes and 
compared against the homozygous with the largest frequency in the particular database being 
analyzed. 
1.7.2 Dependent Variables 
1.7.2.1 Global Functional Outcomes 
Global functional outcome were determined by the neuropsychological evaluation 
measures of Glasgow Outcomes Scale (GOS) and Disability Rating Scale (DRS) at 3 months, 6 
months, 12 months, and 24 months after injury. Mortality rate was defined as subject’s death 
occurring at 3, 6, 12, and 24 months after injury. The 3 month mortality captures death during 
hospitalization. 
1.7.2.2 Cognitive-behavioral Outcomes 
Cognitive-behavioral outcomes were determined by the neuropsychological evaluation 
measures of Neurobehavioral Rating Scale- Revised (NRS-R) and Trails Making Tests (Trails A 
and Trails B) scores at 3, 6, and 12 months post injury.  
1.7.2.3  Biological/ Clinical Data 
Bcl-2 protein was determined from analyzing bagged cerebrospinal fluid (CSF) collected 
during the first 6 days post injury via enzyme-linked immunosorbent assay (ELISA) kit. 
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Neurometabolites: Lactate, pyruvate, and lactate/ pyruvate ratio (LP ratio).  During the 
first 5 days post injury, serial fresh CSF specimens were collected. These specimens were frozen 
and batch processed for the analysis of neurometabolites (lactate [µmol concentration], pyruvate 
[µmol concentration] utilizing high pressure liquid chromatography (HPLC). Lactate/ pyruvate 
ratio was calculated from the ratio of the lactate to pyruvate. 
Cerebral blood flow (CBF): CBF was used to determine cerebral perfusion. CBF is the 
volume of blood in milliliters that passes through the cerebral vessels/100 gm brain tissue with in 
1 minute. Right hemisphere, left hemisphere, and global CBF as determined by the enhanced 
xenon/computed tomography (Xe/CT) scan method. 
1.7.3 Covariates 
1.7.3.1  Age 
Age was utilized as a continuous variable with a range of 16-75 years of age for the 
inclusion criteria. 
1.7.3.2  Race 
Race was dichotomized into Caucasians versus non-caucasians. 
1.7.3.3  Gender 
Gender was defined by standard anatomical terms of male versus female. 
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1.7.3.4  Glasgow Coma Scale (GCS) 
Severe TBI was operationally defined as the admission GCS score of ≤8. GCS was 
dichotomized into two levels of severe coma 3-5 (more severe) versus 6-8. 
1.7.3.5  Hypoxia 
Hypoxia was defined as an oxygen saturation saO2 of <90% for >30 minutes in the field 
or during the admission process.  
1.7.3.6  Hypotension 
Hypotension was defined as sustained systolic blood pressure <90 mmHg for >30 
minutes in the field or during the admission process.  
1.7.3.7  Hypothermia 
Hypothermia was defined as the presence or absence of being enrolled in a randomized 
control clinical trial for a hypothermia intervention and receiving an intervention.  
1.7.3.8  Seizure 
Seizure was defined as a witnessed seizure in the field or during the admission process. 
This information was documented and tracked by research nurse collecting data based on field 
and emergency room documentation.  
1.7.3.9  APOE 
APOE genotype/haplotype (APOEε2, APOEε3, APOEε4) was determined by using 
Restriction Fragment Length Polymorphism (RFLP) technique, polymerase chain reaction (PCR) 
   10
and visualization under light. APOE was operationally defined as the presence or absence of 
APOEε4. 
1.8 CONCEPTUAL FRAMEWORK 
The conceptual framework designed for this study is represented in figure 1-1. It is driven  
by the Wilson Cleary Model of Health Related Quality of Life (Wilson & Cleary, 1995) (See 
Appendix A). This study focused on how the biological/ physiological variation of BCL-2 
genotype influenced outcomes directly and symptom status as directly represented by Bcl-2 
protein levels, neurometabolite concentrations (lactate, pyruvate, and LP ratio), CBF, and 
APOEε4, and how BCL-2 genotypes influenced these factors which then influenced global 
functional and cognitive-behavioral outcomes. The parent data set did not have general health 
perceptions or quality of life data available at the time which these analyses were conducted. 




















-Trails Making Test A
-Trails Making Test B
 
Figure 1-1: Conceptual Framework 
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2.0  BACKGROUND AND SIGNIFICANCE  
2.1 TRAUMATIC BRAIN INJURY 
2.1.1 Facts and Figures 
There are 1.4 million people in the U.S. who seek medical treatment each year for a new 
TBI (Langlois  et al., 2006). Of these 51,000 will die and 235,000 are hospitalized due to their 
injuries. An estimated 1.1 million are treated and released from the emergency room (Langlois et 
al., 2006). There are countless others who sustain a TBI, but never seek medical attention. As a 
consequence of TBI, 5.3 million Americans live with long-term or life long disabilities (125,000 
new cases added each year) (Thurman et al., 1999). The high risk groups are males between the 
ages of 15-24 and people over 75 years of age (Langlois et al., 2006; NINDS, 2008). African  
American’s have the highest death rate from TBI (Langlois et al., 2006). The leading causes of 
TBI are related to falls (28%), motor vehicle- traffic crashes (20%), being stuck by/against 
events (19%), and assaults (11%) (Langlois et al., 2006). Blast related injuries are the number 
one cause of TBI’s in active military personnel (Langlois et al., 2006). Approximately half of all 
TBI’s events involve alcohol (NINDS, 2008). 
One year post injury, 40% of people who were hospitalized for TBI report having at least 
one unmet need for continued services (Corrigan et al., 2004). These needs are largely in the 
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neuropsychological domain; memory and problem solving, managing stress and emotions, 
controlling temper and employment/ job skills issues (Corrigan et al., 2004). 
TBI’s cost the U.S. $60 billion annually related to hospitalization and fatal TBI’s. This 
figure underestimates the personal and life time costs of living with the sequelae after TBI 
(BIAA, 2006). Currently the state of the science in the acute care treatment of patients with 
severe TBI is supportive care with focus on maintaining low intracranial pressure as to avoid 
intracranial hypertension and maintaining adequate cerebral perfusion pressure (Bullock et al., 
1996; Nolan, 2005; Vincent & Berré, 2005).  
2.1.2 Primary Versus Secondary Injury 
There are two types of injury that occur with TBI; primary and secondary injury. First, 
the primary injury produces direct mechanical damage injury that results in contusion, blood 
clots, and fractures (Zhang et al., 2005). Primary injury can be further classified by focal and 
diffuse injuries. Focal injuries are a result of direct injury contact; contusions, epidural 
hematomas, subdural hematomas, subarachnoid and intracranial hemorrhages. Diffuse injuries 
are injuries that are remote from the injury site, noncontact or injuries by rotational force; 
concussions and diffuse axonal injuries (Gennarelli et al., 1998; Meaney et al., 1995; Nolan, 
2005). Prevention is the only way to “treat” primary injuries (Lovasik, et al., 2001; Marion, 
2001; Nolan, 2005;  Vincent & Berré, 2005). A cascade of injury results from the response to the 
primary injury that can produce secondary injury such as ischemia, edema, anoxia, oxidative 
stress, and cytotoxins that damage cell membranes and disrupts the integrity of the blood brain 
barrier and walls of the cerebral vessels (Lovasik et al., 2001; Marion, 2001; Ng et al., 2000; 
Nicoll et al., 1995; Zhang et al., 2005). These cellular level injuries result in vasogenic edema 
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and hyperemia which contribute to the increase of ICP, which is associated with poor outcomes 
(Lovasik, et al., 2001; Marion, 2001). TBI can result in neuronal loss in cortex, hippocampus 
(Kotapka,  Graham, Adams, & Gennarelli, 1992), cerebellum and thalamus regions of the brain 
(Zhang et al., 2005; Raghupathi, 2004). The ability to decrease such injury is dependent on 
improving understanding of the complex, interrelated physiologic process that produce 
secondary injury after TBI. 
Functional outcomes following severe TBI are likely to be dependent upon several 
factors including: primary and secondary cascades of injury factors such as apoptosis and BCL-2 
activity, demographics, biological/clinical data. 
2.1.3 Secondary Injury: Necrosis versus Apoptosis 
There are two common forms of neuronal death following TBI: necrosis and apoptosis 
(Zhang et al., 2005). There are distinct morphological and biochemical differences between these 
two forms of cell death.  
Necrosis is defined as unnatural death of cells and living tissue. Necrosis can occur with 
mechanical injury as well as viruses, hypothermia, hypoxia, ischemia, and metabolic poisons. A 
series of morphological characteristic changes occur. The cell and the organelles (i.e. 
mitochondria) have irreversible swelling (disintegration) related to impaired ability to control 
plasma membrane permeability.  Total lysis occurs with cell membrane breakdown allows cell 
contents leak out which is related to inflammation of surrounding tissues (Leppert, 2006; 
Proskuryakov,  Konoplyannikov, & Gabai, 2003).  On the biochemical level, in necrosis there is 
a loss of regulation of ion homeostasis. There is no energy requirement for necrosis; it is a 
passive process. There is random digestion of DNA and postlytic DNA fragmentation. Necrosis 
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affects groups of contiguous cells. A significant inflammatory response is a hallmark of necrosis 
(Leppert, 2006; Proskuryakov et al., 2003).   
Apoptosis also know as programmed cell death, is an orderly genetically encoded suicide 
program. Cells that undergo apoptosis have morphological characteristic features that differ from 
necrosis. Apoptosis begins with cell cytoplasm shrinking and condensation of the nucleus. The 
mitochondria release cytochrome c, the cell membranes develop bubble like blebs on their 
surface without loss of membrane integrity. The chromatin (DNA and protein) in the nucleus 
degrade. The cell breaks into small, membrane wrapped, fragments also know as apoptotic 
bodies. The mitochondria membranes become leaky due to pore formation related to bcl-2 family 
proteins and allow pro-apoptotic factors to leak out feeding the cascade of events. Phospholipids 
and phosphatidylserines are translocated from hidden with in the plasma membrane to the 
exposed extracellular surface. Phagocytic cells, macrophages, and dendritic cells, bind to the 
phosphatidylserine and then engulf the cell fragments. Phagocytosis may also occur by 
neighboring cells. These phagocytic cells then secrete cytokines that inhibit inflammation; the 
absence of inflammation is a hallmark of apoptosis (Fadok et al., 1992; Leppert, 2006). (Refer to 
figure 2-1). 
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 from http://en.wikipedia.org/wiki/apoptosis 
Figure 2-1: Events of Cellular Apoptosis  
Biochemically, apoptosis is a tightly regulated process involving activation and 
enzymatic steps. Apoptosis is energy dependent, requiring ATP. The fragmentation of the 
genomic DNA is an irreversible event that commits the cell to die and occurs before changes in 
plasma membrane permeability (pre-lytic DNA fragmentation). DNA fragmentation has been 
shown to result from activation of the endogenous Ca2+ and Mg2+ -dependent nuclear 
endonucleases. This enzyme cleaves DNA at sites located between nucleosomal units (linker 
DNA) generating non-random mono- and oligonudeosomal DNA fragments. Leaky 
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mitochondria release cyctochrome C and AIF into the cytoplasm. The caspase cascade is 
activated. Apoptosis affects individual cells and is induced by physiological stimuli (i.e. lack of 
growth factors and changes in hormonal environment). Apoptosis can be a normal regulatory 
process that is necessary is development, tissue turnover, atrophy induced by endocrine stimuli, 
negative selection in the immune system, and T-cell killing. Apoptosis also accounts for cell 
deaths related to exposes from cytotoxic compounds hypoxia and viral infections (Bredesn, 
2000; Elddah & Faden, 2000; Kroemer, 2003; Kromer & Reed, 2000). 
Apoptosis occurs when there is a withdrawal of a positive signal for cell survival (nerve 
growth factor and Interleukin-2) and the receipt of negative signals (increased levels of oxidants 
within the cell, damage to the DNA by the oxidants, UV light, x-rays, chemotherapeutic drugs, 
binding of death activators (TNF-a, TNF-b, FasL) to cell surface receptors (TNF and Fas [aka 
CD95]) (Bredesn, 2000; Elddah & Faden, 2000; Kroemer, 2003; Kromer & Reed, 2000). In TBI 
apoptosis can occurs with in the site of injury and in distant regions days and weeks after trauma. 
2.2 BCL-2 IN APOPTOSIS 
2.2.1 Overview of Apoptosis in TBI 
The bcl-2 oncogene family has a key role in programmed cell death, apoptosis. An 
overview of the apoptosis cascade illustrates the complexity of the apoptosis cascade with direct 
attention on bcl-2 (Lu, Ashwell et al, 2000). The caspase dependent and independent cascades 
will be discussed at length in sections (Section 2.3).  
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After the primary TBI assault three cascades of events transpire to define secondary 
injury. First, primary injury leads to edema, cerebral ischemia and tissue anoxia. Second, the 
blood brain barrier and the cell membranes are injured by the initial injury. The third branch of 
the cascade results in excitotoxin release from the hyperactive and derogate cells (Nicoll et al, 
1995; Lu, Ashwell et al, 2000; Ng et al, 2000). 
Primary injury leads to edema, cerebral ischemia and tissue anoxia. This decreases cell 
energy supply, thus decreasing ion pumping and increasing sodium and calcium in the cells 
which causes mitochondrial damage and activates the bcl-2 family of oncogenes. As the cell 
energy supply decreases, there is a decrease in antioxidant activity which results in the release of 
free radicals. The consequence is damage to cellular macromolecules and activation of caspase 
and calpain that ultimately leads to cell death. Mitochondrial damage further increases tissue 
edema, ischemia and anoxia and further promotes this cascade. Mitochondrial damage will either 
activate the apoptosis promoters, bax and bad or survival promoters, bcl-2 and bcl-xL. If the 
apoptosis promoters are activated, cytochrome c is released which activates caspase and calpain 
and subsequent cell death (Lu, Ashwell et al, 2000).  
The second cascade involves the blood brain barrier and the cell membranes are being 
injured by the initial injury. The disruption of tissue integrity results in an increase in microglial 
activation, proinflammatory cytokines and caspase/ calpain activation and then cell death. 
Disruption in the blood brain barrier and cell membranes also results in the release of free 
radicals which damage macromolecules activate caspase and calpain and lead to cell death. 
Increase in free radicals also further breaks down the blood brain barrier and cell membranes 
which perpetuate the cascade of events. At the same time, injuries to the blood brain barrier and 
cell membrane result in edema, tissue ischemia and anoxia which feed the first cascade of events, 
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including the activation of the bcl-2 family. This second cascade is a key stone because it also 
feeds the third cascade (Lu, Ashwell et al, 2000). 
In the third cascade, excitotoxins are released from the hyperactive and derogated cells. 
This leads to an increase in extracellular glutamate and increase in sodium and calcium in the 
cells. Nitric oxide synthesis activation results in free radical release, phospolipase, endonuclease 
and protein kinase activation which leads to further damage to the cellular macromolecules 
which activate caspase and calpain and hence cell death. The increase of intracellular calcium 
and sodium can directly activate caspases and calpains, and initiate subsequent cell death (Lu, 
Ashwell et al, 2000).  
2.2.2 Bcl-2 Structure 
BCL-2 (B-cell lymphoma 2) specifically, is a protoncogene that inhibits apoptosis; it is a 
survival promoter. It is located with in the mitochondrial membrane, endoplasmic reticulum, and 
nuclear envelope (Lithgow, van Driel, Bertram, & Strasser, 1994). The normal chromosomal 
position for BCL-2 is on18q21 (Tsujimoto, 1984). BCL-2 is encoded by a 230kb gene that 
results in a 22-26 kDa protein. Bcl-2 protein has approximately 239 amino acids (196, 034 bases) 
(Genecards, 2007). Bcl-2 is currently known to have three exons (GenomeUSCS, July 2008) 
with 646 known SNP’s and 36 tagging SNP’s (HapMap, April 2007). The overexpression of Bcl-
2 is associated with G1 arrest in the cell cycle (Chen, Gong, & Almasan, 2000). The Bcl-2 
family has a general structure that consists of a hydrophobic helix surrounded by seven 
amphipathic helices (Figure 2-2). 
   19
   from http://en.wikipedia.org/wiki/Bcl2 
Figure 2-2: BCL-2 Crystal structure 
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2.2.3 Bcl-2 Family Members 
There are two camps in this Bcl-2 family of  protoncogenes; survival promoters and death 
promoters. The membership to each camp is based on the presence or absence of four conserved 
BCL-2 homology (BH) domains designated as BH1, BH2, BH3, and BH4. Each of the BH 
domains corresponds to helical segments and is crucial for functioning. (Refer to Figure 2-3). 
 
from http://en.wikipedia.org/wiki/BCL-2 
Figure 2-3: Bcl-2 Family 
 
The BH’s are essential for homocomplex and heterocomplex formation. All of the 
mammalian BCL-2 family survival promoter members (bcl-2, bcl-xl, bcl-w, and mcl-1) display 
sequence conservation in all four BH domains. BH-4 is essential for the coding of pro-survival 
proteins. BH4 blocks the VDAC channel, which in turn blocks the release of cytochrome c 
(Shimizu, Ide, Yanagida, & Tsujimoto, 2000). Bcl-2 family members who are cell death 
promoter are subdivided into Bax-like and BH3 only groups. All have the absence of BH-4 or 
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have the sole presence of BH-3 homolog domains. The bax-like group (bax, bak, Bok) has a 
structure similar to bcl-2 and binds to bcl-2 (Adams & Cory, 2007). The BH-3 only  group (bid, 
bad, bim, or bik) have sequences that are unrelated to bcl-2 or each other. Bcl-xs is a death 
promoter possessing both BH-3 and -4, because of the absence of BH 1and 2 negates the survival 
ability associated with BH-4 (Graham et al., 2000). Complexes with BH3 domains bax, truncated 
bid (tbid), and bad facilitate the release of cytochrome c via the pore forming capabilities of 
BH3. Pro-survival proteins (bcl-2, bcl-xl, and mcl-1) are capable of preventing the release of 
mitochondrial proteins (i.e. cytochrome c, endonuclease G, and AIF) through the pores (Zhang et 
al., 2005). For example, in the absence of survival factors, BH3 binds and inactivates bcl-2 and 
/or bcl-xl in the outer mitochondrial membrane. Bad is then dephosphorylated, thus promotes 
apoptosis. In the presence of cell survival factors a series of kinases are activated. Bad is then 
phosphorylated, which dissociates itself from Bcl-2 and/ or Bcl-xl allowing for survival 
(Mohamad et al., 2005; Zha, Aime-Sempe, Sato, & Reed, 1996). Heterodimerization is not 
required for pro-survival function but it is essential for the pro-death function of the BH3 only 
group of proteins (Chittenden et al., 1995). 
There transmembrane (Tm) domain is involved in anchoring both survival and death 
promoter proteins of the Bcl-2 family to the mitochondria (Graham et al., 2000). All members of 
the Bcl-2 family have a Tm domain excluding bid. 
2.2.4 The Interaction of Anti- and Pro-Apoptosis Family Members 
The process by which anti- and pro- apoptosis family members interact has yet to be fully 
elucidated. The literature supports that BH-3 only pro-apoptotic proteins can not directly activate 
apoptosis and that they act upstream of bax-like family members to ultimately activate them (bax 
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and bak) and induce apoptosis. Adams and Cory (2007) review the two common theories 
apoptotic activation: 1) direct versus indirect activation and 2) regulation.  
Direct activation is a process by which BH-3 only “activators” (i.e. bim and tbid) bind to 
bax-like family members (bax and bak) thus triggering apoptosis. Other BH-3 only family 
members (i.e. bad ) are “sensitizers” and displace bim and tbid from pro-survival proteins and 
then bim and tbid activate bax and bak. (See figure 2-4a). 
 
 
Reprinted with permission from MacMillan Publishers  Ltd. Adams, J.M. & Cory, S. The bcl-2 apoptotic switch in 
cancer development and therapy. Oncogene, 26, 1324-1337, copyright (2007) 
Figure 2-4: Activation of  Bcl-2 by Pro-Apoptotic Family Members  
Indirect activation of apoptosis proposes that BH-3-only proteins guard specific 
(“selective”) pro-survival proteins and that bad “guards” bcl-2, bcl-xl, and bcl-w. Bim and tbid 
are potent “promiscuous” pro-apoptotic proteins and can bind to a greater range of anti-apoptotic 
proteins (bcl-2, bcl-xl, bcl-w, A1, and mcl-1) and therefore are able to either engage or neutralize 
the pro-survival proteins and prevent them from counteracting bax or bak. (See figure 2-4b). 
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The regulation of bax-like family members (bak and bax) which are proported to lead to 
apoptosis are mediated by BH-3 only proteins. Bak regulation in a healthy cell involves bcl-xl 
and mcl-1 anti-apoptosis proteins. When bak is “primed” or bound to a BH-3 only family 
member it is then also able to bind to the anti-apoptotic family member (i.e. Bcl-xL) and 
consequently is able to inhibit survival. Apoptosis occurs when BH-3 only protein remains 
bound to the anti-apoptosis family member, liberates bak. Free primed bak merge in an oligomer 
formation. This in turn elicits the permeabilization of the outer mitochondrial membrane and 
allows the release of cytochrome c. (See figure 2-5a). 
 
Reprinted with permission from MacMillan Publishers  Ltd. Adams, J.M. & Cory, S. The bcl-2 apoptotic switch in 
cancer development and therapy. Oncogene, 26, 1324-1337, copyright (2007) 
Figure 2-5: Regulation of  Bax-like Pro-Apoptotic Family Members  
Bax regulation in a healthy cell involves bcl-2, bcl-w, A1 and bcl-b anti-apoptosis 
proteins. Like, bak, when bax is “primed” or bound to a BH-3 only family member it is also able 
to bind to the anit-apoptotic family member (i.e. Bcl-2). Apoptosis occurs when BH-3 only 
protein remains bound to the anti-apoptosis family member, liberates bax. Free primed bax 
merge in an oligomer formation. This in turn elicits the permeabilization of the outer 
mitochondrial membrane and allows the release of cytochrome c. In addition, unprimed bax is in 
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the cytosol and the anti-apoptotic family members are able to inhibit bax activation. (See figure 
2-5b). 
2.2.5 Isoforms 
There are two isoforms known for the bcl-2 protein, with alternative splicing; bcl-2α and 
bcl-2ß (Akgul, Moulding, & Edwards, 2004). Bcl-2α is reported to have 239 amino acids, is 
26kDa in size, have BH 1, 2, 3, 4, and TM homolog domains and are active in the mitochondria 
(Akgul et al., 2004). Bcl-2ß has 205 amino acids, is 22 kDa in size, have BH 1,2, 3, and 4 
homolog domains and are active in the cytoplasm (Akgul et al., 2004). 
The human Bcl-2 protein consists of BH domains, the predicted -helical segments, and a 
transmembrane (TM) anchor. The first -helix  is associated with the binding of Raf-1 and 
calcineurin. A long flexible loop between the first and second -helices is required for Bcl-2 
phosphorylation and may represent a negative-regulatory domain. The second -helix  is 
associated with BH3 domain and plays the role is binding during dimerization (ligand domain) of 
Bcl-2 family proteins. The fifth and sixth -helices are predicted to participate in channel 
formation by penetrating lipid bilayers (Reed, 1997).  
Bcl-2 over-expression promotes survival when apoptosis is induced by: deprivation of 
nerve growth factor in sympathetic neurons, serum and growth factor withdrawal, calcium 
ionophore A23187, glucose withdrawal, and membrane perioxidation free radical (Garcia et al., 
1992, Kane, 1993; Mah, 1993, Zhong et al., 1993). Bcl-2 was not found to exhibit survival when 
apoptosis is induced by cytotoxic T-cells (Vaux, Aguila, & Weissman, 1992), TNF 
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(Vanhaesebroeck et al., 1993), B-cell lines (Cuende et al., 1993), and neurons that are dependent 
upon ciliary neurotrophic factor (Allsopp, Wyatt, Paterson, & Davies, 1993). 
2.2.6 Mitochondrial Role in Apoptosis 
The mitochondria play a pivotal role in apoptosis. (See figure 2-6). The mitochondria is a 
cellular organelle that contains two membranes; inner and outer. The inner membrane surrounds 
the mitochondrial matrix. It is highly folded to form cristae, molecular complexes of the electron 
transport chain. This electron transport chain generates the hydrogen ion gradient that is essential 
to make ATP. Cellular ATP is produced by oxidative phosphorylation (Harris & Thompson, 
2000). Homeostasis which maintains intracellular ATP/ADP ratio is a result of the free exchange 
of substrates and ATP/ADP between the mitochondria and the cytosol (Harris & Thompson, 
2000). The outer mitochondrial membrane surrounds the inner mitochondrial membrane. This 
intermembrane space holds proteins specific to apoptosis promoting proteins (cytochrome c, 
AIF, pro-caspases). Transport across the outer membrane is less tightly controlled than transport 
across the inner mitochondrial membrane (Harris & Thompson, 2000).  The voltage dependent 
anion channel (VDAC) is the most common protein in the outer membrane and is permeable to 
molecules less than 5000 daltons making the outer membrane highly permeable (Mannella, 
1992). The outer membrane is impermeable to holo-cytochrome c. The ability to sequester 
cytochrome c/ holo-cytochrome c is essential for cell survival (Yang, 1997; Harris & Thompson, 
2000). The release of cytochome c leads to caspases activation in the apoptosis cascade (Cai, 
Yang, & Jones, 1998; Skulachev, 1998). 
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 Figure 2-6: Bcl-2 Function in the Mitochondria 
 
VDAC and Bcl-2 family proteins reside in the outer membrane of the mitochondria.  
Bcl-2 family of proteins modulates ATP/ADP via the VDAC. VDAC can exist in open or closed 
formation (Vander Heiden et al., 2000). When VDAC is closed ATP/ADP and other metabolic 
anions can not pass from the cytosol through the outer membrane. In the open formation, passage 
is granted, but the BCL-2 family of proteins are the gate keepers that maintain ATP/ADP 
exchange. Therefore hyperpolarization of the mitochondria can be impeded by bcl-2, preventing 
swelling and rupture that leads to the release of cytochrome c and ultimately prevents cell death 
(Rostovtseva & Colombini, 1996; Vander Heiden et al., 2000; Harris & Thompson, 2000). 
Changes in ADP/ATP ratio have been used to differentiate the different modes of cell 
death and viability. Increased levels of ATP and decreased levels of ADP are associated with 
proliferating cells. In cell death there is a continuum where the type of cell death that ensues is 
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related to the severity of the decrease in ATP and increase in ADP. Apoptotic cells have 
decreased levels of ATP and increased levels of ADP. Where as necrosis has a pronounced 
decrease in levels of ATP and increase in levels of ADP (Leppert, 2006). 
2.2.7 Mitochondrial Membrane Potential Regulation by Bcl-2 
Mitochondria regulate cell death mediated by Bcl-2 family of proteins. Bax and Bak are 
associated with mitochondrial membrane permeabilization (MMP). Alterations in MMP are early 
events in the cell death process preceding other non-mitochondrial signs of apoptosis (Kroemer, 
2003). During apoptosis several mitochondrial events occur. There is a loss of mitochondrial 
membrane potential (ΔΨm)[Delta Psim] (electrochemical gradient) across the inner membrane, 
result in uncoupling of oxidative phosphorylation, generation of superoxide free radicals, and 
dumping of matrix associated Ca2+ into the cytosol (Jurgensmeier et al., 1998; Kim, 2005). 
During apoptosis the ΔΨm across the mitochondrial membrane collapses; this collapse commits 
a cell to die (Kroemer, 2003).  
The induction of cellular apoptosis is dependent on mitochondrial permeability transition 
pores (mPTP) (Kroemer & Reed, 2000). The collapse maybe associated to the formation of pores 
in the mitochondria by dimerized Bcl-2 family cell death promoters; Bax or activated Bid, Bak, 
or Bad proteins (Jurgensmeier et al., 1998; Kroemer & Reed, 2000; Leppert, 2006). The 
overexpression of Bcl-2 in cells has been reported to prevent all of the following: the loss of 
ΔΨm, release of cytochrome c, and activation of caspases which are ultimately responsible for 
apoptosis (Jurgensmeier et al., 1998). 
Mitochondria play a significant role in cerebral energy metabolism and cellular Ca2+ 
homeostasis. Mitochondrial alterations in respiration and respiratory control are apparent 1 hour 
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to 14 days after controlled cortical impact injury (Fisksum, 2000). When neurons are exposed to 
excitotoxic levels of excitatory neurotransmitters, it results in the accumulation of Ca2+ in the 
mitochondria, leading to mitochondrial dysfunction and delayed cell death (Fiskum, 2000).  
Compromised ability for respiration and phosporylation affects the mitochondria’s ability to 
sequester Ca2+, which can contribute to cell death related to lowering the ΔΨm and contributes to 
osmotic swelling and lysis (Fiskum, 2000).  The accumulation of Ca2+ can also result in the 
increase of the inner MMP the promotion of pro-apoptotic proteins (i.e. cytochrome c) during the 
exposure to toxic levels of excitatory neurotransmitters. Excessive mitochondrial Ca2+ related to 
excitotoxic cell death (Fiskum, 2000). The increase in Ca2+  is related to bax/bak activity in the 
ER of the apoptosis cascade. Bcl-2 on the ER can interfere with calcium –mediated death signals 
(Thomenius & Distelhorst, 2003). 
2.2.8 Bcl-2 Family’s Mechanism of Anti- and Pro- Apoptosis 
The exact mechanism(s) by which the Bcl-2 family of proteins either promote cell death 
or promote cell survival has yet to be definitively elucidated. Bhar and colleagues (2000) reviews 
the four common theories to explain how cytochrome c may escape from the intermembrane 
space in the mitochondria through the outer membrane of the mitochondria into the cytsosol.  
1.  Ca2+ concentration, pH, voltage or redox state influence whether the PTP are open or closed. 
Mitochondrial depolarization in apoptosis is associated with the permeability transition (PT) 
goes through the permeability transition pore (PTP) opening of the mitochondria matrix. As a 
result of these open pores, there is osmotic swelling in the inner membrane of the mitochondria 
which in turn rupture the outer membrane of the mitochondria and release cytochrome c and 
subsequent cell death (Susin et al., 1998). The pore structure itself is theorized to have two 
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components adenylate translocator (ANT) that is necessary for ATP/ADP exchange and VDAC 
which is regulated by the Bcl-2 family; Bcl-xL (pro-survival) and Bax (pro-death). 
2. Cytochrome c release via Bax expression in VDAC 
3. Bax heterodimers and other pro-death Bcl-2 family members form channels in the outer 
membrane of the mitochondria that allow cytochrome c to release. The formation of these 
channels is believed to be a result of the pro-survival Bcl-2 family members inhibiting the 
polymerization of Bax, lending itself to heterodimer formation and subsequent pore channels.  
4. If PTP is closed during apoptosis then ATP/ADP exchange blocked and accumulates in the 
mitochondria. The lack of ADP renders phosporylation ineffective. The inner membrane swells 
(distends), the outer membrane of the mitochondria ruptures and cytochrome c is then released.  
2.3 BCL-2 FAMILY AND APOPTOSIS CASCADES 
The Bcl-2 family of protoncogenes plays an integral role in the regulation of apoptosis 
(Bredesen, 2000; Garcia et al., 1992; Hockenbery et al., 1990; Kane et al., 1993; Mah et al., 
1993; Myers et al., 1995; Nunez et al., 1990). There are two classic pathways of apoptosis; 
cysteine-dependent aspartate-specific protease “caspase” dependent and “caspase” independent 
apoptosis. The Bcl-2 family function to regulate the permeability of the mitochondrial outer 
membrane and permeability transition pore (mPTP) formation. This is believed to be related to 
the fact that Bcl-2 has the tertiary structure similar to that of a bacterial pore forming protein 
(Muchmore et al.,1996).  
The bcl-2 protein appears to function in a feedback loop system with caspases. It inhibits 
caspase activity either by preventing the release of cytochrome c from the mitochondria and/or 
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by binding to the AIF. Bcl-2 is the regulator of extrinsic and intrinsic caspase dependent 
pathways of apoptosis as well as caspase independent apoptosis (Muchmore et al., 1996). 
2.3.1 Caspase Dependent and Independent Apoptosis Pathways 
2.3.1.1 Caspases 
Cysteine aspartic acid-specific proteases “caspases” typically have one of two function; 
activate pro-inflammatory cytokines or promote apoptosis. Caspases engage in proteolysis which 
is an irreversible form of posttranslational modification (Thornberry & Lazebnik, 1998). There 
are 14 members in the caspase family. Seven members are involved in apoptosis; apoptosis 
activators -8, -9  and apoptosis executioners -2, -3, -6, - 7, -10, -12 (Eldaddah & Faden, 2000; 
Salvesen & Dixit, 1997; Thornberry & Lazebnik, 1998). In the brain certain caspase activity is 
dependent upon the region of the brain that is undergoing apoptosis; caspase -8 and -9 activation 
precedes caspase -3 execution in the cortex (Raghupathi, 2004). While only caspase -9 activation 
is attributable to activating caspase -3 execution in the hippocampus and thalamus (Raghupathi, 
2004). Caspase 3, ultimately cleaved by these activator caspases and apoptosis, is then 
irreversible (Leppert, 2006; Zhang et al., 2005). Apoptosis is typically classified based upon 
caspase activity; the extrinsic and intrinsic pathway and caspase independent pathways. The 
literature suggests that there can be crosstalk between the extrinsic and intrinsic caspase 
dependent pathways via the cleavage of Bid by caspase -8 with subsequent translocation to the 
mitochondria leading to the release of cytochrome c (Li et al., 1998; Luo et al., 1998; Zhang et 
al., 2005). 
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2.3.1.2 Extrinsic Pathway of Apoptosis -Caspase Dependent 
Extracelluar signals, which initiate the extrinsic pathway, may include hormones, growth 
factors, nitric oxide, or cytokines. They are extrinsic because they cross the plasma membrane or 
transduce to affect a response. These signals may promote or inhibit apoptosis. (Refer to figure 
2-7). 
 
Figure 2-7: Extrinsic Caspase Dependent Mitochondrial Apoptosis Pathway 
TNF is a cytokine produced mainly by activated macrophages and is the major extrinsic 
mediator of apoptosis. Most cells in the human body have two receptors for TNF: TNF-R1 and 
TNF-R2. In apoptosis TNF binds to TNF-R1 to initiate the pathway that leads to caspase 
activation via intermediate membrane proteins (TNF receptor-associated death domain 
[TRADD] and Fas-associated death domain protein [FADD]).  Binding to the TNF1 receptor can 
also indirectly lead to the activation of transcription factors involved in cell survival. Following 
TNF-R1 activation in mammalian cells, a balance between pro-apoptotic and anti-apoptotic 
members of the Bcl-2 family is established. Pro-apoptotic homodimers that form in the outer-
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membrane of the mitochondrion are required to make the mitochondrial membrane permeable 
for the release of caspase activators such as cytochrome c and SMAC. When the death signal is 
received, products of the activation cascade displace voltage-dependent anion channel isoform  
(VDAC2) and BAK is able to be activated (Itoh et al., 1991; Muzio et al., 1996;  Salvesen & 
Dixit, 1997). TNF is related to the opening of mPTP, and in doing so, the loss of ΔΨm induces 
ROS and therefore contributing, via PTP opening in the mitochondria matrix, subsequent 
osmotic swelling in the inner membrane of the mitochondria which in turn rupture the outer 
membrane of the mitochondria and release cytochrome c and caspase-8 activation (Bahr, 2000; 
Breckenridge & Xue, 2004; Kim, 2005). This in turn leads to the cleavage of Bid to truncated 
Bid (tBid) which translocates from the cytosol to the outer mitochondrial membrane allowing the 
pores to open and cytochrome c to release (Li, Zhu, Xu, & Yuan, 1998; Luo, Budihardjo, Zou, 
Slaughter, & Wang, 1998). (Refer to figure 2-7).  
Fas is a member of the TNF superfamily. The Fas receptor binds the Fas ligand (FasL), a 
transmembrane protein. The interaction between Fas and FasL results in the formation of the 
death-inducing signaling complex (DISC), which contains the FADD, caspase-8, and caspase-10. 
There are two types of cells, type 1 and type 2. Type 1 processed caspase-8 and directly activates 
other members of the caspase family, and triggers the execution of apoptosis. Type II cells the 
Fas-DISC starts a feedback loop that spirals into increasing release of pro-apoptotic factors from 
mitochondria and the amplified activation of caspase-8. Fas has two known apoptotic pathways, 
Daxx is a Fas binding protein that is able to be blocked by Bcl-2. The other Fas pathway is 
mediated downstream by FADD and is insensitive to Bcl-2 and leads to apoptosis (Yang, 
Khosravi-Far, Chang, & Baltimore, 1997). Initiator caspases (caspase-8) can induce MMP by 
cleaving pro-death Bid into truncated Bid (tBid). It is tBid that amplifies the weak signal of 
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initiator caspases by promoting the release of cytochrome c, Smac/Diablo and Htra2/Omi to 
activate the apoptosome and reverse IAP inhibition of caspases (Breckenridge & Xue, 2004; 
Muzio et al., 1996; Yang, et al., 1997). (Refer to figure 2-7) 
Bcl-2 family of proteins, Bax, Bak, and Bcl-2 are found in the endoplasmic reticulum as 
well as the mitochondria. Therefore these proteins are capable of affecting ER Ca2+ homeostasis 
and Ca2+ uptake by the mitochondria and potentially affecting mPTP (Breckenridge & Xue, 
2004). The over-expression of Bcl-2/Bcl-xL can inhibit the translocation of Bax/Bak and 
therefore preventing oligomerization of the pro-apoptotic proteins. Apoptosis is inhibited by 
sequestering small pro-apoptotic molecules in the mitochondria (Breckenridge & Xue, 2004; 
Kim, 2005; Wang, et al., 2004). There are several kinds of small pro-apoptotic molecules which 
are released from the mitochondria they include; cytochrome c, SMAC/ DIABLO and 
Omi/HtrA2 (Kim, 2005). (Refer to figure 2-7). 
Cytochrome c is an apoprotein. Enzyme cytochrome c heme-lyase adds a heme group to 
the cytochrome c and converts it to a globular protein known as holocytochrome c. It is 
holocytochrome c that is the catalyst to activate caspase (Vander Heiden & Thompson, 1999). 
Once cytochrome c is released it binds with Apaf-1 and ATP, which then bind to pro-caspase-9 
to create a protein complex known as an apoptosome. The apoptosome cleaves the pro-caspase 
to its active form of caspase-9, which in turn activates the effector caspase-3 (Kim, 2005). (Refer 
to figure 2-7). 
Second mitochondrial activator of caspase (Smac /DIABLO) is a caspase coactivator. 
Smac /DIABLO potentates apoptosis triggered by UV and irradiation, cytotoxic drugs and DNA 
damage and ligation of the Fas/CD95 death receptor. Smac/DIABLO escapes from mitochondria 
via a caspase-catalysed event that occurs downstream of cytochrome c release (Adrain, Creagh, 
   34
& Martin, 2001).  Smac/ DIABLO binds to inhibitor of apoptosis proteins (IAPs) and inhibits 
them, preventing the IAPs from arresting the apoptotic process and therefore allowing apoptosis 
to proceed. Smac/ DIABLO also inhibits bcl-2-over-expressing cells (Kim, 2005). (Refer to 
figure 2-7). 
Omi/HtrA2 is a proapoptotic mitochondrial serine protease involved in caspase-
dependent as well as caspase-independent cell death. Omi/HtrA2 is able to cleave itself 
generating an IAP interacting reaper motif (Kim, 2005). Omi/HtrA2 is also important in the 
process of apoptosis independently of the presence of the reaper motif. The release of 
Omi/HtrA2 is promoted by the 'BH3-only' Bcl-2 family member; Bid (Martins, 2002). (Refer to 
figure 2-7). 
As mentioned above there are “Inhibitor of apoptosis proteins” (IAP’s). IAP’s have at 
least five members to this family; c-IAP1, c-IAP2, XIAP, NIAP, and surviving. All IAP’s except 
for NIAP inhibit apoptosis by binding to the active form of terminal/ executioner caspapses-3, -7 
and -9 which cause actual degradation of enzymes. They do not interact with caspase-8 
(Deveraux et al., 1998). (Refer to figure 2-7). 
2.3.1.3 Intrinsic Pathway of  Apoptosis Caspase Dependent  
Intracellular apoptotic signaling is a response initiated by a cell in response to stress; 
glucocorticoids, heat, radiation, nutrient deprivation, viral infection, and hypoxia.  The initiation 
of the intrinsic pathway of caspase dependent apoptosis is triggered by stress on the cellular 
organelle (i.e. mitochondria and ER). In a healthy cell, the outer membranes of the mitochondria 
express the protein Bcl-2 on their surface. Bcl-2 is bound to a molecule of the protein Apaf-1. 
Internal damage in the cell causes Bcl-2 to release Apaf-1 which results is cytochrome c leaking 
out of the mitochondria. (Refer to figure 2-8). The release of cytochrome c and Apaf-1 bind to 
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molecules of caspase-9.  The resulting complex of cytochrome c, Apaf-1, caspase -9 and ATP is 
called the apoptosome (Liu et al., 1996).  As apoptosomes aggregate in the cytosol, caspase-9 
cleaves and activates other caspases, esp. caspase 3. The sequential activation of one caspase by 
another creates an expanding cascade of proteolytic activity which leads to digestion of structural 
protein in the cytoplasm and degradation of chromosomal DNA and phagocytosis of the cell 
(Fiskum, 2000; Kluck et al., 1997; Yang, J. et al., 1997). (Refer to figure 2-8).  
 
Figure 2-8: Intrinsic Pathway of Caspase Dependent Mitochondrial Apoptosis 
Cytochrome C released from the mitochondria can translocate to the ER to block inositil-
(1,4,5)-triphosphate (InsP3) receptor. This amplifies Ca2+ signaling and further release of 
cytochrome c from the mitochondria. ER stress can interfere with the ER Ca2+ homeostasis and 
accumulation of excess protein which activates ER localized caspase 12 contributing to apoptosis 
(Boehning et al., 2003; Larner, Hayes, McKinsey, Pike, & Wang, 2004; Zhang et al., 2005). Bax 
is translocated from the ER to the mitochondria during the process of apoptosis. The 
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translocation results in the oligomerization of Bax/Bak which activates Bax/Bak and the 
subsequent insertion into the outer membrane of the mitochondria forming mPTP’s. Ultimately 
the release of cytochrome c from the mitochondria activates caspase-9, which in turn activates 
the executioner caspase-3 and culminates in apoptosis (Baliga & Kumar, 2003; DeGiorgi, et al., 
2002; Kim, 2005). (Refer to figure 2-8). 
2.3.2 Caspase Independent Apoptosis   
Bcl-2 is at the heart of the caspase independent apoptosis cascade because of its integral 
role in inhibiting mitochondrial membrane permeability (Tanaka et al., 2005). The inhibition of 
bcl-2 allows the pores to open and allows the direct release or indirect activation of  
mitochondrial and nuclear proteins that are able to induce apoptosis without activating the 
caspase cascade some specific examples include; AIF, EndoG, PARP, and  p53. (See figure 2-9). 
Apoptosis Inducing Factor (AIF) is an evolutionary conserved flavoprotien in the 
mitochondria which is released after mitochondrial insult related to mitochondrial membrane 
depolarization (Zhang et al., 2005). AIF is translocated to the nuclei and induces the hallmark 
event of DNA fragmentation. AIF caspase independent apoptosis does occur in TBI, oxidative 
stress, and brain ischemia in vivo (Zhang et al., 2005). (Refer to figure 2-9). 
Endonuclease G (EndoG) is a mitochondrion-specific nuclease. It translocates to the 
nucleus during apoptosis. Once released from mitochondria, endoG cleaves chromatin DNA into 
nucleosomal fragments independently of caspases; therefore a component of the caspase-
independent apoptotic pathway (Li, Luo, & Wang, 2001). (Refer to figure 2-9). 
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 Figure 2-9: Caspase Independent Apoptosis Pathway 
Poly(ADP-ribose) polymerase (PARP) (PARP1) plays a role in both necrotic cell death 
and apoptosis. In severe conditions of depletion of NAD+ via PARP, activation exacerbates 
energy failure in the cell, hence membrane leakage and classic necrosis. When the cell is in 
incomplete energy failure, representative of TBI models of injury, PARP contributes to 
mitochondrial membrane depolarization, AIF release, and apoptosis (Zhang et al., 2005). PARP1 
activation is required for the release and translocation of AIF from the mitochondria to the 
nucleus. Conversely, AIF is necessary for PARP1 dependent cell death (Yu et al., 2002; Yu et 
al., 2006). This results in caspase independent apoptosis. (Refer to figure 2-9). 
Pro-apoptotic gene product, p53 is a transcription factor that leads to the induction and up 
regulation of bax with mitochondrial translocation hence increasing the bax/bcl-2 ratio (Lu, 
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Moochhala, Kaur, & Ling, 2000; Miyashita & Reed, 1995). The protein, p53 indirectly triggers 
the intrinsic caspase dependent cascade due to the increase of Bax resulting in the direct 
activation of the intrinsic pathway by release of cytochrome c from the mitochondria and 
subsequent caspase -9 activation (Bredesen, 2000). The effects of p53 on Bcl-2 expression may 
be attributed to the cis-acting p53 negative response element located at the 5’ untranslated region 
of the BCL-2 gene (Miyashita, Harigai, Hanada, & Reed, 1994). 
2.4 BCL-2 AND TBI 
In the previous section, a detailed explanation was given to the importance of Bcl-2 in 
apoptosis. Apoptosis is an intricate event requiring the orchestration of numerous cellular 
players. This section will review the evidence of the role of bcl-2 as it pertains to TBI. 
Zhang (et al., 2005) speculate a rule of thirds in the types of cell death after TBI; one 
third of cell death is related to caspase dependent apoptosis, one third is associated with caspase 
independent cell death, and the last third is attributed to necrosis. In TBI, apoptosis may be 
triggered by edema (i.e. increased ICP and inflammation) and hemorrhage (Zhang et al., 2005). 
Cells that are vulnerable to apoptosis after TBI include neurons, oligodendrocytes, astrocytes 
(glutamate uptake, lactate, and antioxidant production) and microglia (Zhang et al., 2005). Bcl-2 
can block the axonal injury and loss of axonally transported trophic factors associated with TBI 
(Garcia et al., 1992; Graham et al., 2000). Bcl-2 can also regenerate severed axons (Chen, 
Schneider, Martinou, & Tonegawa, 1997). Apoptosis is apparent 1 hr- 14 days after injury with 
bcl-2 protein levels peaks 12-72 hours after injury in the animal model (Xiong, Lin, Chen, 
   39
Peterson, & Lee, 2001). One study suggests that Bcl-2 expression peaks on day 4 after brain 
injury (Lee, J.  et al., 2004). 
 
2.4.1 Review of the Literature in Animals 
Tables 2-1 to 2-6, reviews all of the Bcl-2 literature with direct relevance to TBI in the 
animal literature from 1960-2008 in the OVID and CINAHL databases, with 23 relevant articles 
spanning 1997-2008.  
The literature commences with an investigation if bcl-2 mRNA increases in the rat brain 
post experimental model TBI. Clark and colleagues (1997) report that bcl-2 mRNA increases in 
the ipsilateral cortex (6, 24, and 72 hours), dentate gyrus (6 and 24 hours), hippocampus cornu 
ammonis area 1[CA1] (24 hours), hippocampus cornu ammonis area 3 [CA3] (6 and 24 hours) 
post TBI. Bcl-2 protein increases in the cortex 8 and 72 hours post injury (P<0.05) compared to 
controls (Clark et al., 1997). These studies established that bcl-2 mRNA and protein increase 
after TBI in experimental adult rat animal models. 
Further studies examined the relationship of injury to the immature brain as apoptosis is 
essential to the developmental process and brain injury may further highten the apoptotic 
process. The 3 and 7 day old immature rat brain undergoes significant apoptosis in the 1 hour 
after injury (Bittigua et al., 1999; Morrison, Eberwine, Meaney, & McIntosh, 2000). In an in 
vitro model of 4 day old rat brain, bcl-2 mRNA expression significantly decreased 24 hours after 
injury compared to controls (P<0.005) and at 6 hours (P<0.01) and return to baseline 48 hours 
injury (Morrison et al., 2000). In the in vivo rat model bcl-2 depression is evident at 2 hours and 
persists for 48 hours and with a slow and incomplete recovery at 120 hours post injury 
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(Felderhoff-Mueser et al., 2002). Apoptosis and/ or the decrease in bcl-2 activity has been noted 
earlier after injury in the immature brain versus the adult brain and may indicate why children 
may have different resposes to similar injury. 
The human BCL-2 transgenic (TG) versus wild type (WT) murine models were utilized 
in three of the studies reviewed (Raghupathi et al., 1998; Nakamura et al., 1999; Tehranian et al., 
2006). The TG models all support the evidence that bcl-2 over-expression is associated with 
significant reduction in the percent of lesion after TBI (P<0.01 to P<0.05). One study reports TG 
mice had a reduced deficits on the incline plane test (P<0.05) versus WT mice, however this 
study also reports no significant differences in other neurological assessments (Raghupathi et al., 
1998). Additional studies also support the evidence that bcl-2 over-expression does not 
significantly improve murine neurological performance on neurological exam and Morris Water 
Maze (MWM) tests  24 hours to 1 week after injury (Nakamura et al., 1999; Tehranian et al., 
2006). The results of Nakumura  et al.  (1999) study are confounded with their report that pre-
injury TG mice have significant learning impairment versus WT (P<0.05). In evaluating the 
potential behavioral and functional outcomes of bcl-2 over-expression after TBI, the limitations 
of the TG model need to be considered. Murines have only small behavioral deficits associated 
with injury to the cortex (Bederson et al., 1986). TG murines have life long over-expression of 
bcl-2 having larger brains than WT littermates (Tehranian et al., 2006) and therefore 
developmental apoptosis is interrupted which may explain the learning deficits in the pre-injured 
TG mice (Nakamura et al., 1999). The over-expression of bcl-2 in humans is not life long. The 
incongruence between decreased lesion volume and behavioral outcomes after TBI as seen in the 
murine population after TBI may not exist in humans. Pediatric humans with increased 
expression of bcl-2 after TBI are reported to have significantly better functional outcomes and 
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decreased mortality than in subjects with negative (low) bcl-2 expression after TBI (Clark et al., 
2000; Ng et al., 2000; Nathoo et al., 2004). 
BCL-2 fusion protein- recombinant adenovirus gene therapy intervention after TBI in rats 
has shown to significantly reduce apoptosis 3 days post injury (P<0.01) (Yang X., Zheng, Liu, & 
Feng, 2006). This is in congruence with the TG models for bcl-2 over-expression which indicate 
decreased lesion size. The gene therapy model indicated that one week after injury the tilt board 
functional outcome measure for the rats were no different than the sham control however, 2-4 
weeks after injury, experimental gene therapy group had significantly better tilt board outcomes 
(P<0.005) (Yang, X. et al., 2006). This maybe a factor of a broader timeframe to ascertain 
differences in outcomes or absence of life long over-expression bcl-2, a combination of both, or 
possibly another factor. 
There are additional intervention studies that resulted in altered bcl-2 expression that 
offer areas of therapeutic means by which to manipulate bcl-2 expression and the potential 
benefits from the altered states.  
An in vitro study used a pharmaceutical bcl-2 protein derivative, Bcl-220-34, to perfuse 
hippocampal slices after a fluid percussion model of injury.   Bcl-220-34 in the hippocampus was 
protective against hypoxia, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
[AMPA], N-methyl-D-aspartic acid [NMDA], and nitric oxide [NO] (Panizzon, Shin, Frautschy, 
& Wallis, 1998). Another pharmaceutical study utilized N-acetylcysteine (NAC), an antioxidant, 
which can inhibit gene expression induced by ROS. It was able to reduce bcl-2 short bands and 
bax in injured rats after TBI (Xiong , Lin, Chen, Peterson, & Lee, 2001). Mifepristone 
(glucocorticoid receptor antagonist) when used as a pretreatment can protect neuronal loss in the 
CA1 hippocampal region 24 hours following TBI. It is also associated with decreased basal bcl-2 
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mRNA in CA1 and dentate gyrus. Mifepristone did not affect basal bax or p53 levels therefore it 
is not believed to be involved with transcriptional regulation of bcl-2, bax, or p53 apoptosis 
related genes (McCullers, Sullivan, Scheff, & Herman, 2002).  Recombinant human 
erythropoietin (rhEPO) was found to increase the expression of bcl-2 mRNA and protein and 
decreased DNA fragmentation in rats with TBI when compared to vehicle treated rats (Liao, Zhi, 
Shi, & He, 2008). While there are several pharmaceutical interventions none of the results have 
been duplicated. More research needs to be conducted in this arena with neurobehavioral 
outcomes added to the study designs. 
An alternate intervention to alter bcl-3 states after TBI in the murine models is hyperbaric 
oxygenation (HBO). Bcl-2 expression was shown to be lower in hypoxic states and that bcl-2 
expression can increase significantly with HBO (Liu, Kim, Yang, Jemmerson, & Wang , 2006 
Vlodavsky, Palzur, Feinsod, & Soustiel, 2005). The mechanism behind this maybe related to 
HBO ability to lower cytochrome c and bax expression at 3, 6, 12 and 24 hours post TBI 
(P<0.05) (Liu et al., 2006).  Additional research needs to be done in this area as well. 
Additional studies examined the relationship of bcl-2 with other pro- and anti-apoptosis 
markers that ascertain the timing and brain location of bcl-2 as a player in the larger apoptosis 
cascades. These studies are important to designing the timing of an intervention for the specific 
location of injury as they pertain to possible alterations in bcl-2 concentrations. Following TBI, 
bcl-2 and bax bands intensities reduce 2 hrs after injury (P<0.05) more importantly the bax:bcl-2 
ratio increases at 2 hrs and remains elevated at 7 days s/p injury (P<0.05) (Raghupathi et al., 
2003). Bcl-2 levels tend to down regulate in early TBI (i.e. 30 minutes to 6 hours) (Dong, Singh, 
Dendle, & Prasad, 2001; Lu, J., Moochhala, Kaur, & Ling, 2000; Raghupathi et al., 2002; 
Strauss, Narayan, & Raghupathi, 2004). However, bcl-2 expression is significantly higher 24 
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hours after injury post injury of TBI of any severity (Hellmich et al., 2005). These studies 
provide some evidence that early post injury there is a reduction in the anti-apoptotic 
concentration of bcl-2 and an increase in bax:bcl-2 ratio. It has yet to be determined if this 
temporal pattern influences neurobehavioral outcomes.  
The location of the injury may play a role in bcl-2 activity. In diffuse traumas, there is an 
increase bax expression, induction of increase in active caspase -3 expression with a 
simultaneous increase in bcl-2 expression for the first 5 days after injury (Cernak, Chapman, 
Hamlin, & Vink, 2002). One study found that bcl-2 mRNA is up regulated ipsilaterally 10 days 
after injury suggesting that the therapeutic window is quiet large (Wennersten, Holmin, & 
Mathiesen, 2003). Yet, cytochrome c significantly increases and bcl-2 significantly decreases 30 
minutes to 72 hours post TBI in the injured cortex and ipsilateral hippocampus (Dong et al., 
2001). One study examined the long term activity of anti-(bcl-2 and heat shock protein 70) and 
pro-(casapes-3 and-9) apoptotic genes at 3, 6 and 24 months post TBI. Both anti- and pro- 
apoptotic genes were down regulated in the hippocampus; long term neuronal survival/loss may 
not be mediated by apoptosis related genes (Shimanura et al., 2005). Due to the evidence that the 
therapeutic window for bcl-2 activity may be as large as 10 days, but cytochrome c activity 
peaks are 72 hours post injury, there may be additional members of the apoptosis cascade that 
may be influencing the temporal/ location pattern exhibited in the bcl-2 concentrations after 
acute experimental TBI in animal models. 
 
Table 2-1: Bcl-2 and Traumatic Brain Injury in Animals: Literature Review 
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display characteristics of apoptosis 
or necrosis which express bcl-2. 

















-Bcl-220-34 provided protection with 
CA1 antidromic PS recovery of 92% 
±1 (P<0.05) 
-Bcl-220-34 protective against 
hypoxia, AMPA, NMDA & NO 
Panizzon et al., 
1998 




Lateral CCI Cortical 
hippocampal 
 -Functional Outcomes 
-Histology 
-7 days s/p CCI TG mice reduced 
cortical lesion (P<0.01) 
-TG mice had reduced deficit in 
cline plan test (P<0.05) vs WT 
No significant difference TG vs WT 
on other neuroscores. 
Raghupathi et 
al., 1998 
Wistar rat pups 

















 TUNEL Immature brain  (3 & 7 days) 
undergoes significant apoptosis in 
the first hour after injury significant 
in all tissue analyzed from (P<0.05 
to P<0.001)  [except in the dentate  
gyrus on day 3] 
bcl-2 levels are down regulated 1 hr 
after trauma. 
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Table 2-1 continued 
 





Tissue Analyzed Treatment Method of Analysis Summary of Results Reference 
8 week old 
BCL-2 TG mice 
n=13 











Percent tissue loss TG smaller vs 
WT hemisphere (P<0.01) 
Hippocamal (P<0.001) 
Dentate Gyrus (P<0.01). 
TG had increased loss in  dorsal 
thalamus (P<0.05) ventral thalamus 
(P<0.01) 
 
MWM 1 week s/p injury TG vs WT 
no significant difference.(Pre-injury 
TG learning impaired P<0.05 vs 
WT)  
Nakamura et al., 
1999 
Male Wistar rats 
n=24 
Weight drop Cerebral cortex  Double 
immunolabelling 
TUNEL 
-2 hours after injury Fos 
immunoreactivity,  
-At 4 hours bax elevated and bcl-2 
down regulated, increase p53 
-colocalization of Bax 
immunoreactivity with bcl-2 and 
p53 
 
Lu et al., 2000 
4 day old Sprague-
Dawley rat pups 
n=19 from 3 
different litters 







of the silicone 
membrane) to 
organotypic 







 Reverse Northern 
Hybridization 
Bcl-2 mRMA expression decreased 
24 hrs after injury compared to 
controls (P<0.005) 6 hr (P<0.01),  
and returned to baseline 48 hours 
after injury. 
 Bax mRNA were not altered after 
injury 
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Table 2-1 continued 





Tissue Analyzed Treatment Method of Analysis Summary of Results Reference 









 RT-PCR (Bcl-2) 
Western Blots  
(cytochrome c) 
Bcl-2 significantly decreased 2 hr s/p 
injury  to 48 hrs in the injured cortex and 
ipsilateral hippocampus. Cytochrome c 
was significantly increased in these 
areas. Cytochrome c increases in the 
injured cortex at 30 min, 48 and 72 hrs; 
and in the ipsilateral hippocampus at 2 to 
72 hrs.  







Western Blots Bcl-2 not detected in uninjured rat brain. 
1, 4 and 12 hrs s/p injury shortened Bcl-2 
bands were detected in injured 
hemisphere. Bax was evident in both the 
uninjured and injured rats. 
Bcl-2 short band and bax  were reduced 
in NAC tx injured rats  
Xiong et al., 
2001 















Trauma triggers a down regulation of 
bcl-2 and bcl-xL evident 2 hrs post 
injury and persisting 48 hors with a slow 
and incomplete recovers by 120 hrs post 
injury (P<0.001) 
Felderhoff-








Cortex  TUNEL 
Morphological changes 
Decreased bcl-2 cellular 
immunoreactivity in the cortex at 2 hrs 
s/p injury. No change in bax levels.  
Loss of bcl-2 at 6 hrs in the hippocampus 
CA3 followed by overt neuronal loss at 
24 hrs s/p injury. No increase of 
apoptosis (bax) in the hippocampus. 
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Table 2-1 continued 













cortex  TUNEL 
Western Blot 
Increased active caspase-3 
expression was correlated with 
increased bcl-2 levels (P<0.001) for 
the first 5 days after injury. 
Bcl-2 overexpression significant 
days 3-5 (P<0.05) in the cortex. 
 Maximal DNA fragmentation at 3 
days after injury 
Cernak et al., 
2002 




Unilateral CCI Hippocampus 





In situ hybridization 
Spironolactone and Mifepristone 
decreased basal Bcl-2 mRNA in 
CA1 and dentate gyrus. They did not 
affect basal bax or p53 levels. Injury 
decreased bcl-2 mRNA in the 
dentate gyrus but did not affect bax 
or p53 levels. 














In situ hybridization 
Bcl-2 and bax bands intensities 
reduce 2 hrs after injury (P<0.05). 
bax:bcl-2 Ratio increases at 2 hrs 








Unilateral CCI Hippocampus  TUNEL 
Immunohistochemistry 
In situ hybridization 
Bcl-2 mRNA was up regulated 
ipsilaterally 10 days after injury 
compared to controls (P<0.05) 















 RNase Protection 
Assays (RPA) 
Bcl-2 decreases 75-80% in the first 6 
hrs after injury and return to normal 
levels by day 1 and decrease again 
until day 3. 











 RNase Protection 
Assays (RPA) 
Bcl-2 expression at 24 hr was higher 
than at 4 hr regardless of TBI 
severity (P=0.046).  
Hellmich et al., 
2005 
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Table 2-1 continued 
 





Tissue Analyzed Treatment Method of Analysis Summary of Results Reference 







(24 hr and 3, 6,& 
12 months) 
 RNase Protection 
Assays (RPA) 
MRNA expression of Bcl-2 and 
Heat Shock protein 70 was down 
regulated in neurons at 3, 6 (BCL-2 
only) and 12 months after TBI 
(P<0.05). 
Caspase -3 and -9 decreased in the 
neurons at 3, 6 (-9 only) and 12 
months after injury (P<0.05). 
Bcl-2, Heat Shock protein 70, 
Casapse -3 and -9 decrease in glial 

















Bcl-2 expression was lower in 
hypoxic rats vs non hypoxic. Bcl-2 
expression increased with HBO in 
hypoxic and non-hypoxic groups 
(P< 0.05) 
















TBI rats with HBO treatment had: 
Lower cytochrome C and BAX 
expression at 3, 6,12 and 24 hrs post 
injury (P<0.05) 
Higher BCL-2 expression at 
3,6,12,24,and 72 hr post injury 
(P<0.01) 
 
Liu et al., 2006 
BCL-2 TG Mice 
WT Mice 
CCI Hippocampus  Western Blot 
TUNEL 
MWM 
BCL-2 TG mice had smaller 
contusion volumes and increased 
number of surviving neuron in CA2 
24 hr after injury (P<0.05) 
No difference in motor function and 
MWM. 
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Table 2-1 continued 
 





Tissue Analyzed Treatment Method of Analysis Summary of Results Reference 
Wistar Rats 
















Behavioral- tilt board 
Experimental group had less 
apoptosis 3 days post injury 
(P<0.01). 
1 week after injury no difference in 
tilt board score; 2-4 weeks after 
injury experimental group had better 
outcomes (P<0.005) 
Yang et al., 2006 

































rhEPO –treated TBI group bcl-2 
mRNA and protein greater than 
vehicle-treated 
Bcl-2 mRNA peaked at 24 hours  
rhEPO –treated less DNA 
fragmentation than vehicle-treated 
rhEPO protects neurons by 
enhancing bcl-2 expression 
 
 
Liao et al., 2008 
  
2.4.2 Review of the Literature in Humans 
The literature on bcl-2 and TBI in humans is limited.  There were seven relevant articles 
that addressed these specific issues in the literature from Ovid search from 1960- 2008. The 
seven articles were published between May 1999 and June 2008 and utilize small sample sizes. 
None of the articles address BCL-2 genotypes. Tables 2-7 and 2-8 summarizes the findings of 
the human studies. 
From the studies that have been conducted in humans the empirical evidence establishes 
that bcl-2 levels increase in humans brain and/or CSF after TBI compared to patients without 
TBI or neurological injury (Clark et al., 1999; Clark et al., 2000; Yang & Xue, 2004).  
TBI subjects who up regulated bcl-2 had an incidence of a lower mortality rate and better 
GOS scores (Clark et al., 2000; Ng et al., 2000; Nathoo et al., 2004). Minambres and colleagues 
(2008), report that  in vivo samples had significantly higher bcl-2 concentration compared to post 
mortem autopsy (p=0.027). However, it is unclear at what time point the post mortem specimens 
were harvested and the inconsistent procedure in fixating the tissues in formalin (surgical tissues 
24 hours and the autopsy brain for 15 days.) This raises questions if the significant down-
regulation of bcl-2 in the post mortem brain tissue was due to a medically relevant conclusion 
that patients with lower concentration of bcl-2 have increased mortality or if bcl-2 levels 
naturally down-regulate post mortem or if the procedure by which the tissues were harvested and 
fixed affected bcl-2 concentrations.  
The time point at which bcl-2 concentrations peak in humans is not clear in the literature. 
One study reported that bcl-2 concentrations increases 8 hours after injury and peak on days 2-3 
and remains higher for 5-7 days (Yang & Xue, 2004) while another study  reports two peak 
   51
   52
points among the patients, day 3 and 5 (Uzan et al.,  2006) the peak window may be patient 
dependent. 
Among the seven studies, three examined ICP as a clinical outcome. One study reports 
that bcl-2 positive patients had lowered ICP trending towards significance (p=0.057), however 
then sample size was small (n=11)(Ng et al., 2000). Two additional studies found there to be no 
effect of bcl-2 concentrations on ICP (n=29, p= 0.8,  Nathoo et al., 2004; n=14, p= 0.9, Uzan et 
al.,  2006). 
 Based on the studies reviewed, there is a growing body of evidence that bcl-2 
concentrations are increased after TBI, and the bcl-2 levels are related to global functional 
outcomes (survival versus mortality) after TBI. More research is needed to establish a 
relationship with clinical, biological, global functional outcomes, and cognitive- behavioral 
outcomes after TBI. None of the studies examined BCL-2 genotypes in the TBI population. This 










 Table 2-2: Bcl-2 and Traumatic Brain Injury in Humans: Literature Review 





Tissue Analyzed Measurements Outcome 
Measure 




All TBI w/ 
surgical 
decompression for   
increased ICP   
Initial GCS 3-15      
Contused cerebral 
cortex (TBI)  





GOS at 3 
months 
median 3 . 
GOS based 




TBI subjects had  bcl-2 levels 
higher  than the controls (P=0.020) 
There was no significant increase in 
bcl-xL or bax expression between 
TBI and controls. 
 












Bcl-2 positive subject had survival 
after 6 months (P=0.01)  
Bcl-2 positive subject had lower 
ICP (P=0.057) 
 






ELISA  on CSF 









Bcl-2 levels increased  
TBI subjects vs control, P=0.01 
Increased bcl-2 in TBI patients that 
survived vs died P=0.02 
 



















Bcl-2 negative status  independent 
predictor of poor outcomes P<0.04, 
odds ratio 5.5 
Bcl-2 Positive patients better GOS 
at 18 months or longer (3.8±1.6) 
P=0.03. 
Bcl-2 positive and negative patients 
no significant difference in ICP 
(p=0.8). 
PIZ was significantly higher for 
Bax (P=0.005) and caspase-3 
(P=0.005). 
Nathoo, et al., 
2004 




Table 2-2 continued 





Tissue Analyzed Measurements Outcome 
Measure 
















Controls had minimal bcl-2 
(mRNA and protein) 
TBI had bcl-2  (mRNA and 
protein) increased 8 hr after 
trauma, peaked 2-3 days later, 
remained higher than controls 
days 5-7. 
Bax (mRNA /protein) was high in 
the controls. Bax became 
significantly higher in TBI at 20-
28 hrs. & 2-3 days post injury. 
Yang, et al., 2004 
Pediatric (n=3) & 
Adults (n=11) 
n= 14 TBI 






GCS≤8 in the TBI 
group 












Caspase-3  correlates to 
ICP(p=0.01) and CCP (p=0.04) 
Bcl-2 concentrations peaks days 3 
and 5 no correlation with ICP, 
CPP, or CT findings (p>0.05) 
No correlation between bcl-2 and 
sFAS or capsase-3. 





Ex vivo study 
n= 16 TBI 














rate at 6 
months 
In viva samples compared to post 
mortem samples had significantly 
higher expression of bcl-2 
(p=0.027) and bcl-xL (p=0.014) 
In vitro studies apoptotic rate pf 
PC12 cells independent factor in 






 2.5 OUTCOMES 
2.5.1 Neuropsychological 
The gold standard in evaluating outcomes after TBI has been the global functional 
outcomes measurement of Glasgow Outcome Score (GOS). GOS is a feasible tool to quickly 
gage a patient’s ability to perform ADL’s and the amount of assistance required (Jennett & 
Bond, 1975; King, Calier & Marion, 2005). There are a host of functional outcome measures to 
assess ADL functioning and participation in care (i.e. GOS, DRS, Functional Independence 
Measurement [FIM], and Community Integration Questionnaire [CIQ]). For research purposes, 
batteries of physical functional outcome test are administered routinely. Less consistent is the 
administration of cognitive-behavioral outcome measurements. Part of this is the reality that TBI 
patients injuries can fall on a continuum of mild to severe and that the measurements of 
outcomes after TBI therefore have the potential of ranging from no impairment to death.  Global 
functional outcome measurements are necessary to capture the outcomes for those with severe 
impairments or death. More sensitive measurements of outcomes, cognitive-behavioral, are 
necessary for those who are capable of participating in neuropsychological testing/ rehabilitation 
to truly assess recovery and impairment.  
Timing of initiating the first neuropsychological testing is debatable. Severe TBI patients 
are often unable to participate in neuropsychological testing during the first 3 months of injury 
because of persistent psychosyndromes that disturb orientation and concentration (Lippert-
Gruner, Kuchta, Hellmich, & Klug, 2006). However, 62% of patients with moderate to severe 
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 TBI, regardless of post traumatic amnesia status, were able to complete a neuropsychological 
outcomes brief battery of tests from 2-6 weeks after injury administered in an inpatient 
rehabilitation setting (Kalmar et al., 2008). In this population, the California Verbal Learning 
Test-II, FAS, and the animal naming tests were the most consistently performed among all 354 
subjects in the study (Kalmar et al., 2008). However, many patients with severe TBI may not 
have met the criteria for the type of intensive inpatient rehabilitation used in this study thus this 
sample was biased towards patients who were able to participate in intensive inpatient 
rehabilitation (typically 180 minutes per day). In order to capture all levels of recovery across the 
continuum, a variety neuropsychological testing should be included in an outcomes battery; 
global functional outcomes and cognitive-behavioral measures. 
The National Institutes of Health Consensus Development Panel on Rehabilitation of 
persons with TBI (1999) systematically summarizes the sequelae of TBI across all severities. 
The neurological consequences of TBI include: movement disorders, seizures, headaches, 
visional changes, and sleep disorders. Pervading medical complications after TBI include: 
pulmonary, metabolic, nutritional, gastrointestinal, musculoskeletal, and dermatological 
dysfunction. The neuropsychological impairments include: cognitive, memory, attention, 
concentration, language, visual perception, executive functioning, abstract reasoning, insight, 
judgment, planning, information possessing, and organization, all which can impact employment 
opportunities and community reintegration. Behavioral sequelae include: decreased ability to 
initiate a response, verbal/ physical aggression, agitation, learning difficulties, impaired self 
awareness, altered sexual functioning, impulsivity, and social disinhibition. Mood disorders, 
personality changes, depression, anxiety, and liable emotional control are all common 
consequences of TBI. The aftermath of TBI can affect physical and psychosocial health and well 
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 being. A concerning 40% of patients in one study report that these neuropsychological 
impairments are unmet needs requiring for intervention 1 year post injury (Corrigan et al., 2004). 
The social consequences and societal burden of the neuropsychological impairments after 
TBI can lead to an increased risk of suicide, divorce, chronic unemployment, economic strain, 
substance abuse (NIH, 1999). Caregiver burden is an additional sequelae related to the severity 
of disability and impairment and is often addressed separately in the literature (Nabors, Seacat, & 
Rosenthal, 2002). Goals of cognitive-behavioral rehabilitation are to improve the capacity to 
process and interpret information and improve social interaction (home, family, and community 
reintegration) (Cicerone, Mott, Azulay, & Friel, 2004). Social and occupational re-integration 
can be a challenge after severe TBI because the severe neurobehavioral sequelae of cognitive 
deficits (attention, memory, information processing speed) and self perception tend not to resolve 
over time ((Lippert-Gruner et al., 2006). In contrast, the functional deficits do improve over time 
(Lippert-Gruner et al., 2006). The functional/ physical improvements in performing ADL’s are 
an important first step in describing recovery, however, these tests do not tell the whole story of 
recovery.  
The literature stresses the importance that neuropsychological testing needs to include 
both global functional outcome and cognitive-behavioral measures as to provided a more 
complete and accurate picture of recovery after TBI, whether mild or severe.  
Neuropsychological rehabilitation is often not covered under insurance on an outpatient 
bases (BIAA, 2007). With more research in this area and interventional studies, the case may be 
made for neuropsychological rehabilitation to be a vital part of long term recovery from TBI. 
With empirical evidence, insurance benefits might then extend the outpatient TBI rehabilitation 
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 coverage to encompass not only the physical and occupation therapy domains but to include  
neuropsychological rehabilitation. 
The measurements utilized to assess the neuropsychological outcomes in this study are 
discussed at length in the Methods section 3.8.2.4.  
2.5.2 Biological and Clinical Outcomes 
2.5.2.1 Lactate and Pyruvate 
Biological predictors are not well defined, but as suggested by the apoptosis cascade of 
events, lactate and pyruvate levels may inform prognosis (Lu, Ashwell & Waite, 2000). Lactate, 
pyruvate, and lactate/pyruvate ratio (L/P) are energy- related metabolites and biochemical 
indicators of brain injury and cerebral anoxia (Kerr  et al., 2003; Wagner et al., 2004 ; Wagner et 
al., 2005 ; Yu et al., 2005). Lactate is a marker for aerobic and anaerobic metabolism and is the 
end product of glycolysis (Kerr  et al., 2003; Wagner et al., 2004 ; Wagner et al., 2005 ; Yu et al., 
2005). Elevated lactate is related to poor outcomes, diminished cerebral blood flow, elevated 
intracranial pressure and ischemia (Kerr et al., 2003; Wagner et al., 2004; Yu et al., 2005). 
Pyruvate is an intermediate in the metabolism of glucose. It is a potent ROS scavenger. Pyruvate 
is protective against ROS in neuronal tissue (Kerr  et al., 2003; Yu et al., 2005). Increased 
pyruvate is associated with decreased cerebral ischemia (Yu et al., 2005).  Lactate and pyruvate 
are often considered in ratio because they are antagonistic to each other (Kerr et al., 2003; 
Wagner et al., 2004; Wagner et al., 2005).  Pyruvate inhibits the translocation and activation of 
p53 proteins, tumor suppressor and regulation of transcription, as is a result of DNA damage 
secondary to oxidant injury (Lee, Kang, Bunger, & Kang, 2003). Bcl-2 expression was increased 
as a result of these events (Lee, Y.,  Kang, Bunger, & Kang, 2004).   Pyruvate has anti-apoptotic 
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 influence through over-expression of bcl-2 (Lee, Y. et al., 2004). There have been no studies that 
examine the relationship between BCL-2 and lactate, pyruvate or L/P ratio after TBI.  
2.5.2.2 CBF 
Secondary brain injury is one consequence of decreased cerebral blood flow (CBF), 
cerebral ischemia. Cerebral ischemia is related to the reduction or complete loss of CBF 
(McLaughlin & Marion, 1996). The cascade continues with a depletion of ATP, anoxic 
depolarization, and spreading depression depolarization. As a result of ischemic changes 
cytochrome c release and apoptosis occurs (Zhao, Steinberg, & Sapolsky, 2007). There is 
evidence of a direct link between bcl-2 and CBF. In a stoke model, bcl-2 knockout mice, 
homozygous knockout mice has significantly larger infarct area more severe reduction in CBF 
(Hata, Gillardon, Michaelidis,  & Hossmann, 1999). In a transient focal ischemia brain injury 
stroke model in rats, 3-methyl-1- phenyl-pyrazolin-5-one (Edaravone), a free radical scavenger 
which inhibits both hydroxyl radical generation and iron-induced peroxidative injuries, was 
found to be protective against ischemia and reduced apoptotic cell death by upregulating bcl-2 
and downregulating bax  (Amemiya et al., 2005). Numerous studies have been conducted on the 
efficacy of hypothermia on ischemia and ischemia related apoptosis with conflicting results 
(Eberspacher et al., 2003; Yenari, et al., 2002; Zhang, Z., Sobel, Cheng, Steinberg, & Yenari, 
2001; Zhao, Yenari, Cheng, Sapolsky, & Steinberg, 2005). Hypothermia increased bcl-2 protein 
expression after global ischemia but had no influence on bax (Zhang, Z. et al., 2001). However, 
one study found that hypothermia inhibits bax expression 4 hours after ischemia but had no 
effect on other proteins (Eberspacher et al., 2003). A difference may be in the type of ischemia. 
In focal ischemia hypothermia was found to not alter bcl-2 or bax expression, but transiently 
blocked cytochrome c in addition there was no caspase activity which maybe indicative of 
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 caspase independent apoptosis (Yenari, et al., 2002). In global ischemia, hypothermia blocked 
caspase activity and the “second large phase” of cytochrome c release, but did not block early 
cytochrome c release (Zhao et al., 2005). Bcl-2 protein levels and gene knock-out models assert 
bcl-2 involvement in CBF. BCL-2 genotypes have not been studied in humans.    
 
2.5.2.3 APOE 
Apolipoprotein E (APOE) is the most documented genetic marker that has been 
associated with outcomes after TBI due to its association with numerous cellular activities and, 
in particular, neuronal plasticity and regulation of neurotoxicity (Chiang, Chang & Hu, 2003). 
The APOE genotype has been studied extensively in the TBI population. APOE is a lipid 
clearance and metabolic protein that facilitates neurotransmission (Mauch et al., 2001; Reyland 
et al., 1991) maintains structural integrity of neuron (Hayashi et al., 2002; Mahley et al., 1988; 
Weisgraber et al., 1994)  is involved with neuronal plasticity (Ignatius et al., 1986; Nathan et al., 
1994; Poirier et al., 1991; Poirier et al., 1994) and regulation of neurotoxicity in TBI (Marques et 
al., 1996; Michikawa et al., 1998; Moulder et al., 1999). In humans it is encoded by a 4-exon 
gene and is located on chromosome 19. The APOE gene has three alleles (APOEє2, APOEє3, 
APOEє4). The 4 allele is associated with increase ß-amyloid deposits (Beffert et al.,1998; LaDu 
et al., 1994; LaDu et al., 1995; Namba et al., 1991) increased circulation of metabolites and 
excitotoxins (Muller et al., 1998; Tolar et al., 1999; Veinberg et al., 2002) and poor outcomes 
after neurological insult (Jordan et al., 1997; Liaquat et al., 2002; Liberman et al., 2002; Lynch et 
al., 2002; Millar et al., 2003 ; Nicoll et al., 1996; Teasdale et al., 1997). However, the 
relationship between ApoE/APOE and apoptosis markers has not yet been clearly defined 
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 (Belton et al., 2003; Moulder, Narita, Chang, Bu & Johnson, 1999; Ong et al., 2003; Wei, Zhang 
& Zhou, 1999).  
There is some empirical evidence that there is a connection between bcl-2 and apoE 
proteins. Early in the investigation of APOE and apoptosis, one Alzheimer’s disease study 
suggested that apoE4 protein neurotoxicity is distinct from classical apoptosis or necrosis 
(Moulder et al., 1999). However, subsequent studies suggest a link. One Alzheimer’s disease 
study of mice bread for senility (SAMP8) or senility resistance (SAMR1) found that mice with 
SAMP8 had an increase in bcl-2 proteins in astrocytes and very low level of neuronal bcl-2 
proteins. The author suggests that this was a compensatory neuroprotective response (Wei et al., 
1999). Studies of APOE knockout mice have found increased apoptosis in other disorders 
(Belton et al., 2003; Ong et al., 2003). Alzheimer’s disease studies in mice support that nicotine 
receptor– mediated protection increases bcl-2 protein levels, which may prevent neuronal cell 
death via blockade of ß-amyloid and glutamate neurontoxicity (Shimohamma et al., 2001). More 
research is needed in this area to describe the relationship between BCL-2 and APOE genotypes 
in humans. 
2.6 SUMMARY 
Apoptosis plays a pivotal role in cell survival after a neurotrauma. Bcl-2 upregulation is 
associated with decreased ischemic areas in the brain and increased cerebral blood flow. The 
literature is sparce on the effect of bcl-2 on functional outcomes after TBI. Bcl-2 is a compeling 
starting point to futher the investigation of the relationship of BCL-2 genotypes to outcomes as 
well as biological/ clinical data. 
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 2.7 SIGNIFICANCE AND INNOVATION 
As a health care community we can not fully explain why some patients have better 
outcomes than others after a severe TBI. Nurses are looked to for answers to these questions 
because we have the most contact hours with TBI patients and their families during their 
extensive acute care and rehabilitation stays. Recovery from TBI may be influenced by genes. 
The study of BCL-2 is in its infancy and BCL-2 genotyping has not been addressed in the TBI 
population, despite the empirical evidence that bcl-2 protein concentrations may affect outcomes. 
With further research, there is the potential for a better understanding of mechanisms of 
secondary injury and the development of a BCL-2 related genetic derivative treatment or 
intervention. These treatments or interventions can potentially decrease the secondary injuries 
associated with TBI and therefore increasing the odds of survival and improving global 
functional and cognitive-behavioral neuropsychological outcomes. 
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 3.0  METHODS 
3.1 DESIGN  
This study utilized a descriptive, longitudinal, prospective between-group, with-in subject 
design to examine BCL-2 genotypes in DNA extracted from CSF or blood specimens and how 
they related to outcomes at 3, 6, 12, and 24 months post injury and biological/ clinical data. This 
study was an ancillary study that utilized biological samples and data collected from federally 
funded studies that examined genes and gene products in TBI patients and how they  related to 
outcomes attained by the TBI patients (APOE and Outcomes After Traumatic Brain Injury, 
R01NR04801; Mitochondrial Genetics of Recovery after Brain Injury, NR008424; the Brain 
Trauma Research Center (BTRC) grant, 5P50NS30318; Injury Control Research Centers: 
"Evaluating the Impact of Neuroendocrine Hormones on Pathophysiology and Outcomes after 
Traumatic Brain Injury, CIRCL/CDC grant , R49/CCR 323155-03.) 
3.2 SAMPLE  
This study used a convenience sample of 230 participants with severe TBI admitted to a 
level 1 trauma center. The level 1 trauma center at the tertiary care institution admits an average 
of 40 severe TBI patients each year. The subjects were admitted from May 2000- April 2007. All 
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 patients admitted to the NeuroTrauma or Trauma Intensive Care Units were screened for 
eligibility based on the following criteria (according to Health Insurance Portability and 
Accountability Act [HIPAA] regulations since 2003). 
3.2.1 Inclusion criteria:  
1. Age 16-75 years 
2. Initial Glasgow Coma Score (GCS) ≤8 (without the influence of neuromuscular 
blocking agents, alcohol or drug effects)  
3. The presence of an external ventricular drain (EVD) per standard of care for ICP 
monitoring and CSF drainage and sampling 
4. Positive computed tomography (CT) scan for TBI 
5. Proxy, signed written consent from next-of-kin 
3.2.2 Exclusion criteria include:  
1) TBI related to penetrating injury/ open head injuries (gunshot wounds or stab wounds) 
2) Pre-existing neurological conditions.  
Protected populations: prisoners, and persons with mental retardation/ developmental 
disabilities, were not recruited. No participant was excluded based upon, gender, race, or 
ethnicity. Children under the age of 16 were not included in the study because there is 
evidence that children respond differently to TBI than adults (Chenn et al, 2004). 
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 3.3 RATIONALE FOR SAMPLE SIZE 
Rationale:  The sample size was based on available subjects in the data base (with both 
biological samples collected and consented for further genetic testing and outcome measures). 
Multiple post hoc power analyses were preformed with Power Analysis and Sample Size 
software [(PASS) NCCS Statistical Software, Kaysville, Utah, 2008] due to the fluctuation in 
sample sizes. (Refer to table 3-1) Power and effect sizes were calculated for each SNP with a 
primary analysis (full) model analysis conducted in a particular database. 










Trails A 30 27
Trails B 30 27
Bcl-2 Protein Levels 42 37
Neurometabolites 36 36
CBF 17 17
*Generalized mixed model to account for binary nature of the mortality outcome.
Biological/ Clinical Outcomes
Type of Analysis




BCL-2 was dichotomized based on the frequency of the genotype in the database which 
was being analyzed.  Therefore, the homozygous genotype with the least frequency was 
combined with the heterozygotes and compared against the homozygous with the largest 
frequency in the particular database.  
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 The power analyses were based on the dichotomized genotypes for each SNP with a 
primary analysis (full model) for the outcomes indicated in specific aim #1.  While specific aim2 
was more exploratory in nature it would be helpful for future studies to ascertain power and ES 
given the current sample size available. Power and ES are presented for the bcl-2 protein and 
neurometabolite pilot data for specific aim #2. Due to the small sample size of the CBF dataset, 
power was not able to be calculated using PASS 2008 (SAS 9.1 was unable to calculate rho 
which was necessary for the analyses.) ES was able to be calculated for the primary analyses.  
Effect size (ES) was calculated based on the fixed effects estimate of each SNP and 
sigma used in the power analyses. Odds ratios were calculated for the mortality outcome 
variable. Tables of the power and ES analyses were included to illustrate that the power and ES 
for each of the studies fluctuated based upon the SNP that was analyzed (Refer to tables 3-2 to 3-
11). Based on these power calculations, a number of the SNP’s had a large enough sample size to 
reject a false null hypothesis (decreased chance of making a type II error) at least 80% of the 
time.  The ES for some SNP’s were adequate for a number of subjects in the given analysis 
because the degree of difference in the fixed effects estimate was quite large. In contrast, other 
SNP’s would warrant a larger sample size in future studies because the fixed effects estimates 
were quite small between the genotypes. Therefore, in future studies, the sample size is 
dependent on the tagging SNP that will be analyzed. 
3.3.1 Specific Aim #1 
Given a sample size of 141, specific aim #1 detected a power of 0.08 to 0.99 to detect an 
ES (absolute value) of 0.13  to 0.46 in the relationship between BCL-2 genotype and GOS after 
severe TBI at 3, 6, 12, and 24 month outcomes at α= .05 when conducting two-sided hypothesis 
   66
 testing controlling for covariates (age, GCS, gender, race, hypothermia, and hypotension). (Refer 
to table 3-2). 





















Points Sigma Rho Power Beta ES
RS12968517 68 (XX) 73 141 0 (0%) -0.1623 4 1.2288 0.9 0.12605 0.87395 -0.1321
RS17759659 58 (XX) 80 138 3 (2.1%) -0.832 4 1.1385 0.8834 0.99339 0.00661 -0.7308
RS1801018 58 (YY) 82 140 1 (0.7%) -0.7987 4 1.1674 0.8873 0.98642 0.01358 -0.6842
RS1944419 34 (XX 103 137 4(2.8%) 0.3097 4 1.2262 0.8967 0.26427 0.73573 0.25257
RS4941185 52 (XX) 88 140 1 (0.7%) 0.1273 4 1.2326 0.9015 0.08905 0.91095 0.10327
RS7236090 41(XX) 97 138 3 (2.1%) 0.1739 4 1.2314 0.8987 0.12074 0.87926 0.14122
RS949037 42 (YY) 94 136 5 (3.5%) 0.5428 4 1.1906 0.8942 0.7262 0.2738 0.45591
Glasgow Coma Scale (GOS) Power Calculation Data      (n=141)
 
Given a sample size of 141, specific aim #1 had a power of 0.01 to 0.99 to detect an ES 
(absolute value) of 0.12 to 0.72 in the relationship between BCL-2 genotype and DRS after 
severe TBI at 3, 6, 12, and 24 month outcomes at α= .05 when conducting two-sided hypothesis 
testing controlling for covariates (age, GCS, gender, race, hypoxia, seizure, hypothermia, and 
hypotension). (Refer to table 3-3). 
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Points Sigma Rho Power Beta ES
RS12968517 68 (XX) 73 141 0 (0%) 1.4148 4 10.4475 0.9615 0.12624 0.87376 0.1354
RS17756073 73(XX) 64 137 4(2.8%) 1.892 4 10.4952 0.9612 0.18632 0.81368 0.1803
RS17759659 58 (YY) 80 138 3 (2.1%) 6.949 4 9.7933 0.956 0.98698 0.01302 0.7096
RS1801018 58 (YY) 82 140 1 (0.7%) 7.1039 4 9.8786 0.9565 0.98942 0.01058 0.7191
RS1944419 34 (XX 103 137 4(2.8%) -2.5393 4 10.3827 0.9597 0.24072 0.75928 -0.2446
RS4941185 52 (XX) 88 140 1 (0.7%) -1.2376 4 10.4881 0.9613 0.10107 0.89893 -0.1180
RS7236090 41(XX) 97 138 3 (2.1%) -2.3443 4 10.4451 0.9611 0.23053 0.76947 -0.2244
RS949037 42 (YY) 94 136 5 (3.5%) -4.4511 4 10.2176 0.9586 0.68468 0.31532 -0.4356
Disabilty Rating Scale (DRS) Power Calculation Data      (n=141)
 
Given a sample size of 141, specific aim #1 had power of 0.18 to 1.0 to detect an odds 
ratio of 0.412 to 5.051 in the relationship between BCL-2 genotype and mortality after severe 
TBI at 3, 6, 12, and 24 month outcomes at α= .05 when conducting two-sided hypothesis testing 
controlling for covariates (age, GCS, gender, race, hypothermia, hypotension, and seizures). 
(Refer to table 3-4). 
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Points Sigma Rho Power Beta ES
RS12968517 68 (XX) 73 141 0 (0%) 0.5804 4 0.9023 -0.2538 1 0.0000 0.6432
RS17756073 73(XX) 64 137 4(2.8%) 0.0529 4 0.9093 -0.2413 0.25242 0.7476 0.0582
RS17759659 58 (YY) 80 138 3 (2.1%) 1.6195 4 0.9569 -0.2268 1 0.0000 1.6925
RS1801018 58 (YY) 82 140 1 (0.7%) 1.6109 4 0.9371 -0.2444 1 0.0000 1.7190
RS4941185 52 (XX) 88 140 1 (0.7%) -0.2074 4 0.9166 -0.2533 0.99955 0.0004 -0.2263
RS7230970 25 (XX) 114 139 2(1.4%) 0.7371 4 0.9587 -0.2465 1 0.0000 0.7688
RS7236090 41(XX) 97 138 3 (2.1%) -0.0565 4 0.9390 -0.2129 0.18802 0.8120 -0.0602
RS949037 42 (YY) 94 136 5 (3.5%) -0.8862 4 0.9122 -0.2456 1 0.0000 -0.9715
Mortality Power Calculation Data      (n=141)
 
 
Given a sample size of 61, specific aim #1 detected a power of 0.06 to 1.0 and an ES 
(absolute value) of  0.0035  to 0.56  in relation to BCL-2 genotype and NRS-R after severe TBI 
at 3, 6, and 12 month outcomes at α= .05 when conducting two-sided hypothesis testing 
controlling for covariates (age, GCS, gender, race, hypothermia, and seizures). (Refer to table 3-
5). 
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Points Sigma Rho Power Beta ES
RS12454712 32 (YY) 29 61 0 (0%) 2.9552 3 9.6591 0.6584 0.27358 0.7264 0.3060
RS1481031 16 (XX) 44 60 1 (1.6%) -1.1614 3 9.7497 0.6608 0.06731 0.9327 -0.1191
RS17756073 29 (XX) 31 60 1 (1.6%) 0.0331 3 9.5488 0.6551 0.03538 0.9646 0.0035
RS17759659 30 (XX) 31 61 0 (0%) 1.8206 3 9.7677 0.6684 1 0.0000 0.1864
RS1944419 13(XX) 48 61 0 (0%) -1.514 3 9.7679 0.6667 0.08108 0.9189 -0.1550
RS4456611 15(YY) 45 60 1 (1.6%) -4.9777 3 8.8296 0.6073 0.59515 0.4049 -0.5638
RS7236090 19(XX) 41 60 1 (1.6%) 4.2506 3 9.5830 0.6502 0.44638 0.5536 0.4436
Neurobehavioral Rating Scale-Revised (NRS-R) Power Calculation Data      (n=61)
 
Given a sample size of 27, specific aim #1 had power of 0.04 to 0.9 to detect an ES 
(absolute value) of  0.07  to 0.95  in the relationship between  BCL-2 genotype and Trails A after 
severe TBI at 3, 6, and 12 month outcomes at α= .05 when conducting two-sided hypothesis 
testing controlling for covariates (age, GCS, gender, race, and hypothermia). (Refer to table 3-6). 





















Points Sigma Rho Power Beta ES
RS12454712 11(YY) 16 27 0 (0%) 7.4566 3 16.0187 0.4399 0.3233 0.6767 0.4655
RS12968517 15(XX) 12 27 0 (0%) 14.3516 3 15.0280 0.3610 0.9023 0.0977 0.9550
RS1381548 8(YY) 19 27 0 (0%) 12.9308 3 15.1374 0.3694 0.7588 0.2413 0.8542
RS1481031 11(XX) 16 27 0 (0%) 2.4441 3 16.4426 0.4679 0.0684 0.9316 0.1486
RS17756073 15(XX) 12 27 0 (0%) 7.4562 3 15.9141 0.4280 0.3365 0.6635 0.4685
RS17759659 15(XX) 11 26 1 (3.7%) -7.8583 3 16.3884 0.4473 0.3299 0.6701 -0.4795
RS1801018 16(YY) 11 27 0 (0%) -6.4113 3 16.2530 0.4635 0.2409 0.7591 -0.3945
RS3810027 10(XX) 17 27 0 (0%) -9.1309 3 15.7146 0.4116 0.4643 0.5358 -0.5810
RS4941185 10(XX) 17 27 0 (0%) -7.8852 3 15.9665 0.4344 0.3483 0.6517 -0.4939
RS7236090 11(YY) 15 26 1 (3.7%) 8.7143 3 16.1428 0.4340 0.4065 0.5935 0.5398
RS8083946 9(YY) 18 27 0 (0%) -1.172 3 16.4636 0.4681 0.0407 0.9593 -0.0712
Trails A Power Calculation Data      (n=27)
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 Given a sample size of 27, specific aim #1 had a power of 0.04 to 0.69 to detect an ES 
(absolute value) of  0.0009  to 0.896  in the relationship BCL-2 genotype and Trails B after 
severe TBI at 3, 6, and 12 month outcomes at α= .05 when conducting two-sided hypothesis 
testing controlling for covariates (age, GCS, gender, race, and hypothermia). (Refer to table 3-7). 





















Points Sigma Rho Power Beta ES
RS12454712 11(YY) 16 27 0 (0%) 26.9143 3 43.9547 0.6641 0.4265 0.5735 0.6123
RS12968517 15(XX) 12 27 0 (0%) -5.8154 3 45.8652 0.6878 0.0557 0.9443 -0.1268
RS1381548 8(YY) 19 27 0 (0%) 37.5431 3 41.8842 0.6267 0.6893 0.3107 0.8964
RS1481031 11(XX) 16 27 0 (0%) 23.0362 3 44.7975 0.6753 0.3168 0.6832 0.5142
RS17756073 15(XX) 12 27 0 (0%) 32.2942 3 42.2470 0.6318 0.6226 0.3774 0.7644
RS17759659 15(XX) 11 26 1 (3.7%) -0.04064 3 47.1284 0.6918 0.0251 0.9749 -0.0009
RS1801018 16(YY) 11 27 0 (0%) -14.458 3 45.4778 0.6841 0.1477 0.8523 -0.3179
RS3810027 10(XX) 17 27 0 (0%) 1.3776 3 45.9581 0.6893 0.0304 0.9696 0.0300
RS4941185 10(XX) 17 27 0 (0%) -16.15 3 45.2483 0.6804 0.1766 0.8234 -0.3569
RS7236090 11(YY) 15 26 1 (3.7%) 7.3982 3 46.6185 0.6943 0.0653 0.9347 0.1587
RS8083946 9(YY) 18 27 0 (0%) 4.7974 3 45.9174 0.6889 0.0472 0.9528 0.1045
Trails B Power Calculation Data      (n=27)
 
3.3.2 Specific Aim #2: 
3.3.2.1 Bcl-2 Protein 
Given a sample size of 37, specific aim #2 had a power of 0.03 to 0.29 to detect an ES 
(absolute value) of  0.01  to 0.24  in the relationship BCL-2 genotype and bcl-2 protein with 
outliers after severe TBI over days1-6 post injury at α= .05 when conducting two-sided 
hypothesis testing controlling for covariates (age, GCS, gender, race, hypoxia, and seizure). 
(Refer to table 3-8). 
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Time Points  Sigma Rho Power Beta ES
RS1026825 11 30 41 6 (14.3%) 0.9364 6 8.515280383 0.0995 0.0909 0.9091 0.109967
RS12454712 17 25 42 5(11.9%) 1.8061 6 8.406241729 0.0872 0.2868 0.7132 0.2148523
RS1481031 18 23 41 5(11.9%) 1.4853 6 8.416923428 0.0895 0.2066 0.7934 0.1764659
RS17756073 22 19 41 6 (14.3%) 1.4255 6 8.539882903 0.0829 0.1943 0.8057 0.1669227
RS4456611 9 32 41 1 (2.4%) 2.0448 6 8.472260619 0.0924 0.2533 0.7467 0.2413523
RS7236090 12 28 40 7 (16.7%) 1.5658 6 8.602435702 0.0647 0.2028 0.7972 0.1820182
RS899968 14 26 40 7 (16.7%) -0.0828 6 8.582767619 0.1029 0.02858 0.9714 -0.009647
Bcl-2 Protein WITH Outliers Power Calculation Data      (n=42)
 
Given a sample size of 37, specific aim #2 had a power of 0.05 to 0.99 to detect an ES of  
0.06  to 0.84  in the relationship BCL-2 genotype and bcl-2 protein without outliers after severe 
TBI over days1-6 post injury at α= .05 when conducting two-sided hypothesis testing controlling 
for covariates  (age, GCS, gender, race, hypoxia, and seizure). (Refer to table 3-9). 




















Time Points  Sigma Rho Power Beta ES
RS1026825 11 30 41 6 (14.3%) 1.2422 6 5.062153692 0.3395 0.1784 0.8217 0.2453896
RS12454712 17 25 42 5(11.9%) 2.6104 6 4.893648945 0.2876 0.7587 0.2413 0.5334261
RS1481031 18 23 41 5(11.9%) 2.4875 6 4.894588849 0.2904 0.7144 0.2856 0.5082143
RS17756073 22 19 41 6 (14.3%) 2.924 6 4.930801152 0.2739 0.8538 0.1462 0.5930071
RS4456611 9 32 41 1 (2.4%) 0.6465 6 5.023166332 0.3294 0.0740 0.9260 0.1287037
RS7236090 12 28 40 7 (16.7%) 3.926 6 4.692184992 0.2058 0.9865 0.0136 0.8367104
RS899968 14 26 40 7 (16.7%) 0.326 6 5.060800332 0.3445 0.04731 0.9527 0.0644167
Bcl-2 Protein WITHOUT Outliers Power Calculation Data      (n=42)
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 3.3.2.2 Neurometabolites 
Given a sample size of 36, specific aim #2 had a power of 0.05 to 0.54 to detect an ES 
(absolute value) of 0.07  to 0.43  in the relationship BCL-2 genotype and lactate concentrations 
over days1-5 post injury at α= .05 when conducting two-sided hypothesis testing controlling for 
covariates (age, GCS, gender, and hypothermia). (Refer to table 3-10). 
Given a sample size of 36, specific aim #2 had a power of 0.07 to 0.97 to detect an ES 
(absolute value) of  0.14  to 1.29  in the relationship BCL-2 genotype and pyruvate 
concentrations over days1-5 post TBI at α= .05 when conducting two-sided hypothesis testing 
controlling for covariates (age, GCS, gender, and hypothermia). (Refer to table 3-10). 
Given a sample size of 36, specific aim #2 had a power of 0.06 to 0.86 to detect an ES 
(absolute value) of  0.097  to 0.75  in the relationship BCL-2 genotype LP ratio over days 1-5 
post TBI at α= .05 when conducting two-sided hypothesis testing controlling for covariates (age, 
GCS, gender, and hypothermia). (Refer to table 3-10). 
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Points  Sigma Rho Power Beta ES
RS1026825 11 25 36  0 (0%) -4906.3 5 13219.3041 0.2114 0.3930 0.6070 -0.3711
RS17759659 7 28 35 1 (2.8%) -6261.9 5 13294.3597 0.2097 0.45147 0.5485 -0.471
RS1801018 6 29 35 1 (2.8%) -6450.3 5 13381.7039 0.209 0.42608 0.5739 -0.482
RS1944419 12 22 34 2 (5.6%) -2795.1 5 13748.8181 0.2316 0.14748 0.8525 -0.2033
RS3810027 18 17 35 1 (2.8%) 5682.92 5 13303.0072 0.2148 0.54438 0.4556 0.42719
RS4941185 12 23 35 1 (2.8%) 882.37 5 13587.8622 0.2424 0.04752 0.9525 0.06494
RS7236090 10 26 36  0 (0%) 2233.58 5 13397.7610 0.2355 0.10729 0.8927 0.16671
RS8083946 19 17 36  0 (0%) 4873.33 5 13204.1660 0.2159 0.44072 0.5593 0.36908
RS949037 14 21 35 1 (2.8%) -961.15 5 13661.2591 0.2363 0.05123 0.9488 -0.0704
RS1026825 11 25 36  0 (0%) 27.8983 5 73.2551 0.6623 0.2333 0.7667 0.38084
RS17759659 7 28 35 1 (2.8%) 83.042 5 64.5219 0.556 0.96659 0.0334 1.28704
RS1801018 6 29 35 1 (2.8%) 69.3412 5 69.9734 0.6177 0.75553 0.2445 0.99096
RS1944419 12 22 34 2 (5.6%) 28.5488 5 71.7020 0.646 0.258 0.7420 0.39816
RS3810027 18 17 35 1 (2.8%) 25.3878 5 72.6595 0.6504 0.22884 0.7712 0.34941
RS4941185 12 23 35 1 (2.8%) -48.843 5 71.0163 0.6339 0.63187 0.3681 -0.6878
RS7236090 10 26 36  0 (0%) 39.4457 5 71.8727 0.6486 0.41278 0.5872 0.54883
RS8083946 19 17 36  0 (0%) 10.092 5 74.1601 0.6705 0.06878 0.9312 0.13608
RS949037 14 21 35 1 (2.8%) 69.1464 5 65.5739 0.5836 0.96266 0.0373 1.05448
RS1026825 11 25 36  0 (0%) -20.463 5 45.8091 0.2223 0.5194 0.4806 -0.4467
RS17759659 7 28 35 1 (2.8%) -34.001 5 45.0379 0.1864 0.85625 0.1438 -0.7549
RS1801018 6 29 35 1 (2.8%) -31.449 5 45.6929 0.1974 0.72746 0.2725 -0.6883
RS1944419 12 22 34 2 (5.6%) -12.335 5 47.6984 0.2442 0.20785 0.7922 -0.2586
RS3810027 18 17 35 1 (2.8%) 17.7995 5 46.6770 0.2429 0.43472 0.5653 0.38133
RS4941185 12 23 35 1 (2.8%) 7.5273 5 47.2491 0.2574 0.10423 0.8958 0.15931
RS7236090 10 26 36  0 (0%) 4.522 5 46.8181 0.2583 0.06022 0.9398 0.09659
RS8083946 19 17 36  0 (0%) 16.3218 5 46.0952 0.2368 0.39728 0.6027 0.35409
RS949037 14 21 35 1 (2.8%) -11.875 5 47.1140 0.2379 0.21456 0.7854 -0.252
Lactate       (n=36)
Pyruvate    (n=36)
LP Ratio      (n=36)
Neurometabolite Power Calculation Data 
 
 
3.3.2.3 Cerebral Blood Flow 
Specific aim #2, CBF in relation to BCL-2 genotype over days 1-5 after injury, was a 
pilot study based on a sub-sample of 17 subjects ES (absolute value)  of 0.105  to 1.46 was 
determined for the right hemisphere CBF.  (Refer to table 3-11). 
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 Specific aim #2, CBF in relation to BCL-2 genotype over days 1-5 after injury, was a 
pilot study based on a sub-sample of 17 subjects ES (absolute value)  of 0.25  to1.69  was 
determined for the left hemisphere CBF.  (Refer to table 3-11). 
Specific aim #2, CBF in relation to BCL-2 genotype over days 1-5 after injury, was a 
pilot study based on a sub-sample of 17 subjects ES (absolute value)  of 0.14  to 1.56 was 
determined for the global CBF.  (Refer to table 3-11). 



















Estimate  Sigma ES
RS1026825 4 13 17 0 (0%) 12.76 13.7996 0.92466
RS12454712 7 10 17 0 (0%) 10.999 14.9211 0.73714
RS12968517 6 11 17 0 (0%) -10.667 14.7037 -0.7255
RS1381548 XX 3 10 13 4 (23.5%) -16.633 12.2233 -1.3608
RS1381548 YY 3 10 13 4 (23.5%) 15.73 10.7703 1.46049
RS1481031 10 7 17 0 (0%) 15.415 15.3307 1.0055
RS17756073 9 8 17 0 (0%) -15.51 12.6463433 -1.2264
RS1801018 6 11 17 0 (0%) 11.881 12.6976376 0.93569
RS3810027 6 10 16 1 (5.9%) 1.5781 14.9843251 0.10532
RS4456611 XX 5 10 15 2 (11.8%) -9.4863 12.5753728 -0.7544
RS4456611 YY 5 10 15 2 (11.8%) 10.687 11.5896506 0.92212
RS4941185 5 12 17 0 (0%) -20.845 11.5684917 -1.8019
RS7236090 8 7 15 2 (11.8%) 13.142 14.8502525 0.88497
RS8083946 5 12 17 0 (0%) 11.358 15.645127 0.72598
RS899968 5 10 15 2 (11.8%) 16.296 12.0536302 1.35196
RS949037 8 9 17 0 (0%) 7.2886 14.3150271 0.50916
RS1026825 4 13 17 0 (0%) 11.811 12.3887 0.95337
RS12454712 7 10 17 0 (0%) 8.4772 13.7546 0.61632
RS12968517 6 11 17 0 (0%) -13.15 13.3417 -0.9856
RS1381548 XX 3 10 13 4 (23.5%) -17.822 10.5347 -1.6917
RS1381548 YY 3 10 13 4 (23.5%) 14.951 9.4444 1.58306
RS1481031 10 7 17 0 (0%) 13.625 14.8074 0.92015
RS17756073 9 8 17 0 (0%) -15.234 11.6038787 -1.3128
RS1801018 6 11 17 0 (0%) 11.301 11.6730459 0.96813
RS3810027 6 10 16 1 (5.9%) 3.3574 13.6213068 0.24648
RS4456611 XX 5 10 15 2 (11.8%) -6.0274 11.4092068 -0.5283
RS4456611 YY 5 10 15 2 (11.8%) 8.8227 10.8295891 0.81468
RS4941185 5 12 17 0 (0%) -18.369 11.1099055 -1.6534
RS7236090 8 7 15 2 (11.8%) 15.048 13.9183332 1.08116
RS8083946 5 12 17 0 (0%) 9.4463 13.913303 0.67894
RS899968 5 10 15 2 (11.8%) 12.631 12.7671453 0.98934
RS949037 8 9 17 0 (0%) 6.2218 13.2815662 0.46845
RS1026825 4 13 17 0 (0%) 12.174 13.0227 0.93483
RS12454712 7 10 17 0 (0%) 9.5863 14.2531 0.67258
RS12968517 6 11 17 0 (0%) -11.11 13.9617 -0.7957
RS1381548 XX 3 10 13 4 (23.5%) -17.5 11.3146 -1.5467
RS1381548 YY 3 10 13 4 (23.5%) 15.633 10.0255 1.55933
RS1481031 10 7 17 0 (0%) 14.914 14.9057 1.00056
RS17756073 9 8 17 0 (0%) -15.99 11.8249736 -1.3522
RS1801018 6 11 17 0 (0%) 12.028 11.9239255 1.00873
RS3810027 6 10 16 1 (5.9%) 1.9944 14.2098557 0.14035
RS4456611 XX 5 10 15 2 (11.8%) -8.512 11.8241279 -0.7199
RS4456611 YY 5 10 15 2 (11.8%) 10.37 10.9936345 0.94327
RS4941185 5 12 17 0 (0%) -19.95 11.1539231 -1.7886
RS7236090 8 7 15 2 (11.8%) 14.095 14.3062923 0.98523
RS8083946 5 12 17 0 (0%) 9.5053 14.5900651 0.65149
RS899968 5 10 15 2 (11.8%) 15.194 12.1519546 1.25033
RS949037 8 9 17 0 (0%) 6.9612 13.6348817 0.51054
CBF Right Hemisphere   (n=17)
CBF Left Hemisphere   (n=17)
CBF Global   (n=17)
Cerebral Blood Flow (CBF) Effect Size (ES) Calculation Data
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 3.4 SETTING 
Subjects were recruited from a level 1 trauma center in a tertiary care institution; the 
University of Pittsburgh Medical Center (UPMC), Pittsburgh Pennsylvania. The acute care phase 
of this study was conducted in the 10 bed Neurotrauma or 10 bed Trauma Intensive Care Units 
over the first 5 days after injury (over the first 6 days of injury for the bcl-2 protein data 
collection only). The outcome data were collected at 3, 6, 12, and 24 months intervals post 
injury; either at UPMC outpatient neurosurgery clinic or the participant’s home/ extended care 
facility. Phone interviews were conducted with either the participant or the primary care giver in 
the event that distance prevented a face to face visit or participant/ caregivers did not want study 
staff members in their home.  All outcome data was collected by a trained neuropsychological 
technician under the supervision of a neuropsychologist. 
3.5 RECRUITMENT 
The parent studies [APOE and Outcomes After Traumatic Brain Injury, R01NR04801; 
Mitochondrial Genetics of Recovery after Brain Injury , NR008424; Brain Trauma Research 
Center (BTRC) grant, 5P50NS30318 and Injury Control Research Centers CIRCL/CDC grant, 
R49/CCR 323155-03] utilized a convenience sample of subjects that were admitted to the UPMC 
for severe TBI. The nurse researchers on call were contacted by the Neurosurgical resident on 
call upon the potential admission of a patient with a severe TBI. During the screening procedure 
potential participants were identified based on the previously described study criteria. Once a 
potential participant was identified, the nurse researcher approached a proxy to describe the 
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 study, aims, data collection procedures, risks and benefits of participation, and obtain informed 
consent.  Proxy consent was obtained from next-of-kin for the initial consent due to the fact that 
all of the participants were in a severe coma with GCS≤8. Assent was obtained once the 
individual’s condition permitted. Both the parent studies and this study were reviewed and 
approved by the University of Pittsburgh Institutional Review Board (IRB) [IRB# 971212; IRB 
#0607083; see appendix B for this study’s IRB approval letter]. Protected populations; children 
under 16, prisoners, and persons with mental retardation/ developmental disabilities, were not 
recruited. No participant was excluded based upon, gender, race or ethnicity. 
3.6 STANDARD MEDICAL CARE 
All potential subjects were admitted to UPMC with a diagnosis of severe TBI within 48 
hours of injury. All participants had a routine CT scan on admission and a GCS≤8 without the 
effects of alcohol, toxins or medications. Patients received aggressive medical treatment as 
outlined by “The Guidelines for the Management of Severe Head Injury” produced by the Brain 
Trauma Foundation and endorsed by the American Association of Neurological Surgeons 
(Bullock et al., 1996). As part of this guideline, external ventricular drains (EVD’s) were placed 
into all participants as part of routine care. In May (2007) the updated guidelines for the 
management of severe traumatic brain was published (Povlishock, 2007). All of the patients in 
this study were admitted from May 2000- April 2007.  
Blood levels were drawn on admission for alcohol, drug, and other toxin levels. Upon 
admission (usually placed in the field) all patients had a cervical collar for immobilization. Due 
to coma state, GCS≤8, therefore unable to protect airway, all participants are on mechanical 
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 ventilation at admission. All of the severe TBI patients were paralyzed and sedated via 
intravenous medications. Train of Four was used to assess level of the medicated state. 
Neurological assessments were performed every 1 hour for the first 24 hours and then every 2 
hours during the participants ICU admission. The paralytics and sedative medications were held 
for 15 minutes, every 1 to 2 hours in order to perform the neurological assessments, which 
included GCS. All of the patients as part of standard of care had an arterial blood line, from 
which blood pressure was continuously measured. All participants were monitored continuously 
for physiological parameters and treatment goals: intracranial pressure (ICP) [≤20 mmHg], 
cerebral perfusion pressure (CPP) [≥60 mmHg], arterial blood pressure (ABP) [≥90 mmHg], 
central venous pressure (CVP) [>7], pulse oximetry, respiratory rate, heart rate and rhythm, and 
core temperature. These variables were documented every 1-2 hours and prn.  The protocol for 
the standard of practice which EVD’s were drained changed over the course of time which the 
data were collected. EVD draining by venting for ICP >20mmHg was the practice from 2000-
2002. EVD passive drainage method was utilized from 2002-2008. Nursing care; participant to 
nurse ratio was 1:1 or 2:1 depending on patient’s condition. Some of the patients received 
hypothermia treatment which was controlled for in the analysis. The subjects enrolled from May 
2002 to July 2005 were cooled to core temperature 33°C. From November 2005 to present 
subjects are cooled to core temperature of 32.5- 34°C. The time to target reach the target 
temperature was 6 hours for a duration of 48 hours for the cooling intervention. The modalities 
of cooling were; ice bags to groin, armpits, cooling 'blankets' to abdomen/thoracic area/thighs 
and iced saline lavage (via NG tube). Hypothermia would not change the participants BCL-2 
genotypes however, it may alter response to therapy in a gene specific manner. 
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 3.7 DATA COLLECTION 
3.7.1 Summary of acute care phase data collection procedures in the parent study 
In the acute care phase, data was collected by project personnel over the first 5 days after 
initial injury (6 days for bcl-2 protein levels). Demographic and medical condition data was 
collected as part of the study protocol on data collection sheets. The data was electronically 
transmitted directly into an automated data entry and verification system (Teleform) or recorded 
on a form that was hand entered and verified. Medical records, electronic medical records, and 
neurological assessments were downloaded off of the medical center electronic documentation 
computer system. The data was recorded into the data base. Data from the parent study data base 
was analyzed in relation to the BCL-2 genotypes.  
3.7.1.1 Collection of Bagged CSF Samples 
As standard medical care and as an inclusion criterion, each participant in the study had 
an EVD in for routine care. The EVD was zeroed and calibrated every 1-2 hours and prn. The 
medical protocol for EVD venting was subject to the chief of neurosurgery at the time the 
specimen was collected. Therefore some of the CSF samples were collected under a continuous 
drainage protocol (EVD at 20 mm Hg above midbrain) and others under a venting protocol 
(EVD at 20 mm Hg above midbrain). The venting protocol required the EVD to remain closed 
for ICP’s ≤ 20 mmHg and vented for 5 minutes should ICP’s rise > 20 mmHg. The elevation of 
the ICP and venting protocol allows for CSF to collect in the drainage bag to gravity. The EVD 
venting protocol changes would not affect the BCL-2 genotype data but could impact 
physiologic data parameters being investigated by this study. The research staff changed the 
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 EVD collection bag every 12 hours using sterile technique as per UPMC protocol. 
Approximately 30 ml of the bag collected CSF was aliquoted into five- 1 ml tubes and five -5 ml 
tubes every 12 hours. The amount of CSF drainage collected every 12 hours was based on CSF 
available after drainage based on the EVD venting protocol. DNA obtained from CSF was 
analyzed for patients for whom blood samples were not available for genotyping BCL-2. This 
process of CSF collection was also utilized in the collection of CSF samples for Bcl-2 protein 
levels. Samples were stored via measurement specific protocols. 
3.7.1.2 Collection of Fresh CSF Samples 
Neurometabolites (lactate, pyruvate, and LP ratio) required the analysis of fresh CSF. 
Based on the procedure of the parent study; the CSF samples were obtained by turning the 
stopcock on the ventriculostomy catheter closest to the patient ; turning the stopcock off to the 
patient; aseptically cleansing the needle insertion port with betadine for 5 minutes per hospital 
protocol; inserting a needle into the port and withdrawing the CSF (3cc’s over 3 minutes) from 
the tubing into a sterile syringe; injecting the CSF into a tube labeled with the patient 
identification number, date, and time of fluid removal and placed in a -80’C degree freezer. The 
samples were thawed and run in batches for lactate and pyruvate concentrations.  
3.7.1.3 Collection of Blood Samples 
Trained research personnel draw 1 purple top tube (EDTA) of blood (approximately 3 
ml) from the participant’s arterial line each morning of the first 5 days post injury. The specimen 
was processed within 48 hours for extraction of the buffy coat and plasma. DNA extracted from 
blood specimens was utilized for BCL-2 genotyping and was used in the genotyping of the 
APOE data.  
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 3.7.1.4 CBF 
Based upon the parent study protocol; Xenon computed topography (XeCT) CBF 
measurements were made using standard commercial CT (computed topography) hardware and 
software scanning system requires for gas delivery and CBF calculations in a subset of subjects. 
Patients were transported from the emergency department or NTICU to the Radiology 
department on days 1, 3, and 5 for routine XeCT CBF measurements when medically stable for 
transport.  XeCT CBF data is not available on all subjects due to medical instability and changes 
in parent study protocol in 2002. All patients were mechanically ventilated using a volume 
ventilator and paralyzed and sedated. Patients were ventilated using a bag –valve mask during 
transport to CT and carbon dioxide was monitored and reached a steady state prior to the scan. 
The arterial pressure was continuously monitored with an intra-arterial catheter attached to a 
pressure transducer prior to and following the procedure. The peripheral arterial oxygen 
saturation was monitored continuously with a pulse oximeter and the end-tidal carbon dioxide 
was monitored and recorded during the procedure. 
After patients were positioned within the scanner along the orbitomental plane, the head 
was immobilized within a vacuum activated cranial mold (Olympic Medical, Seattle, WA, 
U.S.A.). Two baseline scans were conducted consisting of two or three axial planes 5 cm thick 
and 20 cm apart. Four to six enhanced scans were obtained at each of three levels following 
delivery of a mixture of 28% stable xenon and 40% oxygen (XeSCAN: Linde Medical Gases 
Somerset, NJ, U.S.A.) via the ventilator for 4.5 minutes. The end-tidal Xenon concentration was 
recorded by a thermoconductivity analyzer. CBF was measured and calculated from sequential 
CT voxels (series of enhancement values for each voxel 1 x 1 x 10mm3 as a function of time 
(based on a modified Kety equation assuming a single compartment). Approximately 25,000 
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 CBF values were calculated for each CT slice and the image was analyzed as described by Gur et 
al., (1982) and Linskey, et al. (1992). The blood flow was averaged within 2 cm circular regions 
of interest (ROI), by hemisphere and total global flow including white and gray matter. Standard 
of care in our institution was for a Xe/CT CBF to be conducted on Days 1, 3, and 5 as part of this 
protocol. 
3.7.2 Summary of longitudinal outcome phase data collection procedures  
The battery of neuropsychological testing was conducted with each participant at 3, 6, 12, 
and 24 months post TBI. The tests were conducted by trained neuropsychological technician, 
under the direction of a neuropsychologist, in a face to face visit; either at the outpatient 
neurosurgical clinic of the medical center, the participants’ home or rehabilitation setting or via 
phone interview as previously described. 
3.8 MEASUREMENT 
The independent variable in this study for both specific aims #1 and #2 was BCL-2 
genotypes in subjects with severe TBI. The dependent variables for specific aim #1 were DRS, 
GOS, and mortality at 3, 6, 12, and 24 months after injury. NRS-R, Trails A, and Trails B, at 3, 
6, and 12 months post injury. The dependent variables for specific aim #2 are biological/ clinical 
data (bcl-2 protein, neurometabolites [lactate, pyruvate, and LP ratio] and CBF). The covariates 
were age, GCS, gender, race, hypothermia versus normothermia. Some of the sub-studies 
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 allowed for additional documented covariates of hypoxia, hypotension, and seizure activity to be 
added to the statistical models. 
3.8.1 Independent Variable: BCL-2 Genotypes 
3.8.1.1 DNA Extraction from CSF 
DNA extraction was completed by the Conley lab as part of the parent study. The 
following is the protocol which the Conley lab used.  
CSF extraction was conducted using QiAMP midi DNA Kits (Qiagen). The frozen CSF 
specimens were quick thawed in small batches. Into a 15 ml conical tube 2 ml of CSF were 
placed. To the CSF,  200 µl of Protease was added.  Then 2.4 ml of Buffer AL were added and 
mixed thoroughly by vortexing 3X 5 seconds each time. The mixture was then incubated at 70ºC 
for 10 minutes. After the incubation period 2 ml of 96-100% ethanol (ETOH) was added and 
mixed by vortexing. This was done to separate DNA out from other protein. Half of the solution 
was then transferred to Midi column resting in a 15 ml conical tube. The tube was then 
centrifuged at 3000 rpm for 3 minutes. After this process the column was removed from the tube 
and the filtrate was discarded. The column was placed back into the tube and the rest of the 
solution into the column. The tube was again centrifuged at 3000 rpms for 3 minutes.  The 
column was then removed and the filtrate was discarded. The column was returned to the tube 
and 2ml of buffer AW1 was added to the column and centrifuged at 5000 rpm for 1 minute. 
After this process 2 ml of buffer AW2 was added to the column and centrifuged for 15 minutes. 
The column was then placed in a clean 15 ml conical tube and the previous conical tube was 
discarded with wash buffers. To the column 300µl of buffer AE was added then incubated at 
room temperature for 5 minutes, then centrifuged at 5000 rpm for 5 minutes. The 300µl of buffer 
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 AE that was spun down was reloaded and incubated for 5 minutes and centrifuged for 5 minutes. 
The next step was to load 300µl of fresh AE buffer into the column and incubated for 5 minutes 
and centrifuged for 5 minutes. The DNA extraction was then placed into 1.5 ml tube with the 
appropriate UID number and stored at 4°C.  
3.8.1.2 DNA Extraction from Blood 
DNA extraction was completed by the Conley lab as part of the parent study. The 
following is the protocol which the Conley lab used.  
The 3ml blood tubes drawn from the participant were centrifuged at 2500 rpm for 5 
minutes, the buffy coat was then removed, 1ml of a protective freezing solution added, and 
frozen in 50 ml conical tubes at -20ºC until batch extraction. The buffy coat specimens were 
quick thawed in small batches. Into each tube, 3 ml of Lysis solution was placed. The tubes were 
then vortexed and via transfer pipette, contents of the tubes were transferred to a labeled 15 ml 
conical tube. To the tubes 200 µl of 10% SDS was added along with 500µl of Proteinase K 
solution ( 9 ml batch solution made consists of 900 µl of 10% SDS; 36µl of 0.5 M EDTA; 18mg 
of Proteinase K; and 8.1 ml of sterile water.)  The tubes were covered with parafilm and placed 
in a 37ºC rotating oven overnight to digest. The tubes were removed from the oven and 1 ml of 
6M (saturated) NaCl was added per tube and shaken 15 seconds until foamy. The tubes were 
then centrifuged 15 minutes at 2500 rpms.  The supernatant was then transferred to labeled 15 ml 
conical tubes. Then absolute ETOH, at 2X the volume of the supernatant, was added and 
inverted until the DNA precipitated out of the solution. The DNA was removed with sterile loops 
and placed in labeled flip top tubes. To the tubes, 70% ETOH was added to cover the DNA. The 
tubes were then microfuged for 10 minutes at the 14 setting. The ETOH was then pippetted off. 
The tubes were then places in a 37ºC oven until the ETOH evaporated off. Added to each tube 
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 was 1 ml of 1X TE buffer. The tubes were then sealed with parafilm and taped to the sides of 
wheels in the rotating oven. The tubes were allowed to rotate until the DNA pellet goes into 
solution. DNA extracted from the buffy coat of the blood was stored at 4° C. 
 
3.8.1.3 Procedure for BCL-2 Genotype Collection 
The International HapMap Project is a partnership of scientists and funding agencies 
from Canada, China, Japan, Nigeria, the United Kingdom and the United States to develop a 
public resource that assists researchers in finding genes associated with human disease and 
response to pharmaceuticals. Based on HapMap data (April, 2007) there were 20 high priority 
tagging single nucleotide polymorphisms (SNPs) for the BCL-2 gene [(RS= reference SNP 
identification number): RS1026825, RS12454712, RS12968517, RS1381548, RS1481031, 
RS17756073, RS17759659, RS1801018, RS1944419, RS3810027, RS4456611, RS4941185, 
RS7230970, RS7236090,  RS8083946, RS899968, RS949037]. For many of the currently 
chosen SNPs, TaqMan® assays on demand were already available through Applied Biosystems 
Incorporated (ABI).  The SNPs for assays that were not available off the shelf were obtained via 
custom order by ABI design service. ABI was unable to make a successful assay for RS7231914, 
RS18089538, and RS2850762. Therefore this study analyzed the DNA of the eligible subjects 
for 17 tagging SNP’s. The criterion used in the selection of the tagging SNP’s was a minor allele 
frequency (MAF) of ≥30% and r2≥.80. The tagging SNP’s simply tags the haplotype block and 
does not address potential function capabilities. The haplotype block includes sizable regions 
over which there is little evidence for historical recombination and within which only a few 
common haplotypes are observed. The boundaries of blocks and specific haplotypes they contain 
are highly correlated across populations (Gabriel, S. et al., 2002; Micklos et al., 2003). Tagging 
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 SNP’s with a MAF <30% were not examined at this time because of the low prevalence in the 
population of the minor allele and limitations of our available sample size.  
An ABI Prism® 7000 Sequence Detection System was used to conduct allele 
discrimination assays using TaqMan® assays.  This is a highly automated, high throughput 
genotyping method for SNPs.  Primers flank each polymorphism and polymerase chain reaction 
(PCR) is conducted using subject DNA. The main difference between TaqMan® PCR and 
traditional PCR is the use of a probe that is labeled with a reporter and a quencher dye that 
recognizes a specific allele of a SNP.  Each allele of a SNP has its own probe with its own 
reporter dye (See Appendix C).  If the subject’s DNA is homozygous for one allele of the SNP, 
only the probe for that allele will hybridize and only the reporter dye for that allele will be 
liberated and measured by the ABI Prism® 7000 Sequence Detection System.  A heterozygote 
will have both probes hybridize and both reporter dyes measured.  Using this method, each SNP 
can be genotyped accurately and quickly. For each subject, 200ng of DNA was utilized for each 
assay.   
BCL-2 was dichotomized based on the frequency of the genotype in the database which 
was being analyzed.  Therefore, the homozygous genotype with the least frequency was 
combined with the heterozygotes and compared against the homozygous with the largest 
frequency in the particular database.  
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 3.8.2 Dependent Variables 
3.8.2.1 Dependent Variable: Bcl-2 Protein 
Bcl-2 protein concentration analyses were performed by the Wagner research lab. Based 
upon the protocol in the parent study; CSF was passively and continuously drained from EVD 
for 12 hours time periods.  CSF collection bags were collected least twelve time period following 
injury (fewer time periods if the EVD was removed with in this six day window due to the 
patient's improvement or death).  Bagged ventricular CSF was refrigerated and central processed. 
Samples were then centrifuged at 3000 rpm for 10 minutes and aliquoted.  Prior to analysis, 
samples were stored at -80 degrees Celsius until analysis. The concentrations of Bcl-2 protein 
were determined by using a commercially available enzyme linked immuno sorbent assay 
(ELISA) kit [EMD Chemicals Inc., Darmstadt, Germany].  ELISAs were performed according to 
the instructions which accompany the kit. The detection limit for the Bcl-2 kit used is up to 100 
U/mL.  All (100%) of the samples were analyzed in duplicate. 
 
3.8.2.2 Dependent Variable: CBF 
Xenon CT scan:  Cerebral blood flow was typically measured on days 1, 3, and 5 using 
stable Xenon CT (Xe/CT) scan methodology.  A baseline CT scan was obtained.  Medical-grade 
xenon gas (28%) mixed with 40% oxygen (XeScan stable xenon in oxygen USP, Spectra Gas) 
was administered via the endotracheal tube for 4.3 minutes, during which time rapid sequential 
CT scanning of four pre-selected levels of the brain was performed.  Xenon concentrations of 
expired gas were also monitored continuously.  The data obtained was used in conjunction with 
time-dependent xenon concentrations measured in tissue to derive blood flow (mL/100 g 
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 brain/min) by solving the Kety-Schmidt equation for each voxel the of CT image (1x1x10 
mm3=24,000 voxels/CT level).  Regions of interest (ROIs) were plotted on the scans in each of 
10 vascular territories for both sides.  The blood flow measurement was calculated for each ROI, 
each hemisphere and the entire brain.  
 
3.8.2.3 Dependent Variable: Neurometabolites 
Lactate, pyruvate, and lactate/ pyruvate ratio.  Fresh CSF specimens were thawed in 
batches and processed for analysis of neurometabolites (lactate,  pyruvate, and lactate/ pyruvate 
ratio) utilizing high pressure liquid chromatography (HPLC). Lactate (µmol concentration) and 
pyruvate (µmol concentration) were measured by HPLC using an ultraviolet detector (Model 
486, Waters Corporation, Boston, MA) at 214 nm wavelength.  Separation was achieved with a 
programmable autosampler that injected the sample onto a polymeric guard column in line with 
an organic acids column that constantly runs a solution of .1N sulfuric acid at a rate of 0.8 
ml/min (Varian, Walnut Creek, CA).  Peak areas were identified with micro-computer-based 
control Enpower software (Water corporation) with samples calibrated from standard curves of 
known standards. Lactate/ pyruvate ratio was calculated via formula driven excel spread sheet by 
dividing lactate into pyruvate based on the lactate and pyruvate generated/entered by 
Millennium, the system that drives the HPLC. 
3.8.2.4 Dependent Variable: Neuropsychological Outcome Measures 
Global Functional Outcomes 
Glasgow Outcome Scale (GOS): The GOS, a clinical observation scale, categorizes 
global functional outcomes into five levels. It is an ordinal level of measurement: 1- Death, 2-
   88
 Persistent vegetative state, 3 - Severe disability, 4 - Moderate disability, 5 - Good recovery 
(Jennett & Bond, 1975; Jennett, 1976).  A consensus conference in 1998 recommended 
evaluating basic functional assessment at 3, 6, and 12 months following a TBI (Wilson, 
Pettigrew & Teasdale, 1998).  Interrater reliability has been reported from 68 - 95% with kappa 
values from .62 to .79 (Gennarelli et al., 1983; Maas et al., 1983) and correlates well with 
severity of illness and other measures of function such as DRS (Hall, Cope, & Rappaport, 1985). 
Interrater reliability is within the acceptable range when there is adherence to assessment 
guidelines, administration of a structured interview, and training of examiners (Wilson et al, 
1998). (See Appendix D).  The GOS has wide acceptance and established validity (Jennett & 
Bond, 1975; Maas et al., 1983).  
 
Disability Rating Scale (DRS) 
The DRS was designed to assess disability in patients recovering from severe TBI as they 
progress from severe coma to community reintegration (Rappaport, Hal, Hopkins, et al., 1982). 
There are 8 items in the measurement tool. Items 1 to 3 are identical to GCS, except for the 
points allotted. Items 4-6 assess cognitive ability to complete self care activities; knowing how 
and when to attend to feeding, toileting, and grooming needs. The motor (physical) capacity to 
participate in self care activities is accounted for in the seventh item, level of functioning (how 
dependent or independent a patient is when considering both cognitive and motor [physical] 
activities). The eighth item refers to employability options. The total score range from 0 (no 
disability) to 30 (death). The interrater reliability is 0.97- 0.98 (Gouvier, Blanton, et al., 1987 ; 
Rappaport et al., 1982) and test-retest reliability of 0.95 (Gouvier et al., 1987).  (See Appendix 
E).  
   89
  
Mortality 
Mortality is a binary variable (0=alive; 1=dead) and that was coded for by recoding the 
GOS outcome variable into scores 1 versus all others. 
 
The Neurobehavioral Rating Scale- Revised (NRS-R)   
The NRS-R was developed by Levin and colleagues (1990) to increase reliability and 
content validity of the original 1987 version Neurobehavioral Rating Scale (NRS).  The NRS 
was originally a 27 item measurement modified from the Brief Psychiatric Rating Scale (BPRS) 
(Overall & Gorham, 1962) specifically for TBI patients. Both the NRS and the NRS-R 
measurements require a trained examiner. When using the NRS-R, the examiner bases scores 
from a 15-20 minute interview (two-thirds of the items) and patient observation during the 
interview (one-third of the items). The 29 items are scored on a 4 point Likert scale (absent, 
mild, moderate, and severe). NRS-R items address issues such as but not limited to: mental 
flexibility, irritability, tension/anxiety, alertness, attention, decreased initiation/motivation, 
suspiciousness, mental fatigability, hallucinating behavior, and motor retardation. The interrater 
reliability reported ranges from Kappa equal to 0.22 (difficulty planning) to 0.77 (memory 
difficulties); (median Kappa =0.4) (Vanier, Mazaux et al., 2000). Therefore inter-rater agreement 
is dependent on the use of the tool/sub-scale. NRS total score correlates with 6 month GOS 
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 Trails Making Tests 
The Trails Making Test was developed by United States Army psychologists as part of 
the Army Individual Test Battery (1944) and is in the public domain. The test is administered in 
two parts; Trails A which assesses attention and Trails B which assesses mental flexibility.  
There are several options for the administration for this test. This study utilized the commonly 
used Reitan (1958) method of the test administration (Lezek et al. , 2004).    
Trails A 
Attention was evaluated with the Trail Making Test-A (Trails A) which consists of a 
white sheet of paper on which 25 circles are distributed. Each circle contains a number from 1 to 
25 (Basso, Bornstein, & Lang, 1999; Reitan & Wolfson, 1985). Subjects were asked to draw a 
line connecting all circles in numerical sequence as quickly and accurately as possible without 
lifting the pencil from the paper. Errors were immediately pointed out by the test administrator 
and corrected by the subject. The score is the amount of time, in seconds, to complete the test 
and includes any time needed for corrections. The number of errors committed were also 
recorded. Administration time is 3 minutes. This test may also be used to evaluate motor 
processing speed. (See Appendix F). 
Trails B 
Mental Flexibility was evaluated with the Trail Making Test-B (Trails B). The Trails-B 
consists of a white sheet of paper with 25 circles containing numbers 1 to 13 and letters A to L 
(Basso et al.,1999;  Reitan & Wolfson, 1985). Subjects are asked to quickly draw a line 
consecutively connecting all the circles alternating between numbers and letters. The score is the 
amount of time to complete the task. Administration time is 3 minutes. This test may also be 
used to evaluate executive functioning. (See Appendix G). 
   91
 .        
Trails A & Trails B Test Characteristics 
The reliability coefficients vary based on method administration and population tested r= 
.60-.90 (Spreen & Strauss, 1998). Among the general population, performance may decline with 
age and improve with greater years of education (Fullerton, Wu, Zhao, & Johnston, 2003; 
Raudenbush, 1997; Raudenbush & Bryk, 2001; Ryan & Geckle, 2000). Test-retest reliability was 
r = .75 in 23 healthy adults (14 women, 9 men) with a mean age of 32.3 years (Davies, 1968). 
Among the TBI population, mild TBI patients versus controls have a slowing test times with 
increased severity of injury Leininger, Gramling, Farrell, Kreutzer, & Peck, 1990). Patients with 
moderate to severe TBI, have slower test times than controls on Trails B 2-5 years following 
injury (Spikeman, Deelman, & van Zomeren, 2000). Both Trails A and Trails B significantly 
contribute to the prediction as to what degree patients recovering from a moderately to severe 
TBI are independent in their living situation; patients with high Trails A and Trails B scores were 
found to have decreased independence (Acker & Davis, 1989).       
 
3.8.3   Covariates 
3.8.3.1 Covariate: severity of injury: Glasgow Coma Score (GCS) 
The GCS is an instrument developed at the Glasgow Neurological Institute in Scotland 
by Teasdale and Jennett (Teasdale & Jennett, 1974) for a consistent general scale to assess depth 
and duration of impaired consciousness and coma. The GCS has had extensive worldwide testing 
for its usefulness in the assessment and prognosis of head injured patients. It is the clinical 
parameter closely linked to acuity in the head injured patient.  The GCS score has been shown to 
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 be reliable with minimal observer deviation when nurses and physicians tested the scale 
(Teasdale, Knill-Jones & Jennett, 1974). The 15 point scale has 3 aspects of behavioral response 
that are evaluated: best verbal response, best motor response and eye opening. Patients with high 
scores have the best chance of good recovery or moderate disability, and those with the lowest 
scores have an 80% chance of death or persistent vegetative state (Finklestein & Ropper, 1979).  
The predications of outcomes using GCS improves within 72 hours of injury (Jennett et al, 
1976). The GCS at time of admission as documented by the neurosurgeon was be utilized. GCS 
recorded is without the impairment of alcohol, substance or medications. While GCS was be 
used as a covariate in this study, it was also a component of the inclusion criteria.  All subjects 
had a GCS <9. GCS was dichotomized; 3-5 versus 6-8. Dichotomized GCS was used as the 
measure of severity of injury for statistical analysis.  (See Appendix  H). 
3.8.3.2 Covariate: demographic characteristics 
Demographic information (age, gender, race) was collected from the medical record upon 
entry into the study. Age was used as a continuous variable. Race was dichotomized as 
Caucasians vs non-Caucasians due to the lack of variability among the distribution of race. Race 
was omitted from the neurometabolite and CBF analyses due to non-Caucasians cell size of n=1. 
3.8.3.3 Covariate: hypoxia  
Hypoxia is defined as an oxygen saturation saO2 of ≤80% for >30 minutes at the scene of 
the accident or during transport to the hospital. Subjects were coded as 0=no confirmed event 
and 1= confirmed event. 
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 3.8.3.4 Covariate: hypotension  
Hypotension was defined as sustained systolic blood pressure <90 mmHg for >30minutes 
at the scene of the accident or during transport. Subjects were coded as 0=no confirmed event 
and 1= confirmed event. 
3.8.3.5 Covariate: seizure  
Seizure was defined as a witnessed seizure at the scene of the accident or during 
transport. Subjects were coded as 0=no confirmed event and 1= confirmed event. 
3.8.3.6 Covariate: hypothermia treatment 
A subgroup of the sample used were enrolled in a randomized control trial to determine 
efficacy of therapeutic hypothermia in improving outcomes after severe TBI.  Therapeutic 
hypothermia decreases metabolic needs of the brain and may protect the brain from secondary 
injury.  As such, it was important to consider this therapy as a potential covariate in all analysis.  
Hypothermia was defined as follows: 1= subjects who were maintained in a hypothermic state 
(May 2002 to July 2005 cooled to core temperature 33°C; November 2005 to present cooled to 
core temperature of 32.5- 34°C) for the first 48 hours after injury or 0= subjects who were 
maintained in a non-hypothermic state for the first 48 hours after injury. 
3.8.3.7 Covariate: APOEε4  
Restriction Fragment Length Polymorphism (RFLP) analysis was utilized.  First, a 
polymerse chain reaction (PCR) procedure was be set up as follows:  200ng of DNA was 
combined with 0.9nM of each primer flanking the variants (forward: 5' - TAA GCT TGG CAC 
GGC TGT CCA AGG A -3' and reverse: 5' - ACA GAA TTC GCC CCG GCC TGG TAC AC - 
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 3')., 0.6U of taq polymerase, 1.5mM MgC12, IX reaction buffer and 200uM of each dNTP in a 
total reaction volume of 25ul.  Each sample was exposed to thermal cycling with a 
programmable thermal cycler (MJ Research, model PTC-200).   Thirty cycles of denaturation at 
95oC for one minute, annealing at 57oC for thirty seconds, and extension at 72oC for one minute, 
amplified the PCR product, which was then exposed to HhaI restriction endonuclease to perform 
the RFLP analysis.  The digested products were electrophoresed on a 6% polyacrylamide gel 
stained with ethidium bromide for DNA band detection and genotype assignment based on 
presence or absence of the original. A computer generated picture of the gel was recorded.  Two 
independent researchers reviewed the pictures and assign an APOE genotype based on 
appropriate banding.  Genotyping will be repeated in 10% of the samples to assure reliability.  
(See Appendix I). 
3.9 DE-IDENTIFICATION PROCESS 
Each patient screened for the parent study was assigned a unique identification number 
(UID). This number was the mechanism by which the data collected (raw data form and 
specimens) was de-identified.  Throughout the study the UID number was used. Under the 
design of this study the primary investigator did not have access to link the UID’s to any 
identifiable information. 
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 3.10 STORAGE 
The consent forms, which contain identity information, are kept separate from the data in 
a locked file cabinet.  The data records are kept in a locked file cabinet and the database 
information are kept secure by password protection. The consent forms, data records, and 
databases are also secured in a locked office. 
3.11 DATA MANAGEMENT 
The data are linked by the UID’s. The data base for this study did not contain any 
personal identification data. The data base was compiled by the personnel at the Brain Trauma 
Research Center at the University of Pittsburgh. In the parent study the APOE genotype data was 
hand entered and verified. Demographic and severity of injury data was extracted from the chart 
by study personnel, documented on data entry forms and entered electronically.  Lactate and 
Pyruvate were electronically entered into an excel file by the Millennium software.  For this 
study the BCL-2 genotyping data was the only new variable for which data needed to be entered. 
The TAQ MAN report data was exported to an Excel file, from which the data was merged with 
the pertinent variables from the parent study. All of the databases were in Excel spreadsheet. The 
excel spreadsheet were exported into SPSS [SPSS Inc., Chicago, Ill., versions 15 and 16] and 
SAS [SAS institute Inc., Cary, NC., version 9.1] statistical packages. SPSS was utilized for 
descriptive statistics and recoding the data. SAS was employed for preliminary and primary 
mixed models and generalized mixed models analyses. 
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 3.12 DATA ANALYSIS PLAN 
3.12.1 Preliminary Analyses 
3.12.1.1 Accuracy 
Accuracy of the data was assessed by screening for missing or out of range data. 
Frequency tables were performed for all categorical and ordinal variables (all 17 of the BCL-2 
SNP’s, GOS, mortality, age, GCS, gender, race, hypothermia, hypoxia, hypotension, seizures, 
and APOEε4 allele presence). Descriptive statistics (range, mean, median, mode) were 
preformed on the continuous variables (DRS, NRS-R, Trails A, Trails B, Bcl-2 protein, 
neurometabolites [lactate, pyruvate, LP ratio], and CBF) to assess the accuracy of those data. In 
order to accommodate missing data on the continuous variables mixed models analysis was used; 
GOS, while an ordinal variables, was treated as a continuous variable (Wagner et al., 2004). To 
accommodate the missing data in the Mortality (binary outcome) generalized mixed models was 
employed (i.e. participant lost to follow-up). Overall, missing data was examined but no attempt 
was made to impute missing values. NRS-R and Trails Making Tests can not accommodate an 
outcome for subjects who died or those who are too cognitively impaired to complete the 
measures. These subjects were removed from the overall data set to form a subset as it is not 
meaningful to include these people in the analyses. With this said, the data is not missing at 
random and the results are only generalizable to people who have had a severe TBI and have 
made a degree of cognitive recovery that they are able to participate in the measure. Other 
dependent variable missing data were assumed to be missing at random (lost to follow-up, 
patient/family refused, incarceration, the data were stopped being collected on all patients). 
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 3.12.1.2 Distribution assumptions 
Normality 
Normality was assessed by examining histograms, skewness, and kurtosis for the 
continuous variables (DRS, GOS, NRS-R, Trails A, Trails B, Bcl-2 protein, neurometabolites 
[lactate, pyruvate, LP ratio], and CBF). Outliers or extreme values were noted in the Bcl-2 
protein database as indicated by scatter plots. The extreme values were verified with the lab and 
protocol. Analyses were run with and without outliers. No gross non-normality was found among 
the other continuous variables. 
HWE 
Hardy-Weinberg Equilibrium was used to assess the distribution of the 17 BCL-2 SNP 
genotypes. Based upon this theory from population genetics there is an expected distribution of 
genotypes (where p2= genotype frequency of homozygous wild type; 2pq= genotype frequency 
of each alleles contribution from the heterozygous genotype; q2= frequency of homozygous 
variant). (See figure 3-1). 
p2 +2pq+q2=1 
Figure 3-1: Hardy-Weinberg Equation 
This formula was adapted to accommodate TAQ MAN assay labeling and is mathematically 
accurate. (See figure 3-2).       
X2 +2XY+Y2=1 
Figure 3-2:  Adapted Hardy-Weinberg Equation 
HWE’s were calculated for each SNP using a formula driven Excel spreadsheet. This was 
completed for the overall sample genotyped, global functional outcomes (GOS, DRS, and 
mortality) analyses as well as for all of the sub-analyses (NRS-R, Trails Making Tests, Bcl-2 
protein, Neurometabolites, and CBF.).  Violations of HWE were confirmed with Chi Square tests 
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 to ascertain if the disequilibrium was statistically significant. For detailed information on HWE 
for the overall genotyping and each subsequent dependent variable please see tables 4-2, 4-4,  
4-15, 4-19, 4-27, 4-33, and 4-43. 
3.12.1.3 Preliminary (Abbreviated) Model Analyses: Continuous Dependent 
Variables 
An abbreviated mixed models analysis was performed for each of the continuous/ordinal 
dependent variables (GOS, DRS, NRS-R, Trails A, Trails B, Bcl-2 protein, neurometabolites 
[lactate, pyruvate, and LP ratio] and CBF [right hemisphere, left hemisphere, and global) 
independently with each individual SNP (17) and the time point variable. Each of the 
continuous/ ordinal dependent variables were also analyzed independently with each individual 
covariate and time. This was done to select the SNP’s and covariates of interest for the Primary 
Full Mixed Models analyses. The conservative criterion used for the selection of a SNP or 
covariate into the Primary analysis was Type 3 tests with P ≤0.2. (Bendel & Afifi, 1977) 
recommend a less conservative P≤0.1.) This was a conservative significance level that was set a 
priori in order to focus the analyses.  In addition, covariates that were deemed prudent through 
the evidence in the literature (age, gender, race, GCS, and hypothermia) were chosen a priori to 
be used in the Primary Full Mixed Models analyses regardless of significance for Type 3 tests. 
These predetermined covariates were added to each model unless there was a cell size of one or 
less for that covariate. 
3.12.1.4 Preliminary (Abbreviated) Model Analyses: Binary Dependent Variable 
The process of the preliminary (abbreviated) model analysis of the binary variable of 
mortality mirrors that of the process for the continuous variables with exception that a 
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 generalized mixed model was used to accommodate for the binary nature of mortality (alive vs 
dead) and a conservative Type 3 X2≤ 0.3 criterion (Hosmer & Lemeshow , 2000) 
3.12.2 Primary Analysis 
Analysis of specific aims: 
1. Specific Aim 1: Compare the relationship between BCL-2 genotype and global 
functional outcomes, cognitive-behavioral outcomes, and mortality attained by patients who have 
sustained a severe TBI. 
RQ1. Is there a relationship between BCL-2 genotype and global functional outcomes 
(GOS and DRS), cognitive-behavioral outcomes (NRS-R, Trails A, and Trails B) and mortality 
attained by patients who have sustained a severe TBI?  
Global Functional Outcomes 
GOS: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
race, hypothermia, and hypotension were included in the model versus GOS. 
DRS: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
race, hypothermia, hypoxia, hypotension, and seizure were included in the model versus DRS. 
Mortality: A generalized mixed model analysis of the SNP of interest, time point, age, 
GCS, gender, race, hypothermia, hypoxia, hypotension, and seizure were included in the model 
versus mortality. 
Cognitive-behavioral Outcomes 
NRS-R: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
race, hypothermia, and seizure were included in the model versus NRS-R. 
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 Trails Making Tests 
Trails A: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
race, and hypothermia were included in the model versus Trails A. Hypoxia and hypotension 
were not included in the model despite Type 3 test significance due to only 1 subject meeting 
criteria in each of those covariates. 
Trails B: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
race, and hypothermia were included in the model versus Trails A. Hypoxia and hypotension 
were not included in the model despite Type 3 test significance due to only 1 subject meeting 
criteria in each of those covariates. 
 
2. Specific Aims 2: Compare the relationship between BCL-2 genotype and biological/ 
clinical data.  
RQ2. Is there a relationship between BCL-2 genotype and biological/ clinical data (bcl-2 
protein, neurometabolites [lactate, pyruvate, LP ratio], and CBF [right hemisphere, left 
hemisphere, and global] from patients who have sustained a severe TBI? 
Bcl-2 Protein 
Bcl-2 Protein with outliers: A mixed models analysis of the SNP of interest, time point, 
age, GCS, gender, race, hypoxia, and seizure were included in the model versus Bcl-2 Protein 
level.  None of the subjects in this subgroup were treated with hypothermic protocol. 
Bcl-2 Protein without outliers: There is evidence that bcl-2 protein peaks between days 3 
and 4 after injury (Lee et al., 2004; Xiong et al., 2001)). Based on preliminary descriptive 
analysis there are 2 potential extreme values.  A separate analysis was performed without the 2 
extreme values. A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
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 race,  hypoxia, and seizure were included in the model versus Bcl-2 Protein level.  None of the 
subjects in this subgroup were treated with the hypothermic protocol 
Neurometabolites 
Lactate: A mixed models analysis of the SNP of interest, time point, age, GCS, gender,  
and hypothermia were included in the model versus lactate concentration.  There was only one 
non-caucasian subject in this subgroup; therefore, race was not used in this analysis. 
Pyruvate: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
\and hypothermia were included in the model versus pyruvate concentration. There was only one 
non-caucasian subject in this subgroup; therefore, race was not used in this analysis. 
L/P ratio: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
and hypothermia were included in the model versus L/P ratio. There was only one non-caucasian 
subject in this subgroup; therefore race was not used in this analysis. 
CBF  
Right Hemisphere: A mixed models analysis of the SNP of interest, time point, age, GCS, 
gender, and hypothermia were included in the model versus right hemisphere. There was only 
one non-caucasian subject in this subgroup; therefore, race was not used in this analysis. 
Left Hemisphere: A mixed models analysis of the SNP of interest, time point, age, GCS, 
gender, and hypothermia were included in the model versus left hemisphere. There was only one 
non-caucasian subject in this subgroup; therefore, race was not used in this analysis. 
Global: A mixed models analysis of the SNP of interest, time point, age, GCS, gender, 
and hypothermia were included in the model versus global. There was only one non-caucasian 
subject in this subgroup; therefore race was not used in this analysis. 
   102
 4.0  RESULTS  
4.1 SAMPLE DESCRIPTION FOR OVERALL GENOTYPES 
The subjects enrolled in this study were injured between May 2000 and April 2007. The 
mean age of the overall sample of 230 subjects genotyped was 34.4 year old (range 16-73; SD± 
14.8). (see figure 4-1). The genotype information is reported in table 4-1. 
Table 4-1: BCL-2 Genotype Information 
SNP RS Number
        
Alleles 
Base Δ
        
Ancestral 
Allele
           
Homozygous 
XX Allele 
           
Homozygous  
YY Allele









Frequency Location of the Tagging SNP Position
3' end RS17756073 A/G A 111 (AA) 27 (GG) 83 (A/G) 221 0.310 0.3 intron 58960763
I RS4456611 C/T T 57 (CC) 50 (TT) 113(C/T) 220 0.484 0.467 intron 58961432
I RS1026825 A/G T 65(AA) 52 (GG) 112 (A/G) 229 0.472 0.458 intron 58971255
I RS7230970 C/T T 44 (CC) 79 (TT) 93(C/T) 220 0.411 0.473 intron 58972056
I RS899968 A/C A 40 (AA) 83 (CC) 99(A/C) 221 0.405 0.425 intron 58973244
I RS4941185 A/G A 77 (AA) 45 (GG) 102(A/G) 225 0.427 0.4 intron 58974534
I RS12454712 C/T T 31(CC) 99 (TT) 98 (C/T) 228 0.351 0.362 intron 58996864
I RS1481031 A/G A 95 (AA) 24 (GG) 107(A/G) 226 0.343 0.325 intron 59003065
I RS3810027 C/G G 99 (CC) 28(GG) 98(C/G) 225 0.342 0.331 intron 59054958
I RS8083946 A/G A 47 (AA) 87(GG) 95(A/G) 216 0.438 0.333 intron 59056901
I RS1944419 A/T T 58 (AA) 51(TT) 111(A/T) 220 0.484 0.458 intron 59075593
I RS12968517 C/T T 99 (CC) 35(TT) 94(C/T) 228 0.360 0.292 intron 59092951
I RS7236090 C/T T 63(CC) 55(TT) 103(C/T) 224 0.475 0.45 intron 59098091
I RS1381548 A/G A 40 (AA) 81(GG) 101(A/G) 222 0.408 0.392 intron 59108376
I RS17759659 A/G A 83 (AA) 31(GG) 110(A/G) 224 0.384 0.483 intron 59109624
I RS949037 C/T C 49 (CC) 70(TT) 103(C/T) 229 0.439 0.4 intron 59129993
5' end RS1801018
        
A/G
           





 The sample was primarily Caucasian (n=213; 92.6%) and male (n=178; 77.4%) (see 
figure 4-2 and 4-3). The majority of the sample genotyped had admission GCS of 6-8 (n=136; 
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59.1%) (see figure 4-4). The mechanism of injury for the majority of the sample was related to 
an automobile crash (n=114; 49.6%) (see figure 4-5). Of the subjects enrolled in the study 
n=40 (17.4%) received a hypothermia intervention. In the overall sample the presence of 
sustained hypoxia (n=28; 12.7%), hypotension (n=19; 8.3%), documented pre-admission 
seizures (n=8; 3.5%), and the presence of APOE ε4 (n=58; 25.2%) were considered as 
covariates.  Refer to table 4-2 for sample description.  
All of the SNP’s genotyped for the overall sample met or approached the Hardy-
Weinberg Equilibrium (HWE) criteria for genotype representation in a population. For the 
SNP’s (RS4941185, RS7230970, RS 7236090, RS8083946, RS899968, and RS 949037) that 
had attained HWE values that were not equal to 1, a Chi Square test was performed to assess 
if there was a significant difference.  Only RS8083946 significantly deviated from 
anticipated HWE (X2=4.76139; P=0.02911). Refer to table 4-2 for the Chi Square Results. 
Refer to specific tables (4-2, 4-4, 4-15, 4-19, 4-27, 4-33, and 4-43)  for genotype frequencies 
for each SNP and HWE calculations for the overall sample and each portion of specific aims 
1 and 2. From this overall sample, subjects were “selected” for inclusion in the outcomes 
data and/ or clinical/ biological data analyses based on the availability of the data being 
analyzed in comparison to genotypes. Refer to table 4-3 for a summary of the sample sizes 
for each of the analyses. 
 Table 4-2: BCL-2 Genotypes Overall Summary Descriptive Data 
Variable n= Mean Std. Deviation Range
Age 230 34.38 14.836 16-73
Frequency (%)
Frequency (%) of 
Unknown






Dichotomized GCS 226 score 3-5 90 (39.1%) 4 (1.7%)
score 6-8 136 (59.1%)
Gender 230 Male 178 (77.4%) 0
Female 52 (22.6%)
Race 230 Caucasian 213 (92.6%) 0
African American 13 (5.7%)
Asian 1 (0.43%)
Hispanic 1 (0.43%)
Hypothermic 230 40 (17.4%) 0
Hypoxia 176 28 (12.7%) 54 (23.5%)
Hypotensive 176 19 (8.3%) 54 (23.5%)
Seizures 176 8 (3.5%) 54 (23.5%)
APOEє4 225 58 (25.2%) 5 (2.2%)
SNP n= XX Allele YY Allele XY Allele Undetermined X Y HWE X 2 P
RS1026825 229 65 52 112 1 (0.4%) 0.528384279 0.47162 1 . .
RS12454712 228 31 99 98 2 (0.9%) 0.350877193 0.64912 1 . .
RS12968517 228 99 35 94 2 (0.9%) 0.640350877 0.35965 1 . .
RS1381548 222 40 81 101 8 (3.5%) 0.407657658 0.59234 1 . .
RS1481031 226 95 24 107 4 (1.7%) 0.657079646 0.34292 1 . .
RS17756073 221 111 27 83 9 (3.9%) 0.690045249 0.30995 1 . .
RS17759659 224 83 31 110 6 (2.6%) 0.616071429 0.38393 1 . .
RS1801018 228 44 82 102 2 (0.9%) 0.416666667 0.58333 1 . .
RS1944419 220 58 51 111 10 (4.3%) 0.515909091 0.48409 1 . .
RS3810027 225 99 28 98 5 (2.2%) 0.657777778 0.34222 1 . .
RS4456611 220 57 50 113 10 (4.3%) 0.515909091 0.48409 1 . .
RS4941185 225 77 45 102 6 (2.6%) 0.568888889 0.42667 0.99113 1.107 0.2926
RS7230970 220 44 79 93 14 (6.1%) 0.411363636 0.57045 0.96397 2.8899 0.0891
RS7236090 224 63 55 103 9 (3.9%) 0.511160714 0.47545 0.97339 0.98174 0.3218
RS8083946 216 47 87 95 1 (0.4%) 0.4375 0.62269 1.12399 4.76139 0.0291*
RS899968 221 40 83 99 8 (3.5%) 0.404977376 0.59955 1.00907 1.19416 0.2745
RS949037 229 49 70 103 8 (3.5%) 0.438864629 0.53057 0.9398 0.90063 0.3426
* X 2  p≤ 0.05 
Hardy-Weinberg Equilibrium
BCL-2 Genotypes Overall Summary Descriptive Data
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Figure 4-1: TBI Age Distribution 











Figure 4-2: TBI Racial Distribution 
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Figure 4-3: TBI Gender Distribution 



































Figure 4-4: Frequency of Admission GCS in Overall Sample 
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Trails A 30 27
Trails B 30 27
Bcl-2 Protein Levels 42 37
Neurometabolites 36 36
CBF 17 17
*Generalized mixed model to account for binary nature of the mortality outcome.
Biological/ Clinical Outcomes
Type of Analysis




Table 4-3: Summary Table of Sample Size 




 4.2 RESEARCH QUESTIONS 
4.2.1 The Specific Aims and the Research Questions  
1. Specific Aim 1: Compare the relationship between BCL-2 genotype and global 
functional outcomes, cognitive-behavioral outcomes, and mortality attained by patients 
who have sustained a severe TBI. 
RQ1. Is there a relationship between BCL-2 genotype and global functional 
outcomes (GOS and DRS), cognitive-behavioral outcomes (NRS-R, Trails A, and Trails 
B), and mortality attained by patients who have sustained a severe TBI?  
4.2.1.1 Global Functional Outcomes 
Sample Description 
The mean age of the overall sample of 201 subjects was 34.2 year old (range 16-72; SD± 
14.4). The sample was primarily Caucasian (n=188; 93.5%) and male (n=159; 79.1%). The 
majority of the sample genotyped had admission GCS of 6-8 (n=117; 58.2%). Of the subjects 
enrolled in the study 38 (18.9%) received a hypothermia intervention. In the overall sample the 
presence of sustained hypoxia (n=26;12.94%), hypotension (n=12; 5.97%), documented pre-
admission seizures (n=8; 3.98%), and the presence of APOE ε4 (n=46; 22.89%) were considered 
as covariates. Refer to table 4-4 for sample description. All of the SNP’s genotyped for the 
overall sample met the HWE criteria for genotype representation in a population. Refer to table 
4-4 for genotype frequencies for each SNP and HWE calculations. 
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 When reviewing the available data, a trend of decreasing number of subjects with data 
available in each of the outcome time points was noted.  This can be explained by the following 
rationales; the subject did not reach the time point milestone evaluation based on date of injury 
and loss to attrition due to refused the assessment, unable to contact/find, or in prison. 
At the 3 month outcomes data collection of the 201 subjects in this analysis 198 (98.5%) 
of the subjects were captured for a mortality rate approximately one quarter of the sample (n=51; 
25.4%). The mortality rate stabilizes in reference to the 6, 12, and 24 month outcome data with 
adding seven confirmed subject deaths by the 24 month outcome time point. (See table 4-4). 
Interestingly at a 12 months post injury according to GOS scores; 27.9% of the subjects 
had died (GOS=1), 20.4% had a poor outcome (GOS= 2-3), 30.8% (GOS= 4-5) had a good 
outcome, and 21.4% of the subjects outcome was either too early to evaluate or unknown. (See 
table 4-4). 
The DRS means at the 3, 6, and 12 months outcomes evaluation classify the disability of 
the subjects as having severe limitations (DRS score 12-16). At the 24 months outcomes 
evaluation,  41.3% of the subjects outcomes are unknown, and the mean score of the known 
subjects was 17.3 placing the outcomes in the extremely severe limitations category, however, all 
of the scores from the patients who had died, 58 of the 118 subjects or 49.2% known outcomes, 
are included in the  24 months statistics. (See table 4-4). 
 
Preliminary Analysis (Abbreviated Mixed Models) 
In the preliminary mixed model analyses, each of the SNP’s was analyzed individually 
for a relationship to each of the global functional outcome variables (GOS and DRS) over time. 
Each of the covariates was analyzed for potential relationship with the global functional outcome 
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 variable over time. By doing the preliminary analyses the SNP’s and covariates of interest were 
ascertained and were used in building the larger model. (Refer to tables 4-5 and 4-6). 
The preliminary mixed models analyses for GOS indicated that the SNP’s and covariates 
of interest, meeting the criterion (P for Type-3 Tests P<0.2) were: RS12968517 (genotypes 
P=0.0899; dichotomized genotype P=0.5371); RS 17759659 (genotypes P=0.0524; dichotomized 
genotype P=0.0153); RS 1801018 (genotypes P=0.0923; dichotomized genotype P=0.18273); 
RS1944419 (genotypes P=0.3303; dichotomized genotype P=0.1465); RS4941185 (genotypes 
P=0.0376; dichotomized genotype P=0.4693); RS 7236090 (genotypes P=0.0966; dichotomized 
genotype P=0.2195); RS949037 (genotypes P=0.197; dichotomized genotype P=0.437); Time 
(months) (P <.0001); Age (P <.0001); GCS (P <.0001); and Gender (P= 0.1085). Race 
(P=0.3485) and hypothermia (P= 0.6511) were not indicated in the preliminary analyses, 
however, they were added to the full model as discussed in the methods section. (Refer to tables 
4-5 and 4-6). 
The preliminary mix models analyses for DRS indicated that the SNP’s and covariates of 
interest, meeting the criterion were: RS12968517 (genotypes P=0.0722; dichotomized genotype 
P=0.4163); RS17756073 (genotypes P=0.1981; dichotomized genotype P=0.6903); RS17759659 
(genotypes P=0.0325; dichotomized genotype P=0.0089); RS1801018 (genotypes P=0.0298; 
dichotomized genotype P=0.0813); RS1944419 (genotypes P=0.3075; dichotomized genotype 
P=0.1244); RS4941185 (genotypes P=0.0272; dichotomized genotype P=0.7106); RS7236090 
(genotypes P=0.0121; dichotomized genotype P=0.061); RS949037 (genotypes P=0.1441; 
dichotomized genotype P=0.508); Time (months) (P <.0001); Age (P <.0001); GCS (P <.0001); 
Gender (P= 0.1696); Hypoxia (P= 0.1972); Hypotension (P= 0.1131); and Seizures (P= 0.1676).  
Race (P=0.6144) and hypothermia (P= 0.3417) were not indicated in the preliminary analysis, 
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however, were added to the full model as discussed in the methods section. Unlike GOS, the 
preliminary analyses of DRS data, hypoxia, hypotension, and seizure covariates did meet the 
criterion. (Refer to tables 4-5 and 4-6). 
 
Variable n= Mean Std. Deviation Range
Age 201 34.16 14.395 16-72
Frequency (%)
Frequency (%)     
of Unknown
GCS 201 score 3 to 5 84(41.8%) 0
score 6 to 8 117(58.2%) 0
Gender (Male) 201 159(79.1%) 0
Race (Caucasian) 201 188(93.5%) 0
Hypothermic 198 38(19.2%) 3 (1.5%)
Hypoxia 148 26(17.6%) 53 (24.6%)
Hypotensive 148 12(8.1%) 53 (24.6%)
Seizures 148 8(5.4%) 53 (24.6%)
APOEε4   196 46(23.5%) 5 (2.5%)
GOS Death (1)
Vegitative   
State (2) Severe (3) Moderate (4) Good (5) Unknown
 3 months 182 51(25.4%) 16(7.96%) 74(36.8%) 32(15.9%) 9(4.5%) 19 (9.5%)
 6 months 182 55(27.4%) 11(5.5%) 54(26.9%) 37(18.4%) 25(12.4%) 19 (9.5%)
 12 months 159 56(27.9%) 9(4.5%) 32(15.9%) 34(16.9%) 28(13.9%) 43 (21.4%)
24 months 118 58(28.9%) 4 (1.99%) 16(7.96%) 13 (6.5%) 27(13.4%) 83 (41.3%)
DRS Mean Std. deviation Range
Frequency (%)   
of Unknown
 3 months 178 15.39 11.62 0-30 23 (11.44%)
 6 months 181 13.96 12.358 0-30 20 (9.95%)
 12 months 155 14.72 13.025 0-30 44 (22.9%)
24 months 118 17.33 13.595 0-30 83 (41.3%)
Mortality Death Unknown
 3 months 198 51(25.4%) 3 (1.5%)
 6 months 186 55(27.4%) 15 (7.5%)
 12 months 162 56(27.9%) 39 (19.4%)
24 months 118 58(28.9%) 83 (41.3%)
SNP n= XX YY XY X Y HW E
RS1026825 201 59 49 93 0.524875622 0.47512438 1.0000
RS12454712 199 25 91 83 0.334170854 0.66582915 1.0000
RS12968517 200 90 31 79 0.6475 0.3525 1.0000
RS1381548 195 34 70 91 0.407692308 0.59230769 1.0000
RS1481031 198 87 21 90 0.666666667 0.33333333 1.0000
RS17756073 196 98 26 72 0.683673469 0.31632653 1.0000
RS17759659 197 74 28 95 0.616751269 0.38324873 1.0000
RS1801018 199 41 72 86 0.422110553 0.57788945 1.0000
RS1944419 192 50 46 96 0.510416667 0.48958333 1.0000
RS3810027 196 85 25 86 0.653061224 0.34693878 1.0000
RS4456611 193 49 48 96 0.502590674 0.49740933 1.0000
RS4941185 195 66 39 90 0.569230769 0.43076923 1.0000
RS7230970 193 40 67 86 0.430051813 0.56994819 1.0000
RS7236090 193 57 47 89 0.525906736 0.47409326 1.0000
RS8083946 200 42 77 81 0.4125 0.5875 1.0000
RS899968 195 36 76 83 0.397435897 0.6025641 1.0000
RS949037 194 44 64 86 0.448453608 0.55154639 1.0000
Frequency (%)
Frequency (%)
 BCL-2 Genotypes Versus GOS, DRS, and Mortality Descriptive Data
Hardy-Weinberg Equilibrium





 Preliminary Analysis (Abbreviated) Generalized Mixed Models: Mortality 
The preliminary generalized mixed models analysis for Mortality indicated that the 
SNP’s and covariates of interest, meeting the criterion (Type 3 X2 <0.3) were: RS12968517 
(genotypes P=0.1177, OR= 2.5; dichotomized genotype P=0.3732; OR=1.3); RS 17756073 
(genotypes P=0.2853, OR= 2.1; dichotomized genotype P=0.6031, OR=0.84); RS 17759659 
(genotypes P=0.1953, OR=0.86; dichotomized genotype P=0.0737, OR=1.8); RS 1801018 
(genotypes P=0.2143, OR=0.69; dichotomized genotype P=0.6498, OR=1.2); RS4941185 
(genotypes P=0.2763, OR=1.73; dichotomized genotype P=0.3528, OR=0.72); RS7230970 
(genotypes P=0.2953, OR=0.78; dichotomized genotype P=0.8845, OR=1.05); RS7236090 
(genotypes P=0.0994, OR=1.42; dichotomized genotype P=0.136, OR=0.59); Time (months) (P 
<.0001); Age (P <.0001, OR=1.05); GCS (P <.0001, OR=0.198); Gender (P= 0.3014, OR=1.5), 
Race (P=0.2963, OR=.049); and seizures (P= 0.1658, OR=3.32). Hypothermia (P= 0.9) was not 
indicated in the preliminary analysis, however, it was added to the full model as discussed in the 
methods section. Unlike DRS and/or GOS, RS1944419, RS949037, hypoxia, and hypotension 
did not meet the criterion.  (Refer to table 4-10 and 4-11). 
 
Primary Mixed Models Analysis for Global Functional Outcomes: Overview 
Primary full mixed models were built for GOS and DRS using the SNP of interest from 
the preliminary analyses (RS12968517, RS17756073, RS 17759659, RS 1801018, RS1944419, 
RS4941185, RS7236090, and RS949037), time (month), age, GCS, gender, race, hypothermia, 
and hypotension. (Refer to tables 4-7 to 4-9). In the DRS model additional covariates of seizure 
and hypoxia were indicated to be added by the preliminary analysis.  While SNP RS17756073 
was not indicated in GOS preliminary analysis, models were built using this SNP’s as to provide 
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 comparison across the global functional outcome measures. The covariates of seizure and 
hypoxia were not included in the GOS because the P for type 3 test criterion were not significant 
for those covariates and could decrease the power of the analysis. 
Primary full generalized mixed models were built for mortality using the SNP of interest 
from the preliminary analyses RS12968517, RS17756073, RS17759659, RS1801018, 
RS4941185, RS7230970, RS7236090, time (months), age, GCS, gender, race, seizures and 
hypothermia. While SNP RS949037, was not indicated in the mortality preliminary analysis, 
models were built using this SNP’s because it was significant in the GOS and DRS analyses and 
as to provide comparison across the global functional outcome measures. (RS1944419 was not 
significant in GOS or DRS and therefore was omitted in the mortality analysis).  The covariates 
of seizure and hypoxia were not included in the mortality analyses because they did not meet the 
set criterion. Overall in the analyses, time, age, and GCS remained significant across all of the 
full models for DRS, GOS, and mortality. 
Primary Mixed Models for GOS  
The mixed model with SNP RS12968517, genotype YY is significant (P= 0.0242) with 
overall genotype marginally significant (P for type 3 F tests =0.0591). YY genotype is associated 
with a decrease in GOS scores and is therefore associated with poorer outcomes. The 
significance of this SNP was not evident in the dichotomized analysis (P=0.455). See figures 6 
and 4-7 for the adjusted GOS means over time versus genotype/ dichotomized genotype for this 
SNP. Gender was found to been marginally significant (genotypes P=0.0728; dichotomized 
genotype P=0.0845) with females having lower GOS scores, therefore, poorer outcomes. (Refer 
to table 4-7). 
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Figure 4-6: GOS Adjusted Means vs. Genotypes 






























Figure 4-7: GOS Adjusted Means vs. Dichotomized Genotypes rs12968517 & rs17759659 
The mixed model with RS17759659, genotype XX is significant (P<.0001) with overall 
genotype significant (P for type 3 F tests =0.0003). XX genotype is associated with increased 
GOS scores and is therefore associated with good outcomes (two copies of X) (See figures 4-6 
and 4-7). This SNP was significant in the dichotomized analysis (P<.0001); subjects with 0 
copies of X or heterozygous, have significantly lower GOS scores and poorer outcomes. Race 
was found to been marginally significant genotypes (P=0.0521) and significant for dichotomized 
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 genotype (P=0.0477). Caucasians tend to have higher GOS scores and therefore better outcomes. 
(Refer to table 4-7). 
The mixed model with RS1801018 genotype YY is significant (P< .0001) with overall 
genotype significant (P for type 3 F tests =0.0004). YY genotype is associated with higher GOS 
scores and is therefore associated with good outcomes (See figure 4-6). This SNP was significant 
in the dichotomized analysis (P=.0002); subjects with 0 copies of Y or heterozygous, have 
significantly lower GOS scores and poorer outcomes (See figure 4-8). Race was found to been 
significant in the models (genotypes P=0.0392; dichotomized genotype (P=0.0277). Caucasians 
have higher GOS scores and therefore better outcomes in this sample. (Refer to table 4-8). 






























Figure 4-8: GOS Adjusted Means vs Dichotomized Genotypes rs1801018 and rs949037 
The mixed model with RS949037 genotype XX is significant (P=0.0425) with overall 
genotype significant (P for type 3 F tests =0.0074). XX genotype is associated with increased 
GOS scores and is therefore associated with good outcomes (See figures 4-6 and 4-8). This SNP 
was significant in the dichotomized analysis YY (P=0.0168) subjects with 2 copies of X or 
heterozygous, have significantly higher GOS scores and hence better outcomes. There were no 
significant trends in gender or race in this model. (Refer to table 4-9). 
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 The mixed models analyses indicated that the following SNP’s were not significant 
RS17756073 (genotypes P=0.736; dichotomized genotype P=0.3851); RS1944419 (genotypes 
P=0.3673; dichotomized genotype P=0.1973); RS4941185 (genotypes P=0.2874; dichotomized 
genotype P=0.5567); and RS7236090 (genotypes P=0.138; dichotomized genotype P=0.4572). 
(Refer to tables 4-7 to 4-9). 
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 Primary Mixed Models with DRS as the Global Functional Outcome 
The primary models with SNP RS12968517 genotype YY was significant (P= 0.0277) 
with overall genotype marginally significant (P for type 3 F tests =0.0667). YY genotype is 
associated with increased DRS scores and is therefore associated with poor outcomes. This trend 
was not evident in the dichotomized analysis (P=0.4585). There was a trend towards statistical 
significance of the therapeutic hypothermia variable (genotypes P=0.0546; dichotomized 
genotype P=0.0924) with the absence of therapeutic hypothermia associated with lower DRS 
scores (better outcomes). (Refer to table #4-7). 
The mixed model with RS17759659, genotype XX (P= 0.0002) with overall genotype 
significant (P for type 3 F tests =0.0006). XX genotype is associated with decreased DRS scores 
and is therefore associated with good outcomes. This SNP was significant in the dichotomized 
analysis (P=.0001); subjects with 0 copies of X or heterozygous, have an increase in DRS, and 
therefore poorer outcomes. (Refer to table 4-7). 
The mixed model with RS1801018 genotype YY (P<.0001) with overall genotype 
significant (P for type 3 F tests =0.0002). YY genotype is associated with decreased DRS scores 
and is therefore associated with good outcomes. This SNP was significant in the dichotomized 
analysis (P=0.0002) subjects with 0 copies of Y or heterozygous, have an increase in DRS, and 
therefore poorer outcomes. There was a trend towards significance when evaluating the covariate 
race (genotypes P=0.0862; dichotomized genotype P=0.0599). Caucasian subjects had lower 
DRS scores and therefore better outcomes. There was a trend towards significance when 
evaluating therapeutic hypothermia (P=0.0759). The absence of therapeutic hypothermia was 
associated with a trend of lower DRS scores. (Refer to table 4-8). 
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(Refer to tables 4-7 to 4-9).
The mixed models analyses indicated that the following SNP’s were not significant: 
RS17756073 (genotypes P=0.227; dichotomized genotype P=0.2291); RS1944419 (genotypes 
P=0.4339; dichotomized genotype P=0.2293); RS4941185 (genotypes P=0.3357; dichotomized 
genotype P=0.5137); and RS7236090 (genotypes P=0.1167; dichotomized genotype P=0.249). 
The mixed model with RS949037 genotype XX (P=0.037) with overall genotype 
significant (P for type 3 F tests =0.0094). XX genotype was associated with decreased DRS 
scores and is therefore associated with good outcomes. This SNP was significant in the 
dichotomized analysis YY (P=0.0255) subjects with 2 copies of X or heterozygous, lower DRS 
scores, hence 1 or 2 copies of X are related to better outcomes There was a trend towards 
significance when assessing the therapeutic hypothermia variable in the dichotomized analysis 
with the dichotomized genotypes (P=0.0609). The absence of therapeutic hypothermia was 





















































Figure 4-9: DRS and Hypothermia for SNP rs949037 
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 Table 4-5: Preliminary Mixed Models Analysis for Global Functional Outcomes 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS1026825 201 xx -0.1143 0.6178 0.8819 0.8631 0.6734 0.8945
yy -0.0352 0.8852 0.7578 0.7256
xy
yy & xy 0.1021 0.6308 0.6308 -0.6012 0.752 0.752
xx 
RS12454712 199 xx -0.3608 0.2462 0.3122 2.2884 0.4096 0.6374
yy 0.1076 0.6042 -0.2825 0.8787
xy
xx & xy -0.1928 0.3215 0.3215 0.8128 0.6392 0.6392
yy
RS12968517 200 xx -0.053 0.8017 0.0899* 0.1417 0.9396 0.0722*
yy -0.6093 0.0354* 5.5154 0.0323*
xy
yy & xy -0.1209 0.5371 0.5371 1.4154 0.4163 0.4163
xx 
RS1381548 195 xx -0.0157 0.955 0.9804 0.5343 0.8276 0.9747
yy -0.0432 0.8429 0.03393 0.9861
xy
xx & xy 0.03897 0.8486 0.8486 0.1114 0.9513 0.9513
yy
RS1481031 198 xx -0.1783 0.3891 0.5321 1.7951 0.3294 0.5027
yy 0.1394 0.6751 -0.9535 0.7469
xy
yy & xy 0.2051 0.2968 0.2968 -1.9755 0.259 0.259
xx 
RS17756073 196 xx -0.1358 0.525 0.3823 1.9944 0.2916 0.1981*
yy -0.4394 0.1673* 4.8816 0.0797*
xy
yy & xy 0.02052 0.9171 0.9171 -0.6964 0.6903 0.6903
xx 
RS17759659 197 xx 0.4732 0.0249* 0.0524* -4.7556 0.0114* 0.0325*
yy -0.0504 0.8615 -0.4299 0.8673
xy
yy & xy -0.4848 0.0153* 0.0153* 4.6576 0.0089* 0.0089*
xx 
RS1801018 199 xx 0.4464 0.084* 0.0923* -4.5709 0.0458* 0.0298*
yy 0.4156 0.084* -4.6159 0.0174*
xy
xx & xy -0.2704 0.1827* 0.1827* 3.1398 0.0813* 0.0813*
yy
RS1944419 192 xx -0.2987 0.2096 0.3303 3.125 0.1424* 0.3075
yy 0.0826 0.7374 0.1354 0.9503
xy
yy & xy 0.3253 0.1465* 0.1465* -3.0811 0.1244* 0.1244*
xx 
RS3810027 196 xx 0.1009 0.6318 0.8667 -0.667 0.7217 0.8271
yy 0.1206 0.7036 -1.6432 0.554
xy
yy & xy -0.0746 0.7068 0.7068 0.2722 0.9967 0.9967
xx 
* p≤ 0.2
Preliminary Mixed Models Analysis for Global Funcational Outcomes
DRSGOS
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Table 4-5 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS4456611 193 xx -0.2262 0.3468 0.5268 2.3024 0.2866 0.4656
yy -0.2216 0.3655 2.0398 0.3446
xy
yy & xy 0.1541 0.4965 0.4965 -1.6217 0.4255 0.4255
xx 
RS4941185 195 xx -0.3443 0.1188* 0.0376* 2.5731 0.1886* 0.0272*
yy -0.6379 0.0141* 6.1868 0.0079*
xy
yy & xy 0.1509 0.4693 0.4693 -0.6868 0.7106 0.7106
xx 
RS7230970 193 xx 0.1165 0.6602 0.8506 -2.0889 0.3702 0.6176
yy 0.1102 0.6198 -1.4009 0.4821
xy
xx &xy -0.0744 0.7183 0.7183 0.7376 0.6899 0.6899
yy
RS7236090 193 xx -0.1148 0.6197 0.0966* 1.8843 0.3546 0.0121*
yy 0.4436 0.0753* -5.0602 0.0211*
xy
yy & xy 0.2661 0.2195 0.2195 -3.6046 0.061* 0.061*
xx 
RS8083946 200 xx 0.2847 0.2802 0.543 -2.4921 0.2877 0.4966
yy 0.1421 0.5159 0.08201 0.9663
xy
xx &xy -0.0457 0.819 0.819 -0.9192 0.6051 0.6051
yy
RS899968 195 xx -0.2583 0.3395 0.6309 1.7189 0.4837 0.7668
yy -0.0939 0.6636 0.8627 0.655
xy
xx &xy 0.01604 0.936 0.936 -0.3535 0.8431 0.8431
yy
RS949037 194 xx 0.4098 0.1042* 0.197* -4.1966 0.064* 0.1441*
yy -0.0214 0.9238 -0.1662 0.9335
xy
xx &xy 0.1611 0.437 0.437 -1.2295 0.508 0.508
yy
Covariates
Time (Months) 201 3 -0.3347 <.0001* <.0001* 1.8984 <.0001* <.0001*
6 -0.1686 0.0008* 0.5673 0.0325*
12 -0.0887 0.0806* 0.03159 0.906
24
Age 201 -0.0352 <.0001* <.0001* 0.2919 <.0001* <.0001*
GCS  201 1.0036 <.0001* <.0001* -10.058 <.0001* <.0001*
Gender 201 -0.3766 0.1085* 0.1085* 2.8824 0.1696* 0.1696*
Race 201 -0.3677 0.3485 0.3485 -1.7531 0.6144 0.6144
Hypothermic 200 0.1095 0.6511 0.6511 -2.0581 0.3417 0.3417
Hypoxia  142 0.2509 0.3814 0.3814 -3.2762 0.1972* 0.1972*
Hypotensive 142 0.4556 0.2242 0.2242 -5.2691 0.1131* 0.1131*
Seizures  148 -0.558 0.2639 0.2639 6.1357 0.1676* 0.1676*
APOEє4 196 0.03907 0.8645 0.8645 -0.6825 0.7389 0.7389
* p≤ 0.2
DRSGOS
Preliminary Mixed Models Analysis for Global Funcational Outcomes
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 Table 4-6: Primary Mixed Models Analyses of Global Functional Outcomes and BCL-2 SNP's 
Variable
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -0.0256 0.9111 0.0591 yy & xy -0.1623 0.455 0.455 xx 0.2511 0.9012 0.0667 yy & xy 1.4148 0.4585 0.4585
yy -0.7091 0.0242* xx yy 6.1021 0.0277* xx
xy xy
Month 3 -0.3395 <.0001*** <.0001*** 3 -0.3396 <.0001*** <.0001*** 3 1.7602 <.0001*** <.0001*** 3 1.7613 <.0001*** <.0001***
6 -0.1419 0.0205* 6 -0.142 0.0204* 6 0.5209 0.1083 6 0.522 0.1076
12 -0.1112 0.0728 12 -0.1113 0.0726 12 -0.0309 0.9252 12 -0.0312 0.9247
24 24 24 24
Age -0.0337 <.0001*** <.0001*** -0.0344 <.0001*** <.0001*** 0.2853 <.0001*** <.0001*** 0.2938 <.0001*** <.0001***
GCS 0.9993 <.0001*** <.0001*** 1.0457 <.0001*** <.0001*** -10.14 <.0001*** <.0001*** -10.58 <.0001*** <.0001***
Gender -0.4678 0.0728 0.0728 -0.4566 0.0845 0.0845 3.1476 0.1687 0.1687 3.1514 0.1745 0.1745
Race  0.5239 0.152 0.152 0.5277 0.1553 0.1553 -3.5941 0.2589 0.2589 -3.7406 0.247 0.247
Hypoxia -2.7634 0.2361 0.2361 -3.2292 0.1712 0.1712
Seizure 3.2549 0.4401 0.4401 1.6909 0.6883 0.6883
Hypothermia 0.4552 0.1556 0.1556 0.4129 0.2035 0.2035 -5.6043 0.0546 0.0546 -4.9462 0.0924 0.0924
Hypotension 0.3315 0.3471 0.3471 0.3602 0.3143 0.3143 -1.7397 0.58 0.58 -2.0276 0.5249 0.5249
Genotype xx 0.08323 0.7165 0.736 yy & xy -0.1832 0.3851 0.3851 xx -0.8247 0.6757 0.227 yy & xy 1.892 0.2991 0.2991
yy -0.396 0.27077 xx yy 4.1805 0.1699 xx
xy xy
Time 3 -0.3296 <.0001*** <.0001*** 3 -0.0329 <.0001*** <.0001*** 3 1.6994 <.0001*** <.0001*** 3 1.6986 <.0001*** <.0001***
6 -0.1281 0.0386* 6 -0.1276 6 0.4555 0.1651 6 0.4534 0.1671
12 -0.0978 0.1201 12 0.0977 12 -0.1023 0.7597 12 -0.1033 0.7575
24 . 24 24 24
Age -0.0364 <.0001*** <.0001*** -0.0363 <.0001*** <.0001*** 0.3143 <.0001*** <.0001*** 0.3125 <.0001*** <.0001**
GCS 1.0489 <.0001*** <.0001*** 1.0736 <.0001*** <.0001*** -10.4 <.0001** <.0001*** -10.638 <.0001*** <.0001***
Gender -0.3757 0.158 0.158 -0.334 0.2047 0.2047 2.5735 0.2642 0.2642 2.105 0.3571 0.3571
Race  0.4952 0.1795 0.1795 0.4835 0.19 0.19 -3.6254 0.2557 0.2557 -3.4581 0.2795 0.2795
Hypoxia -3.7757 0.1128 0.1128 -3.5179 0.1394 0.1394
Seizure 1.5069 0.7207 0.7207 1.4733 0.7276 0.7276
Hypothermia 0.3822 0.2417 0.2417 0.4047 0.2146 0.2146 -4.4813 0.1265 0.1265 -4.7371 0.1069 0.1069
Hypotension 0.3955 0.2592 0.2592 0.387 0.2697 0.2697 -2.4304 0.4382 0.4382 -2.4173 0.4422 0.4422
Genotype xx 0.847 <.0001*** 0.0003** yy & xy -0.832 <.0001*** <.0001*** xx -7.2388 0.0002** 0.0006** yy & xy 6.949 0.0001*** 0.0001***
yy 0.07353 0.8062 xx yy -1.4389 0.5877 xx
xy xy
Time 3 -0.3475 <.0001*** <.0001*** 3 -0.3474 <.0001*** <.0001*** 3 1.7625 <.0001*** <.0001*** 3 1.7627 <.0001*** <.0001***
6 -0.1297 0.0343* 6 -0.1296 0.0344* 6 0.4667 0.1513 6 0.4666 0.1514
12 -0.1082 0.0814 12 -0.1082 0.0813 12 -0.0741 0.8226 12 -0.0736 0.8239
24 24 24 24
Age -0.0405 <.0001*** <.0001*** -0.0406 <.0001*** <.0001*** 0.3381 <.0001*** <.0001*** 0.339 <.0001*** <.0001***
GCS 0.9565 <.0001*** <.0001*** 0.9562 <.0001*** <.0001*** -9.6293 <.0001*** <.0001*** -9.6263 <.0001*** <.0001***
Gender -0.2488 0.3096 0.3096 -0.2416 0.3185 0.3185 1.2488 0.5638 0.5638 1.1075 0.6051 0.6051
Race  0.6728 0.0521 0.0521 0.6806 0.0477* 0.0477* -4.8495 0.1111 0.1111 -4.9981 0.0984 0.0984
Hypoxia -2.5131 0.2557 0.2557 -2.4304 0.2692 0.2692
Seizure 3.0807 0.4385 0.4385 2.8996 0.463 0.463
Hypothermia 0.2778 0.3603 0.3603 0.2843 0.3456 0.3456 -4.0601 0.1455 0.1455 -4.1747 0.1324 1324
Hypotension 0.334 0.307 0.307 0.3272 0.3135 0.3135 -2.1823 0.4647 0.4647 -2.0922 0.4815 0.4815
RS17759659  (n=139)




* ≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
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 Table 4-6 contined 
Variable
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx 0.3537 0.2009 0.0004** xx & xy -0.7987 0.0002** 0.0002** xx -3.8674 0.11 0.0002** xx & xy 7.1039 0.0002** 0.0002**
yy 0.8987 <.0001*** yy yy -8.1741 <.0001** yy 
xy xy
Time 3 -0.3376 <.0001*** <.0001*** 3 -0.3383 <.0001*** <.0001*** 3 1.7266 <.0001*** <.0001*** 3 1.7285 <.0001*** <.0001***
6 -0.1346 0.0292* 6 -0.1349 0.0289* 6 0.4829 0.1383 6 0.4836 0.1377
12 -0.1121 0.073 12 -0.1125 0.0721 12 -0.0581 0.8605 12 -0.0567 0.864
24 24 24 24
Age -0.0376 <.0001*** <.0001*** -0.0384 <.0001*** <.0001*** 0.3126 <.0001*** <.0001*** 0.3221 <.0001*** <.0001***
GCS 1.0147 <.0001*** <.0001*** 1.0106 <.0001*** <.0001*** -10.221 <.0001*** <.0001*** -10.186 <.0001*** <.0001***
Gender -0.3251 0.1872 0.1872 -0.2755 0.2587 0.2587 1.942 0.3659 0.3659 1.3785 0.5177 0.5177
Race  0.7376 0.0392* 0.0392* 0.7862 0.0277* 0.0277* -5.273 0.0862 0.0862 -5.794 0.0599 0.0599
Hypoxia -1.8446 0.4064 0.4064 -1.488 0.5034 0.5034
Seizure 4.8055 0.2325 0.2325 4.037 0.3151 0.3151
Hypothermia 0.2665 0.3902 0.3902 0.3404 0.2659 0.2659 -4.1436 0.1352 0.1352 -4.8929 0.0759 0.0759
Hypotension 0.3574 0.2763 0.2763 0.3316 0.3127 0.3127 -2.2932 0.4328 0.4328 -2.1867 0.4571 0.4571
Genotype xx -0.2594 0.3096 0.3673 yy & xy 0.3097 0.1973 0.1973 xx 2.1712 0.335 0.4339 yy & xy -2.5393 0.2293 0.2293
yy 0.1485 0.5565 xx yy -1.0388 0.6321 xx
xy xy
Time 3 -0.3374 <.0001*** <.0001*** 3 -0.3376 <.0001*** <.0001*** 3 1.7457 <.0001*** <.0001*** 3 1.7461 <.0001*** <.0001***
6 0.135 0.0331* 6 -0.1347 0.0335* 6 0.4545 0.1764 6 0.4534 0.1774
12 -0.1031 0.1081 12 -0.103 0.1083 12 -0.0989 0.7723 12 -0.099 0.7721
24 24 24 24
Age -0.0329 <.0001*** <.0001*** -0.0335 <.0001*** <.0001*** 0.2818 <.0001*** <.0001*** 0.2856 <.0001*** <.0001***
GCS 1.0488 <.0001*** <.0001*** 1.051 <.0001*** <.0001*** -10.799 <.0001*** <.0001*** -10.817 <.0001*** <.0001***
Gender -0.2678 0.3191 0.3191 -0.2695 0.3148 0.3148 1.1567 0.6213 0.6213 1.1545 0.6209 0.6209
Race  0.4843 0.1868 0.1868 0.4823 0.1875 0.1875 -3.3098 0.2976 0.2976 -3.2846 0.2998 0.2998
Hypoxia -2.7125 0.2611 0.2611 -2.6122 0.2758 0.2758
Seizure 2.1386 0.6145 0.6145 2.2926 0.5871 0.5871
Hypothermia 0.3696 0.2642 0.2642 0.3822 0.2462 0.2462 -4.5781 0.1278 0.1278 -4.713 0.1143 0.1143
Hypotension 0.3401 0.3493 0.3493 0.3247 0.3691 0.3691 -1.6289 0.615 0.615 -1.5405 0.6328 0.6328
Genotype xx -0.2457 0.2868 0.2874 yy & xy 0.1273 0.5567 0.5567 xx 2.1697 0.2824 0.3357 yy & xy -1.2376 0.5137 0.5137
yy -0.4326 0.1433 xx yy 3.4122 0.1857 xx
xy xy
Time 3 -0.3426 <.0001*** <.0001*** 3 -0.3417 <.0001*** <.0001*** 3 1.7592 <.0001*** <.0001*** 3 1.7564 <.0001*** <.0001***
6 -0.1339 0.0291 6 -0.1335 0.0296* 6 0.5149 0.1167 6 0.5141 0.1173
12 -0.1122 0.0711 12 -0.1116 0.0727 12 -0.0325 0.9223 12 -0.0339 0.9191
24 24 24 24
Age -0.0358 <.0001*** <.0001*** -0.0349 <.0001*** <.0001*** 0.3063 <.0001*** <.0001*** 0.2992 <.0001*** <.0001***
GCS 0.9982 <.0001*** <.0001*** 1.0453 <.0001*** <.0001*** -10.255 <.0001*** <.0001*** -10.629 <.0001*** <.0001***
Gender -0.3401 0.1877 0.1877 -0.392 0.1272 0.1272 2.2038 0.3268 0.3268 2.5998 0.245 0.245
Race  0.5014 0.1784 0.1784 0.4423 0.234 0.234 -3.4924 0.2789 0.2789 -3.0207 0.3472 0.3472
Hypoxia -3.2135 0.1825 0.1825 -3.3843 0.1612 0.1612
Seizure 1.2542 0.7683 0.7683 1.5083 0.7237 0.7237
Hypothermia 0.3896 0.2324 0.2324 0.3847 0.2402 0.2402 -4.7146 0.1128 0.1128 -4.6755 0.1169 0.1169
Hypotension 0.3751 0.2961 0.2961 0.3656 0.3103 0.3103 -2.2304 0.4867 0.4867 -2.0742 0.5186 0.5186
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
RS1801018   (n=141)
RS1944419  (n=138)
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Variable
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Ty
Genotype xx -0.0219 0.9288 0.138 yy & xy 0.1739 0.4572 0.4572 xx 1.1494 0.5893 0.1167 yy & xy -2.3443 0.249 0.249
yy 0.5052 0.0652 xx yy -4.0751 0.0852 xx
xy xy
Time 3 -0.3378 <.0001*** <.0001*** 3 -0.3366 <.0001*** <.0001*** 3 1.7236 <.0001*** <.0001*** 3 1.7208 <.0001*** <.0001***
6 -0.1292 0.0354* 6 -0.1287 0.0363* 6 0.4639 0.1526 6 0.4611 0.1551
12 -0.1072 0.0847 12 -0.1075 0.0842 12 -0.0653 0.8427 12 -0.0644 0.8449
24 24 24 24
Age -0.0363 <.0001*** <.0001*** -0.0356 <.0001*** <.0001*** 0.305 <.0001*** <.0001*** 0.2999 <.0001*** <.0001***
GCS 1.0229 <.0001*** <.0001*** 1.0539 <.0001*** <.0001*** -10.181 <.0001*** <.0001*** -10.501 <.0001*** <.0001***
Gender -0.4313 0.0921 0.0921 -0.4046 0.1164 0.1164 3.022 0.1755 0.1755 2.7781 0.2153 0.2153
Race  0.7414 0.0588 0.0588 0.5252 0.1629 0.1629 -5.7685 0.0902 0.0902 -3.9841 0.2215 0.2215
Hypoxia -3.0492 0.1929 0.1929 -2.9755 0.2071 0.2071
Seizure 1.5105 0.7177 0.7177 1.7048 0.6854 0.6854
Hypothermia 0.3722 0.2531 0.2531 0.4257 0.1937 0.1937 -4.711 0.1082 0.1082 -5.1979 0.0775 0.0775
Hypotension 0.2937 0.3992 0.3992 0.3483 0.3202 0.3202 -1.5677 0.6156 0.6156 -1.9938 0.5251 0.5251
Genotype xx 0.5303 0.0425* 0.0074** xx & xy 0.5428 0.0168* 0.0168* xx -4.8164 0.037* 0.0094** xx & xy -4.4511 0.0255* 0.0255*
yy -0.3604 0.1333 yy yy 2.9064 0.164 yy 
xy xy
Time 3 -0.3343 <.0001*** <.0001*** 3 -0.3332 <.0001*** <.0001*** 3 1.7356 <.0001*** <.0001*** 3 1.7335 <.0001*** <.0001***
6 -0.1298 0.0348* 6 -0.1282 0.0371* 6 0.4818 0.1457 6 0.4763 0.1503
12 -0.1025 0.0997 12 -0.1025 0.0998 12 -0.0592 0.8605 12 -0.0579 0.8634
24 24 24 24
Age -0.0388 <.0001*** <.0001*** -0.0387 <.0001*** <.0001*** 0.3244 <.0001*** <.0001*** 0.325 <.0001*** <.0001***
GCS 1.0187 <.0001*** <.0001*** 1.0357 <.0001*** <.0001*** -10.263 <.0001*** <.0001*** -10.436 <.0001*** <.0001***
Gender -0.3143 0.2144 0.2144 -0.3036 0.2361 0.2361 1.7571 0.4327 0.4327 1.7117 0.4509 0.4509
Race  0.3388 0.3389 0.3389 0.4523 0.2024 0.2024 -1.8825 0.5444 0.5444 -2.9236 0.3473 0.3473
Hypoxia -1.381 0.5509 0.5509 -2.0047 0.3896 0.3896
Seizure 3.031 0.4568 0.4568 2.4372 0.5539 0.5539
Hypothermia 0.3156 0.3197 0.3197 0.4405 0.163 0.163 -4.5249 0.1153 0.1153 -5.4111 0.0609 0.0609
Hypotension 0.2392 0.4743 0.4743 0.3288 0.3279 0.3279 -1.532 0.6118 0.6118 -2.1826 0.4736 0.4736
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
RS7236090  (n=139)
RS949037 (n=137)









 Primary Generalized Mixed Models Analyses for Mortality  
Among the full models analyzed, time was consistently found to be related to an increase 
in mortality the further from the time of the injury (i.e. 24 months post injury compared to 3 
months post injury (Type 3 X2 <.0001; OR= 3.75- 4.36). Increasing age was consistently related 
associate with an increase in mortality (P<.0001; Type 3 X2 =0.0002; OR=1.1). A statistical 
trend was found for the dichotomized GCS covariate; people who are admitted with a higher 
GCS had a decrease in mortality GCS (P<.0001; Type 3 X2 <.0001; OR= 0.08). (Refer to tables 
4-12 to 4-14), 
The mixed model with SNP RS12968517, genotype YY is significant (P=0.0115; OR= 
6.38) with overall genotype marginally significant (Type 3 X2 =0.0493). YY genotype was 
associated with increase in mortality. A significant statistical trend was not present in the 
dichotomized genotype analysis (P=0.2544; OR= 1.79). Hypothermia was found to been 
marginally significant in the models (genotypes Type 3 X2=0.0534; OR= 0.24; dichotomized 
genotype Type 3 X2=0.0863; OR= 0.27) having higher mortality. (Refer to table 4-12). 
The mixed model with RS17759659, genotype XX is significant (P=.0092; OR= 0.17) 
with overall genotype significant (Type 3 X2=0.0075). XX genotype was associated with 
decreased mortality. This SNP was significant in the dichotomized analysis (Type 3 X2=0.0031; 
OR=5.05); subjects with 0-1 copies of X had an increase in mortality. (Refer to table 4-12). 
The mixed model with RS1801018 genotype YY is significant (P=0.0026; OR= 0.14) 
with overall genotype significant (Type 3 X2=0.0055). YY genotype was associated with 
survival. This SNP was significant in the dichotomized analysis (Type 3 X2=.0035; OR= 5.01); 
subjects with 1-2 copies of Y are associated with mortality. Race was found to been marginally 
significant in the models (genotypes Type 3 X2=0.0621; OR= 0.18; dichotomized genotype Type 
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 3 X2=0.056; OR= 0.16). Caucasians have higher survival rate. Hypothermia was found to been 
marginally significant in the models [genotypes Type 3 X2=0.1057; OR= 1/0.26 (3.8); 
dichotomized genotype Type 3 X2=0.0702; OR= 1/0.23 (4.3)] having lower mortality. (Refer to 
table 4-13). 
The mixed model with RS7230970 genotype XX (P=0.0548; OR= 0.19) and YY 
(P=0.0582; OR= 0.30) showed trends towards significance with overall genotype (Type 3 
X2=0.054). XX and YY genotypes are both associated with a decrease in mortality. These trends 
were not significant in the XX dichotomized analysis (Type 3 X2=0.17; OR= 2.09). Hypothermia 
was found to been significant in the models [genotypes Type 3 X2=0.0227, OR= 1/0.09 (11.1); 
dichotomized genotype Type 3 X2=0.0446; OR= 1/0.17 (5.89)] having higher mortality. (Refer 
to table 4-13). 
The mixed model with RS949037 overall genotypes showed trends towards significance 
(Type 3 X2=0.0551) while YY was not statically significant, the OR indicated a trend (P=0.2827; 
OR= 1.9) and was related to increased mortality. This trend was not significant in the 
dichotomized analysis [1-2 copies of YY] ( Type 3 X2=0.1112, OR= 0.41). There was also a 
trend towards statistical significance when evaluating therapeutic hypothermia in the models 
[genotypes Type 3 X2=0.0688, OR= 1/0.24 (4.2)]; dichotomized genotype Type 3 X2=0.0599, 
OR= 1/0.22 (4.5)] having higher mortality. (Refer to table 4-14). 
The mixed models analyses indicated that the following SNP’s were not significant: 
RS17756073 (genotypes Type 3 X2=0.7177; dichotomized genotype Type 3 X2=0.9098, OR= 
1.05); RS4941185 (genotypes Type 3 X2=0.8593; dichotomized genotype Type 3 X2=0.6581, 
OR= 0.81); and RS7236090 (genotypes Type 3 X2=0.5572; dichotomized genotype Type 3 
X2=0.9116, OR= 0.95). (Refer to tables 4-12 to 4-14). 
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Summary of Global Functional Outcome Results 
In analyzing the 17 BCL-2 SNP’s genotype and dichotomized genotype data there are 
four SNP’s which have significant findings. In the GOS, DRS, and mortality models  
RS12968517 was associated with poor outcomes. The 2 SNP’s (RS17759659 andRS1801018) 
were associated with good outcomes across the GOS, DRS, and mortality rates. SNP RS949037 
was significantly related to good outcomes for GOS and DRS, however a trend was identified in 
the mortality outcome. Time points of the assessment, age, and GCS on admission were 
consistently significant across all of the models. Gender, race, and hypothermia were on occasion 
implicated as potential significant covariates in the mixed models/ generalized mixed models. 
(Refer to tables 4-7 to 4-9 and 4-12 to 4-14). 
 
 Table 4-7: Preliminary Generalized Mixed Models of Mortality Outcomes 
 
 
BCL-2 SNP n= Genotype coefff Odds Ratio Z Type 3 X 2 
RS1026825 201 xx 0.2626 1.3003065 -0.4744 0.9996 0.4849 0.7371
yy -0.0299 0.9705426 -0.809 0.7491 0.94
xy
yy & xy -0.2737 0.7605602 -0.9504 0.4029 0.4278 0.4373
xx 
RS12454712 199 xx 0.299 1.3485096 -0.6821 1.2802 0.5502 0.7525
yy -0.0883 0.9154862 -0.7734 0.5969 0.8006
xy
xx & xy 0.1625 1.1764483 -0.4733 0.7984 0.6163 0.6155
yy
RS12968517 200 xx 0.009 1.0090406 -0.7045 0.7226 0.9802 0.1177*
yy 0.9176 2.5032753 0.0415 1.7937 0.0401
xy
yy & xy 0.2864 1.331625 -0.3488 0.9216 0.3769 0.3732
xx 
RS1381548 195 xx 0.1099 1.1161664 -0.7869 1.0066 0.8103 0.8293
yy 0.2207 1.2469493 -0.4843 0.9258 0.4843
xy
xx & xy -0.1907 0.8263805 -0.8518 0.4703 0.5718 0.5757
yy
RS1481031 198 xx -0.0576 0.9440275 -0.7207 0.6054 0.8648 0.9355
yy -0.2009 0.8179942 -1.3258 0.9239 0.7262
xy
yy & xy 0.0212 1.0214263 -0.6147 0.6571 0.948 0.948
xx 
RS17756073 196 xx 0.4096 1.5062152 -0.3216 1.1409 0.2722 0.2853*
yy 0.74 2.0959355 -0.2159 1.6958 0.1292
xy
yy & xy -0.1686 0.8448468 -0.8039 0.4668 0.6031 0.6031
xx 
RS17759659 197 xx -0.6401 0.5272397 -1.3673 0.0871 0.0845 0.1953*
yy -0.1457 0.864417 -1.0464 0.755 0.7512
xy
yy & xy 0.6064 1.8338178 -0.0883 1.3012 0.0871 0.0737*
xx 
RS1801018 199 xx -0.7312 0.481331 -1.6051 0.1428 0.1011 0.2143*
yy -0.3758 0.6867397 -1.0883 0.3368 0.3013
xy
yy & xy 0.1535 1.1659078 -0.517 0.8239 0.6537 0.6498
xx 
RS1944419 192 xx 0.1924 1.2121553 -0.5649 0.9498 0.6185 0.882
yy 0.0333 1.0338607 -0.7899 0.8565 0.9368
xy
yy & xy -0.1813 0.8341851 -0.8912 0.5286 0.6166 0.6219
xx 
RS3810027 196 xx -0.3122 0.7318351 -0.9922 0.3679 0.3683 0.6354
yy -0.3237 0.7234673 -1.3871 0.7397 0.5507
xy
yy & xy 0.2419 1.2736668 -0.4052 0.8889 0.4638 0.4615
xx 
Preliminary Generalized Mixed Models of Mortality Outcomes
  *  =X 2  p≤ 0.3
95% Confidence 
Limits
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 Table 4-7 contiued 
BCL-2 SNP n= Genotype coefff Odds Ratio Z Type 3 X 2 
RS4456611 193 xx 0.434 1.5434189 -0.3481 1.2162 0.2768 0.4351
yy 0.4092 1.5056128 -0.3555 1.1739 0.2943
xy
yy & xy -0.2862 0.7511124 -0.10075 -0.4351 0.4367 0.449
xx 
RS4941185 195 xx 0.5056 1.65798 -0.2195 1.2307 0.1718 0.2763*
yy 0.5488 1.7311744 -0.2873 1.385 0.1983
xy
yy & xy -0.3199 0.7262217 -0.9819 0.3421 0.3436 0.3528
xx 
RS7230970 193 xx -0.6641 0.5147366 -1.533 0.2048 0.1341 0.2953*
yy -0.2481 0.7802819 -0.9758 0.4795 0.5039
xy
xx & xy 0.0503 1.0515865 -0.63 0.7305 0.8849 0.8845
yy 
RS7236090 193 xx 0.3519 1.4217663 -0.3616 1.0654 0.3337 0.0994*
yy -0.6465 0.5238761 -1.5802 0.2872 0.1747
xy
yy & xy -0.5295 0.5888993 -1.2037 0.1447 0.1237 0.136*
xx 
RS8083946 200 xx -0.4074 0.665378 -1.2951 0.4803 0.3684 0.6376
yy -0.078 0.9249644 -0.7697 0.6137 0.8252
xy
xx & xy -0.0497 0.9515148 -0.6899 0.5905 0.8791 0.8793
yy
RS899968 195 xx 0.6605 1.93576 -0.2241 1.5452 0.1434 0.366
yy 0.2676 1.3068243 -0.4461 0.9813 0.4624
xy
xx & xy -0.0646 0.9374424 -0.7078 0.5787 0.844 0.8443
yy
RS949037 194 xx -0.3035 0.7382299 -1.2092 0.6021 0.5113 0.579
yy 0.1797 1.1968583 -0.5278 0.8872 0.6187
xy
xx & xy -0.2646 0.7675129 -0.9291 0.4 0.4352 0.4417
yy
Covariates
Time (Months) 201 24 0.9395 1 0.7023 1.1768 <.0001 <.0001*
12 0.3544 2.5587017 0.19 0.5188 <.0001
6 0.1366 1.4253252 0.007 0.2662 0.0388
3
Age 201 0.0485 1.0496954 0.0263 0.0707 <.0001 <.0001*
GCS  201 -1.6171 0.1984734 -2.2825 -0.9517 <.0001 <.0001*
Gender 201 0.4001 1.4919739 -0.328 1.1282 0.2814 0.3014
Race 201 -0.7055 0.4938616 -1.8623 0.4513 0.232 0.2963
Hypothermic 200 -0.1005 0.9043851 -0.8372 0.6362 0.7892 0.7911
Hypoxia  142 0.2899 1.3362939 -0.5809 1.1607 0.5141 0.5055
Hypotensive 142 -0.5568 0.5730399 -1.654 0.5404 0.3199 0.3437
Seizures  148 1.2025 3.3284276 -0.9324 3.3373 0.2696 0.1658*
APOEε4 196 -0.0238 0.976481 -0.7643 0.7167 0.9497 0.9499
  *  =X 2  p≤ 0.3
Preliminary Generalized Mixed Models of Mortality Outcomes
 95% Confidence 
Limits
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 Table 4-8:  Primary Generalized Mixed Models Analyses of Mortality Outcomes and BCL-2 SNP's 
Genotype coefff
Odds 
Ratio Z Type 3 X 2 Genotype coefff
Odds 
Ratio Z Type 3 X 2 
Genotype xx -0.0382 0.96252 -1.1453 1.0690 0.9461 0.0493* yy & xy 0.5804 1.786753 -0.4325 1.5934 0.2614 0.2544
yy 1.8525 6.37574 0.4154 3.2897 .0115* xx 
xy
Time (Months) 24 1.4739 4.36623 1.0512 1.8966 <.0001*** <.0001*** 24 1.4125 4.106208 0.9897 1.8353 <.0001*** <.0001***
12 0.5011 1.65054 0.2187 0.7835 .0005** 12 0.4979 1.645263 0.2187 0.7771 .0005**
6 0.1718 1.18744 -0.0747 0.4184 0.1719 6 0.1675 1.182345 -0.0712 0.4062 0.169
3 3
Age 0.0772 1.08026 0.0370 0.1174 .0002** 0.0005** 0.0709 1.073474 0.0356 0.1062 <.0001*** 0.0005**
GCS  -2.5193 0.08052 -3.6508 -1.3878 <.0001*** <.0001*** -2.518 0.080621 -3.5229 -1.5131 <.0001*** <.0001***
Gender 0.7537 2.12485 -0.3053 1.8127 0.163 0.1179 0.762 2.142557 -0.3224 1.8464 0.1684 0.1837
Race -1.1605 0.31333 -2.5421 0.2212 0.0997* 0.1569 -1.233 0.291417 -2.5915 0.1256 0.0753 0.139
Hypothermic -1.4352 0.23807 -2.6872 -0.1831 .0247* 0.0534 -1.312 0.269281 -2.6522 0.0282 0.055 0.0863
Hypotensive -0.6907 0.50123 -1.9734 0.5920 0.2912 0.3018 -0.6924 0.500374 -2.0532 0.6685 0.3187 0.3269
Seizures  0.2778 1.32022 -1.7165 2.2721 0.7848 0.7731 0.1926 1.212398 -1.9718 2.357 0.8615 0.8571
Genotype xx 0.1646 1.17892 -0.8534 1.1825 0.7513 0.7177 yy & xy 0.0529 1.054324 -0.8617 0.9675 0.9098 0.9098
yy 0.6714 1.95698 -0.9339 2.2767 0.4123 xx 
xy
Time (Months) 24 1.3487 3.85241 0.9261 1.7714 <.0001*** <.0001*** 24 1.3447 3.837035 0.9301 1.7954 <.0001*** <.0001***
12 0.4792 1.61478 0.1981 0.7602 .0008** 12 0.4883 1.629544 0.2039 0.7726 .0008**
6 0.1667 1.1814 -0.0810 0.4143 0.1871 6 0.1615 1.175272 -0.0871 0.4101 0.2028
3 3
Age 0.0758 1.07875 0.0416 0.1101 <.0001*** 0.0002** 0.0751 1.077992 0.0399 0.1102 <.0001*** 0.0002**
GCS  -2.5665 0.0768 -3.6133 -1.5197 <.0001*** <.0001*** -2.6023 0.074103 -3.6346 -1.57 <.0001*** <.0001***
Gender 0.6053 1.8318 -0.4828 1.6935 0.2756* 0.2938 0.4987 1.646579 -0.5748 1.5721 0.3625 0.3787
Race -1.08 0.3396 -2.5153 0.3553 0.1403 0.1973 -1.0514 0.349448 -2.4062 0.3033 0.1282 0.1949
Hypothermic -1.395 0.24783 -2.7864 -0.0036 0.0494* 0.0751 -1.4306 0.239165 -2.7794 -0.0817 0.0376* 0.0645
Hypotensive -0.4364 0.64636 -1.7413 0.8685 0.5122 0.5133 -0.3877 0.678616 -1.7081 0.9327 0.565 0.5645
Seizures  0.3646 1.43994 -1.8449 2.5740 0.7464 0.7331 0.4045 1.498553 -1.7852 2.5942 0.7173 0.7015
Genotype xx -1.7814 0.1684 -3.1219 -0.4408 0.0092** 0.0075** yy & xy 1.6195 5.050564 0.3189 2.9202 .0147* 0.0031**
yy -0.6233 0.53617 -1.9120 0.6655 0.3432 xx 
xy
Time (Months) 24 1.3191 3.74005 0.8818 1.7564 <.0001*** <.0001*** 24 1.2805 3.598438 0.8419 1.719 <.0001*** <.0001***
12 0.5505 1.73412 0.2228 0.8782 0.001** 12 0.5353 1.707961 0.2136 0.857 .0011**
6 0.1561 1.16894 -0.1029 0.4151 0.2375 6 0.1477 1.159165 -0.1043 0.3998 0.2506
3 3
Age 0.0918 1.09615 0.0471 0.1366 <.0001*** <.0001*** 0.0909 1.095159 0.0469 0.1348 <.0001*** <.0001***
GCS  -2.6174 0.07299 -3.7840 -1.4509 <.0001*** <.0001*** -2.5867 0.075268 -3.7247 -1.4487 <.0001*** <.0001***
Gender 0.5786 1.78354 -0.5629 1.7202 0.3205 0.3399 0.5144 1.672635 -0.6347 1.6634 0.3803 0.394
Race -1.2239 0.29408 -2.5108 0.0629 0.0623 0.1087 -1.3282 0.264954 -2.6139 -0.0425 .0429* 0.0961
Hypothermic -1.2639 0.28255 -2.7850 0.2572 0.1034 0.1241 -1.3064 0.270793 -2.8266 -0.2138 0.0921 0.1172
Hypotensive -0.4876 0.6141 -1.8369 0.8616 0.4788 0.479 -0.4479 0.638969 -1.8426 0.9469 0.5291 0.5275
Seizures  0.4462 1.56236 -1.5836 2.4760 0.6666 0.6503 0.3358 1.399059 -1.6832 2.3548 0.7444 0.7329
Variables





Analysis of GEE Parameter Estimates Analysis of GEE Parameter Estimates
95% Confidence 
Limits
Primary Generalized Mixed Models Analyses of  Mortality Outcome and BCL-2 SNP
* X 2  p≤ 0.05; **X 2    p≤ 0.01; ***X 2   p≤ 0.0001  
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 Table 4-8 continued 
Genotype coefff
Odds 
Ratio Z Type 3 X 2 Genotype coefff
Odds 
Ratio Z Type 3 X 2 
Genotype xx -1.0477 0.35074 -2.3834 0.2879 0.1242 0.0055** yy & xy 1.6109 5.007316 0.4024 2.8194 .009** .0035**
yy -1.9454 0.14293 -3.2108 -0.6801 .0026** xx 
xy
Time (Months) 24 1.3458 3.84126 0.9214 1.7702 <.0001*** <.0001*** 24 1.275 3.578701 0.862 1.688 <.0001*** <.0001***
12 0.5362 1.7095 0.2363 0.8361 0.0005** 12 0.4924 1.636238 0.2022 0.7827 .0009**
6 0.2108 1.23467 -0.0432 0.4649 0.1039 6 0.1805 1.197816 -0.0638 0.4248 0.1476
3 3
Age 0.0852 1.08893 0.0449 0.1256 <.0001*** 0.0004** 0.0842 1.087846 0.0451 0.1233 <.0001*** 0.0002**
GCS  -2.7356 0.06486 -3.8590 -1.6122 <.0001*** <.0001*** -2.6201 0.072796 -3.6544 -1.5858 <.0001*** <.0001***
Gender 0.5469 1.72789 -0.6603 1.7542 0.3746 0.3928 0.4031 1.496457 -0.7714 1.5775 0.5012 0.5121
Race -1.7043 0.1819 -3.1224 -0.2862 0.0185 0.0621 -1.8294 0.16051 -3.2378 -0.421 .0109* 0.056
Hypothermic -1.3365 0.26276 -2.8328 0.1598 0.08 0.1057 -1.4903 0.225305 -2.946 -0.0346 .0448* 0.0702
Hypotensive -0.4179 0.65843 -1.7319 0.8961 0.5331 0.5354 -0.3439 0.709 -1.7248 1.037 0.6255 0.6245
Seizures  0.9825 2.67113 -1.4457 3.4107 0.4278 0.4155 0.7289 2.072799 -1.595 3.0529 0.5387 0.522
Genotype xx 0.2696 1.30944 -0.6961 1.2354 0.5843 0.8593 yy & xy -0.2074 0.812695 -1.1236 0.7087 0.6572 0.6581
yy 0.2039 1.22618 -1.2899 1.6977 0.7891 xx 
xy
Time (Months) 24 1.4091 4.09227 0.9832 1.8351 <.0001*** <.0001*** 24 1.4153 4.117722 0.9915 1.839 <.0001*** <.0001***
12 0.4927 1.63673 0.2158 0.7697 0.0005** 12 0.4914 1.634603 0.2134 0.7694 .0005**
6 0.1562 1.16906 -0.0792 0.3915 0.1934 6 0.1556 1.168359 -0.0812 0.3925 0.1978
3 3
Age 0.0744 1.07724 0.0402 0.1086 <.0001*** 0.0002** 0.0739 1.076699 0.0387 0.1092 <.0001*** 0.0002**
GCS  -2.524 0.08014 -3.5678 -1.4802 <.0001*** <.0001*** -2.549 0.07816 -3.5453 -1.5527 <.0001*** <.0001***
Gender 0.5355 1.7083 -0.5311 1.6022 0.3251 0.3358 0.5677 1.764205 -0.4515 1.587 0.275 0.2903
Race -0.9892 0.37187 -2.3365 0.3581 0.1502 0.2067 -0.9665 0.380412 -0.2305 0.3721 0.157 0.2144
Hypothermic -1.2773 0.27879 -2.6708 0.1163 0.0724 0.1085 -1.2792 0.27826 -2.6711 0.1127 0.0717 0.1075
Hypotensive -0.6475 0.52335 -2.0495 0.7545 0.3653 0.3713 -0.6433 0.525555 -2.0401 0.7535 0.3667 0.3724
Seizures  0.2266 1.25433 -1.9994 2.4525 0.8419 0.8372 0.2784 1.321014 -1.9475 2.5043 0.8064 0.7997
Genotype xx -1.6522 0.19163 -3.3382 0.0339 0.0548 0.054 yy & xy 0.7371 2.089866 -0.3661 1.8404 0.1904 0.17
yy -1.2079 0.29882 -2.4578 0.0420 0.0582 xx 
xy
Time (Months) 24 1.4528 4.27507 0.9700 1.9356 <.0001*** <.0001*** 24 1.4012 4.060069 0.9589 1.8436 <.0001*** <.0001***
12 0.4944 1.63951 0.1801 0.8087 0.0021** 12 0.4863 1.626288 0.198 0.7745 .0009**
6 0.1776 1.19435 -0.1128 0.4681 0.2306 6 0.1512 1.163229 -0.1028 0.4051 0.2433
3 3
Age 0.0971 1.10197 0.0585 0.1357 <.0001*** <.0001*** 0.0882 1.092207 0.0523 0.1241 <.0001*** <.0001***
GCS  -3.4687 0.03116 -4.9089 -2.0285 <.0001*** <.0001*** -2.9738 0.051109 -3.9907 -1.957 <.0001*** <.0001***
Gender 0.5176 1.678 -0.6071 1.6423 0.3671 0.3852 0.5945 1.812125 -0.539 1.728 0.304 0.3246
Race -1.7047 0.18183 -3.1846 -0.2248 0.024* 0.0856 -1.0361 0.354836 -2.4629 0.3907 0.1547 0.2165
Hypothermic -2.3842 0.09216 -4.1698 -0.5986 0.0089** 0.0227* -1.749 0.173948 -3.2171 -0.281 .0195* 0.0446*
Hypotensive 0.1158 1.12277 -1.4269 1.6585 0.883 0.8835 -0.465 0.628135 -1.8723 0.9422 0.5172 0.5136
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Genotype coefff
Odds 
Ratio Z Type 3 X 2 Genotype coefff
Odds 
Ratio Z Type 3 X 2 
Genotype xx -0.1195 0.88736 -1.1331 0.8942 0.8173 0.5572 yy & xy -0.0565 0.945066 -1.0552 0.9421 0.9117 0.9116
yy -0.7971 0.45063 -2.3619 0.7678 0.3181 xx 
xy
Time (Months) 24 1.2943 3.64844 0.8887 1.6999 <.0001*** <.0001*** 24 1.3305 3.782934 0.9203 1.7408 <.0001*** <.0001***
12 0.4459 1.5619 0.1797 0.7121 0.001** 12 0.4796 1.615428 0.1968 0.7625 .0009**
6 0.1367 1.14648 -0.0975 0.3709 0.2526 6 0.156 1.168826 -0.0902 0.4022 0.2144
3 3
Age 0.0781 1.08123 0.0405 0.1158 <.0001*** 0.0002** 0.0764 1.079394 0.0413 0.1114 <.0001*** 0.0002**
GCS  -2.5966 0.07453 -3.6382 -1.5549 <.0001*** <.0001*** -2.617 0.073022 -3.6345 -1.5995 <.0001*** <.0001***
Gender 0.6854 1.98457 -0.4002 1.7711 0.2159 0.2234 0.5763 1.779442 -0.4628 1.6154 0.277 0.2903
Race -1.384 0.25057 -3.0015 0.2335 0.0935 0.1336 -1.0701 0.342974 -2.4741 0.3338 0.1352 0.1885
Hypothermic -1.4222 0.24118 -2.8239 -0.0205 .0467* 0.0691 -1.4428 0.236265 -2.8362 -0.0494 .0424* 0.0634
Hypotensive -0.3188 0.72702 -1.7484 1.1109 0.6621 0.6636 -0.3783 0.685025 -1.7204 0.9639 0.5807 0.5801
Seizures  0.5124 1.66929 -1.6629 2.6877 0.6443 0.6301 0.4144 1.513462 -1.769 2.5977 0.7099 0.6954
Genotype xx -1.101 0.33254 -2.4680 0.2661 0.1145 0.0551 yy & xy -0.8862 0.412219 -1.9451 0.1728 0.101 0.1112
yy 0.6168 1.85299 -0.5086 1.7422 0.2827 xx 
xy
Time (Months) 24 1.2459 3.47606 0.8257 1.6661 <.0001*** <.0001*** 24 1.2937 3.646253 0.872 1.7154 <.0001*** <.0001***
12 0.4171 1.51755 0.1368 0.6974 0.0035** 12 0.446 1.562051 0.1626 0.7294 .002**
6 0.1257 1.13394 -0.1126 0.3640 0.3011 6 0.1289 1.137576 -0.1116 0.3695 0.2935
3 3
Age 0.0802 1.0835 0.0443 0.1162 <.0001*** 0.0002** 0.078 1.081123 0.0427 0.1133 <.0001*** 0.0003**
GCS  -2.4704 0.08455 -3.5463 -1.3945 <.0001*** <.0001*** -2.4448 0.086743 -3.4938 -1.3958 <.0001*** <.0001***
Gender 0.5398 1.71566 -0.6561 1.7356 0.3764 0.3943 0.5063 1.659141 -0.6514 1.6641 0.3913 0.4088
Race -0.911 0.40212 -2.4244 0.6025 0.2381 0.2738 -1.1254 0.324523 -2.6401 0.3892 0.1453 0.1996
Hypothermic -1.4116 0.24375 -2.7640 -0.0592 .0408* 0.0688 -1.5125 0.220358 -2.8862 -0.1388 .0309* 0.0599
Hypotensive -0.2086 0.81172 -1.5624 1.1451 0.7626 0.7621 -0.3431 0.709567 -1.6722 0.9859 0.6129 0.6125
Seizures  0.4395 1.55193 -1.7440 2.6230 0.6932 0.6782 0.2914 1.3383 -1.8547 2.4375 0.7902 0.7807
* X 2  p≤ 0.05; **X 2    p≤ 0.01; ***X 2   p≤ 0.0001 
Variables
RS949037 (n=137) this was an add on b/c of the drs/ gos results
Primary Generalized Mixed Models Analyses of  Mortality Outcome and BCL-2 SNP
RS7236090 (n=139)
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 4.2.1.2 Cognitive Behavioral Outcomes  
Sub-sample description; Cognitive-Behavioral Outcomes: NRS-R 
The mean age of the overall sample of 94 subjects was 31.24 years old (range 16-67; 
SD± 12.07). The sample was primarily Caucasian (n=91; 96.8%) and male (n=75; 79.8%). The 
majority of the sample genotyped had admission GCS of 6-8 (n=71; 75.5%). Of the subjects 
enrolled in the study (n=21; 22.3%) received therapeutic hypothermia.  In the overall sample, the 
presence of hypoxia (n=12; 12.77%), hypotension (n=6; 6.38%), and documented seizures (n=6; 
6.98%), and the genotype of APOE ε4 (n=22; 23.4%) were considered. Refer to table 4-15 for 
sample description. All of the SNP’s genotyped for the overall sample met the HWE criteria for 
genotype representation in a population. Refer to table 4-15 for genotype frequencies for each 
SNP and HWE calculations. 
NRS-R was analyzed at the 3, 6, and 12 month outcome time points. The time point of 24 
months was excluded due to low sample size. Descriptive statistics for the NRS-R score are 
included in table #. The mean of the NRS-R scores consistent, ranging from 40.3-41.9 over the 
year of outcome measures. There was a consistent level of mild to moderate cognitive-behavioral 
issues among the subjects.  
Preliminary Mixed Models Analysis for Cognitive-Behavioral Outcomes: NRS-R 
In the preliminary mixed models analyses, each SNP was analyzed individually for a 
relationship with NRS-R over time. Each of the covariates was analyzed for potential 
relationship with NRS-R. By doing this the SNP’s and covariates of interest in building the 
larger model were ascertained. The criterion used was a P for Type 3 tests of ≤0.2 in addition to 
covariates that were deemed prudent through the evidence in the literature (age, gender, race, 
GCS, and hypothermia). (Refer to table 4-16). 
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 The preliminary mixed model analyses for NRS-R indicated that the SNP’s and 
covariates of interest, meeting the criterion were: RS12454712 (genotypes P=0.0456; 
dichotomized genotype P=0.233); RS1481031 (genotypes P=0.1249; dichotomized genotype 
P=0.3432); RS17756073 (genotypes P=0.2039; dichotomized genotype P=0.0881); RS17759659 
(genotypes P=0.0776; dichotomized genotype P=0.02668); RS 1944419 (genotypes P=0.1585; 
dichotomized genotype P=0.1382; RS4456611 (genotypes P=0.18888; dichotomized genotype 
P=0.0765); RS7236090 (genotypes P=0.0272; dichotomized genotype P=0.0072); age (P= 
0.0019); and seizures (P= 0.0748).  Time (months) (P=0.8966), GCS (P=0.3761), gender (P= 
0.9465), race (P=0.2342), and hypothermia (P= 0.2865) were not indicated to be significant in 
the preliminary analysis, however, they were controlled for in the full model. (Refer to table 4-
16). 
 
Primary Mixed Models Analyses for Cognitive-Behavioral Outcomes: NRS-R 
The sample size for the primary analysis of the full model was n=61 compared to the 
n=94 in the preliminary analyses. The decrease in the sample size was due to unknown/ missing 
data for the seizure variable. In analyzing the 7 BCL-2 SNP’s of interest there were two SNP’s 
which had significant findings. (Refer to tables 4-17 and 4-18). 
The mixed model with SNP RS17756073: genotype XX (P= 0.0514) with overall 
genotype marginally significant (P for type 3 F tests =0.1041). XX genotype was associated with 
a decrease in NRS-R scores and therefore is associated with better outcomes. This trend was 
significantly evident in the dichotomized analysis (P=0.0331); subjects with no X alleles or only 
1 X allele(YY and XY) had significantly higher NRS-R scores, worse outcomes. A documented 
presence of seizures preadmission were found to been marginally significant (genotypes 
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P=0.0544; dichotomized genotype P=0.0519) and associated with higher NRS-R scores. (Refer 
to table 4-17). 
The mixed models analysis with RS4456611 in the full model resulted in trends towards 
significance on all accounts, overall genotype (P for type 3 F tests =0.0992). This trend was 
evident in the dichotomized analysis (P=0.065) with YY being associated with higher NRS-R 
scores, indicating poorer outcomes; Subjects with 0-1 copies of the Y allele have trend of better 
outcomes. Age was found to trend towards significance (genotypes P=0.0805; dichotomized 
genotype P=0.0684). Increasing age was associated with having higher NRS-R scores and 
therefore poor outcomes. Seizure was found to trend towards significance (genotypes P=0.0812; 
dichotomized genotype P=0.0732). A documentation of pre-admission seizures was related to 
having higher NRS-R scores compared to those without known seizures and therefore poorer 
outcomes. (Refer to table 4-18). 
The mixed models analyses indicated that the following SNP’s were not significant 
predictors of NRS-R: RS12454712 (genotypes P=0.4012; dichotomized genotype P=0.2214); 
RS1481031 (genotypes P=0.9115; dichotomized genotype P=0.6693); RS17759659 (genotypes 
P=0.3314; dichotomized genotype P=0.4579); RS1944419 (genotypes P=0.8539; dichotomized 
genotype P=0.6165) and RS7236090 (genotypes P=0.2497; dichotomized genotype P=0.0959). 
Among the models for SNP’s that were not significant, age and seizures on pre admission were 
covariates of interest in the model with trending statistical significance (age, P= 0.0379-0.0789; 
seizures, P=0.0388-0.0783). Increasing age and preadmission seizures were consistently 
associated with poor outcomes in this subsample. (Refer to tables 4-17 and 4-18). 
  
 
 Table 4-9: BCL-2 Genotypes and NRS-R Descriptive Data 
Variable n= Mean Std. Deviation Range





GCS 94 score 3 to 5 23(24.5%) 0
score 6 to 8 71(75.5%)
Gender (male) 94 75(79.8%) 0
Race (Caucasian) 94 91(96.8%) 0
Hypothermic 94 21(22.3%) 0
Hypoxia 59 12(12.77%) 35 (37.23%)
Hypotensive 59 6(6.38%) 35 (37.23%)
 Seizures 61 6(6.38%) 31 (35.12)
APOE4  90 22(23.4%) 4 (4.26%)
NRS-R n= Mean Std. Deviation Range
Frequency 
(%)of Unknown
 3 months 64 40.3 9.89 29-75 30(31.91%)
 6 months 74 40.74 9.41 29-74 20 (21.28%)
 12 months 69 41.9 12.97 29-85 25 (26.6%)
SNP n= XX YY XY X Y HWE
RS1026825 94 25 26 43 0.494680851 0.50531915 1.0000
RS12454712 94 9 46 39 0.303191489 0.69680851 1.0000
RS12968517 94 44 11 39 0.675531915 0.32446809 1.0000
RS1381548 90 15 37 38 0.377777778 0.62222222 1.0000
RS1481031 92 35 11 46 0.630434783 0.36956522 1.0000
RS17756073 93 39 13 41 0.639784946 0.36021505 1.0000
RS17759659 94 38 15 41 0.622340426 0.37765957 1.0000
RS1801018 93 26 32 35 0.467741935 0.53225806 1.0000
RS1944419 91 22 20 49 0.510989011 0.48901099 1.0000
RS3810027 93 42 11 40 0.666666667 0.33333333 1.0000
RS4456611 90 16 25 49 0.45 0.55 1.0000
RS4941185 90 28 14 48 0.577777778 0.42222222 1.0000
RS7230970 88 20 25 43 0.471590909 0.52840909 1.0000
RS7236090 90 26 25 39 0.505555556 0.49444444 1.0000
RS8083946 93 16 38 39 0.38172043 0.61827957 1.0000
RS899968 92 13 39 40 0.358695652 0.64130435 1.0000
RS949037 91 22 33 36 0.43956044 0.56043956 1.0000
 BCL-2 Genotypes and NRS-R Descriptive Data
Hardy-Weinberg Equilibrium
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 Table 4-10: Preliminary Mixed Models Analyses BCL-2 vs. NRS-R 
SNP n= Genotype coefff P P for Type-3 Test SNP n= Genotype coefff P P for Type-3 Test 
RS1026825 94 xx -3.1409 0.1986* 0.3753 RS4456611 90 xx -1.2087 0.6544 0.1888*
yy 0.04537 0.9849 yy 3.6873 0.1175*
xy xy
xx & xy -1.2178 0.5832 0.5832 xx & xy -3.9777 0.0765* 0.0765*
yy yy
RS12454712 94 xx 3.582 0.3079 0.0456* RS4941185 90 xx 0.4017 0.8649 0.7641
yy -3.8089 0.0644* yy -1.8885 0.5287
xy xy
xx & xy 4.4656 0.233 0.233 yy & xy -0.8372 0.7096 0.7096
yy xx 
RS12968517 94 xx -1.3235 0.5359 0.7665 RS7230970 88 xx 0.1218 0.9639 0.8531
yy 0.4897 0.8823 yy 1.3635 0.5881
xy xy
yy & xy 1.4329 0.4731 0.4731 xx & xy -1.3255 0.5726 0.5726
xx yy
RS1381548 90 xx -2.7593 0.3421 0.5796 RS7236090 90 xx -5.9396 0.0121* 0.0272*
yy -1.6521 0.4563 yy -0.287 0.9051
xy xy
xx & xy 0.8825 0.6686 0.6686 yy & xy 5.8278 0.0072* 0.0072*
yy xx 
RS1481031 92 xx -0.877 0.688 0.1249* RS8083946 93 xx 2.408 0.4125 0.7025
yy 6.0508 0.0707* yy 0.3246 0.8831
xy xy
yy & xy 1.9983 0.3432 0.3432 xx & xy 0.357 0.8613 0.8613
xx yy
RS17756073 93 xx -3.8707 0.076* 0.2039 RS899968 92 xx -2.7203 0.3862 0.6626
yy -1.6042 0.5996 yy -1.1659 0.5885
xy xy
yy & xy 3.4654 0.0881* 0.0881* xx & xy 0.5295 0.7931 0.7931
xx yy
RS17759659 94 xx -0.7398 0.7279 0.0776* RS949037 91 xx -2.2179 0.402 0.4586
yy 5.6594 0.0492* yy 1.1366 0.6239
xy xy
yy & xy 2.2554 0.2668 0.2668 xx & xy -1.9536 0.3526 0.3526
xx yy
RS1801018 93 xx 0.4225 0.8659 0.8039 Covariates
yy -1.1793 0.623 Time (Months) 94 3 0.373 0.8006 0.8966
xy 6 -0.2864 0.835
12
xx & xy 1.3612 0.5222 0.5222 Age 94 0.07604 0.0019* 0.0019*
yy GCS  94 2.0633 0.3761 0.3761
RS1944419 91 xx 2.6426 0.2906 0.1585* Gender 94 0.1679 0.9465 0.9465
yy -3.138 0.2226 Race 94 -6.9721 0.2342 0.2342
xy Hypothermic 94 -2.4932 0.2865 0.2865
Hypoxia  59 1.2398 0.6379 0.6379
yy & xy -3.5683 0.1382* 0.1382* Hypotensive 59 2.3247 0.5359 0.5359
xx Seizures  61 -6.7635 0.0748* 0.0748*
RS3810027 93 xx 3.0567 0.1419* 0.2948 APOEє4 90 0.4914 0.8378 0.8378
yy 3.1578 0.32
xy
yy & xy -2.3638 0.2273 0.2273
xx 
Preliminary Mixed Models Anaylsis 
BCL-2 versus NRS-R
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 Table 4-11: Primary Mixed Models Analyses of NRS-R and BCL-2 SNP's 
Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx 3.1112 0.5562 0.4012 xx & xy 2.9552 0.2214 0.2214
yy -2.5692 0.3078 yy
xy
Time (Months) 3 2.0285 0.1496 0.2935 3 2.0103 0.1536 0.2946
6 1.6257 0.2009 6 1.6449 0.1958
12 12
Age 0.1824 0.0789 0.0789 0.1979 0.0475* 0.0475*
GCS 0.6564 0.8316 0.8316 0.9711 0.7473 0.7473
Gender 0.0768 0.9811 0.9811 0.08747 0.9783 0.9783
Race  -4.627 0.4224 0.4224 -4.1425 0.4639 0.4639
Seizure -5.8315 0.1719 0.1716 -6.2428 0.1354 0.1354
Hypothermia -0.7293 0.8252 0.8252 -0.466 0.8857 0.8857
Genotype xx 1.1161 0.6928 0.9115 yy & xy -1.1614 0.6693 0.6693
yy -0.2513 0.9449 xx
xy
Time (Months) 3 2.1546 0.1312 0.2548 3 2.124 0.1366 0.2631
6 1.7452 0.1738 6 1.7296 0.1778
12 12
Age 0.1934 0.0575 0.0575 0.1932 0.055 0.055
GCS 1.6591 0.5957 0.5957 1.6413 0.5948 0.5948
Gender 1.4179 0.6579 0.6579 1.4 0.6582 0.6582
Race  -3.5959 0.5406 0.5406 -3.6597 0.5265 0.5265
Seizure -9.8397 0.0407* 0.0407* -9.8262 0.0388* 0.0388*
Hypothermia 0.6396 0.8489 0.8489 0.6503 0.8445 0.8445
Genotype xx -5.22 0.0514 0.1041 yy & xy 5.248 0.0331* 0.0331*
yy 0.1657 0.9648 xx
xy
Time (Months) 3 2.2143 0.1156 0.2332 3 2.1842 0.1204 0.2412
6 1.7656 0.1635 6 1.7497 0.1674
12 12
Age 0.1639 0.1026 0.1026 0.1639 0.099 0.099
GCS -0.5927 0.8491 0.8491 -0.5964 0.8462 0.8462
Gender 1.2356 0.6912 0.6912 1.215 0.6922 0.6922
Race  -3.1898 0.5752 0.5752 -3.2362 0.5636 0.5636
Seizure -8.0352 0.0544 0.0544 -8.0318 0.0519 0.0519
Hypothermia -0.15 0.9633 0.9633 -0.1669 0.9583 0.9583
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
Primary Mixed Models Analyses of                                                                      
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Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -0.6033 0.8172 0.3314 yy & xy 1.8206 0.4579 0.4579
yy 5.1123 0.1987 xx
xy
Time (Months) 3 2.0576 0.1426 0.2658 3 2.0428 0.1462 0.2735
6 1.7384 0.1698 6 1.7181 0.1756
12 12
Age 0.213 0.0379* 0.0379* 0.2065 0.0444* 0.0444*
GCS 2.2396 0.4796 0.4796 1.5404 0.6226 0.6226
Gender 0.2679 0.9329 0.9329 0.9047 0.7746 0.7746
Race  -5.1003 0.3748 0.3748 -4.8255 0.4024 0.4024
Seizure -7.7964 0.0701 0.0701 -6.7008 0.1122 0.1122
Hypothermia 0.6227 0.8503 0.8503 -0.0621 0.9849 0.9849
Genotype xx 1.3005 0.681 0.8539 yy & xy -1.514 0.6165 0.6165
yy -0.7463 0.7962 xx
xy
Time (Months) 3 2.0911 0.138 0.2689 3 2.0543 0.1449 0.2796
6 1.6992 0.1813 6 1.6787 0.1867
12 12
Age 0.1839 0.0783 0.0783 0.1893 0.0617 0.0617
GCS 1.4943 0.6451 0.6451 1.4049 0.6545 0.6545
Gender 0.7488 0.8176 0.8176 0.8273 0.7958 0.7958
Race  -4.4672 0.4406 0.4406 -4.3924 0.4431 0.4431
Seizure -6.8657 0.1076 0.1076 -6.8218 0.106 0.106
Hypothermia -0.1416 0.966 0.966 -0.1802 0.9562 0.9562
Genotype xx -3.2884 0.2627 0.0992 xx & xy -4.9777 0.065 0.065
yy 3.9228 0.1673 yy
xy
Time (Months) 3 2.2506 0.1017 0.1905 3 2.2222 0.1066 0.1992
6 1.9197 0.1128 6 1.8983 0.1277
12 12
Age 0.1567 0.0805 0.0805 0.1632 0.0684 0.0684
GCS 0.6409 0.8222 0.8222 -0.2486 0.9277 0.9277
Gender -1.9713 0.5119 0.5119 -1.0876 0.7073 0.7073
Race  -2.1103 0.707 0.707 -1.532 0.784 0.784
Seizure -6.5108 0.0812 0.0812 -6.6863 0.0732 0.0732
Hypothermia -1.1029 0.7041 0.7041 -0.9036 0.7551 0.7551
Genotype xx -4.0415 0.1535 0.2497 yy & xy 4.2506 0.0959 0.0959
yy 0.5587 0.8588 xx
xy
Time (Months) 3 2.0173 0.1554 0.2967 3 1.9991 0.1584 0.3002
6 0.16508 0.196 6 1.6451 0.1972
12 12
Age 0.1857 0.0634 0.0634 0.1859 0.0601 0.0601
GCS 0.8952 0.7673 0.7673 0.9049 0.7622 0.7622
Gender 0.5163 0.8694 0.8694 0.5334 0.8635 0.8635
Race  -2.8704 0.6293 0.6293 -3.1854 0.5729 0.5729
Seizure -6.4849 0.1209 0.1209 -6.5703 0.1096 0.1096
Hypothermia 0.3886 0.9076 0.9076 0.5308 0.8688 0.8688
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
RS4456611   (n=60)
Primary Mixed Models Analyses of                                                                      
NRS-R as Cognitive-Behavioral Outcome and BCL-2 SNP








 Sub-sample Description   Cognitive-Behavioral Outcomes: Trails Making Tests 
The mean age of the overall sample of 30 subjects was 33.17 years old (range 17-60; 
SD± 11.002). The sample was primarily Caucasian (n=24; 88.9%) and male (n=22; 81.5%). The 
majority of the sample had admission GCS of 6-8 (n=19; 70.4%) (See figure 4-10). Only 2 
(7.4%) of the subjects in this sub-sample received therapeutic hypothermia.  In the overall 
sample the presence of sustained hypoxia (n=1; 4 %), hypotension (n=1; 4 %), documented pre-
admission seizures (n=0) and the presence of APOE ε4 (n=6; 23.1%) were considered. Refer to 
table 4-19 for sample description. All of the SNP’s genotyped for the overall sample met the 
HWE criteria for genotype representation in a population. Refer to table 4-19 for genotype 
frequencies for each SNP and HWE calculations.  










































Figure 4-10: Trails Making Tests & Dichotomized GCS 
Trails A and Trails B were analyzed at the 3, 6, and 12 month outcome time points. The 
sample size at the 3 month outcomes evaluation is low (n=6; 77.8% missing data). In summer of 
2005, the decision to stop collecting Trails Making Test data at the 3 month time point was made 
due to inability of subjects to participate at this early stage of recovery.  The higher percentage of 
subjects in vegetative state and severe disability as indicated in the 3 months GOS scores (ref to 
   141
 table 4-19) effected eligibility to perform the test. The sample size for the 6 month and 12 month 
outcomes are equal (n=22; 18.5% missing data). Trails A scores (measured in seconds) improve 
with time, indicating that the subject’s attention to task improves. Trails B scores (measured in 
seconds) improve with time, indicating that the subject’s mental flexibility improves with time as 
well. (Refer to table 4-19). 
Preliminary Mixed Models Analysis for Cognitive-Behavioral Outcomes: Trails Making 
Tests 
In the preliminary mixed models analyses, each SNP was analyzed individually for a 
relationship with Trails A and Trails B over time. Each of the covariates were analyzed for 
potential relationship with Trails A and Trails B. By doing this the SNP’s and covariates of 
interest in building the larger model were ascertained. The  criterion used was a P for Type 3 
tests of ≤0.2 in addition to covariates that are deemed prudent through the evidence in the 
literature (age, gender, race, GCS, hypothermia).  
Trails A 
The preliminary mixed model analyses for Trails A indicated that the SNP’s of interest 
meeting the significance criterion were: RS12454712 (genotypes P=0.3136; dichotomized 
genotype P=0.1229); RS12968517(genotypes P=0.2941; dichotomized genotype P=0.1281);  RS 
1381548 (genotypes P=0.0695; dichotomized genotype P=0.0225); RS1481031 (genotypes 
P=0.024; dichotomized genotype P=0.7551); RS 17756073 (genotypes P=0.0916; dichotomized 
genotype P=0.2669); RS 17759659 (genotypes P=0.2924; dichotomized genotype P=0.1766); RS 
1801018 (genotypes P=0.1043; dichotomized genotype P=0.0475); RS3810027 (genotypes 
P=0.0238; dichotomized genotype P=0.1893); RS4941185 (genotypes P=0.0373; dichotomized 
genotype P=0.0838); RS7236090 (genotypes P=0.0215; dichotomized genotype P=0.1866); and 
   142
 RS8083946 (genotypes P=0.0709; dichotomized genotype P=0.3083).  The covariates of interest 
were: GCS (P= 0.1314), hypothermia (P= 0.0191), hypoxia (P= 0.1535), and hypotension (P= 
0.1535), however hypoxia and hypotension were not included in the models due to low sample 
size in each group (n=1). (Refer to table 4-20 and 4-21). 
 The covariates not meeting the statistical criterion, but included in the full models were: 
time (months) (P=0.6923); age (P= 0.7936); Gender (P= 0.467) and Race (P=0.4104). (Refer to 
table 4-20 and 4-21). 
Trails B 
The preliminary mixed model analyses for Trails B indicated that the SNP’s of interest 
meeting the criterion were: RS12454712 (genotypes P=0.26; dichotomized genotype P=0.1013);  
RS 1381548 (genotypes P=0.1167; dichotomized genotype P=0.037);); RS 17756073 (genotypes 
P=0.1129; dichotomized genotype P=0.1133); RS 1801018 (genotypes P=0.1835; dichotomized 
genotype P=0.1008); RS4941185 (genotypes P=0.3783; dichotomized genotype P=0.1825); 
RS7236090 (genotypes P=0.1592; dichotomized genotype P=0.4147); and RS8083946 
(genotypes P=0.1664; dichotomized genotype P=0.1606).  The covariates of interest were: time 
(months) (P=0.1135), hypothermia (P= 0.0549), hypoxia (P= 0.1682), and hypotension (P= 
0.1682), however hypoxia and hypotension were not included in the models due to low sample 
size in each group (n=1). (Refer to table 4-20 and 4-21). 
The covariates not meeting the statistical criterion, but included in the full models were: 
age (P= 0.3197), GCS (P= 0.2635), Gender (P= 0.8871) and Race (P=0.52). (Refer to table 4-20 
and 4-21). 
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 While the following SNP’s  did not meet the criterion for Trails B, but did meet the criterion for 
Trails A, RS12968517, RS1481031, RS17759659, and  RS3810027. Full models were 
considered for these SNP’s in the primary analyses for comparison to Trails A results.  
 
 Primary Mixed Models Analysis for Trails Making Tests 
Primary Mixed Models Analysis for Trails A 
The mixed model with SNP RS12968517: genotype XX (P= 0.0305) with overall 
genotype trending towards significance (P for type 3 F tests =0.087). XX genotype is associated 
with decrease Trails A scores and was therefore associated with better outcomes (attention). This 
trend was evident in the dichotomized analysis (P=0.0289). Subjects with 0-1 copies of the X 
allele have higher Trails A scores and therefore poorer outcomes. The covariates in this model 
that were significant to Trails A were; GCS was found to been significantly associated with 
Trails A (genotypes P=0.0119; dichotomized genotype P=0.0108), with higher GCS scores on 
admission being associated with higher Trails A scores (longer times); poor outcomes. 
Compared to the subjects in the hypothermia protocol, those who were not hypothermic were 
found to have significantly higher Trails A scores (genotypes P=0.0218; dichotomized genotype 
P=0.0208); poor outcomes. (Refer to table 4-22). 
The mixed model with SNP RS13815487: genotype YY (P= 0.0515) with overall 
genotype not significant (P for type 3 F tests =0.1203). YY genotype is associated with decrease 
Trails A scores and was therefore associated with better outcomes (attention). This trend was 
evident in the dichotomized analysis (P=0.0366). Subjects with 0-1 copies of the Y allele have 
higher Trails A scores and therefore poorer outcomes. The covariates in this model that were 
significant to Trails A were; GCS was found to been significant (genotypes P=0.0529; 
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 dichotomized genotype P=0.0438), with higher GCS scores on admission being associated with 
higher Trails A scores (longer times); poor outcomes. Compared to the subjects in the 
hypothermia protocol, those who were not hypothermic were found to have significantly higher 
Trails A scores (genotypes P=0.0338; dichotomized genotype P=0.0291); poor outcomes. (Refer 
to table 4-23). 
The mixed model with SNP RS3810027: genotype XX (P= 0.0196); and YY (P= 0.0351) 
with overall genotype significant (P for type 3 F tests =0.032). Compared to subjects with 
heterozygous (XY), subjects who were homozygous for wild type or he variant, had significantly 
higher Trails A scores and was therefore associated with poorer outcomes (attention). GCS was 
found to been significant (genotypes P=0.4196; dichotomized genotype P=0.0669), with higher 
GCS scores on admission being associated with higher Trails A scores (longer times); poor 
outcomes. Compared to the subjects in the hypothermia protocol, those who were not 
hypothermic were found to have significantly higher Trails A scores (genotypes P=0.0079; 
dichotomized genotype P=0.0064); poor outcomes. (Refer to table 4-25). 
The mixed model with SNP RS7236090: genotype XX (P= 0.0396); and YY (P= 0.0387) 
with overall genotype marginally significant (P for type 3 F tests =0.0577). Compared to subjects 
with heterozygous (XY), subjects who were homozygous for wild type or he variant, had 
significantly lower Trails A scores and was therefore associated with good outcomes. (Refer to 
table 4-26). 
The mixed model with SNP RS8083946: genotype XX (P= 0.0285) with overall 
genotype showed trends towards statistical significance (P for type 3 F tests =0.0835). XX 
genotype was associated with higher Trails A scores and was therefore associated with poor 
outcomes; decreased attention. This trend was not evident in the dichotomized analysis 
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 (P=0.8682). The covariates in this model that showed trends towards significance in relation to 
Trails A were; GCS (genotypes P=0.1211; dichotomized genotype P=0.0657), with higher GCS 
scores on admission being associated with higher Trails A scores (longer times); poor outcomes. 
Compared to the subjects in the hypothermia protocol, those who were not hypothermic were 
found to have trends towards significantly higher Trails A scores (genotypes P=0.0079; 
dichotomized genotype P=0.0064); poor outcomes. (Refer to table 4-26). 
Primary Mixed Models Analysis for Trails B  
The mixed model with SNP RS1381548: genotype YY (P= 0.044) with overall genotype  
was non-significant (P for type 3 F tests =0.1195). However, in the dichotomized analysis, YY 
genotype was associated with decrease Trails B scores and was therefore associated with better 
outcomes (mental flexibility) (P=.0391). In contrast, subjects with 0-1 copies of the Y allele have 
significantly higher Trails B scores. The covariates in this model that showed trends towards 
significance to Trails B were; time (genotypes P=0.0733; dichotomized genotype P=0.069) as 
Trails B tests administered closer to time of injury (3 month evaluation compared to 12 months 
post injury) had longer Trails B time scores indicating that less mental flexibility. GCS was 
found to been marginally significant (genotypes P=0.0809; dichotomized genotype P=0.0788), 
with higher GCS scores on admission being associated with higher Trails B scores (longer 
times); poor outcomes. Compared to the subjects in the hypothermia protocol, those who were 
not hypothermic were found to have marginally significantly higher Trails B scores (genotypes 
P=0.0681; dichotomized genotype P=0.0655); poor outcomes. (Refer to table 4-23). 
The mixed model with SNP RS17756073: genotype XX (P= 0.0532) with overall 
genotype was non-significantly associated with Trails B scores (P for type 3 F tests =0.1456). 
Individuals with two copies of the X allele had lower Trails B scores and therefore associated 
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with better outcomes (mental flexibility). This trend was evident in the dichotomized analysis 
with a marginal significant relationship between the SNP and Trails B scores (P=0.0516). 
Individuals with 0-1 copies of X had higher Trails B time and was associated with decreased 
mental flexibility. The covariates in this model that were marginally /significant to Trails B 
were; GCS (genotypes P=0.0736; dichotomized genotype P=0.0714), with higher GCS scores on 
admission being associated with higher Trails B scores (longer times), higher GCS are associated 
with poor outcomes. Compared to the subjects in the hypothermia protocol, those who were not 
hypothermic were found to have marginally significantly higher Trails B scores (genotypes 
P=0.1415; dichotomized genotype P=0.0319); poor outcomes. (Refer to table 4-24). 
In summary, among the SNP analyzed for scores on the Trails Making Tests (Trails A 
and Trails B), RS1381548 was implicated as a SNP of interest. Higher GCS on admission was 
found to have statistically significantly higher Trails A and Trails B scores or poorer outcomes 
compared to subjects admitted with a lower GCS score.
 Table 4-12: BCL-2 Genotypes Versus Trails Making Tests Descriptive Data 
Variables n= Mean Std. Deviation Range





GCS 27 score 3 to 5 8 (29.6%) 0
score 6 to 8 19(70.4%)
Gender (male) 27 22(81.5%) 0
Race (Caucasian) 27 24(88.9%) 0
Hypothermic 27 2(7.4%) 0
Hypoxia 25 1(4%) 2 (7.41%)
Hypotensive 25 1(4%) 2 (7.41%)
Seizures 27 0 0
APOEε4   26 6(23.1%) 1 (3.7%)
Trails Making Tests n= Mean Std. Deviation Range
Frequency % of 
Unknown
Trails A
 3 months 6 33.5 13.31 19-54 21(77.8%)
 6 months 22 41.05 16.66 15-79 5(18.5%)
12 months 22 36.91 18.96 10-83 5(18.5%)
Trails B
3 months 6 89.17 36.68 44-131 21(77.8%)
 6 months 22 95.87 57.35 3-300 5(18.5%)
12 months 22 85.95 38.91 33-179 5(18.5%)
SNP n= XX YY XY X Y HWE
RS1026825 10 5 12 27 0.592592593 0.40740741 1.0000
RS12454712 4 11 12 27 0.37037037 0.62962963 1.0000
RS12968517 15 2 10 27 0.740740741 0.25925926 1.0000
RS1381548 5 8 14 27 0.444444444 0.55555556 1.0000
RS1481031 11 4 12 27 0.62962963 0.37037037 1.0000
RS17756073 15 1 11 27 0.759259259 0.24074074 1.0000
RS17759659 15 2 9 26 0.75 0.25 1.0000
RS1801018 4 16 7 27 0.277777778 0.72222222 1.0000
RS1944419 5 6 16 27 0.481481481 0.51851852 1.0000
RS3810027 10 5 12 27 0.592592593 0.40740741 1.0000
RS4456611 7 6 13 26 0.519230769 0.48076923 1.0000
RS4941185 10 2 15 27 0.648148148 0.35185185 1.0000
RS7230970 6 11 10 27 0.407407407 0.59259259 1.0000
RS7236090 4 11 11 26 0.365384615 0.63461538 1.0000
RS8083946 8 9 10 27 0.481481481 0.51851852 1.0000
RS899968 7 9 10 26 0.461538462 0.53846154 1.0000
RS949037 10 5 11 26 0.596153846 0.40384615 1.0000
 BCL-2 Genotypes Versus Trails Making Tests Descriptive Data
Hardy-Weinberg Equilibrium
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 Table 4-13: Preliminary Mixed Models Analyses for the Trails Making Tests 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS1026825 27 xx 4.5196 0.5166 0.805 4.9557 0.8011 0.7158
yy 1.4964 0.8633 19.9951 0.4188
xy
yy & xy -4.0879 0.522 0.522 0.7902 0.9655 0.9655
xx
RS12454712 27 xx 0.2609 0.9763 0.3136 6.681 0.7907 0.26
yy -9.4225 0.1585* -26.96 0.1538*
xy
xx & xy 9.4965 0.1229* 0.1229* 28.6688 0.1013 0.1013*
yy
RS12968517 27 xx -8.4604 0.1965* 0.2941 6.4201 0.7367 0.931
yy 4.8798 0.6823 -1.6717 0.9626
xy
yy & xy 9.3073 0.1281* 0.1281* -6.7412 0.7033 0.7033
xx
RS1381548 27 xx 4.1072 0.5896 0.0695* -4.8366 0.8279 0.1167*
yy -13.49 0.0459* -39.719 0.0443*
xy
xx & xy 14.6129 0.0225* 0.0225* 38.5489 0.037* 0.037*
yy
RS1481031 27 xx -2.18 0.7344 0.024* -11.881 0.5201 0.2376
yy -15.097 0.0841* -42.662 0.0943*
xy
yy & xy -1.9702 0.7551 0.7551 0.6783 0.9699 0.9699
xx
RS17756073 27 xx -8.9559 0.1348* 0.0916* -31.977 0.0669* 0.1129*
yy -33.488 0.0606* -65.31 0.1747*
xy
yy & xy 6.7477 0.2669 0.2669 27.2651 0.1133* 0.1133*
xx
RS17759659 26 xx 10.5502 0.1262* 0.2924 8.6219 0.6686 0.846
yy 9.8784 0.4188 18.544 0.6141
xy
yy & xy -8.6282 0.1766* 0.1766* -5.0944 0.7842 0.7842
xx
RS1801018 27 xx 7.7341 0.4243 0.1043* 23.7917 0.3925 0.1835*
yy 14.8893 0.0371* 37.2176 0.0688*
xy
xx & xy -12.239 0.0475* 0.0475* -28.837 0.1008* 0.1008*
yy
RS1944419 27 xx 9.9139 0.2218 0.2974 18.9721 0.4196 0.5419
yy -4.5381 0.5361 20.3002 0.3516
xy
xx & xy 6.9173 0.338 0.338 -15.76 0.4496 0.4496
yy
RS3810027 27 xx 13.6042 0.0313* 0.0238* 7.9726 0.6731 0.2583
yy 19.3832 0.0168* 39.4572 0.1052*
xy
yy & xy -8.2504 0.1893* 0.1893* 3.3622 0.8536 0.8536
xx
* p≤ 0.2
Preliminary  Mixed Models Anaylsis BCL-2 versus Trails Making Tests 
Trails A  Trails B
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 Table 4-13 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS4456611 26 xx 5.5315 0.4607 0.4869 -9.0855 0.6845 0.9189
yy 8.9745 0.2604 -3.7355 0.8739
xy
xx & xy -7.0888 0.3388 0.3388 0.5397 0.9803 0.9803
yy
RS4941185 27 xx 13.1124 0.0322* 0.0373* 25.5936 0.1701* 0.3783
yy 21.7224 0.0596* 15.2361 0.658
xy
yy & xy -10.667 0.0838* 0.0838* -23.889 0.1825* 0.1825*
xx
RS7230970 27 xx 8.6351 0.2944 0.5671 2.8771 0.9042 0.8987
yy 3.9647 0.5725 -6.9887 0.7324
xy
xx & xy -0.6542 0.9175 0.9175 8.0703 0.653 0.653
yy
RS7236090 26 xx -21.263 0.0151* 0.0215* -45.353 0.0854* 0.1592*
yy -14.675 0.0225* -27.738 0.149*
xy
xx & xy 8.3842 0.1866* 0.1866* 14.9231 0.4147 0.4147
yy
RS8083946 27 xx 14.7858 0.0408* 0.0709* 26.6297 0.2031 0.1664*
yy -0.0049 0.9995 -13.914 0.4901
xy
xx & xy 6.6697 0.3083 0.3083 25.8721 0.1606* 0.1606*
yy
RS899968 26 xx 2.2068 0.7866 0.8722 -5.5186 0.8118 0.6348
yy -2.0584 0.7848 -20.019 0.356
xy
xx & xy 2.9521 0.6547 0.6547 17.7382 0.3511 0.3511
yy
RS949037 26 xx -1.8485 0.7963 0.9568 -19.274 0.3494 0.6175
yy -2.0285 0.8213 -15.266 0.5493
xy
yy & xy 1.3037 0.8414 0.8414 14.6773 0.4337 0.4337
xx
Covariates
Time (months) 27 3 3.6677 0.5706 0.6923 27.7681 0.0555* 0.1135*
6 3.1438 0.4275 12.7622 0.1395*
12 . .
Age 27 -0.0776 0.7936 0.7936 0.823 0.3197 0.3197
GCS 27 9.9724 0.1314* 0.1314* 21.0076 0.2635 0.2635
Gender 27 -5.952 0.467 0.467 -3.2324 0.8871 0.8871
Race 27 -7.7874 0.4104 0.4104 -17.328 0.52 0.52
Hypothermic 27 26.1905 0.0191* 0.0191* 61.1685 0.0549* 0.0549*
Hypoxia 25 21.97 0.1535* 0.1535* 60.5626 0.1682* 0.1682*
Hypotensive 25 21.97 0.1535* 0.1535* 60.5626 0.1682* 0.1682*
Seizures 0
APOEε4 26 5.592 0.4444 0.4444 9.5593 0.6512 0.6512
* p≤ 0.2
NA NA
Preliminary  Mixed Models Anaylsis BCL-2 versus Trails Making Tests 
Trails A  Trails B
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 Table 4-14: Primary Mixed Models Analyses for Trails Making Tests and BCL-2 SNP's 
Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx 3.667 0.6936 0.4561 xx & xy 7.4566 0.2298 0.2298 xx 31.8107 0.2337 0.1668 xx & xy 26.9143 0.14 0.14
yy -6.6763 0.312 yy yy -20.3132 0.2745 yy 
xy xy
Time (months) 3 3.9187 0.5409 0.7422 3.8272 0.548 0.7378 3 28.2084 0.0522 0.1218 3 28.4536 0.05* 0.1149
6 2.5664 0.5156 2.6333 0.5025 6 11.514 0.1838 6 11.8489 0.1707
12 12 12
Age -0.01647 0.9567 0.9567 -0.0564 0.8406 0.8406 1.1506 0.1811 0.1811 0.8142 0.3187 0.3187
GCS 15.1863 0.0416* 0.0416* 14.3327 0.04* 0.04* 44.6549 0.0331* 0.0331* 37.8349 0.0599 0.0599
Gender    3.0716 0.7183 0.7183 2.4834 0.7627 0.7627 22.1635 0.3481 0.3481 16.9955 0.4685 0.4685
Race  0.7567 0.9391 0.9391 -0.5447 0.9526 0.9526 17.934 0.5246 0.5246 6.8439 0.7995 0.7995
Hypothermia 26.52 0.036* 0.036* 26.0353 0.0346* 0.0346* 63.7296 0.0692 0.0692 59.9851 0.0882 0.0882
Genotype xx -15.6631 0.0305* 0.087 yy & xy 14.3516 0.0289* 0.0289* xx 2.7219 0.9039 0.8951 yy & xy -5.8154 0.7773 0.7773
yy -5.4007 0.619 xx yy -13.6506 0.708 xx
xy xy
Time (months) 3 5.4142 0.3966 0.6052 5.477 0.3888 0.5985 3 29.2066 0.048* 0.113 3 29.1621 0.0477* 0.1129
6 3.1092 0.4289 3.1113 0.427 6 11.84 0.1758 6 11.7712 0.1774
12 12 12
Age -0.09896 0.7108 0.7108 -0.07557 0.7699 0.7699 0.7539 0.3948 0.3948 0.8115 0.343 0.343
GCS 18.2788 0.0119* 0.0119* 17.1832 0.0108* 0.0108* 33.5792 0.138 0.138 30.9802 0.1406 0.1406
Gender    9.6927 0.2565 0.2565 9.1529 0.2708 0.2708 11.0431 0.6839 0.6839 0.97425 0.7115 0.7115
Race  -5.9533 0.5012 0.5012 -6.1913 0.4756 0.4756 5.9296 0.8426 0.8426 5.4075 0.8529 0.8529
Hypothermia 26.1369 0.0218* 0.0218* 25.7196 0.0208* 0.0208* 76.8013 0.0417* 0.0417* 75.8718 0.039* 0.039*
Trails A Trails B
RS12454712 (n=27) 
RS12968517 (n=27)
Primary  Mixed Models Analyses of  Cognitive- Behavioral Outcomes: Trails Making Tests and BCL-2 SNP
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001  
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Table 4-14 continued 
Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx 0.1532 0.9842 0.1203 xx & xy 12.9308 0.0366* 0.0366* xx -7.24 0.7513 0.1195 xx & xy 37.5431 0.0391* 0.0391*
yy -12.8583 0.0515 yy yy -39.2619 0.044* yy 
xy xy
Time (months) 3 6.3216 0.3291 0.5413 3 6.2883 0.329 0.5356 3 0.325211 0.0286* 0.0733 3 32.6531 0.0273* 0.069
6 3.2988 0.4061 6 3.3353 0.3964 6 12.5058 0.1536 6 12.751 0.1429
12 12 12 12
Age 0.02737 0.9205 0.9205 0.02702 0.9182 0.9182 1.0229 0.2117 0.2117 1.0702 0.1756 0.1756
GCS 12.8173 0.0529 0.0529 12.8165 0.0438* 0.0438* 33.6835 0.0809 0.0809 32.6457 0.0788 0.0788
Gender    -1.3161 0.8698 0.8698 -1.2906 0.8682 0.8682 3.158 0.8909 0.8909 4.2545 0.8487 0.8487
Race  -2.7622 0.7546 0.7546 -2.751 0.7456 0.7456 1.7135 0.9481 0.9481 0.2885 0.9909 0.9909
Hypothermia 24.6427 0.0338* 0.0338* 24.5304 0.0291* 0.0291* 61.7036 0.0681 0.0681 60.4372 0.0655 0.0655
Genotype xx -1.7675 0.7934 0.2611 yy & xy 2.4441 0.7274 0.7274 xx -20.9682 0.295 0.2192 yy & xy 23.0362 0.2612 0.2612
yy -18.8485 0.1139 xx yy -46.015 0.185 xx
xy xy
Time (months) 3 4.6394 0.4674 0.7167 3 4.2165 0.5112 0.7211 3 29.0819 0.0471* 0.1132 3 28.4989 0.0507 0.1149
6 2.3144 0.5547 6 2.6218 0.5057 6 11.4957 0.1864 6 12.0174 0.1664
12 12 12 12
Age 0.02717 0.9245 0.9245 -0.04162 0.8877 0.8877 1.1198 0.1839 0.1839 0.9805 0.2497 0.2497
GCS 9.1083 0.2195 0.2195 13.6126 0.0631 0.0631 28.594 0.1842 0.1842 38.9161 0.0641 0.0641
Gender    -6.6272 0.5178 0.5178 2.4292 0.7844 0.7844 0.7965 0.9781 0.9781 22.0559 0.3818 0.3818
Race  -14.7801 0.2928 0.2928 0.3684 0.9726 0.9726 -16.8972 0.6783 0.6783 19.9491 0.5226 0.5226
Hypothermia 17.0883 0.2615 0.2615 31.9764 0.0179* 0.0179* 55.899 0.2096 0.2096 90.6725 0.0203* 0.0203*
Trails A Trails B
RS1381548  (n=27)
RS1481031 (n=27)
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
Primary  Mixed Models Analyses of  Cognitive- Behavioral Outcomes: Trails Making Tests and BCL-2 SNP
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Table 4-14 continued 
Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -8.347 0.164 0.3471 yy & xy 7.4562 0.1958 0.1958 xx -33.7229 0.0532 0.1456 yy & xy 32.2942 0.0516 0.0516
yy -15.5602 0.5007 xx yy -24.4641 0.7041 xx
xy xy
Time (months) 3 3.4323 0.594 0.7615 3 3.7909 0.5524 0.7324 3 27.6693 0.0581 0.1286 3 27.849 0.0551 0.1227
6 2.6153 0.5095 6 2.713 0.491 6 11.8794 0.1728 6 11.9242 0.1696
12 12 12 12
Age 0.007088 0.9802 0.9802 0.01269 0.9642 0.9642 1.0894 0.1827 0.1827 1.0984 0.1705 0.1705
GCS 13.6389 0.0478* 0.0478* 13.2431 0.0507 0.0507 34.5537 0.0736 0.0736 33.9206 0.0714 0.0714
Gender    1.5482 0.861 0.861 -0.4497 0.9566 0.9566 7.412 0.7617 0.7617 4.2598 0.8502 0.8502
Race  -1.8591 0.8396 0.8396 -2.3175 0.7987 0.7987 0.2351 0.9929 0.9929 -0.4245 0.9868 0.9868
Hypothermia 23.6748 0.101 0.101 29.0384 0.0152* 0.0152* 61.5636 0.1415 0.1415 70.9545 0.0319* 0.0319*
Genotype xx 8.62 0.2276 0.4623 yy & xy -7.8583 0.2206 0.2206 xx -0.5805 0.9786 0.9973 yy & xy -0.0406 0.9983 0.9983
yy 3.2913 0.788 xx yy -2.7462 0.9425 xx
xy xy
Time (months) 3 5.0747 0.4439 0.6831 3 5.0962 0.4389 0.675 3 29.2598 0.0541 0.1347 3 29.0301 0.0551 0.1369
6 2.7275 0.5086 6 2.7764 0.4994 6 11.1573 0.2234 6 11.0901 0.2253
12 12 12 12
Age -0.06529 0.8345 0.8345 -0.05132 0.865 0.865 0.831 0.3863 0.3863 0.08228 0.3729 0.3729
GCS 10.8412 0.1597 0.1597 11.3663 0.1191 0.1191 32.4669 0.1682 0.1682 32.0363 0.1484 0.1484
Gender    2.975 0.7423 0.7423 2.6613 0.7613 0.7613 11.382 0.6654 0.6654 12.0664 0.644 0.644
Race  2.2726 0.8824 0.8224 2.4074 0.8072 0.8072 3.3398 0.9152 0.9152 3.2939 0.9139 0.9139
Hypothermia 30.7984 0.0165* 0.0165* 31.1314 0.0126* 0.0126* 74.3693 0.054 0.054 74.1193 0.0469* 0.0469*
Trails A Trails B
RS17756073  (n=27)
RS17759659   (n=26)
Primary  Mixed Models Analyses of  Cognitive- Behavioral Outcomes: Trails Making Tests and BCL-2 SNP
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001  
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 Table 4-14 continued 
Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -5.0222 0.6645 0.5763 xx & xy -6.4113 0.3369 0.3369 xx -8.4272 0.8067 0.7414 xx & xy -14.458 0.4594 0.4594
yy 4.3639 0.6 yy yy 11.0095 0.6537 yy 
xy xy
Time (months) 3 5.409 0.4044 0.6466 3 5.4518 0.3992 0.6334 3 30.8112 0.0383* 0.0941 3 30.8082 0.0378* 0.0925
6 2.6762 0.4953 6 2.7882 0.4763 6 12.0421 0.1681 6 12.0924 0.1651
12 12 12 12
Age -0.1168 0.6944 0.6944 -0.1072 0.712 0.712 0.686 0.4353 0.4353 0.7096 0.4063 0.4063
GCS 13.0442 0.0885 0.0885 11.8486 0.0895 0.0895 32.2102 0.1484 0.1484 30.3329 0.1369 0.1369
Gender    4.2316 0.6532 0.6532 2.6088 0.7566 0.7566 18.3606 0.5084 0.5084 15.4089 0.5274 0.5274
Race  1.5324 0.8779 0.8779 0.7863 0.9348 0.9348 9.6999 0.746 0.746 8.4983 0.7679 0.7679
Hypothermia 29.528 0.047* 0.047* 26.5284 0.0366* 0.0366* 70.954 0.1053 0.1053 65.849 0.0764 0.0764
Genotype xx 14.7678 0.0196* 0.032* yy & xy -9.1309 0.1304 0.1304 xx 6.9443 0.7356 0.6448 yy & xy 1.3776 0.9406 0.9406
yy 18.566 0.0351* xx yy 27.002 0.3566 xx
xy xy
Time (months) 3 3.8674 0.5428 0.7307 3 3.1303 0.624 0.8061 3 30.4952 0.0399* 0.0965 3 29.5679 0.0466* 0.1066
6 2.6891 0.4946 6 2.273 0.5642 6 12.1766 0.1649 6 11.8855 0.1734
12 12 12 12
Age -0.2317 0.3817 0.3817 -0.04229 0.8771 0.8771 0.5211 0.565 0.565 0.7989 0.3524 0.3524
GCS 5.3 0.4196 0.4196 12.1681 0.0669 0.0669 22.6062 0.3235 0.3235 32.5197 0.1136 0.1136
Gender    8.2332 0.2881 0.2881 3.5851 0.6583 0.6583 18.8668 0.465 0.465 12.3254 0.6181 0.6181
Race  -2.2696 0.7899 0.7899 2.1649 0.8137 0.8137 -3.9488 0.8956 0.8956 2.7617 0.9246 0.9246
Hypothermia 29.7727 0.0079** 0.0079** 33.1874 0.0064** 0.0064** 68.3584 0.0643 0.0643 73.7587 0.0439* 0.0439*
Trails A Trails B
RS1801018   (n=27)
RS3810027 (n=28)
Primary  Mixed Models Analyses of  Cognitive- Behavioral Outcomes: Trails Making Tests and BCL-2 SNP
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001  
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Model 
Variables coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx 10.2107 0.1141 0.1747 yy & xy -7.8852 0.2103 0.2103 xx 17.1999 0.3866 0.6806 yy & xy -16.15 0.3881 0.3881
yy 16.4091 0.1671 xx yy 7.1988 0.8424 xx
xy xy
Time (months) 3 4.9014 0.4405 0.7029 3 4.5355 0.4773 0.6962 3 30.007 0.0417* 0.1017 3 29.7865 0.0423* 0.102
6 2.2232 0.5707 6 2.6794 0.4956 6 11.822 0.1765 6 11.8961 0.1717
12 12 12 12
Age -0.03237 0.9076 0.9076 -0.09768 0.7282 0.7282 0.7603 0.3882 0.3882 0.07294 0.3883 0.3883
GCS 7.3429 0.3001 0.3001 10.0654 0.1524 0.1524 25.6996 0.2487 0.2487 26.9254 0.1987 0.1987
Gender    0.969 0.9036 0.9036 1.1646 0.8865 0.8865 12.0077 0.6237 0.6237 12.0581 0.6145 0.6145
Race  -1.2454 0.8902 0.8902 0.08205 0.9929 0.9929 5.8733 0.8386 0.8386 6.4886 0.8167 0.8167
Hypothermia 27.4807 0.0199* 0.0199* 29.6733 0.0136* 0.0136* 73.1311 0.0467* 0.0467* 74.0561 0.0378* 0.0378*
Genotype xx -19.0883 0.0396* 0.0577 xx & xy 8.7143 0.2446 0.2446 xx -24.4786 0.4162 0.6766 xx & xy 7.3982 0.7452 0.7452
yy -16.5922 0.0387* yy yy -17.1129 0.5097 yy 
xy xy
Time (months) 3 5.7374 0.4075 0.5452 3 4.2003 0.5437 0.6581 3 27.2757 0.0822 0.1411 3 26.2848 0.0918 0.1535
6 3.7673 0.3474 6 3.3423 0.4056 6 13.0496 0.1423 6 12.8968 0.1463
12 12 12 12
Age -0.2845 0.3193 0.3193 -0.06836 0.8134 0.8134 0.5472 0.5634 0.5634 0.8109 0.3616 0.3616
GCS 5.8035 0.4275 0.4275 9.0268 0.2546 0.2546 25.2404 0.3114 0.3114 29.5223 0.2241 0.2241
Gender    -0.7977 0.9178 0.9178 -0.7137 0.9324 0.9324 9.7398 0.702 0.702 10.1955 0.6864 0.6864
Race  -13.0203 0.2299 0.2299 -8.3621 0.4698 0.4698 -7.9336 0.8293 0.8293 -1.9891 0.9556 0.9556
Hypothermia 17.9347 0.1277 0.1277 28.3169 0.0223* 0.0223* 59.0178 0.1472 0.1472 71.7483 0.0585 0.0585
Genotype xx 16.6332 0.0285* 0.0835 xx & xy -1.172 0.8682 0.8682 xx 29.6515 0.2122 0.4384 xx & xy 4.7974 0.8185 0.8185
yy 9.7958 0.1854 yy yy 10.6299 0.6556 yy 
xy xy
Time (months) 3 5.2131 0.426 0.6605 3 4.252 0.5103 0.7273 3 30.9382 0.0379 0.0944 3 29.782 0.0436 0.1044
6 2.7372 0.4943 6 2.5609 0.5164 6 11.8775 0.1751 6 11.9251 0.1718
12 12 12 12
Age -0.1347 0.6077 0.6077 -0.05476 0.8515 0.8515 0.6241 0.4645 0.4645 0.7757 0.3695 0.3695
GCS 9.8973 0.1211 0.1211 13.0922 0.0657 0.0657 26.2499 0.2025 0.2025 31.7487 0.1249 0.1249
Gender    10.1414 0.2343 0.2343 1.728 0.8406 0.8406 25.4296 0.3439 0.3439 11.531 0.6418 0.6418
Race  -4.2471 0.6178 0.6178 -1.6106 0.8665 0.8665 -0.3901 0.9889 0.9889 4.208 0.8826 0.8826
Hypothermia 32.1908 0.0107* 0.0107* 31.2224 0.023* 0.023* 73.7601 0.0612 0.0612 70.318 0.0771 0.0771
RS8083946  (n=27)
Trails A Trails B
RS4941185  (n=27)
RS7236090  (n=26)
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
Primary  Mixed Models Analyses of  Cognitive- Behavioral Outcomes: Trails Making Tests and BCL-2 SNP
 




 4.2.2 Specific Aim 2 
2. Specific Aims 2: Compare the relationship between BCL-2 genotype and biological/ 
clinical data.  
RQ2. Is there a relationship between BCL-2 genotype and biological/ clinical data (bcl-2 
protein, neurometabolites [lactate, pyruvate, LP ratio], and CBF [right hemisphere, left 
hemisphere, and global] from patients who have sustained a severe TBI? 
4.2.2.1 Bcl-2 Protein Concentrations 
Sub-sample description  Bcl-2 Protein 
The mean age of the overall sample of 42 subjects was 33.5 years old (range 18-69; SD± 
13.9). The sample was primarily Caucasian (n=37; 88.1%) and male (n=33; 78.6%). Slightly 
over half of this sub-sample had admission GCS of 3-5 (n=22; 52.4%). None of the subjects in 
this cohort received a hypothermia intervention. In the overall subsample, the presence of 
sustained hypoxia (n=12; 28.6%), hypotension (n=1; 2.4%), documented pre-admission seizures 
(n=9; 21.4%), and the occurrence of APOE ε4 (n=17; 41.5%) were considered. Refer to table 4-
27 for sample description. All of the SNP’s genotyped for the protein sub-sample met the HWE 
criteria for genotype representation in a population except RS949037 (X2=3.879121; 
P=0.04889). Refer to table 4-27 for genotype frequencies for each SNP and HWE calculations. 
Bcl-2 protein concentrations (U/mL) were analyzed at days 1-6 post injury. Descriptive 
statistics for the Bcl-2 protein concentrations are included in table 4-27. For day 3 (range 
maximum 74.81 U/mL) and day 4 (range maximum 55.16 U/mL ) post injury there is 1 extreme 
value on each of those days by different subjects (See figure 4-11). These extreme levels were 
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 within normal limits for the ELISA kit and as discussed in the background and literature section 
there is evidence that Bcl-2 protein levels can peak as late as day four after neurotrauma (Lee et 
al, 2004; Xiong et al, 2001). Therefore, because the values were extreme to this data set analyses 
are shown with and without these extreme values or “outliers” (See figures 4-11 & 4-12).  
 




































Figure 4-11: Average Daily Bcl-2 Protein Concentrations WITH Outliers 
 



































Figure 4-12:  Average Daily Bcl-2 Protein Concentrations WITHOUT Outliers 
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 Preliminary Mixed Models Analysis for Bcl-2 Protein Levels 
In the preliminary mixed models analyses, each SNP was analyzed individually for a 
relationship with Bcl-2 protein (with and without outliers) over time. Each of the covariates was 
analyzed for potential relationship with Bcl-2 protein (with and without outliers). By doing this 
the SNP’s and covariates of interest in building the larger model were ascertained. The criterion 
used was a P for Type 3 tests of ≤0.2. In addition, covariates that were deemed prudent through 
the evidence in the literature (age, gender, race, and GCS) were added to the primary full model. 
Hypothermia was not used in the model as none of the subjects received a hypothermia 
intervention. (Refer to tables 4-28 and 4-29). 
The preliminary mixed model analysis for Bcl-2 Protein with outliers indicated that the 
SNP’s and covariates of interest, meeting the criterion are: RS1026825 (genotypes P=0.1956; 
dichotomized genotype P=0.0975); RS12454712 (genotypes P=0.0105; dichotomized genotype 
P=0.0245); RS 1481031 (genotypes P=0.1782; dichotomized genotype P=0.175); RS4456611 
(genotypes P=0.1613; dichotomized genotype P=0.0586); RS7236090 (genotypes P=0.2312; 
dichotomized genotype P=0.0843); RS899968 (genotypes P=0.1946; dichotomized genotype 
P=0.5241); gender (P= 0.1587); race (P=0.0266); hypoxia (P=0.0378); and seizures (P= 0.0558). 
Time (days) (P=0.6211), age (P= 0.2622), and GCS (P=0.7642) were not indicated in the 
preliminary analysis, however, they were controlled for in the full model. (Refer to tables 4-28 
and 4-29). 
The preliminary mixed model analysis for Bcl-2 Protein without outliers indicated that 
the SNP’s and covariates of interest, meeting the criterion are: RS1026825 (genotypes P=0.2292; 
dichotomized genotype P=0.0899); RS12454712 (genotypes P=0.0016; dichotomized genotype 
P=0.0023); RS 1481031 (genotypes P=0.0708; dichotomized genotype P=0.0549); RS17756073 
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 (genotypes P=0.0763; dichotomized genotype P=0.2168); RS4456611 (genotypes P=0.3106; 
dichotomized genotype P=0.123); RS7236090 (genotypes P=0.0503; dichotomized genotype 
P=0.0212); gender (P= 0.1626); race (P=0.1481); hypoxia (P=0.0302); and seizures (P= 0.0885). 
Time (days) (P=0.3939), age (P= 0.4817), and GCS (P=0.5821) were not indicated in the 
preliminary analysis, however, they were controlled for in the full model. (Refer to tables  4-28 
and 4-29). 
 
Primary Mixed Models Analyses for Bcl-2 Protein 
Bcl-2 Protein without outliers: In analyzing the 6 BCL-2 SNP’s (RS1026825, 
RS12454712, RS1481031; RS4456611; RS7236090; and RS899968) of interest in relation to the 
Bcl-2 protein concentrations (with outlier data) none SNP’s had significant or marginally 
significant findings. None of the covariates included in the model were significant. (Refer to 
tables  4-30 to 4-32). 
Bcl-2 Protein without outliers: In analyzing the 6 BCL-2 SNP’s of interest (RS1026825, 
RS12454712, RS1481031, RS17756073, RS4456611, and RS7236090) in relation to the Bcl-2 
protein levels (without outliers) 4 of the SNP’s  had either marginally significant or significant 
relationships with the Bcl-2 protein concentrations (without outliers). (Refer to tables  4-30 to 4-
32). 
The mixed model with SNP RS12454712: genotype YY was marginally (P= 0.0714) with 
overall genotype (P for type 3 F tests =0.1686). YY genotype is associated with decrease Bcl-2 
protein concentrations. This trend was marginally significant evident in the dichotomized 
analysis (P=0.0646). In contrast, subjects with 0-1 copies of the Y allele had significantly higher 
bcl-2 protein concentrations. Time of sample from injury was found to be significant (genotypes 
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 P=0.0036; dichotomized genotype P=0.0031), Bcl-2 protein concentrations spiked on days 2, 4, 
& 5 compared to day 6. (Refer to table  4-30). 
The mixed models analysis with RS1481031 genotype XX (P= 0.018) with marginal 
significance overall (P for type 3 F tests =0.0547) was associated with lower blc-2 protein 
concentrations. This trend was evident in the dichotomized analysis (P=0.0599). In contrast, 0-1 
X alleles was associated with higher bcl-2 concentrations. Time was found to been significant 
(genotypes P=0.0029; dichotomized genotype P=0.0023). Bcl-2 protein concentrations spiked on 
days 2, 4, & 5 compared to day 6.  Gender was found to be marginally significant (genotypes 
P=0.0578; dichotomized genotype P=0.0906), with females having lower bcl-2 protein 
concentrations. Seizure was found to be significant (genotypes P=0.0452; dichotomized 
genotype P=0.0315). History of a pre-admission seizure was related to having lower bcl-2 
protein concentrations. (Refer to table  4-31). 
The mixed models analysis with RS17756073 genotype XX (P= 0.0103) and YY 
(P=0.0084) with overall genotype significant (P for type 3 F tests= 0.0055). XX and YY 
genotypes are associated with a decrease Bcl-2 protein levels compared to subjects who were 
heterozygous (XY). When the subjects were dichotomized, 0-1 X alleles, there was an associated 
with a trend in higher bcl-2 levels (P=0.083). Time was found to been significant (genotypes 
P=0.0018; dichotomized genotype P=0.0032). Bcl-2 protein levels spiked on days 2, 4, & 5 
compared to day 6.  Gender was found to be significant (genotypes P=0.049; dichotomized 
genotype P=0.06), with females having lower bcl-2 protein concentrations. (Refer to table 4-31). 
The mixed models analysis with RS7236090 genotype XX (P= 0.0028) and YY 
(P=0.0475) with overall genotype significant (P for type 3 F tests =0.0056). XX and YY 
genotypes are associated with decreased bcl-2 protein concentrations compared to subjects who 
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were heterozygous (XY). In contrast, subjects with 0-1 X alleles had significantly higher bcl-2 
concentrations in the dichotomized analysis (P=0.0112). Time was found to been significant 
(genotypes P=0.009; dichotomized genotype P=0.0058). Bcl-2 protein concentrations spiked on 
day 5 compared to day 6. Gender was found to be significant (genotypes P=0.0042; 
dichotomized genotype P=0.0121), with females having lower bcl-2 protein concentrations. 
Seizure was found to be marginally significant (genotypes P=0.092; dichotomized genotype 
P=0.0802). History of a pre-admission seizure was related to having lower bcl-2 protein 
concentrations. (Refer to table 4-32). 
The mixed models analyses indicated that the following SNP’s were not significant: 
RS1026825 (genotypes P=0.6688; dichotomized genotype P=0.5182); RS4456611 (genotypes 
P=0.7884; dichotomized genotype P=0.7136). Like the SNP’s in the primary analyses that were 
marginally/ significant, the models for the SNP’s that were not significant continued to report 
trends that the covariates of time, gender, and seizures on pre admission remained of interest 
with marginal or statistically significant relationships. Among all of the models the covariates of 
age, GCS, race, and hypoxia were not indicated as marginally or statistically significant. (Refer 






 Table 4-15: BCL-2 Genotypes vs. Bcl-2 Protein Concentrations Descriptive Data 
Variables n= Mean Std. Deviation Range
Age 42 33.5 ± 13.9 18-69
Frequency (%)
Frequency % of 
Unknown
GCS 42 score 3 to 5 22 (52.4%) 0
score 6 to 8 20 (47.6%)
Gender (male) 42 33 (78.6%) 0
Race (Caucasian) 42 37 (88.1%) 0
Hypothermic 42 0 (0%) 0
Hypoxia 37 12 (28.6%) 5 (11.9%)
Hypotensive 42 1 (2.4%) 0
 Seizures 38 9 (21.4%) 4 (9.52%)
APOEε4   41 17 (41.5%) 1 (2.38%)
Frequency 
(%) of 
Unknown                           With the Outliers                                                       Without the Outliers
Bcl-2 Protein Levels (U/mL) n= Mean Std. Deviation Range Mean Std. Deviation Range
Day 1 15 27(64.29%) 9.76 ± 7.91 3.84-37.12 9.76 ± 7.91 3.84-37.12
Day 2 27 15(35.71%) 12.71 ± 7.10 5.42-29.17 12.71 ± 7.10 5.42-29.17
Day 3 25 17 (40.48%) 14.2 ± 13.74 5.039-74.81 11.68 ± 5.53 5.04-24.34
Day 4 30 12 (28.57%) 13.84 ± 9.57 5.77-55.16 12.42 ± 5.64 5.77-27.06
Day 5 27 15(35.71%) 14.07 ± 6.08 4.76-25.64 14.07 ± 6.08 4.76-25.64
Day 6 10 32 (76.19%) 10.34 ± 10.15 2.19-37.88 10.34 ± 10.15 2.19-37.88
SNP n= XX YY XY X Y HWE X 2 P
RS1026825 41 11 9 21 0.524390244 0.475609756 1 . .
RS12454712 42 10 17 15 0.416666667 0.583333333 1 . .
RS12968517 41 15 7 19 0.597560976 0.402439024 1 . .
RS1381548 42 9 16 17 0.416666667 0.583333333 1 . .
RS1481031 41 18 6 17 0.646341463 0.353658537 1 . .
RS17756073 41 22 2 17 0.743902439 0.256097561 1 . .
RS17759659 40 18 3 19 0.6875 0.3125 1 . .
RS1801018 42 6 21 15 0.321428571 0.678571429 1 . .
RS1944419 41 9 9 23 0.5 0.5 1 . .
RS3810027 42 16 9 17 0.583333333 0.416666667 1 . .
RS4456611 41 9 8 24 0.512195122 0.487804878 1 . .
RS4941185 42 14 7 21 0.583333333 0.416666667 1 . .
RS7230970 42 6 15 21 0.392857143 0.607142857 1 . .
RS7236090 40 12 10 18 0.525 0.475 1 . .
RS8083946 42 13 14 15 0.488095238 0.511904762 1 . .
RS899968 40 6 14 20 0.4 0.6 1 . .
RS949037 40 13 13 14 0.5 0.525 1.050625 3.879121 0.04889*
 BCL-2 Genotypes Versus Bcl-2 Protein Concentrations: Descriptive Data
* X 2  p≤ 0.05 
Hardy-Weinberg Equilibrium
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 Table 4-16: Preliminary Mixed Models Analyses of Bcl-2 Protein Concentrations 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS1026825 41 xx -4.39 0.0729* 0.1956* -3.3724 0.0916* 0.2292
yy -1.81 0.4637 -0.621 0.7611
xy
yy & xy 3.8005 0.0975* 0.0975* 3.1644 0.0899* 0.0899*
xx . . . . . .
RS12454712 42 xx -4.76 0.0458* 0.0105* -3.5379 0.057* 0.0016*
yy -6.21 0.0037* -6.1622 0.0004*
xy
xx & xy -4.4405 0.0245* 0.0245* 4.8188 0.0023* 0.0023*
 yy . . . . . .
RS12968517 41 xx 0.416 0.8472 0.3323 0.2418 0.8927 0.4469
yy -3.83 0.1845* -2.6976 0.2534
xy
yy & xy -1.3419 0.5184 0.5184 -0.9173 0.5914 0.5914
xx . . . . . .
RS1381548 42 xx -3.52 0.1669* 0.3163 -1.5628 0.457 0.3794
yy 0.03168 0.9884 1.4087 0.4341
xy
xx & xy -1.2071 0.5544 0.5544 -1.9428 0.239 0.239
 yy . . . . . .
RS1481031 41 xx -3.7108 0.0863* 0.1782* -3.9397 0.0252* 0.0708*
yy -3.6858 0.2032 -3.0363 0.1972*
xy
yy & xy 2.7475 0.175* 0.175* 3.1526 0.0549* 0.0549*
xx . .
RS17756073 41 xx -1.6183 0.4248 0.2945 -2.7071 0.094* 0.0763*
yy -7.4686 0.1382* -7.5283 0.059*
xy
yy & xy 0.9293 0.6428 0.6428 1.9954 0.2168 0.2168
xx . .
RS17759659 40 xx 1.2531 0.5556 0.832 0.8589 0.6242 0.8795
yy 1.1864 0.7837 0.8302 0.8114
xy
yy & xy -1.1089 0.5854 0.5854 -0.7536 0.6527 0.6527
xx 
RS1801018 42 xx -1.4772 0.676 0.877 -0.9099 0.7397 0.4777
yy 0.2586 0.9033 1.66 0.3398
xy
xx & xy -0.5815 0.7671 0.7671 -1.8828 0.2375 0.2375
 yy . .
RS1944419 41 xx -2.5145 0.3275 0.3848 -1.3488 0.5224 0.5679
yy 1.6703 0.5073 1.3254 0.526
xy
yy & xy 2.9994 0.2208 0.2208 1.7297 0.3887 0.3887
xx . .
xx & xy -2.3695 0.3307 0.3307 -1.6984 0.3959 0.3959
 yy . .
RS3810027 42 xx 3.1514 0.1639* 0.3221 2.5882 0.1627* 0.3731
yy 2.9288 0.2504 1.4223 0.4999
xy
yy & xy -1.9446 0.3325 0.3325 -2.0379 0.2159 0.2159
xx . .
Preliminary  Mixed Models Analysis of Bcl-2 Protein 
 With Outliers Without Outliers
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 Table 4-16 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS4456611 41 xx -4.7406 0.0577* 0.1613* -2.9723 0.1474* 0.3106
yy -0.9053 0.7171 0.1827 0.9303
xy
yy & xy 4.5329 0.0586* 0.0586* 3.0261 0.123* 0.123*
xx . .
RS4941185 42 xx -1.1329 0.6065 0.8725 0.02389 0.9895 0.8906
yy -0.6322 0.827 1.0792 0.6466
xy
yy & xy 0.9835 0.6352 0.6352 0.2324 0.8915 0.8915
xx . .
RS7230970 42 xx -0.0753 0.9792 0.5177 1.3803 0.5713 0.7857
yy -2.3479 0.2738 -0.3609 0.8393
xy
xx & xy 2.3529 0.2437 0.2437 0.6826 0.6843 0.6843
 yy . .
RS7236090 40 xx -3.9205 0.1099* 0.2312 -4.7304 0.0152* 0.0503*
yy -0.1206 0.9621 -1.7211 0.3847
xy
yy & xy 3.8863 0.0843* 0.0843* 4.124 0.0212* 0.0212*
xx . .
RS8083946 42 xx 2.9841 0.2094 0.4055 1.8123 0.3595 0.5974
yy 2.5477 0.297 1.649 0.4093
xy
xx & xy -0.973 0.6448 0.6448 -0.7345 0.6705 0.6705
 yy . .
RS899968 40 xx -5.1738 0.0919* 0.1946* -3.7782 0.1293 0.2978
yy 0.2363 0.913 -0.3002 0.8671
xy
xx & xy -1.3507 0.5241 0.5241 -0.5452 0.7554 0.7554
 yy . .
RS949037 40 xx -1.4638 0.5469 0.5959 -1.2654 0.5344 0.8142
yy 1.1755 0.6436 -0.3412 0.8711
xy
yy & xy 1.9651 0.3652 0.3652 1.1139 0.5322 0.5322
xx . .
xx & xy -1.8852 0.4034 0.4034 -0.2727 0.8827 0.8827
 yy . .
Covariates
Time (Days) 42 1 0.1901 0.9589 0.6211 0.296 0.9029 0.3939
2 3.0666 0.3639 2.7943 0.2136
3 4.2136 0.2139 1.3459 0.5476
4 3.6772 0.2637 1.6467 0.4493
5 3.7846 0.2485 3.3156 0.1187*
6 . .
Age 42 -0.0809 0.2622 0.2622 -0.0418 0.4817 0.4817
GCS  42 -0.5906 0.7642 0.7642 -0.8952 0.5821 0.5821
Gender 42 -3.509 0.1587* 0.1587* -2.8289 0.1626* 0.1626*
Race 42 -6.1515 0.0266* 0.0266* -3.4737 0.1481* 0.1481*
Hypothermic 0 n/a n/a
Hypoxia  37 4.47 0.0378* 0.0378* 3.4754 0.0302* 0.0302*
Hypotensive 42 -3.7415 0.5107 0.5107 -4.5433 0.3539 0.3539
Seizures  41 4.2432 0.0558* 0.0558* 3.0976 0.0885* 0.0885*
APOE4 41 -1.5947 0.4276 0.4276 0.1293 0.9385 0.9385
* p≤ 0.2
Preliminary  Mixed Models Analysis of Bcl-2 Protein 
 With Outliers Without Outliers
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 Table 4-17: Primary Mixed Models Analyses of BCL-2 SNP's and Bcl-2 Protein Concentrations 
Variables
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -1.6789 0.5598 0.6589 yy & xy 0.9364 0.7322 0.7322 xx -1.607 0.4276 0.6688 yy & xy 1.2422 0.5182 0.5182
yy -2.3143 0.3999 xx yy -1.21 0.5362 xx
xy . xy
Time (Day) 1 0.1793 0.9626 0.1792 1 0.6546 0.8624 0.1226 1 0.6911 0.7362 0.0045** 1 0.8393 0.6796 0.0033**
2 4.0786 0.2668 2 4.742 0.1866 2 4.2033 0.0348* 2 4.4096 0.0245*
3 6.058 0.0967 3 6.7029 0.0604 3 3.5609 0.0682 3 3.759 0.0507
4 5.7239 0.1063 4 6.4117 0.0633 4 4.018 0.0362* 4 4.23 0.0249*
5 5.6224 0.0973 5 3.1103 0.0674 5 5.6441 0.002** 5 5.8006 0.0013**
6 . . 6 6 6
Age -0.1233 0.1874 0.1874 -0.1108 0.2288 0.2288 -0.0608 0.3614 0.3614 -0.0521 0.4184 0.4184
GCS 0.375 0.8588 0.8588 0.7116 0.7315 0.7315 -1.1278 0.4538 0.4538 -1.01 0.4952 0.4952
Gender -4.2878 0.1416 0.1416 -3.1662 0.2207 0.2207 -3.6923 0.0662 0.0662 -3.1511 0.0074** 0.0074**
Race  -2.511 0.4188 0.4188 -3.3393 0.2595 0.2595 -0.5057 0.8248 0.8248 -0.9542 0.6574 0.6574
Hypoxia -1.7269 0.5892 0.5892 -0.5714 0.8431 0.8431 -0.6814 0.7712 0.7712 -0.0815 0.9692 0.9692
Seizure 5.3779 0.094 0.094 4.5036 0.1361 0.1361 4.3373 0.0599 0.0599 3.8861 0.071 0.071
Genotype xx -2.1739 0.4082 0.4722 xx & xy 1.8061 0.3675 0.3675 xx -0.793 0.6591 0.1686 xx & xy 2.6104 0.0646 0.0646
yy -2.7359 0.2366 yy yy -2.9539 0.0714 yy
xy . xy
Time (Day) 1 0.2906 0.9382 0.1579 1 0.70104 0.8482 0.1429 1 0.8232 0.684 0.0036** 1 0.9039 0.6522 0.0031**
2 4.4481 0.2079 2 4.8919 0.161 2 4.5849 0.0178* 2 4.6761 0.0147*
3 6.0456 0.0845 3 6.3974 0.0658 3 3.5611 0.0605 3 3.6306 0.0541
4 5.8957 0.0835 4 6.2383 0.0649 4 4.1002 0.028* 4 4.1769 0.0242*
5 5.6761 0.0874 5 6.0125 0.068 5 5.6913 0.0016** 5 5.7653 0.0013**
6 . . 6 6 6
Age -0.0823 0.3237 0.3237 -0.1071 0.1715 0.1715 -0.0452 0.4305 0.4305 -0.0533 0.3217 0.3217
GCS 0.2057 0.9194 0.9194 0.1072 0.9579 0.9579 -1.585 0.263 0.263 -1.6248 0.2446 0.2446
Gender -2.279 0.3861 0.3861 -2.5564 0.327 0.327 -2.2933 0.191 0.191 -2.3862 0.1662 0.1662
Race  -4.1002 0.1587 0.1587 -3.7782 0.1885 0.1885 -1.4435 0.4802 0.4802 -1.3357 0.5049 0.5049
Hypoxia 0.4455 0.8779 0.8779 -0.1712 0.9512 0.9512 0.661 0.7464 0.7464 0.4223 0.8285 0.8285
Seizure 3.5495 0.2432 0.2432 4.0712 0.1721 0.1721 3.0503 0.1476 0.1476 3.2469 0.1116 0.1116
Primary  Mixed Models Analyses of  BCL-2 SNP and Bcl-2 Protein
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
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 Table 4-17 continued 
Variables
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -2.9331 0.1655 0.2658 yy & xy 1.4853 0.4281 0.4281 xx -3.502 0.018* 0.0547 yy & xy 2.4875 0.0599 0.0599
yy -3.9702 0.1579 xx yy -2.9332 0.1305 xx
xy xy
Time (Day) 1 0.8132 0.8261 0.1912 1 0.6952 0.8515 0.1424 1 0.91 0.6485 0.0029* 1 0.8819 0.6597 0.0023**
2 4.9004 0.1587 2 5.0433 0.1487 2 4.7438 0.0128* 2 4.818 0.0119*
3 6.0326 0.0521 3 6.3381 0.0686 3 3.4289 0.0677 3 3.547 0.0596
4 5.979 0.0761 4 6.2134 0.0662 4 4.0291 0.0289* 4 4.1429 0.0252*
5 5.9126 0.0719 5 6.0839 0.0648 5 5.7427 0.0013** 5 5.8146 0.0011**
6 . 6 6 6
Age -0.0536 0.528 0.528 -0.103 0.1989 0.1989 -0.0091 0.8737 0.8737 -0.0422 0.4432 0.4432
GCS -0.3942 0.8461 0.8461 0.2054 0.9191 0.9191 -1.9819 0.1548 0.1548 -1.5636 0.2603 0.2603
Gender -3.4476 0.1727 0.1727 -2.9672 0.2429 0.2429 -3.1664 0.0578 0.0578 -2.8498 0.0906 0.0906
Race  -4.5933 0.1189 0.1189 -3.3807 0.2353 0.2353 -1.6864 0.4089 0.4089 -0.6927 0.7261 0.7261
Hypoxia 0.8186 0.7736 0.7736 -0.1135 0.9679 0.9679 1.1577 0.5541 0.5541 0.5503 0.779 0.779
Seizure 4.3064 0.1371 0.1371 4.8107 0.1014 0.1014 3.979 0.0452 0.0452 4.3559 0.0315 0.0315
Genotype xx -2.107 0.267 0.2149 yy & xy 1.4255 0.4558 0.4558 xx -3.145 0.0103* 0.0055** yy & xy 2.2924 0.083 0.083
yy -6.7406 0.1178 xx yy -7.3466 0.0084** xx
xy xy
Time (Day) 1 0.9869 0.7962 0.1356 1 0.6572 0.1401 1 1.066 0.6013 0.0018** 1 0.9595 0.6418 0.0032**
2 5.2944 0.1391 2 4.8335 2 5.0847 0.0087** 2 4.6471 0.0175*
3 6.8892 0.052 3 6.6062 3 4.1061 0.0309* 3 3.7923 0.0478*
4 6.6347 0.0549 4 6.4212 4 4.6425 0.0131* 4 4.3462 0.0216*
5 6.3803 0.0575 5 6.2551 5 6.2637 0.0006** 5 6.0393 0.0009**
6 6 6 6
Age -0.1023 0.1771 0.1771 -0.1113 0.1565 0.1565 -0.0464 0.3125 0.3125 -0.0587 0.2712 0.2712
GCS 0.4793 0.816 0.816 1.1396 0.5851 0.5851 -0.8615 0.4876 0.4876 -0.259 0.8533 0.8533
Gender -2.9102 0.2425 0.2425 -3.0312 0.237 0.237 -2.9444 0.049* 0.049* -3.1699 0.06 0.06
Race  -3.7946 0.1758 0.1758 -3.8692 0.1838 0.1838 -1.249 0.4653 0.4653 -1.3015 0.5142 0.5142
Hypoxia 0.3702 0.8941 0.8941 -0.3841 0.8927 0.8927 0.94 0.579 0.579 0.2505 0.8979 0.8979
Seizure 3.7478 0.2019 0.2019 4.0127 0.1862 0.1862 2.8577 0.1087 0.1087 3.2176 0.1151 0.1151
RS1481031 (n=37)
RS17756073  (n=36)
Primary  Mixed Models Analyses of  BCL-2 SNP and Bcl-2 Protein
 With Outliers  Without Outliers
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001  
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Variables
coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test coefff P  P for Type-3 Test
Genotype xx -2.0729 0.4274 0.724 yy & xy 2.0448 0.4184 0.4184 xx -0.4286 0.8137 0.7884 yy & xy 0.6465 0.7136 0.7136
yy -0.1588 0.9468 xx yy 0.9865 0.5607 xx
xy xy
Time (Day) 1 0.9478 0.8051 0.1174 1 0.93 0.8071 0.1146 1 1.0821 0.5983 0.0018** 1 0.9812 0.6312 0.0018**
2 5.7335 0.1106 2 5.7087 0.1098 2 5.3028 0.0068** 2 5.2329 0.0073**
3 6.9939 0.0509 3 6.9788 0.0499 3 3.898 0.0423* 3 3.8343 0.045*
4 6.7372 0.0528 4 6.7363 0.0511 4 4.4514 0.0184* 4 4.3763 0.0199*
5 6.5549 0.0515 5 6.5517 0.0505 5 6.0566 0.0008** 5 6.006 0.0009*8
6 6 6 6
Age -0.1065 0.1943 0.1943 -0.1071 0.1836 0.1836 -0.5727 0.331 0.331 -0.0552 0.3419 0.3419
GCS 0.7081 0.7531 0.7531 0.777 0.7134 0.7134 -1.0297 0.5191 0.5191 -1.2843 0.3975 0.3975
Gender -3.0167 0.2439 0.2439 -3.025 0.2365 0.2365 -3.307 0.0624 0.0624 -3.2929 0.0607 0.0607
Race  -3.2858 0.2632 0.2632 -3.2858 0.2535 0.2535 -0.6033 0.7758 0.7758 -0.7157 0.7314 0.7314
Hypoxia -0.352 0.9061 0.9061 -0.4162 0.8852 0.8852 0.3078 0.8871 0.8871 0.5191 0.8055 0.8055
Seizure 3.8698 0.2193 0.2193 3.8854 0.2095 0.2095 4.0182 0.0697 0.0697 3.9134 0.0726 0.0726
Genotype xx -1.942 0.4007 0.5976 yy & xy 1.5658 0.4809 0.4809 xx -4.3665 0.0028** 0.0056** yy & xy 3.6926 0.0112* 0.0112*
yy -2.1102 0.4641 xx yy -3.4194 0.0475* xx
xy xy
Time (Day) 1 0.31 0.9398 0.2047 1 0.0722 0.9859 0.1695 1 -0.1839 0.9309 0.009** 1 -0.3006 0.8886 0.0058**
2 4.5722 0.2405 2 4.5212 0.2448 2 3.5139 0.0831 2 3.5968 0.0802
3 6.361 0.0986 3 6.3055 0.101 3 2.6627 0.1812 3 2.7299 0.1759
4 6.0823 0.1032 4 6.1744 0.0972 4 3.2731 0.0932 4 3.4517 0.0806
5 5.7184 0.1133 5 5.7721 0.1095 5 4.9731 0.0079** 5 5.0982 0.0071**
6 6 6 6
Age -0.1573 0.0804 0.0804 -0.1672 0.058 0.058 -0.0762 0.1428 0.1428 -0.0929 0.0867 0.0867
GCS 0.3645 0.8636 0.8636 0.2344 0.9106 0.9106 -1.7279 0.168 0.168 -1.9335 0.1405 0.1405
Gender -3.8284 0.1514 0.1514 -3.568 0.1716 0.1716 -4.5549 0.0042** 0.0042** -4.0466 0.0121* 0.0121*
Race  -4.1093 0.2159 0.2159 -3.0649 0.2949 0.2949 -1.7183 0.3773 0.3773 -0.0157 0.9932 0.9932
Hypoxia -0.9479 0.7455 0.7455 -1.2946 0.6497 0.6497 -0.301 0.8609 0.8609 -0.8177 0.6482 0.6482
Seizure 4.2082 0.1663 0.1663 4.3672 0.1455 0.1455 2.9982 0.092 0.092 3.2648 0.0802 0.0802
Genotype xx -2.6135 0.4656 0.7618 yy -0.0828 0.9702 0.9702 xx -3.0574 0.2314 0.4714 yy 0.326 0.8353 0.8353
yy -0.2078 0.9272 xx & xy yy -0.6656 0.6738 xx & xy
xy xy
Time (Day) 1 0.7587 0.8432 0.1231 1 0.6607 0.863 0.1316 1 0.8949 0.66 0.0025** 1 0.8541 0.675 0.0028**
2 5.3129 0.1437 2 5.1989 0.1515 2 4.8663 0.0129* 2 4.8266 0.0137*
3 7.0775 0.0497* 3 6.8926 0.055 3 3.962 0.0387* 3 3.8668 0.0436*
4 6.6669 0.0582 4 6.5432 0.0623 4 4.3461 0.0213* 4 4.276 0.0235*
5 6.3688 0.0594 5 6.2512 0.0637 5 5.9399 0.001** 5 5.8708 0.0011**
6 6 6 6
Age -0.095 0.3203 0.3203 -0.1197 0.179 0.179 -0.0306 0.6498 0.6498 -0.0608 0.3388 0.3388
GCS 0.3684 0.8702 0.8702 0.5327 0.811 0.811 -1.7125 0.276 0.276 -1.5582 0.3228 0.3228
Gender -3.2708 0.2394 0.2394 -3.1831 0.2479 0.2479 -3.5405 0.0606 0.0606 -3.4341 0.0698 0.0698
Race  -3.1743 0.2928 0.2928 -3.2172 0.2816 0.2816 -0.7596 0.7215 0.7215 -0.8268 0.7004 0.7004
Hypoxia -0.6255 0.8368 0.8368 -0.2397 0.9354 0.9354 0.0172 0.9937 0.9937 0.5548 0.796 0.796
Seizure 4.9639 0.1116 0.1116 4.6642 0.1265 0.1265 4.6295 0.0363* 0.0363* 4.1397 0.0562 0.0562
RS899968   (n=35)
RS7236090   (n=35)
RS4456611   (n=41)
* p≤ 0.05; ** p≤ 0.01; *** p≤ 0.0001 
Primary  Mixed Models Analyses of  BCL-2 SNP and Bcl-2 Protein
 With Outliers  Without Outliers
 




 4.2.2.2 Neurometabolites 
Sub-sample Description  Neurometabolites 
The mean age of the overall sample of 36 subjects was 31.4 years old (range 17-71; SD± 
13.9). The sample was all Caucasian and primarily male (n=27; 75%). Over half of the sub-
sample had admission GCS of 6-8 (n=21; 58.3%). Of the subjects enrolled in the study, 15 
(41.7%) received therapeutic hypothermia.  In the sub-sample the presence of sustained hypoxia 
(n=6; 16.67%), hypotension (n=5; 13.89%), documented pre-admission seizures (n=1; 2.78%), 
and the occurrence of APOE ε4 (n=8; 22.22%) were covariates of consideration. Refer to table 4-
33 for sample description. All of the SNP’s genotyped for the neurometabolite sub-sample met 
the HWE criteria for genotype representation in a population except RS4941185 
(X2=15.277345; P=<.0001) and RS899968 (X2=11.26643; P=<.0001). Refer to table 4-33 for 
genotype frequencies for each SNP and HWE calculations. 
Lactate, pyruvate and lactate pyruvate ratio (LP) levels were analyzed at days 1-5 post 
injury. Descriptive statistics for the lactate and pyruvate levels and LP ratios for each of the 5 
days are included in table 4-33.  
 
Preliminary Mixed Models Analysis for Neurometabolites 
In the preliminary mixed models analyses, each SNP was analyzed individually for a 
relationship with lactate, pyruvate, and LP concentrations over time. Each of the covariates was 
analyzed for potential relationship with lactate, pyruvate, and LP concentrations over time. By 
doing this the SNP’s and covariates of interest in building the larger model were ascertained. The 
criterion used was a P for Type 3 tests of ≤0.2 in addition to covariates that are deemed prudent 
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 through the evidence in the literature (age, gender, GCS, and hypothermia). Race was not used in 
the model as all of the subjects were Caucasian. (Refer to tables 4-34 to 4-37). 
Lactate 
The preliminary mixed model analyses for lactate indicated that the SNP’s and covariates 
of interest, meeting the criterion were: RS17759659 (genotypes P=0.2042; dichotomized 
genotype P=0.0742); RS1801018 (genotypes P=0.1385; dichotomized genotype P=0.0473); 
RS1944419 (genotypes P=0.3196; [preliminary models were run for both homozygous wild type 
and variant  because of equal sample size] XX dichotomized genotype P=0.1285; YY 
dichotomized genotype P=0.4567); RS3810027 (genotypes P=0.1781; dichotomized genotype 
P=0.0905); RS7236090 (genotypes P=0.1776; dichotomized genotype P=0.2821); RS8083946 
(genotypes P=0.2161; dichotomized genotype P=0.1124); time (days) (P=0.0107); GCS 
(P=0.1429); gender (P= 0.0448).  Age (P= 0.5091) and hypothermia (P=.6106) were not 
indicated in the preliminary analysis, however, they were controlled for in the primary full 
model. (Refer to tables 4-34 to 4-37). 
Pyruvate 
The preliminary mixed model analysis for pyruvate indicated that the SNP’s and 
covariates of interest, meeting the criterion were: RS17759659 (genotypes P=0.0079; 
dichotomized genotype P=0.0019); RS1801018 (genotypes P=0.0595; dichotomized genotype 
P=0.0192); RS3810027 (genotypes P=0.1022; dichotomized genotype P=0.169); RS4941185 
(genotypes P=0.0727; dichotomized genotype P=0.0211); RS7236090 (genotypes P=0.2753; 
dichotomized genotype P=0.1062); RS949037 (genotypes P=0.0581; dichotomized genotype 
P=0.0207); and time (days) (P=0.0008). Age (P= 0.7648), GCS (P=0.6887), gender (P= 0.4182), 
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 and hypothermia (P=0.3964) were not indicated in the preliminary analysis, however, they were 
controlled for in the primary full model. (Refer to tables 4-34 to 4-37). 
Lactate: Pyruvate Ratio  
The preliminary mixed model analysis for LP indicated that the SNP’s and covariates of 
interest, meeting the criterion were: RS1026825 (genotypes P=0.2824; dichotomized genotype 
P=0.1089); RS17759659 (genotypes P=0.0183; dichotomized genotype P=0.0048); RS1801018 
(genotypes P=0.0255; dichotomized genotype P=0.0075); RS1944419 (genotypes P=0.2738; 
[preliminary models were run for both homozygous wild type and variant  because of equal 
sample size] XX dichotomized genotype P=0.1055; YY dichotomized genotype P=0.4335); 
RS3810027 (genotypes P=0.3672; dichotomized genotype P=0.1694); RS4941185 (genotypes 
P=0.1247; dichotomized genotype P=0.7522); RS7236090 (genotypes P=0.138; dichotomized 
genotype P=0.3901); RS8083946 (genotypes P=0.0281; dichotomized genotype P=0.1461); 
RS949037 (genotypes P=0.3937; dichotomized genotype P=0.1739); time (days) (P=0.006); 
GCS (P=0.1107); gender (P= 0.0543).  Age (P= 0.6126) and hypothermia (P=.7937) were not 
indicated in the preliminary analysis, however, they were controlled for in the primary full 
model. (Refer to tables 4-34 to 4-37). 
 
Primary Mixed Models Analyses for Neurometabolites 
Lactate 
In analyzing the 6 BCL-2 SNP’s (RS17759659, RS1801018, RS1944419, RS3810027, 
RS7236090, and RS8083946) of interest in relation to the lactate levels none SNP’s had 
significant findings. SNP’s (RS3810027 and RS8083946) were marginally significant. Time and 
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 gender were consistently marginally or statistically significant in relation to lactate levels among 
the mixed models analyzed for these SNP’s. (Refer to tables 4-38 to 4-42). 
The mixed model with SNP RS3810027: genotype XX was marginally significant (P= 
0.0521) with overall genotype (P for type 3 F tests =0.01396). XX genotype is associated with a 
decrease in lactate concentrations. In contrast subjects with 0-1 X alleles have a trend of higher 
lactate concentrations in the dichotomized analysis (P=0.0791). Time of sample from injury was 
found to be significant (genotypes P=0.0084; dichotomized genotype P=0.0088), lactate 
concentrations are significantly higher days 1 and 2 post injury in relation to day 5. (Refer to 
table 4-40). 
The mixed model with SNP RS8083946: genotype YY was significant (P= 0.037) with 
overall genotype (P for type 3 F tests =0.0725). YY genotype is associated with a decrease in 
lactate concentrations. This trend was not significant in the dichotomized analysis (P=0.1021). 
Time of sample from injury was found to be significant (genotypes P=0.0124; dichotomized 
genotype P=0.0103), lactate concentrations are significantly higher days 1 and 2 post injury in 
relation to day 5. Gender was found to be significant (genotypes P=0.026; dichotomized 
genotype P=0.0727) and was associated with higher lactate levels in females. (Refer to table 4-
41). 
Pyruvate 
In analyzing the 6 BCL-2 SNP’s (RS17759659, RS1801018, RS3810027, RS4941185, 
RS7236090, and RS949037) of interest in relations to the pyruvate concentrations 4 SNP’s 
(RS17759659, RS1801018, RS4941185, and RS949037) had significant findings. Time was the 
only consistently significant in relation to pyruvate concentrations among the mixed models 
analyzed for these SNP’s. (Refer to tables 4-38 to 4-42).  
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 The mixed model with SNP RS17759659: genotype YY was significant (P= 0.0016) with 
overall genotype (P for type 3 F tests =0.0049). YY genotype is associated with a decrease in 
pyruvate concentrations. In contrast subjects with 0-1 Y alleles have significantly higher 
pyruvate concentrations in the dichotomized analysis (P=0.0011). Time of sample from injury 
was found to be significant (genotypes P=0.0011; dichotomized genotype P=0.0011), only day 1 
was significantly higher that day 5. (Refer to table 4-38). 
The mixed model with SNP RS1801018: genotype XX was significant (P= 0.0231) with 
overall genotype (P for type 3 F tests =0.00594). XX genotype is associated with a decrease in 
pyruvate concentrations. In contrast, subjects with 0-1 copies of the X allele have significantly 
higher pyruvate concentrations in the dichotomized analysis (P=0.0175). Time of sample from 
injury was found to be significant (genotypes P=0.0022; dichotomized genotype P=0.0021), only 
day 1 was significantly higher that day 5. (Refer to table 4-39). 
The mixed model with SNP RS4941185: genotype XX was marginally significant (P= 
0.0651) with overall genotype (P for type 3 F tests =0.1303). XX genotype is associated with an 
increase in pyruvate concentrations. In contrast, subjects with 0-1 X alleles have significantly 
higher pyruvate concentration in the dichotomized analysis (P=0.0416). Time of sample from 
injury was found to be significant (genotypes P=0.001; dichotomized genotype P=0.001), only 
day 1 was significantly higher that day 5. (Refer to table 4-40). 
The mixed model with SNP RS949037: genotype YY was significant (P= 0.0063) with 
overall genotype (P for type 3 F tests =0.0136). YY genotype is associated with a decrease in 
pyruvate concentrations. In contrast, subjects with 0-1 Y alleles had significantly higher pyruvate 
concentrations in the dichotomized analysis (P=0.0032). Time of sample from injury was found 
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 to be significant (genotypes P=0.0027; dichotomized genotype P=0.0027), only day 1 was 
significantly higher that day 5. (Refer to table 4-42). 
Lactate: Pyruvate (LP) Ratio 
In analyzing the 9 BCL-2 SNP’s (RS1026825, RS17759659, RS1801018, RS1944419, 
RS3810027, RS4941185, RS7236090, RS8083946, and RS949037) of interest in relations to the 
LP ratios, 2 SNP’s (RS17759659 and RS1801018) had significant findings and 1 SNP was 
marginally significant (RS8083946). Time was the only consistently significant in relation to LP 
ratios among the mixed models analyzed for these SNP’s. (Refer to tables 4-38 to 4-42).  
The mixed model with SNP RS17759659: genotype YY was significant (P= 0.01) with 
overall genotype (P for type 3 F tests =0.0287). YY genotypes were associated with an increase 
in LP ratios. In contrast, subjects with 0-1 Y alleles had significantly lower LP ratios as indicated 
in the dichotomized analysis (P=0.0079). Time of sample from injury was found to be significant 
(genotypes P=0.00133; dichotomized genotype P=0.0033), days 1 and 2 were significantly 
higher that day 5. (Refer to table 4-38). 
The mixed model with SNP RS1801018: genotype XX was significant (P= 0.0342) with 
overall genotype (P for type 3 F tests =0.0661). XX genotypes were associated with an increase 
in LP ratios. In contrast, subjects with 0-1 X alleles had significantly lower LP ratios as indicated 
in the dichotomized analysis (P=0.024). Time of sample from injury was found to be significant 
(genotypes P=0.0087; dichotomized genotype P=0.009), days 1 and 2 were significantly higher 
that day 5. (Refer to table 4-39). 
The mixed model with SNP RS8083946: genotype YY was significant (P= 0.0388)  and 
genotype XX was marginally significant (P= 0.0783) with overall genotype (P for type 3 F tests 
=0.064). XX and YY genotypes were associated with a decrease in LP ratios. The dichotomized 
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    174
analysis (YY compared to XX and XY) was not significant (P=0.1235). Time of sample from 
injury was found to be significant (genotypes P=0.007; dichotomized genotype P=0.0057), days 
1 and 2 were significantly higher that day 5. Gender was statistically significant (genotypes P= 
0.038; dichotomized genotypes P=0.1156), compared to males, females had higher LP ratios. 






 Table 4-18: BCL-2 Genotypes vs. Neurometabolite Descriptive Data 
Varaibles n= Mean Std. Deviation Range
Age 36 31.14 13.9 17-71
Frequency (%)
Frequency (%) of 
Unknown
GCS 36 scores 3 to 5 15(41.7%) 0
scores 6 to 8 21(58.3%) 0
Gender (male) 36 27(75%) 0
Race (Caucasian) 36 all caucasian 0
Hypothermic 36 15(41.7%) 0
Hypoxia 15 6(16.7%) 21 (58.33%)
Hypotensive 15 5(13.9%) 21 (58.33%)
Seizures 17 1(2.78%) 19 (52.78%)
APOEε4   36 8(22.2%) 0




Day 1 30 12751.2 21410.34 1228.57- 1206600.79 3(8.33%)
Day 2 33 10084.91 20316.16 1737.895-120799.91 6 (16.67%)
Day 3 33 5061.11 2591.21 1836.46-13186.45 6 (16.67%)
Day 4 29 4470.85 19104.22 1868.55-9026.36 7 (19.44%)
Day 5 23 4342.79 2263.85 1534.66-10100.6 13 (36.11%)
Pyruvate Concentration (μmol)
Day 1 29 228.84 92.19 83.06-429.63 4 (11.11%)
Day 2 33 204.19 71.36 93.20-359.58 6 (16.67%)
Day 3 33 193.04 62.5 84.3-361.5 6 (16.67%)
Day 4 29 204.95 61.14 104.07-328.89 7 (19.44%)
Day 5 23 193.1 67.91 98.62-374.34 13 (36.11%)
Lactate Pyruvate (LP) Ratio
Day 1 29 50.73 54.91 11.89-303.9 4 (11.11%)
Day 2 33 48.5 84.32 13.84-501.74 6 (16.67%)
Day 3 33 27.7 14.36 15.51-71.85 6 (16.67%)
Day 4 29 21.89 6.62 8.99-34.48 7 (19.44%)
Day 5 23 22.27 7.93 9.14-45.36 13 (36.11%)
SNP n= XX YY XY X Y HWE X 2 P
RS1026825 36 11 9 16 0.527777778 0.4722222 1
RS12454712 36 5 17 14 0.333333333 0.6666667 1
RS12968517 36 18 6 12 0.666666667 0.3333333 1
RS1381548 36 3 10 23 0.402777778 0.5972222 1
RS1481031 36 19 4 13 0.708333333 0.2916667 1
RS17756073 36 16 4 16 0.666666667 0.3333333 1
RS17759659 35 6 7 22 0.485714286 0.5142857 1
RS1801018 35 6 5 24 0.514285714 0.4857143 1
RS1944419 34 12 10 12 0.529411765 0.4705882 1
RS3810027 35 18 3 14 0.714285714 0.2857143 1
RS4456611 36 8 5 23 0.541666667 0.4583333 1
RS4941185 35 12 8 15 0.414285714 0.3 0.510204082 15.277345 <.0001
RS7230970 35 6 10 19 0.442857143 0.5571429 1
RS7236090 36 10 9 17 0.513888889 0.4861111 1
RS8083946 36 4 19 13 0.291666667 0.7083333 1
RS899968 36 7 12 7 0.291666667 0.4305556 0.521604938 11.26643 <.0001
RS949037 35 4 14 17 0.357142857 0.6428571 1
 BCL-2 Genotypes Versus Neurometabolite Descriptive Data
Hardy-Weinberg Equilibrium
* X 2  p≤ 0.05  
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 Table 4-19: Preliminary Mixed Models Analyses of  BCL-2  vs Neurometabolites 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS1026825 36 xx 4195.96 0.2456 0.4704 -32.6433 0.1831* 0.4061 18.638 0.1371* 0.2824
yy 271.58 0.9447 -14.104 0.5887 0.5235 0.969
xy
yy & xy -4116.6 0.2161 0.2161 27.7345 0.2163 0.2163 -18.5 0.1089* 0.1089*
xx 
RS12454712 36 xx -3528.5 0.4863 0.5313 -27.6095 0.4116 0.6849 -11.86 0.506 0.6446
yy -3569.4 0.2861 -126904 0.5766 -9.993 0.3954
xy
xx & xy 2742.67 0.3736 0.3736 5.7549 0.7833 0.7833 7.1742 0.5074 0.5074
 yy
RS12968517 36 xx 1392.19 0.6898 0.6479 -4.9823 0.8337 0.8955 4.0849 0.7377 0.6251
yy -2593.7 0.5723 -14.7417 0.6411 -10.47 0.5143
xy
yy & xy -2300.5 0.4555 0.4555 -0.01439 0.9995 0.9995 -7.776 0.4706 0.4706
xx 
RS1381548 36 xx -1498.9 0.8166 0.6891 0.4193 0.9917 0.6745 -3.776 0.8675 0.7952
yy -3019.6 0.3948 -20.6643 0.3869 -8.321 0.5033
xy
xx & xy 2897.41 0.403 0.403 20.7356 0.3715 0.3715 8.0002 0.5097 0.5097
 yy
RS1481031 36 xx -4189.6 0.2074 0.4023 -5.2076 0.8198 0.9641 -12.38 0.289 0.4843
yy -4717.1 0.3743 -7.855 0.829 -16.91 0.3654
xy
yy & xy 3131.11 0.3094 0.3094 3.4249 0.8701 0.8701 8.5776 0.4281 0.4281
xx 
* p≤ 0.2
Lactate Pyruvate Lactate:Pyruvate Ratio
Preliminary Mixed Models Analysis of BCL-2 vs Neurometabolites
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 Table 4-19 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS17756073 36 xx 3191.72 0.3382 0.5863 10.6194 0.6346 0.6596 9.0445 0.4375 0.5853
yy 3391.75 0.55007 -20.1993 0.5621 15.848 0.3699
xy
yy & xy -2446.8 0.4313 0.4313 -14.8255 0.4796 0.4796 -5.554 0.6109 0.6109
xx 
RS17759659 35 xx -335.54 0.9409 0.2042 -3.1097 0.9049 0.0079* -1.896 0.8975 0.0183*
yy 6689.86 0.0876* -76.3575 0.0025* 35.223 0.0069*
xy
xx & xy -6752.8 0.0742* 0.0742* 75.7433 0.0019* 0.0019* -35.57 0.0048* 0.0048*
 yy
RS1801018 35 xx 7814.96 0.0568* 0.1385* -61.233 0.0271* 0.0595* 35.557 0.0106* 0.0255*
yy -823.32 0.8679 13.1922 0.6636 -5.943 0.7189
xy
yy & xy -7931.3 0.0473* 0.0473* 63.2985 0.0192* 0.0192* -36.37 0.0075* 0.0075*
xx 
RS1944419 34 xx 5154.19 0.1914* 0.3196 -15.5471 0.5476 0.7973 19.048 0.1621* 0.2738
yy -6.1375 0.9988 -1.0016 0.9693 0.2034 0.9882
xy
yy & xy -5159.3 0.1285* 0.1285* 15.0531 0.4987 0.4987 -18.95 0.1055* 0.1055*
xx 
xx & xy 2626.87 0.4567 0.4567 -6.6137 0.7689 0.7689 9.5461 0.4335 0.4335
 yy
RS3810027 35 xx -6157.4 0.0661* 0.1781* -39.9896 0.0663* 0.1022* -16.65 0.1599* 0.3672
yy -4413 0.429 -61.8993 0.1031* -7.554 0.7039
xy
yy & xy 5332.65 0.0905* 0.0905* 28.8401 0.169* 0.169* 15.239 0.1694* 0.1694*
xx 
* p≤ 0.2
Preliminary Mixed Models Analysis of BCL-2 vs Neurometabolites
Lactate Pyruvate Lactate:Pyruvate Ratio
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 Table 4-19 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS4456611 36 xx -3353.7 0.3819 0.6724 -32.1672 0.2098 0.3662 -7.778 0.5643 0.7924
yy -280.69 0.9503 -27.6985 0.3626 3.489 0.8253
xy
yy & xy 3309.04 0.3693 0.3693 27.1041 0.2763 0.2763 8.4793 0.5137 0.5137
xx 
RS4941185 35 xx 2359.65 0.5031 0.2027 51.3918 0.0309* 0.0727* 5.8862 0.6275 0.1247*
yy 7206.88 0.076* 4.3265 0.867 28.153 0.0453*
xy
yy & xy 107.17 0.9746 0.9746 -49.9683 0.0211* 0.0211* 3.7163 0.7522 0.7522
xx 
RS7230970 35 xx -2715.1 0.5403 0.6349 -5.7876 0.847 0.6096 -12.79 0.4054 0.4918
yy -3242.5 0.3865 22.012 0.3809 -13.59 0.2967
xy
xx & xy 2608.44 0.4633 0.4633 -23.3713 0.3253 0.3253 10.609 0.3931 0.3931
 yy
RS7236090 36 xx -5606.7 0.1201* 0.1776* -37.6731 0.1273* 0.2753 -18.24 0.1439* 0.138*
yy -5747.4 0.1311* -2.6619 0.9165 -23.81 0.0743*
xy
yy & xy 3657.3 0.2821 0.2821 36.7929 0.1062* 0.1062* 10.252 0.3901 0.3901
xx 
RS8083946 36 xx -3979.5 0.453 0.2161 37.1854 0.3033 0.4971 -18.85 0.3089 0.0281*
yy -5713.5 0.0837* -3.5528 0.874 -19.6 0.0888*
xy




Preliminary Mixed Models Analysis of BCL-2 vs Neurometabolites
Lactate
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 Table 4-19 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS899968 36 xx -2570 0.5468 0.75 3.4057 0.9055 0.9905 -8.845 0.5523 0.7123
yy -2213.7 0.5317 -0.5919 0.9804 -9.003 0.467
xy
xx & xy 1519.08 0.647 0.647 1.5553 0.9443 0.9443 6.5937 0.5693 0.5693
 yy
RS949037 35 xx -44.545 0.9936 0.6988 20.7994 0.5227 0.0581* -3.567 0.8523 0.3937
yy 2753.72 0.4198 -43.2223 0.0419* 14.652 0.2137
xy
xx & xy -2766.9 0.3937 0.3937 46.9819 0.0207* 0.0207* -15.25 0.1739* 0.1739*
 yy
Covariates
Time (Days) 36 1 9286.03 0.0058* 0.0107* 47.1822 0.0002* 0.0008* 30.865 0.0081* 0.006*
2 6638 0.0424* 15.18 0.2077 29.304 0.0098*
3 1517.87 0.6387 3.553 0.7659 8.1207 0.4668
4 628.01 0.8488 11.9472 0.3238 1.6195 0.8866
5 . . . . . .
Age 36 -73.195 0.5091 0.5091 0.2241 0.7648 0.7648 -0.198 0.6126 0.6126
GCS  36 -4538.6 0.1429* 0.1429* -8.4914 0.6887 0.6887 -17.23 0.1107* 0.1107*
Gender 36 6931.03 0.0448* 0.0448* 19.1683 0.4182 0.4182 23.434 0.0543* 0.0543*
Race 17
Hypothermic 36 1576.42 0.6106 0.6106 17.5545 0.3964 0.3964 2.8457 0.7937 0.7937
Hypoxia  15 7660.51 0.2729 0.2729 -6.8801 0.8228 0.8228 29.357 0.2249 0.2249
Hypotensive 15 2814.74 0.7134 0.7134 1.0373 0.9747 0.9747 5.6277 0.8329 0.8329
Seizures  17 3304.32 0.8173 0.8173 2.7005 0.9648 0.9648 12.67 0.7989 0.7989
APOEε4 36 919.92 0.8035 0.8035 -27.7319 0.257 0.257 4.2516 0.7429 0.7429
* p≤ 0.2
Preliminary Mixed Models Analysis of BCL-2 vs Neurometabolites
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 Table 4-20: Primary Mixed Models Analyses of BCL-2 and Neurometabolites 
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 Table 4-20 continued 
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 Table 4-20 continued 
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 Table 4-20 continued 
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 4.2.2.3 Cerebral Blood Flow 
Sub-sample Description Cerebral Blood Flow 
The mean age of the sub-sample of 17 subjects was 31.94 years old (range 16-65; SD± 
17.594). The sample was all Caucasian and primarily male (n=13; 76.5%). Over half of the sub-
sample had an admission GCS of 3-5 (n=9; 52.9%). Of the subjects enrolled in the study, a 
portion received therapeutic hypothermia (n=8; 41.2%).  In the overall sub-sample the presence 
of sustained hypoxia (n=4; 23.53%), hypotension (n=4; 23.53%), hypoxia (n=4; 23.53%), 
documented pre-admission seizures (n=0) and the occurrence of APOEε4 (n=4; 23.53%), were 
considered. Refer to table 4-43 for sample description. All of the SNP’s genotyped for the CBF 
sub-sample met the HWE criteria for genotype representation in a population. Refer to table 4-43 
for genotype frequencies for each SNP and HWE calculations. 
Right hemisphere, left hemisphere, and global CBF were analyzed over days 1-5 post 
injury. CBF peaked overall on day 1 across the three regions analyzed. Descriptive statistics for 
the CBF are included in table 4-43.  
 
Preliminary Mixed Models Analysis for CBF  
In the preliminary mixed models analyses, each SNP was analyzed individually for a 
relationship with right hemisphere, left hemisphere, and global CBF over time. Each of the 
covariates was analyzed for potential relationship with right hemisphere, left hemisphere, and 
global CBF over time. By doing this the SNP’s and covariates of interest in building the larger 
model were ascertained. The criterion used was a P for Type 3 tests of ≤0.2 in addition to 
covariates that are deemed prudent through the evidence in the literature (age, gender, GCS, and 
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 hypothermia). Race was not included in the model as all of the subjects were Caucasian. (Refer 
to tables 4-44 to 4-47). 
Right Hemisphere  
The preliminary mixed model analyses for right hemisphere indicated that there were 13 
SNP’s and 2 covariates of interest, meeting the criterion were: RS1026825 (genotypes P=0.014; 
[preliminary models were run for both homozygous variant and wild type because of equal 
sample size] XX dichotomized genotype P=0.3736; YY dichotomized genotype P=0.0307); 
RS12454712 (genotypes P=0.3432; dichotomized genotype P=0.0132); RS1381548 (genotypes 
P=0.1529; [preliminary models were run for both homozygous wild type and variant  because of 
equal sample size] XX dichotomized genotype P=0.1484; YY dichotomized genotype 
P=0.0538); RS1481031 (genotypes P=0.017; dichotomized genotype P=0.004); RS17756073 
(genotypes P=0.0436; dichotomized genotype P=0.0172); RS1801018 (genotypes P=0.016; 
dichotomized genotype P=0.0332); RS3810027 (genotypes P=0.0542; dichotomized genotype 
P=0.8445); RS4456611 (genotypes P=0.1067; [preliminary models were run for both 
homozygous wild type and variant  because of equal sample size] XX dichotomized genotype 
P=0.1003; YY dichotomized genotype P=0.0428); RS4941185 (genotypes P=0.161; 
dichotomized genotype P=0.0552); RS7236090 (genotypes P=0.1314; dichotomized genotype 
P=0.2243); RS8083946 (genotypes P=0.0444; dichotomized genotype P=0.1117); RS899968 
(genotypes P=0.0099; dichotomized genotype P=0.004); RS949037 (genotypes P=0.0406; 
dichotomized genotype P=0.4167); time (day) (P=0.0788); and gender (P= 0.0406). Age (P= 
0.3142), GCS (P=0.3733), and hypothermia (P=.7908) were not indicated in the preliminary 
analysis, however, they were controlled for in the full model. (Refer to tables 4-44 to 4-47). 
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 Left Hemisphere  
The preliminary mixed model analyses for left hemisphere indicated that there were 13 
SNP’s and 4 covariates of interest, meeting the criterion were: RS1026825 (genotypes P=0.0193; 
[preliminary models were run for both homozygous variant and wild type because of equal 
sample size] XX dichotomized genotype P=0.327; YY dichotomized genotype P=0.0362); 
RS12968517 (genotypes P=0.1629; dichotomized genotype P=0.0703); RS1381548 (genotypes 
P=0.1992; [preliminary models were run for both homozygous variant and wild type  because of 
equal sample size] XX dichotomized genotype P=0.1249; YY dichotomized genotype 
P=0.0792); RS1481031 (genotypes P=0.0378; dichotomized genotype P=0.0089); RS17756073 
(genotypes P=0.0354; dichotomized genotype P=0.0153); RS1801018 (genotypes P=0.0384; 
dichotomized genotype P=0.0325); RS3810027 (genotypes P=0.1197; dichotomized genotype 
P=0.5906); RS4456611 (genotypes P=0.1833; [preliminary models were run for both 
homozygous variant and wild type because of equal sample size] XX dichotomized genotype 
P=0.1233; YY dichotomized genotype P=0.0879); RS4941185 (genotypes P=0.2766; 
dichotomized genotype P=0.1039); RS7236090 (genotypes P=0.1457; dichotomized genotype 
P=0.173); RS8083946 (genotypes P=0.0609; dichotomized genotype P=0.1049); RS899968 
(genotypes P=0.0568; dichotomized genotype P=0.0273); RS949037 (genotypes P=0.1161; 
dichotomized genotype P=0.6107); time (day) (P=0.1381); age (P= 0.1435); GCS (P=0.1981); 
and gender (P= 0.0352). Hypothermia (P=0.9048) was not indicated in the preliminary analysis, 
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 Global  
The preliminary mixed model analyses for Global indicated that there were 14 SNP’s and 
2 covariates of interest, meeting the criterion were: RS1026825 (genotypes P=0.0183; 
[preliminary models were run for both homozygous variant and wild type  because of equal 
sample size] XX dichotomized genotype P=0.3657; YY dichotomized genotype P=0.0381); 
RS12454712 (genotypes P=0.4041; dichotomized genotype P=0.185); RS12968517 (genotypes 
P=0.3197; dichotomized genotype P=0.1666); RS1381548 (genotypes P=0.1614; [preliminary 
models were run for both homozygous variant and wild type  because of equal sample size] XX 
dichotomized genotype P=0.1309; YY dichotomized genotype P=0.0587); RS1481031 
(genotypes P=0.0214; dichotomized genotype P=0.0049); RS17756073 (genotypes P=0.0333; 
dichotomized genotype P=0.012); RS1801018 (genotypes P=0.0198; dichotomized genotype 
P=0.0244); RS3810027 (genotypes P=0.0715; dichotomized genotype P=0.7653); RS4456611 
(genotypes P=0.1079; [preliminary models were run for both homozygous variant and wild type 
because of equal sample size] XX dichotomized genotype P=0.1008; YY dichotomized genotype 
P=0.044); RS4941185 (genotypes P=0.204; dichotomized genotype P=0.0727); RS7236090 
(genotypes P=0.1384; dichotomized genotype P=0.2008); RS8083946 (genotypes P=0.0545; 
dichotomized genotype P=0.1278); RS899968 (genotypes P=0.0198; dichotomized genotype 
P=0.0084); RS949037 (genotypes P=0.0737; dichotomized genotype P=0.4698); time (day) 
(P=0.1092); and gender (P= 0.0327). Age (P= 0.2507), GCS (P=0.3032), and hypothermia 
(P=0.8968) were not indicated in the preliminary analysis, however, they were controlled for in 
the full model. (Refer to tables 4-44 to 4-47). 
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 Primary Mixed Models Analyses for CBF  
Right Hemisphere CBF 
 In analyzing the 13 BCL-2 SNP’s (RS1026825, RS12454712, RS1381548, RS1481031, 
RS17756073, RS1801018, RS3810027, RS4456611, RS4941185, RS7236090, RS8083946, 
RS899968, and RS949037) of interest from the preliminary analyses, in relation to the right 
hemisphere CBF, 10 SNP’s had significant findings (RS1026825, RS1381548, RS1481031, 
RS17756073, RS1801018, RS4456611, RS4941185, RS7236090, RS899968, and RS949037). 
Time was consistently statistically significant and gender was implicated as significant or 
trending for 2 SNP’s (RS1801018 and RS4941185) in relation to right hemisphere CBF among 
the mixed models analyzed for these SNP’s. (Refer to tables 4-48 to 4-54)  
The mixed model with SNP RS1026825: genotype YY was significant (P= 0.0117) with 
overall genotype (P for type 3 F tests =0.0135). YY genotype is associated with a decrease in 
right hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.024). In 
contrast, subjects with 0-1 Y alleles had significantly higher right hemisphere CBF. Time of test 
from injury was found to be significant (genotypes P=0.0171; dichotomized genotype 
P=0.0254), compared to CBF on day 5, day 1 CBF was significantly higher and CBF on day 4 
was significantly lower than day 4. (Refer to table 4-48). 
The mixed model with SNP RS1381548: genotype YY was significant (P= 0.0477) with 
overall genotype (P for type 3 F tests =0.0681). YY genotype is associated with a decrease right 
hemisphere CBF. This trend was significant in the YY dichotomized analysis (P=0.0216).  In 
contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was 
found to be marginally significant (genotypes P=0.0869; YY dichotomized genotype P=0.0556), 
with day 4 CBF trending to lower CBF’s. (Refer to table 4-49). 
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 The mixed model with SNP RS1481031: genotype XX was significant (P= 0.0071) with 
overall genotype (P for type 3 F tests =0.0174). XX genotype is associated with a decrease in 
right hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0046). In 
contrast, subjects with 0-1 X alleles had significantly higher CBF. Time of test from injury was 
found to be significant (genotypes P=0.0108; dichotomized genotype P=0.0051), day 1 was 
associated with significantly higher and day 4 was associated with significantly lower CBF 
compared to day 5. (Refer to table 4-50). 
The mixed model with SNP RS17756073: genotype XX (P= 0.1421) with overall 
genotype (P for type 3 F tests =0.0322). XX genotype is associated with an increase in right 
hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0116). In 
contrast, subjects with 0-1 X alleles had significantly lower CBF. Time of test from injury was 
found to be significant (genotypes P=0.024; dichotomized genotype P=0.0194); CBF on day 1 
was significantly higher compared to day 5. (Refer to table 4-50). 
The mixed model with SNP RS1801018: genotypes XX (P= 0.0002) and YY (P= 0.0007) 
were both significant with overall genotype (P for type 3 F tests =0.0021). XX and YY 
genotypes were associated with a decrease in right hemisphere CBF. This trend was significant 
in the dichotomized analysis (P=0.0391). In contrast, subjects with 0-1 copies of the X allele had 
a significant increase in CBF. Time of test from injury was found to be significant (genotypes 
P=0.0014; dichotomized genotype P=0.0279); day 1-3 were associated with significantly higher 
CBF compared to CBF on day 5. Gender was found to be significant in the genotype model 
(genotypes P=0.009; dichotomized genotype P=0.3626) with males having a decrease in right 
hemisphere CBF. (Refer to table 4-51). 
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 The mixed model with SNP RS3810027: genotype XX (P= 0.0292) with overall 
genotype (P for type 3 F tests =0.0829). XX genotype is associated with an increase in right 
hemisphere CBF. This trend was not significant in the YY dichotomized analysis (P=0.79). Time 
of test from injury was found to be marginally significant (genotypes P=0.0153; YY 
dichotomized genotype P=0.1024); day 4 was associated with significantly lower CBF compared 
CBF on day 5. (Refer to table 4-51). 
The mixed model with SNP RS4456611: genotype YY (P= 0.1356) with overall 
genotype (P for type 3 F tests =0.0927). YY genotype is associated with a decrease right 
hemisphere CBF. This trend was significant in the YY dichotomized analysis (P=0.0295). In 
contrast, subjects with 0-1 Y alleles had a significant increase in CBF. Time of test from injury 
was found to be marginally significant (genotypes P=0.0994; YY dichotomized genotype 
P=0.0838), day 1 was associated with significantly higher CBF. (Refer to table 4-52). 
The mixed model with SNP RS4941185: genotype YY was significant (P= 0.0193) with 
overall genotype (P for type 3 F tests =0.0539). YY genotype is associated with an increase in 
right hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0132). In 
contrast, subjects with 0-1 Y alleles had lower CBF. Time of test from injury was found to be 
significant (genotypes P=0.0429; dichotomized genotype P=0.0294); day 1 was associated with 
significantly higher CBF and day 4 was associated with a trend in lower CBF when compared to 
day 5 CBF’s. Gender was found to be marginally significant in the models (genotypes P=0.0753; 
dichotomized genotype P=0.0641) with males having a decrease in right hemisphere CBF. (Refer 
to table 4-52). 
The mixed model with SNP RS7236090: genotype YY (P= 0.0273) with overall 
genotype (P for type 3 F tests =0.0306). YY genotype was associated with an increase in right 
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 hemisphere CBF. This trend was not significant in the dichotomized analysis (P=0.1119). Time 
of test from injury was found to be marginally significant in the genotypes model (genotypes 
P=0.0626; dichotomized genotype P=0.1196); day 4 was associated with lower CBF. (Refer to 
table 4-53). 
The mixed model with SNP RS8083946: genotype YY (P= 0.087) with overall genotype 
(P for type 3 F tests =0.0666). YY genotype is associated with an increase in right hemisphere 
CBF. This trend was not significant in the dichotomized analysis (P=0.1435). Time of test from 
injury was found to be marginally significant in the genotypes model (genotypes P=0.036; 
dichotomized genotype P=0.0634); day 1 associated with a higher trend in CBF and day 4 had 
significantly lower CBF when compared to day 5 CBF’s. (Refer to table 4-53). 
The mixed model with SNP RS899968: genotype YY (P= 0.0124) with overall genotype 
(P for type 3 F tests =0.0135). YY genotype is associated with a decrease in right hemisphere 
CBF. This trend was significant in the dichotomized analysis (P=0.0033). In contrast subjects 
with 0- Y alleles had significantly higher CBF. Time of test from injury was found to be 
significant (genotypes P=0.0316; dichotomized genotype P=0.0269), day 1 had significantly 
higher CBF. (Refer to table 4-54). 
The mixed model with SNP RS949037: genotypes XX (P=0.0293) and YY (P= 0.0729) 
had significantly lower right hemisphere CBF when compared to heterozygous genotypes. The 
overall genotype was significant (P for type 3 F tests =0.048). This trend was not significant in 
the YY dichotomized analysis (P=0.2432). Time of test from injury was found to be marginally 
significant in the genotypes model (genotypes P=0.0707; dichotomized genotype P=0.1518), day 
1 had a trend for higher CBF’s. (Refer to table 5-54). 
 
   192
 Left Hemisphere CBF 
In analyzing the 13 BCL-2 SNP’s (RS1026825, RS12968517, RS1381548, RS1481031, 
RS17756073, RS1801018, RS3810027, RS4456611, RS4941185, RS7236090, RS8083946, 
RS899968, and RS949037) of interest in relations to the left hemisphere CBF, 8 SNP’s had 
significant findings (RS1026825, RS1381548, RS1481031, RS17756073, RS1801018, 
RS4941185, RS7236090, and RS899968). Time was consistently statistically significant in 
relation to left hemisphere CBF among the mixed models analyzed for these SNP’s. (Refer to 
tables 4-48 to 4-54).  
The mixed model with SNP RS1026825: genotype YY was significant (P= 0.0134) with 
overall genotype (P for type 3 F tests =0.0132). YY genotype was associated with a decrease in 
left hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0296). In 
contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was 
found to be significant (genotypes P=0.0345; dichotomized genotype P=0.0515); day 1 had 
significantly higher CBF. (Refer to table 4-48). 
The mixed model with SNP RS12968517: genotype YY was marginally significant (P= 
0.0767) with overall genotype (P for type 3 F tests =0.1715). YY genotype was associated with 
an increase in left hemisphere CBF. This trend was significant in the YY dichotomized analysis 
(P=0.0768). In contrast, subjects with 0-1 Y alleles had significantly lower CBF. Time of test 
from injury was found to be significant (genotypes P=0.0643; YY dichotomized genotype 
P=0.0485); day 1 had significantly higher CBF. (Refer to table 4-49). 
The mixed model with SNP RS1381548: genotype YY was significant (P= 0.0591) with 
overall genotype (P for type 3 F tests =0.0668). YY genotype was associated with a decrease left 
hemisphere CBF. This trend was significant in the YY dichotomized analysis (P=0.0187). In 
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 contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was 
found to be significant (genotypes P=0.0722; YY dichotomized genotype P=0.0351); day 2 and 
day 4 were associated with lower CBF when compared to day 5 CBF. Age was marginally 
significant (genotypes P=0.062; YY dichotomized genotype P=0.0624) with increasing age 
associated with decreased left hemisphere CBF. GCS was statistically significant (genotypes 
P=0.0844; YY dichotomized genotype P=0.0327); subjects with higher GCS on admission scores 
had higher CBF. Hypothermia was marginally significant (genotypes P=0.1856; YY 
dichotomized genotype P=0.081) with normothermic subjects having decreased left hemisphere 
CBF. (Refer to table 4-49). 
The mixed model with SNP RS1481031: genotype XX was significant (P= 0.0165) with 
overall genotype (P for type 3 F tests =0.0417). XX genotype was associated with a decrease in 
left hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0105). In 
contrast, subjects with 0-1 X alleles had significantly higher CBF. Time of test from injury was 
found to be significant (genotypes P=0.0336; dichotomized genotype P=0.0162); day 1 was 
associated with higher CBF and day 4 was associated with lower CBF. (Refer to table 4-50). 
The mixed model with SNP RS17756073: genotype XX (P= 0.143) with overall 
genotype (P for type 3 F tests =0.022). XX genotype was associated with an increase in left 
hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0086). In 
contrast, subjects with 0-1 X alleles had significantly lower CBF. Time of test from injury was 
found to be significant (genotypes P=0.0305; dichotomized genotype P=0.0232); day 1 was 
associated with higher CBF. (Refer to table 4-50). 
 The mixed model with SNP RS1801018: genotypes XX (P= 0.0021) and YY (P=0.0248) 
were significant with an overall genotype significance (P for type 3 F tests =0.0099). Both 
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 genotypes were associated with decreasing left hemisphere CBF. This trend was significant in 
the XX dichotomized analysis (P=0.0356). In contrast, subjects with 0-1 X alleles had 
significantly higher CBF. Time of test from injury was found to be significant (genotypes 
P=0.0145; dichotomized genotype P=0.0536); days 1-3 had significantly higher left hemisphere 
CBF than on day 5. Gender was found to be marginally significant in the genotype model 
(genotypes P=0.0805; dichotomized genotype P=0.5185) with males having a decrease in left 
hemisphere CBF. (Refer to table 4-51). 
The mixed model with SNP RS4456611: genotype YY (P= 0.1487) with overall 
genotype (P for type 3 F tests= 0.185). YY genotype is associated with a decrease left 
hemisphere CBF. This trend was marginally significant in the YY dichotomized analysis 
(P=0.0623). In contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test 
from injury was found not to have any overall statistical significance. (Refer to table 4-52). 
The mixed model with SNP RS4941185: genotype YY was significant (P= 0.0534) with 
overall genotype (P for type 3 F tests =0.0853). YY genotype was associated with an increase in 
left hemisphere CBF. This trend was significant in the dichotomized analysis (P=0.0221). In 
contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was 
found to be marginally significant (genotypes P=0.0709; dichotomized genotype P=0.0775); day 
1 was associated with a trend towards higher CBF. (Refer to table 4-52). 
The mixed model with SNP RS7236090: genotype YY (P= 0.0272) with overall 
genotype (P for type 3 F tests =0.0224). YY genotype was associated with an increase in left 
hemisphere CBF while XX (P= 0.0848) had a trend towards lower CBF. In the XX  
dichotomized analysis (P=0.0549), subjects with 0-1 X alleles had a trend towards significantly 
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 higher CBF. Time of test from injury was not found to have an overall significant trend. (Refer 
to table 4-53). 
The mixed model with SNP RS899968: genotype YY (P= 0.0558) with overall genotype 
(P for type 3 F tests =0.0906). YY genotype was associated with a decrease in left hemisphere 
CBF. This trend was significant in the dichotomized analysis (P=0.0264). In contrast, subjects 
with 0-1 Y alleles had significantly higher CBF. Time of test from injury was not found to have 
an overall significant trend. (Refer to table 4-54). 
The mixed model with SNP RS949037: genotype XX (P= 0.0535) with overall genotype 
(P for type 3 F tests =0.0898). XX genotype was associated with a decrease in left hemisphere 
CBF. Subjects with 0-1 Y alleles did not have a significantly higher CBF in the dichotomized 
analysis (P=0.2937). Time of test from injury was not found to have an overall significant trend. 
(Refer to table 5-54). 
Global CBF 
In analyzing the 14 BCL-2 SNP’s (RS1026825, RS12454712, RS12968517, RS1381548, 
RS1481031, RS17756073, RS1801018, RS3810027, RS4456611, RS4941185, RS7236090, 
RS8083946, RS899968, and  RS949037) of interest from the preliminary analyses,  in relation to 
the global CBF, 10 SNP’s had significant findings (RS1026825, RS1381548, RS1481031, 
RS17756073, RS1801018, RS4456611, RS4941185, RS7236090, RS899968, and rs949037). 
Time was consistently statistically significant and gender was occasionally marginally significant 
in relation to global CBF among the mixed models analyzed for these SNP’s. (Refer to tables 4-
48 to 4-54). Figure4-13 depicts the Average Global CBF for each of the statistically significant 
or statistically tending SNP’s. 
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Figure 4-13: Average Global CBF by Tagging SNP 
The mixed model with SNP RS1026825: genotypes XX (P=0.0651) and YY (P= 0.0139) 
were significant with an overall genotype (P for type 3 F tests =0.0156). Both genotypes were 
associated with a decrease in global CBF. In the YY dichotomized analysis, subjects with 0-1 Y 
alleles had significantly higher global CBF (P=0.0287). Time of test from injury was found to be 
significant (genotypes P=0.0273; dichotomized genotype P=0.0403); day 1 was associated with a 
trend towards higher CBF among all genotypes. (See figure 4-14 and table 4-48). 



































Figure 4-14: Average Global CBF for SNP rs1026825 
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 The mixed model with SNP RS1381548: genotype YY was significant (P= 0.0475) with 
overall genotype (P for type 3 F tests =0.0604). YY genotype was associated with a decrease 
global CBF. This trend was significant in the YY dichotomized analysis (P=0.0177). In contrast, 
subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was found to 
be significant (genotypes P=0.0777; YY dichotomized genotype P=0.0432); with days 2 (YY) 
and 4 (XY) associated with a trend towards lower CBF. (See figure 4-15 and table 4-49). 






































Figure 4-15: Average Daily Global CBF for SNP rs1381548 
The mixed model with SNP RS1481031: genotype XX was significant (P= 0.0086) with 
overall genotype (P for type 3 F tests = 0.0218). XX genotype was associated with a decrease in 
global CBF. This trend was significant in the dichotomized analysis (P=0.0055). In contrast, 
subjects with 0-1 X alleles had significantly higher CBF. Time of test from injury was found to 
be significant (genotypes P=0.0177; dichotomized genotype P=0.0082); day 1 was associated 
with higher global CBF (genotype XX) and day 4 was associated with lower CBF (genotype 
XY). (See figure 4-16 and table 4-50). 
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Figure 4-16: Average Daily Global CBF for rs1481031 
The mixed model with SNP RS17756073: genotype XX (P= 0.1032) with overall 
genotype (P for type 3 F tests =0.0221). XX genotype was associated with an increase in global 
CBF. This trend was significant in the dichotomized analysis (P=0.0075). In contrast, subjects 
with 0-1 X alleles had significantly lower CBF. Time of test from injury was found to be 
significant (genotypes P=0.0266; dichotomized genotype P=0.0292); day 1 (YY) was associated 
with a trend towards higher CBF. (See Figure 4-17 and refer to table 4-50). 




































Figure 4-17: Average Daily Global CBF for SNP rs17756073 
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 The mixed model with SNP RS1801018: genotypes XX (P= 0.0003) and YY (P=0.0031) 
were significant with an overall genotype (P for type 3 F tests =0.003). Both genotypes were 
associated with a decrease in global CBF. This trend was significant in the dichotomized analysis 
(P=0.0292). Subjects with 0-1 X alleles had significantly higher CBF. Time of test from injury 
was found to be significant (genotypes P=0.0035; dichotomized genotype P=0.0365); day 1(XX) 
and day 3 (XY) had significantly higher global CBF compared to day 5 CBF. (See Figure 4-18 
and table 4-51). Gender was found to be significant in the genotype model (genotypes P=0.0166; 
dichotomized genotype P=0.3546) with males with XX and XY genotypes have a decrease in 
global CBF. [Note: Male XX n=4; YY n=4; XY n=5 and Females XX n=2 and XY n=2]. (See 
figure 4-19 and table 4-51). 

































Figure 4-18:Average Daily Global CBF for SNP rs1801018 
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Figure 4-19: Average Global CBF by Gender for SNP rs1801018 
The mixed model with SNP RS4456611: genotype YY (P= 0.1238) with overall marginal 
genotype significance (P for type 3 F tests =0.0983). YY genotype was associated with a 
decrease global CBF. This trend was significant in the YY dichotomized analysis (P=0.0306). In 
contrast, subjects with 0-1 Y alleles had significantly higher CBF. Time of test from injury was 
not found to be significant from day 5. (Refer to figure 4-20 and table 4-52). 




































Figure 4-20: Average Daily CBF for SNP rs4456611 
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 The mixed model with SNP RS4941185: genotype YY was significant (P= 0.0249) with 
overall genotype (P for type 3 F tests =0.0608). YY genotype was associated with an increase in 
global CBF. This trend was significant in the dichotomized analysis (P=0.0143). In contrast, 
subjects with 0-1 Y alleles had significantly lower CBF. Time of test from injury was found to be 
significant (genotypes P=0.0609; dichotomized genotype P=0.0483); day 1 (XY) had higher 
CBF’s. (See figure 4-21 and table 4-52).  Gender was found to be marginally significant 
(genotypes P=0.0763; dichotomized genotype P=0.0607) with males with XY genotype having 
decrease in global CBF. (See figure 4-22 and table 4-52).  





































Figure 4-21: Average Daily Global CBF for SNP rs4941185 


































Figure 4-22: Average Global CBF by Gender for SNP rs4941185 
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 The mixed model with SNP RS7236090: genotype YY (P= 0.0261) with overall 
genotype (P for type 3 F tests =0.0255). YY genotype was associated with an increase in global 
CBF. This trend was marginally significant in the XX dichotomized analysis (P=0.0797). 
Subjects with 0-1 X alleles had marginally significant higher CBF. Time of test from injury was 
found to be marginally significant in the genotypes model (genotypes P=0.08; dichotomized 
genotype P=0.1508); day 4 trending towards lower CBF. (Refer to table 4-53). 
The mixed model with SNP RS899968: genotype YY (P= 0.0216) with overall genotype 
(P for type 3 F tests =0.0273). YY genotype was associated with a decrease in global CBF. This 
trend was significant in the dichotomized analysis (P=0.0068). In contrast, subjects with 0-1 Y 
alleles had significantly higher CBF. Time of test from injury was found to be marginally 
significant (genotypes P=0.0722; dichotomized genotype P=0.0617); day 1 trending toward 
higher global CBF for all genotypes. (See figure 4-23 and table 4-54). 





































Figure 4-23: Average Daily Global CBF for SNP rs899968 
The mixed model with SNP RS949037: genotypes XX (P= 0.0432) and YY (P= 0.078) 
were trending towards significance with overall genotype (P for type 3 F tests =0.068). Both 
genotypes were associated with a decrease in global CBF. The YY dichotomized analysis 
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(P=0.2528). Time of test from injury was found not to be significant for P for type 3 F tests. 
(Refer to table 4-54). 
 
 Table 4-21: BCL-2 Genotypes vs Cerebral Blood Flow Descriptive Data 
Variable n= Mean Std. Deviation Range




GCS 17 score 3 to 5 9(52.9%) 0
score 6 to 8 8(47.1%)
Gender (male) 17 13(76.5%) 0
Race (Caucasian) 17 all caucasian 0
Hypothermic 17 7(41.2%) 0
Hypoxia 8 4(23.53%) 9 (52.94%)
Hypotensive 8 4(23.53%) 9 (52.94%)
Seizures 8 0 9 (52.94%)
APOEє4   17 4(23.5%) 0
Cerebral Blood Flow (CBF) 




Day 1 6 52.9967 18.13562 32.45-77.25 11(64.71%)
Day 2 8 40.3525 13.16545 26.55-63.78 9 (52.94%)
Day 3 7 45.0886 14.79306 33.68-73.67 10 (58.82%)
Day 4 4 43.9275 15.213 30.98-63.3 13 (76.47%)
Day 5 6 41.5567 8.01225 30.6-50.68 11(64.71%)
Left Hemisphere CBF
Day 1 6 52.6767 19.08808 30.45-79.10 11(64.71%)
Day 2 8 45.2788 10.43846 34.98-64.43 9 (52.94%)
Day 3 7 45.81 13.60251 34.80-70.53 10 (58.82%)
Day 4 4 44.75 13.4268 32.7-60.9 13 (76.47%)
Day 5 6 42.9317 8.48712 29.83-51.93 11(64.71%)
Global CBF
Day 1 6 52.7967 18.59752 31.33-78.15 11(64.71%)
Day 2 8 42.0838 11.5842 31.80-63.93 9 (52.94%)
Day 3 7 45.3886 14.24907 34.35-72.33 10 (58.82%)
Day 4 4 44.315 13.60251 31.8-62.1 13 (76.47%)
Day 5 6 42.28 8.33709 30.13-51.43 11(64.71%)
SNP n= XX YY XY X Y HWE
RS1026825 17 5 4 8 0.529411765 0.470588 1.0000
RS12454712 17 1 7 9 0.323529412 0.676471 1.0000
RS12968517 17 3 6 8 0.411764706 0.588235 1.0000
RS1381548 13 3 3 7 0.5 0.5 1.0000
RS1481031 17 10 1 6 0.764705882 0.235294 1.0000
RS17756073 17 9 4 4 0.647058824 0.352941 1.0000
RS17759659 16 4 3 9 0.53125 0.46875 1.0000
RS1801018 17 6 4 7 0.558823529 0.441176 1.0000
RS1944419 14 8 1 5 0.75 0.25 1.0000
RS3810027 16 5 6 5 0.46875 0.53125 1.0000
RS4456611 15 5 5 5 0.5 0.5 1.0000
RS4941185 17 4 5 8 0.470588235 0.529412 1.0000
RS7230970 15 2 6 7 0.366666667 0.633333 1.0000
RS7236090 15 8 1 6 0.733333333 0.266667 1.0000
RS8083946 17 5 4 8 0.529411765 0.470588 1.0000
RS899968 15 3 5 7 0.433333333 0.566667 1.0000
RS949037 17 3 8 6 0.352941176 0.647059 1.0000
 BCL-2 Genotypes Versus Cerebral Blood Flow (CBF) Descriptive Data
Hardy-Weinberg Equilibrium
 
   205
 Table 4-22: Preliminary Mixed Models Analyses for Cerebral Blood Flow 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS1026825 17 xx -9.0706 0.0685* 0.014* -8.6857 0.0772* 0.0193* -8.868 0.0749* 0.0183*
yy -12.819 0.0108* -12.0476 0.0141* -12.27 0.0138*
xy
yy & xy 5.12 0.3736 0.3736 5.3601 0.327 0.327 5.076 0.3657 0.3657
xx
xx &xy 11.3571 0.0307* 0.0307* 10.6461 0.0362* 0.0362* 10.752 0.0381* 0.0381*
yy
RS12454712 17 xx 5.4746 0.5291 0.3432 5.4593 0.517 0.428 6.1656 0.4742 0.4041
yy -5.6423 0.3651 -4.3607 0.4577 -4.332 0.4717
xy
xx &xy 8.3455 0.132* 0.132* 6.7399 0.2016 0.2016 7.1724 0.185* 0.185*
yy
RS12968517 17 xx 4.8373 0.543 0.3953 4.7076 0.5176 0.1629* 4.8599 0.5256 0.3197
yy 9.4376 0.1865* 12.5031 0.0603* 10.16 0.1407*
xy
xx &xy -8.3711 0.2185 0.2185 -11.4696 0.0703* 0.0703* -9.084 0.1666* 0.1666*
yy
RS1381548 14 xx 4.9697 0.5776 0.1529* 6.9199 0.4192 0.1992* 5.9394 0.4943 0.1614*
yy -9.0538 0.1604* -6.7807 0.2749 -8.185 0.1941*
xy
yy & xy -11.742 0.1484* 0.1484* -11.7325 0.1249* 0.1249* -11.86 0.1309* 0.1309*
xx
xx &xy 10.9311 0.0538* 0.0538* 9.6739 0.0792* 0.0792* 10.537 0.0587* 0.0587*
yy
RS1481031 17 xx -14.323 0.0067* 0.017* -12.6014 0.0151* 0.0378* -13.78 0.0083* 0.0214*
yy 5.0043 0.5565 3.7281 0.6697 4.3585 0.6104
xy
yy & xy 14.6698 0.004* 0.004* 13.0316 0.0089* 0.0089* 14.152 0.0049* 0.0049*
xx
* p≤ 0.2
Preliminary Mixed Models Analysis of BCL-2 vs Cerebral Blood Flow (CBF)
Right Hemipshere Left Hemisphere Global
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 Table 4-22 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS17756073 17 xx 7.3972 0.2821 0.0436* 6.3622 0.3236 0.0354* 7.9418 0.2312 0.0333*
yy -5.3304 0.3923 -6.2189 0.2961 -5.04 0.403
xy
yy & xy -11.727 0.0172* 0.0172* -11.3905 0.0153* 0.0153* -12.02 0.012* 0.012*
xx
RS17759659 16 xx -8.0749 0.2947 0.4832 -5.6266 0.4362 0.5314 -6.397 0.391 0.556
yy -6.7559 0.3709 -7.294 0.3111 -6.619 0.3699
xy
yy & xy 5.5755 0.4351 0.4351 2.9304 0.6626 0.6626 3.9498 0.5674 0.5674
xx
RS1801018 17 xx -19.525 0.0044* 0.016* -16.7009 0.0116* 0.0384* -18.6 0.0055* 0.0198*
yy -13.985 0.0508* -9.8965 0.1504* -11.8 0.0887*
xy
yy & xy 11.819 0.0332* 0.0332* 11.1768 0.0325* 0.0325* 12.024 0.0244* 0.0244*
xx
RS1944419 15 xx 5.6973 0.4292 0.5087 5.284 0.4407 0.6575 4.8928 0.4821 0.5966
yy 10.0959 0.2687 6.6799 0.4406 8.4794 0.3375
xy
yy & xy -1.8862 0.7655 0.7655 -2.8975 0.6256 0.6256 -1.788 0.7691 0.7691
xx
RS3810027 17 xx 21.5939 0.0176* 0.0542* 16.7122 0.0499* 0.1197* 19.609 0.025* 0.0715*
yy 8.4871 0.1813* 4.7022 0.4374 7.1364 0.2461
xy
xx &xy 1.0642 0.8445 0.8445 2.7435 0.5906 0.5906 1.5644 0.7653 0.7653
yy
RS4456611 15 xx 3.2847 0.5947 0.1067* 4.272 0.4779 0.1833* 3.5598 0.5535 0.1079*
yy -7.5215 0.1942* -5.2781 0.3501 -7.16 0.2064
xy
xx -8.2888 0.1003* 0.1003* -7.4861 0.1233* 0.1233* -8.102 0.1008* 0.1008*
yy & xy
xx &xy 9.3945 0.0428* 0.0428* 7.7593 0.0879* 0.0879* 9.1978 0.044* 0.044*
yy
* p≤ 0.2
Preliminary Mixed Models Analysis of BCL-2 vs Cerebral Blood Flow (CBF)
Right Hemipshere Left Hemisphere Global
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 Table 4-22 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS4941185 17 xx 1.5958 0.8111 0.161* 0.2561 0.9682 0.2766 1.1299 0.8624 0.204
yy 16.3856 0.0587* 12.9805 0.1179* 14.891 0.0788*
xy
xx &xy -15.943 0.0552* 0.0552* -12.9401 0.1039* 0.1039* -14.57 0.0727* 0.0727*
yy
RS7230970 15 xx -3.181 0.7092 0.6307 2.7692 0.7346 0.6401 -1.751 0.8332 0.6167
yy 4.8305 0.5209 6.3298 0.356 5.6081 0.4339
xy
xx &xy -6.0003 0.3724 0.3724 -5.6019 0.3669 0.3669 -6.213 0.3333 0.3333
yy
RS7236090 17 xx -4.6234 0.4529 0.1314* -5.4305 0.3642 0.1457* -4.935 0.4144 0.1384*
yy 23.3969 0.1004* 20.4592 0.1347* 21.907 0.1143*
xy
yy & xy 7.7755 0.2243 0.2243 8.3728 0.173* 0.173* 7.997 0.2008 0.2008
xx
RS8083946 17 xx -6.5011 0.3373 0.0444* -6.2256 0.3193 0.0609* -5.69 0.3788 0.0545*
yy 10.3421 0.0722* 9.3136 0.1003* 10.178 0.0774*
xy
yy & xy 10.5603 0.1117* 0.1117* 9.8882 0.1049* 0.1049* 9.6382 0.1278* 0.1278*
xx
RS899968 16 xx 10.1619 0.2778 0.0099* 10.135 0.293 0.0568* 10.081 0.2837 0.0198*
yy -13.58 0.0147* -9.9491 0.0831* -12.32 0.0294*
xy
xx &xy 15.5102 0.004* 0.004* 12.1311 0.0273* 0.0273* 14.371 0.0084* 0.0084*
yy
* p≤ 0.2
Preliminary Mixed Models Analysis of BCL-2 vs Cerebral Blood Flow (CBF)
Right Hemipshere Left Hemisphere Global
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 Table 4-22 continued 
SNP n= Genotype coefff P P for Type-3 Test coefff P P for Type-3 Test coefff P P for Type-3 Test 
RS949037 16 xx -15.491 0.0178* 0.0406* -12.617 0.0473* 0.1161* -13.85 0.0324* 0.0737*
yy -7.9366 0.1263* -5.8576 0.2539 -7.228 0.1655*
xy
xx &xy 4.492 0.4167 0.4167 2.6616 0.6107 0.6107 3.8902 0.4698 0.4698
yy
Covariates
Time (Days) 17 1 12.8884 0.0578* 0.0788* 11.8996 0.0665* 0.1381* 12.419 0.0625* 0.1092*
2 0.9564 0.8783 3.8836 0.5203 1.9738 0.7483
3 5.5708 0.3984 4.7525 0.4531 5.3005 0.4142
4 -11.84 0.1975* -8.9343 0.3048 -10.13 0.2571
5 . . . .
Age 17 -0.1767 0.3142 0.3142 -0.2326 0.1435* 0.1435* -0.191 0.2507 0.2507
GCS  17 -5.2122 0.3733 0.3733 -6.8174 0.1981* 0.1981* -5.69 0.3032 0.3032
Gender 17 -13.718 0.0406* 0.0406* -12.9261 0.0352* 0.0352* -13.54 0.0327* 0.0327*
Race 17
Hypothermic 17 -1.6147 0.7908 0.7908 0.6692 0.9048 0.9048 -0.751 0.8968 0.8968
Hypoxia  8 -2.7392 0.7794 0.7794 -7.0666 0.3688 0.3688 -3.967 0.6478 0.6478
Hypotensive 8 -9.6525 0.2964 0.2964 -1.2524 0.8752 0.8752 -6.887 0.4104 0.4104
Seizures  8




Preliminary Mixed Models Analysis of BCL-2 vs Cerebral Blood Flow (CBF)
Right Hemipshere Left Hemisphere Global
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 Table 4-23: Primary Mixed Models of BCL-2 SNP and Cerebral Blood Flow 
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 Table 4-23 continued 
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4.3 SUMMARY INDEX  
Tables 4-55 to 4-57 is an index of the statistically significant and trending 
findings presented in the results section. These tables are cataloged by dependent 
variable, covariates, and independent variables. 
 Table 4-24: Index of Significant Findings for Dependent Variables 
Dependent Variable Index of Significant Findings in Full/ Primary Model Findings
Neuropsychological Outcomes
GOS rs12968517, rs17759659, rs1801018, rs949037, time, age, GCS, gender,  race
DRS rs12968517, rs17759659, rs1801018, rs949037,  time, age, GCS, race, hypothermia
Mortality
rs12968517, rs17759659, rs1801018,   rs7230970, rs949037, time, age, GCS, race, 
hypothermia
NRS-R  rs17756073, rs4456611,  age, seizure
Trails A  rs12968517, rs1381548,  rs3810027, rs7236090, rs8083946, GCS, hypothermia
Trails B  rs1381548, rs17756073,   time,  GCS,  hypothermia
Bcl-2 Protein
with Outliers age
 without Outliers rs12454712,  rs1481031, rs17756073, rs7236090,  time, gender, seizure
Neurometabolites
Lacate rs1381548,  rs8083946, time, gender
Pyruvate rs17759659, rs1801018, rs4941185,  rs949037, time
LP Ratio rs17759659, rs1801018, rs8083946,  time, gender
CBF
Right Hemisphere
rs1026825, rs12454712,  rs1381548, rs1481031, rs17756073, rs1801018,  
rs3810027,  rs4456611, rs4941185,   rs7236090, rs8083946,  rs899968, rs949037, 
time, gender
Left Hemisphere
rs1026825,  rs12968517, rs1381548, rs1481031, rs17756073, rs1801018,  
rs4941185, rs7236090,  rs899968, rs949037, time, age, GCS, gender, hypothermia
Global
rs1026825, rs1381548, rs1481031, rs17756073, rs1801018, rs4456611, rs4941185,   
rs7236090, rs899968, rs949037,  time, age, GCS, gender
BOLD= statistically significant (P≤ 0.05)
Italicized=  marginally significant  (P= 0.05 -0.09)  
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 Table 4-25: Index of Significant Findings for Covariates 
Covariates Index of Significant Findings in Full/ Primary Model Findings
Time
rs1026825, rs12454712, rs12968517, rs1381548, rs1481031, rs17756073, 
rs17759659, rs1801018, rs1944419, rs3810027, rs4456611, rs4941185,  rs7236090, 
rs8083946, rs899968, rs949037, GOS, DRS, Mortality,  Trails B, bcl-2 protein 
without outliers, lactate, pyruvate, LP ratio, CBF Rt.Hemisphere, CBF, Lt. 
Hemisphere, CBF Global
Age
 rs12454712, rs12968517,  rs17756073, rs17759659, rs1801018, rs1944419,  
rs4456611, rs4941185,  rs7236090, rs949037, GOS, DRS, Mortality, NRS-R,  bcl-2 
protein with outliers,  CBF, Lt. Hemisphere, CBF Global
GCS 
rs12454712, rs12968517, rs1381548, rs1481031,  rs17756073, rs17759659, 
rs1801018, rs1944419, rs3810027,  rs4941185, rs7236090, rs8083946, rs949037, 
GOS, DRS, Mortality, Trails A, Trails B, CBF Lt. Hemisphere, CBF Global
Gender (Male) 
rs1026825, rs12968517,  rs1481031, rs17756073, rs17759659, rs1801018, 
rs4456611,  rs4941185,  rs7236090, rs8083946, rs899968,  rs949037, GOS, bcl-2 
protein without outliers, lactate,  LP ratio, CBF Rt.Hemisphere, CBF Lt. 
Hemisphere, CBF Global
Race (Caucasian) rs17759659, rs1801018, rs7230970, rs7236090, rs949037, GOS, DRS, Mortality      
Hypothermic 
rs12454712, rs12968517, rs1381548, rs1481031, rs17756073, rs17759659, 
rs1801018,  rs3810027,  rs4941185,  rs7230970, rs7236090, rs8083946,  rs949037,  




rs1026825,  rs1481031, rs17756073, rs17759659, rs4456611, rs7236090 , rs899968,  
NRS-R,  bcl-2 protein without outliers
APOEε4   
BOLD= statistically significant (P≤ 0.05)
Italicized=  marginally significant  (P= 0.05 -0.09)  
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 Table 4-26: Index of Significant Findings for Independent Variables 
Independent Variable Index of Significant Findings in Full/ Primary Model Findings
SNP's
3' end RS17756073
NRS-R,  Trails B,  bcl-2 protein without outliers, CBF Rt.Hemisphere, CBF, Lt. 
Hemisphere, CBF Global, time, age, GCS, gender, hypothermia,  seizure
I RS4456611  NRS-R,    CBF Rt.Hemisphere, CBF Global,  time, age, gender,seizure
I RS1026825  CBF Rt.Hemisphere, CBF, Lt. Hemisphere, CBF Global, time,  gender, seizure
I RS7230970 Mortality,  time, age, GCS,  race,  hypothermia
I RS899968  CBF Rt.Hemisphere, CBF, Lt. Hemisphere, CBF Global,  time,  gender,  seizure
I RS4941185
pyruvate,  CBF Rt.Hemisphere, CBF, Lt. Hemisphere, CBF Global, time, age, GCS, 
gender,  hypothermia
I RS12454712  bcl-2 protein without outliers,   CBF Rt.Hemisphere,   time, age, GCS, hypothermia 
I RS1481031
bcl-2 protein without outliers,  CBF Rt.Hemisphere, CBF, Lt. Hemisphere, CBF Global, 
time, age, GCS , gender, hypothermia,  seizure
I RS3810027 Trails A, lactate,  CBF Rt.Hemisphere, time, GCS,   hypothermia
I RS8083946
Trails A,  lactate, LP ratio, CBF Rt.Hemisphere, CBF Global, time, age, GCS, 
gender, race, hypothermia, hypoxia, hypotension, seizure
I RS1944419 time, age, GCS
I RS12968517
GOS, DRS, Mortality, Trails A,   CBF, Lt. Hemisphere, time, age, GCS, gender, 
hypothermia
I RS7236090
 Trails A,   bcl-2 protein without outliers,  CBF Rt.Hemisphere, CBF, Lt. 
Hemisphere, CBF Global, time, age, GCS, gender, race,  hypothermia, seizure
I RS1381548
Trails A, Trails B,  CBF Rt.Hemisphere, CBF, Lt. Hemisphere, CBF Global, time, 
GCS, hypothermia
I RS17759659
GOS, DRS, Mortality,   pyruvate, LP ratio,  time, age, GCS, gender,  race, 
hypothermia,  seizure
I RS949037
GOS, DRS, Mortality,  pyruvate,  CBF Rt.Hemisphere, CBF, Lt. Hemisphere,  CBF 
Global, time, age, GCS, gender,  hypothermia
5' end RS1801018
GOS, DRS, Mortality, pyruvate, LP ratio, CBF Rt.Hemisphere, CBF, Lt. Hemisphere, 
CBF Global, time, age, GCS, gender,  race, hypothermia
BOLD= statistically significant (P≤ 0.05)
Italicized=  marginally significant  (P= 0.05 -0.09)  
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 4.4 SUMMARY OF FINDINGS TABLES 
Tables 4-58 to 4-62 are summary tables of the statistically significant and trending findings presented in the results 
section. These tables allow for the comparison of the SNP with the genotype with interptrative outcomes and statistics for each 
of the analyses. 
Table 4-27: Summary of Findings for Global Functional Outcomes 
SNP GOS DRS Mortality
3’ rs1801018 Good* Good* Survival*
| variant (AA  & AG) p=0.0002 p=0.0002 Type 3 X2 =0.0035 OR: 5.01 (0.4024 to 2.8194)
| rs949037 Good* Good* Survival†
| variant (TT & CT) p=0.0168 p=0.0255 Type 3 X2 =0.0551 
| CC   Z=0.1145   OR: 0.333 (-2.468  to 0.2661) 
| TT  Z=0.2827   OR:1.853 (-0.509  to 1.742) 
| rs17759659 Good* Good* Survival*
| variant (GG  & AG) p<0.0001 p<0.0001 Type 3 X2 =0.0031  OR: 5.05  (0.3189- 2.9202)
| rs12968517       Poor* Poor* Mortality *
| variant (CC) p=0.0242 p=0.0277 Z=0.0115   OR: 6.378 (0.4154 to 3.2897)
| rs7230970 - - Survival†
| Type 3 X2 = 0.054
| homozygous variant (CC) CC   Z=0.0548   OR: 0.191 (-3.3382  to 0.0339) 
5’ Wild Type (TT) TT  Z=0.0582   OR: 0.299 (-2.4578  to 0.042) 
* statically significant P<0.05 or Z<0.05 or X2<0.05
† statically trending P= 0.05-0.09 or Z=0.05-0.09 or X2=0.05-0.09
Summary of Findings: Global Functional Outcomes
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 Table 4-28: Summary of Findings: Cognitive-Behavioral Outcomes 
 SNP Allele NRS-R Trails A Trails B
3’ rs17756073 variant (GG  & AG) Poor* Poor †
|  p=0.0331 p=0.0516
| rs4456611 variant (CC & CT) Good†
|  p=0.065
| rs1381548 variant (AA & AG) Poor* Poor*
|  p=0.0366 p=0.0391
| rs12968517 variant (TT & CT)  Poor*
|  p=0.0289
| rs7236090 homozygous wild type (TT) Good †
|  p=0.0396 P for F test
|  p= 0.0577
| homozygous variant (CC)
|  p=0.0387 
| rs3810027 homozygous wild type (CC) Poor*
|  p=0.0196 P for F test
| P=0.032 
| homozygous variant (GG)
|  p=0.0351
| rs8083946 homozygous variant (AA)  Poor*
5’  p=0.0285
* statically significant P<0.05
† statically trending P= 0.05-0.09
Summary of Findings: Cognitive-Behavioral Outcomes
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 Table 4-29: Summary of Findings: Bcl-2 Protein Concentrations Without Outliers 
SNP Allele Bcl-2 Protein without outliers
3’ rs12454712 variant (TT & CT) Increase† 
| p=0.0646              (Good) 
| rs17756073 homozygous variant (TT) Decreased*
| p=0.0084               (Poor)
| rs1481031 homozygous wild type (AA) Decreased*
| p=0.018                 (Poor)
| rs7236090 variant (TT & CT) Increase*
5’  p=0.0112             (Good)
* statically significant P<0.05
† statically trending P= 0.05-0.09
Summary of Findings: Bcl-2 Protein Concentrations
 
Table 4-30: Summary of Findings: Neurometabolite Concentrations 
SNP Lactate Pyruvate LP Ratio
3’ rs8083946 Decrease* Decrease*
| homozygous wild type (GG) p=0.037 (Good) p= 0.0388 (Good)
| rs3810027 Increase†
| variant (GG & CG) P= 0.0791 (Poor)
| rs17759659 Increase* Decrease†
| variant (AA & AG) p= 0.0011 (Good) p= 0.0791 (Good)
| rs1801018 Increase* Decrease*
|  variant (GG & AG) p= 0.0175 (Good) p= 0.024(Good)
|  rs949037 Increase*
5’ variant (CC & CT) p= 0.0032 (Good)
* statically significant P<0.05
† statically trending P= 0.05-0.09
Summary of Findings: Neurometabolite Concentrations
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SNP Allele Global CBF Right Hemisphere CBF Left Hemisphere CBF
3’ rs17756073 variant (GG & AG) Decrease* Decrease* Decrease*
| p= 0.0075          (Poor) p= 0.0116          (Poor) p= 0.0086         (Poor)
| rs4456611  variant (CC & CT) Increase* Increase* Increase†
| p= 0.0306          (Good) p= 0.0295         (Good) p= 0.0632          (Good)
| rs1026825  variant (AA & AG) Increase* Increase* Increase*
| p= 0.0287         (Good) p= 0.024         (Good) p= 0.0296         (Good)
| rs899968 variant (AA & CC) Increase* Increase* Increase*
| p= 0.0068          (Good) p= 0.0033          (Good) p= 0.0264          (Good)
| rs4941185 variant (AA & AG) Decrease* Decrease* Decrease*
| p= 0.0143          (Poor) p= 0.0132          (Poor) p= 0.0221          (Poor)
| rs1481031 variant (GG & AG) Increase* Increase* Increase*
| p= 0.0055          (Good) p= 0.0046          (Good) p= 0.0105          (Good)
| rs7236090 homozygous variant (TT) Increase† Increase†
| p= 0.0797         (Good) p= 0.0549         (Good)
| rs1381548 variant (AA & AG) Increase* Increase* Increase*
| p= 0.0177          (Good) p= 0.0216         (Good) p= 0.0187          (Good)
| rs949037 homozygous variant (CC) Decrease* Decrease* Decrease†
| p= 0.0432          (Poor) p= 0.048         (Poor) p= 0.0535          (Poor)
| rs1801018 Decrease* Decrease* Decrease*
| (Poor) (Poor) (Poor)
| P for F test  p=0.003  p=0.021 p=0.0099 
| homozygous wild type (AA) p=0.0003 p=0.0002 p=0.0021 
5’ homozygous variant (GG) p=0.0031 p=0.0007 p=0.0248
* statically significant P<0.05
† statically trending P= 0.05-0.09
Summary of Findings: Global Cerebral Blood Flow




 5.0  DISCUSSION 
The findings of each specific aim of this study support the claim that there is a 
relationship between BCL-2 genotypes and outcomes after TBI; both the biological/ clinical 
variables in the acute phase of treatment and the long term global functional and cogitative-
behavioral neuropsychological outcomes. 
5.1 HWE 
All of the SNP’s analyzed in this study were in HWE for the overall genotyped sample 
(n=230) or was not significantly out of HWE, with the exception of rs8083946. TBI subjects are 
assumed to be representative of the general population (i.e. TBI is a random event and there are 
no known genes that place a person at an increased risk). According to HapMap data (July 2008) 
for the CEU population, based on a chromosome sample center of 120, the allele frequency for 
rs8083946 is A=0.333 and G=0.667. This study found that based on a chromosome sample of 
460, the A(X)=0.4375 and G(Y)=0.6227 with  14 subjects (6.09%) being undetermined. The 
discrepancy in the findings may be related to issues with the assay or genotyping error. To note, 
this SNP also had the highest frequency of undetermined genotypes among the 17 SNP’s 
analyzed, which furthers the support that there were issues with the assay. In summary, caution 
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 needs to be employed when drawing conclusions that surround SNP rs8083946 due to HWE 
violations which calls to questions the validity of the data. 
5.2 NEUROPSYCHOLOGICAL OUTCOMES 
5.2.1 GOS & DRS & Mortality  (Refer to figures 5-1 to 5-3) 
This study shows that there is a relationship between BCL-2 genotypes and global 
functional outcomes. SNP’s rs17759659, homozygous variant (GG);  rs949037, homozygous 
variant (TT); and rs1801018 homozygous wild type (AA) allele were all associated with  
increased GOS and decreased DRS (good outcomes). All of the SNP’s were statistically 
significant on both genotype and dichotomized genotype with post hoc power estimates from 
0.684-0.989. There is increased confidence that the sample size was adequate to support the 
conclusion that these genotypes for these SNP’s are related to better outcomes. SNP’s 
rs17759659 and rs1801018 in the mortality analyses were both statistically significant on the 
genotype analyses and have a power of 1 for each. SNP rs17759659, homozygous variant (GG) 
genotype in a TBI patient is 5.05 times (95% CI: 0.3189- 2.9202) more likely to survive. TBI 
patients with rs1801018 homozygous wild type (AA) allele are 5.01 times (95% CI: 0.4024- 
2.8194) more likely to survive their injuries. However, SNP rs949037 genotypes was marginally 
significant in the mortality analysis with homozygous variant (TT) being 0.412 times (95% CI: -
1.9451 to 0.1728) more likely to survive the injury. The findings are consistent for these SNP’s 
among the global functional outcome data. Biologically, these 3 SNP’s may be related to exon 2.  
There is substantial linkage disequilibrium (LD), spanning 27, 235 base pairs, for rs1801018  
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 with rs17759659 (r2=.634) and rs949037 (r2=.687). Rs1801018, rs17759659, and rs949037 were 
also implicated in the neurometabolite and cerebral blood flow analyses, which may provide a 










































































































G= Genotype                             † = good outcome







B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Pyruvate 
Figure 5-1: GOS and BCL-2 Tagging SNP’s 










































































































G= Genotype                             † = good outcome
D= Dichotomized Genotype       ‡ = poor outcome
ES= Effect size
3’




B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Pyruvate 




















































































Mortality: Tagging SNP’s BCL-2
= statistically significant
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G= Genotype                             † = good outcome




Exon 3 Exon 1
Exon 2
 
B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Pyruvate 
Figure 5-3: Mortality and BCL-2 Tagging SNP’s 
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 Rs12968517 genotypes was marginally significant in the GOS and DRS analyses with 
lower post hoc power estimate (Power= 0.126). The trend supports that the homozygous wild 
type (CC) allele was associated with decreased GOS and increased DRS (poor outcomes). Due to 
the lower power associated with this finding the conclusions are limited. However, in the 
mortality analyses there was statistical significance, SNP rs12968517, homozygous wild type 
(CC) genotype is associated with a 1.79 times (95% CI: -0.4325 to 1.5934) increased likelihood 
to die from the TBI. SNP’s rs12968517 compared to the findings in the GOS and DRS analysis, 
this SNP is more sensitive to survival/death than global functioning on a continuum. The LD 
correlations of rs12968517 with the SNP’s rs1801018, rs17759659, and rs949037 are not 
available in the HapMap database. This indicates that there is most likely a different “surrogate 
function” f
This lack of correlation o iated more strongly with 
surviva
or this SNP than the others implicated in these global functional outcomes analyses. 
r LD may explain why is rs12968517 assoc
l/mortality than with other global functioning measures that assess activities of daily 
living. SNP’s rs7230970 was a SNP of interest only in the global functional outcome of mortality 
being marginally significant with post hoc power of 1.0. Both rs7230970 homozygous wild type 
(CC) and homozygous variant (TT) genotypes were associated with 2.089 times (95% CI:  
-0.3661 to 1.8404) decreased mortality in a TBI patient when compared to those who were 
heterozygous (CT). SNP’s rs7230970 position is distant from the cluster of significant SNP’s for 
global functioning. The LD with the highest correlation with this SNP is rs956572 r2=0.598 in 
the same intron region as rs7230970.  
The covariates of interest in this study among the global functional outcomes (time, age, 
GCS, race, and hypothermia) are supported by the literature (Cifu et al., 1996a; Cifu, Kaelin & 
Wall, 1996b; Pillai, Kolluri & Praharaj, 2003; Jiang, Gao, Li, Yu, & Zhu, 2002; Girard et al., 
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 1996; King, Carlier & Marion, 2005; Labi et al. 2003). Caucasians in this study have higher GOS 
scores and there for better outcomes which may be related to genetic differences, however, the 
under-representation of  non-caucasians may have biased these data. 
5.2.2 Cognitive Behavioral Outcome Measures 
5.2.2.1 NRS-R 
SNP’s rs17756073 and rs4456611 are the two SNP’s of interest in the NRS-R analyses. 
(Refer 
ower for this analysis was 
very low (power= 0.035) therefore what we can say is limited. The LD for this SNP covers 3,530 
b-studies, while having smaller sample sizes 
but high post hoc power and large ES, found that rs17756073 the homozygous wild type 




to figure 5-4).  Despite the proximity of these two SNP’s the LD is not available in the 
HapMap database. The surrogate “function” of the two tagging SNP’s is likely to be different.  
SNP rs17756073 is a SNP of interest in the NRS-R outcome measures. The homozygous 
wild type (AA) genotype was associated with a decrease in NRS-R scores and therefore is 
associated with better outcomes. Subjects with the presence of the variant allele (GG or AG) had 
significantly higher NRS-R scores; worse outcomes. The post hoc p
base pairs in the intron region. In the subsequent su
genotype (AA) 
trations, or based on the literature worse outcomes, which is in contrast to the NRS-R 
findings. However, the homozygous wild type genotype (AA) in the global CBF analysis, which 
was related to increased CBF corroborates the findings that for NRS-R, rs17756073 AA allele
ciated with good outcomes. 
SNP rs4456611 in the primary (full) model resulted in trends towards significance the 
presence of the variant allele  (CC or CT) was associated with lower NRS-R scores, indicating 
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 better outcomes. The post hoc power for this analysis was power=0.595. This SNP covers a LD 
region of 14,775 base pairs in the same intron region. As subsequent sub-studies would suggest, 
NRS-R scores as a representation of cognitive behavioral outcomes maybe related at CBF. Our 
findings suggest that global CBF for SNP’s rs4456611 the presence of the variant allele (CC or 
CT)  was related to an increase in CBF which may be associated with good outcomes.  
SNP’s rs17756073 and rs4456611 were also implicated in the bcl-2 protein and cerebral 
blood flow analyses, which may provide a physiological explanation to the NRS-R findings. 
Increasing age and preadmission seizures were consistently associated with poor 


























































































G= Genotype                             † = good outcome

















Figure 5-4: NRS-R and BCL-2 Tagging SNP’s 
5.2.2.2 Trails Making Tests 
Trails A  
 
B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Py
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 SNP’s rs12968517 homozygous wild type (CC), rs13815487 homozygous wild type 
(GG), and rs7236090 homozygous for wild type (TT) or the variant (CC), all were associated 
with decrease Trails A scores and was therefore associated with better outcomes (attention). 
(Refer to figure 5-5). Despite being located in the same region they cover a span of 15, 425 base 
pairs. The LD for rs12968517 compared to rs13815487 or rs7236090 are both unavailable in the 
HapMap data base. The LD between rs13815487 and rs7236090 is very low correlation 
(r2=0.091). The highest published LD correlation by HapMap for SNP rs13815487 is r2=0.173. 
None of the surrogate SNP’s for rs12968517 are shared by rs13815487 and rs7236090 at greater 
than r2= 0.186 correlation. These SNP’s appear to be independent of each other. 
Based on the biology of LD, the action/ surrogate action of rs12968517 is likely 
encomp or the 
dichotomized genotype ana hoc power of 0.902. This 
study supports that the region of BCL-2 tagged by rs12968517 is associated with decreased 
es. The action/ surrogate action of rs13815487 is likely to be 
nt for Trails A because of the low correlation with other SNP’s. The SNP was found to 
be stat
ass the surrogate SNP for Trails A. The SNP is statistically significant f
lysis (P=0.0289) with an adequate post 
Trails A score; better outcom
independe
istically significant for lower Trails A score, for the dichotomized genotype analysis 
(P=0.0366) with a post hoc power of 0.759. SNP rs7236090’s action/ surrogate action is likely to 
encompass a surrogate SNP’s for Trails A. This analysis was trending towards significance for 
the genotypes analysis (P=0.0577) with a low post hoc power of 0.406, while not conclusive, it is 
of interest for future studies. 
SNP’s rs3810027 and rs8083946 are 1,943 base pairs apart. For both rs3810027 and 
rs8083946 analyses were underpowered (power= 0.464; power= 0.041, respectively). SNP’s 
rs3810027 homozygous for wild type (CC) and the variant (GG) and rs8083946 homozygous 
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 variant
say. Based on these findings in the Trails A analyses and in 
concord
 (AA) had higher Trails A scores and were therefore associated with poorer outcomes 
(attention).  LD of rs8083946 with rs3810027 r2=0.505. They act for surrogates for 6 out of 7 
SNP’s with an LD > 0.6 [rs7243091 (for rs8083946 only); rs1165975; rs1296167; rs9630855; 
rs7231914;  rs4987768; rs7240326]. While the analyses for these SNP’s were underpowered, 
future studies with larger sample sized may implicate these SNP’s and/or their surrogates as 
SNP’s of interest in poor attention after TBI. SNP’s rs3810027 and rs8083946 were also 
implicated in the lactate concentration sub-study. The presence of rs3810027 variant allele (GG 
or CG) was associated to an increase in lactate, which is consistent with the increase Trails A 
scores being associated with poor outcomes.  SNP rs8083946 homozygous allele GG was related 
to lower lactate levels, which would be associated with good outcomes however, rs8083946 may 
have been a problematic as
ance with the lactate findings the underling mechanism for lactate concentration 
regulation and bcl-2 may also affect attention after TBI. CBF may also provide a physiological 
underpinnings. 






























































































G: P= 0.032 ‡
D: P= 0.1304
ES= -0.58
D: P= 0.0289 G: P= 0.0577†
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G= Genotype                             † = good outcome
ES= Effect size







B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Pyruvate 
Figure 5-5: Trails A and BCL-2 Tagging SNP's 
Trails B 
SNP’s rs1381548 homozygous wild type (GG) and rs17756073 homozygous wild type 
(AA) were associated with significantly lower Trails B completion times therefore better 
outcom
highest know LD with an 1548 is likely to have an 
ent action associated with better Trails B scores. Despite statistical significance for the 
genotyp
Ex
es (mental flexibility). (Refer to figure 5-6). As discussed in Trails A, SNP’s rs1381548 
other SNP’s is r2=0.173. Therefore, rs138
independ
e analysis (P=0.0391) the post hoc power was very low (Power= 0.0304).  SNP 
rs17756073 is a surrogate for 3 SNP’s with LD r2 >0.6 (range 0.778-0.958) (rs4987834, 
rs4987828, rs4987827). These SNP’s are likely to act in concert with each other. The statistical 
significance was trending (P=0.0516) and post hoc power (0.623) for the analyses of this SNP 
with the Trails B data were indicative of a trend in these data. Based on the biological and 
clinical data sub-studies, Trails B shares in common the significant SNP’s indicated in bcl-2 
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 protein concentration and CBF which may serve as the underlying biological explanation for the 
mental flexibility results.  
Commonalities in the Trails Making neuropsychological outcomes were that rs1381548 
was significant in both Trails A and Trails B analyses and covariates of interest. The presence of 
the homozygous variant allele (AA) for SNP rs1381548 was associated with higher test scores. 
There were three main themes in the covariates for the Trails A and Trails B data; time, GCS, 
and hypothermia.  Time was sensitive for Trails B tests alone. When the test was administered 
closer to time of injury (3 month evaluation compared to 12 months post injury) subjects had 
longer Trails B time scores indicating that less mental flexibility and this is reflected in the 
literature (Spikeman et al., 2000). One finding that was counterintuitive was that higher GCS 
scores on admission were associated with higher Trails A and Trails B scores (longer times); 
poor outcomes. This finding may be related to the higher number of subjects with high GCS 
(n=19; 70.4%) vs. low number with low GCS (n=8; 29.6%) which can skew the results. For both 
Trails A and Trails B the subjects who did not receive a hypothermia intervention were found to 
have higher scores, this supports the literature that hypothermia is neuroprotective after TBI 
(Mcilvoy, 2005). 

































































































G= Genotype                             † = good outcome








B= BCL-2 Protein; C= Cerebral Blood Flow; L= Lactate; LP= Lactate Pyruvate Ratio; P=Pyruvate 
Figure 5-6: Trails B and BCL-2 Tagging SNP's 
While the explanation for the neuropsychological outcomes may be rooted in the function 
of exon 2, intronic mRNA stability, the mechanism the regulates bcl-2 protein concentrations or 
CBF, as implicated in subsequent sub-studies, our findings could be explained by different 
SNP’s having different functions in different parts of the brain. This hypothesized difference in 
the SNP’s function stems from the biology of bcl-2 and the apoptosis pathways. For example, 
caspases are active in different regions of the brain and that bcl-2 protein is expressed differently 
in different regions of the brain (Clark et al, 1997). Cognitive-behavioral function is believed to 
be rooted in different parts of the brain than motor functioning or survival. Therefore, the 
implication of different SNP’s maybe related to these factors.   
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 5.3 BIOLOGICAL/ CLINICAL DEPENDENT VARIABLES 
5.3.1 Bcl-2 Protein 
As discussed in the methods, the bcl-2 protein concentration data were analyzed with and 
without outliers. The demographics of the two subjects with the bcl-2 protein concentration 
outliers were representative of the entire sample. As stated in the methods and results, the two 
samples with higher concentrations were within normal limits of the ELISA. However, the two 
samples were outliers to the dataset. The data was analyzed with and without bcl-2 protein 
concentration outliers. The findings suggested that there were no statistically significant or 
trending SNP’s when the data was analyzed with the outliers. In contrast, the analyses without 
the outliers revealed SNP’s that were statistically significant and/or trending SNP’s (rs17756073, 








































































































G= Genotype                             † = increase (good) 







Figure 5-7: Bcl-2 Protein Concentrations and BCL-2 Tagging SNP's 
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The findings of this study may be related to small sample size (n=41) or the small cell 
sizes of covariates (gender and preadmission seizure). Methodologically, the piece of protein that 
is being interrogated for in the ELISA test may not encompass all of the neuroprotective nature 
of bcl-2, the piece may not be specific to the bcl-2α isoform and also be analyzing bcl-2β, or that 
the SNP’s chosen may not be the optimal SNP’s to analyze the piece of protein that is begin 
analyzed. 
SNP’s rs12454712 homozygous wild type (TT), rs17756073 homozygous wild type (AA) 
and homozygous variant (GG), rs1481031 homozygous wild type (AA), and rs7236090 
homozygous wild type (CC) and homozygous variant (TT) were all associated with statistically 
significant or a trending decrease in bcl-2 protein concentrations.  
SNP rs17756073 is a surrogate for 3 additional SNP’s with LD r2 >0.6 (range 0.778-
0.958) (3,530 base pair range) in the same intron region. The analyses for this SNP had an 
adequate post hoc power (Power=0.854).  
SNP rs1481031 is a surrogate for 19 SNP’s with r2>0.6 (range of r2=0.611-0.811) and 
spans 21,042 base pairs. All of the surrogate SNP’s are located to the same intron region, and are 
likely to be involved with mRNA stability. The analyses for this SNP had a post hoc power of 
0.759. 
 SNP rs7236090 is a surrogate for 1 additional SNP rs8089538 (r2=0.663) in the intron 
region. Among the SNP’s analyzed, this SNP was most significant for both the genotype and 
dichotomized genotype analyses, had the largest post hoc power (0.987) and ES (0.837). This 
SNP was 1,031,902 base pairs from the exon 2 region. There was significant LD decay that 
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 implies that it is not associated with the exon 2 function, however, more research needs to be 
done to further explore this relationship. 
Surrogate SNP’s for rs12454712 have no known SNP’s with r2> 0.154 and is located in 
the intron region. The analyses for this SNP had a power of 0.7144.  
The three covariates of interest in these analyses were time, gender, history of pre-
admission seizures. In the analyses of the SNP’s of interest, bcl-2 protein concentrations spiked 
typically on days 2, 4, and 5 compared to day 6. This finding additional empirical evidence to the 
literature that bcl-2 protein peaks between day 2 and 5 following TBI in humans (Uzan et al, 
2006; Yang & Xue, 2004). 
This study found that the nine females compared to the 33 males had statistically 
significant (or trending) lower bcl-2 protein concentrations in all of the full models analyzed. 
The age range for the females was 20-60 years with mean of 35 years. The finding that females 
have lower bcl-2 protein concentrations compared to males is counterintuitive compared to the 
literature that suggests that there is a connection between higher bcl-2 protein concentrations and 
estrogen (Soustiel, Palzur, Nevo, Thaler, & Vlodavsky, 2005; Wise, Dubal, Wilson, & Rau, 
2000; Zhang, L., et al., 2004) and that bcl-2 is theoretically more neuroprotective in females 
(Soustiel et al., 2005; Wagner, et al, 2005; Wise et al.,2000). However, estrogen can also be 
found in males as testosterone is known to be converted to estradiol in the brain (Behl & 
Manthey, 2000). It is plausible that the males could have higher estrogen levels than the females 
and that preinjury and postinjury concentrations may differ. Estrogen is reported to have 
neuroprotective effects by maintaining cerebral blood flow, antioxidant properties, impeded 
excitotoxic injury and promoting the production of growth factor (Soustiel et al., 2005; Wagner, 
et al, 2005; Wise et al., 2000). In murine studies, bcl-2 is found to increase in the presence of 
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 estrogen/ estrogen treatment thus believed to inhibit apoptosis (Soustiel et al., 2005; Wise et al., 
2000; Zhang, L., et al., 2004). Estradiol increased bcl-2 expression and decrease cerebral infarct 
(hypoxic-ischemic damage) in non diabetic female mice and was overall significantly 
neuroprotective compared to males (Zhang, L., et al., 2004). In estrogen-treated animals, there 
was a marked and significant reduction of apoptosis in comparison with non-treated animals. 
Soustiel and colleagues (2005) furthers found that estrogen treatment mice had a reduction 
caspase 3, a significant increase in bcl-2 expression, and no effect on bax expression after 
experimental TBI. Estrogen is therefore likely to have its action in the caspase dependent 
pathway of apoptosis.  
Pre-admission seizures are common after severe TBI. About 25 percent of patients with 
brain contusions or hematomas and about 50 percent of patients with penetrating head injuries 
will develop immediate seizures (seizures that occur within the first 24 hours of the injury) 
(NINDS, 2008). In our study, 9 of the 42 subjects used in the bcl-2 protein analyses had a 
documented history of a pre-admission seizure. This event was significantly related to having 
lower bcl-2 protein concentrations. The relationship of positive seizures with low bcl-2 protein 
concentrations (and presumably poor outcomes based on the literature) is suspected (Henshall, 
2007; Henshall & Simon, 2005; Shinoda et al., 2003). The mechanism by which seizure and low 
bcl-2 protein concentrations are connected may be that the intrinsic pathway of apoptosis is 
triggered after seizures by the rise in intracellular calcium (Henshall, 2007; Henshall & Simon, 
2005; Shinoda et al., 2003).  In the rat model epilepsy model in the hippocampus there is 
evidence of the release of cytochrome c, apaf-1, and caspase 9 and-3, and with the rise in 
intracellular calcium activation of pro-apoptotic bcl-2 family members (bad, bim, and bid) 
(Henshall, 2007; Henshall & Simon, 2005). The extrinsic apoptosis caspase dependent pathway 
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 and the role of TNF as the trigger has also been implicated in cell death post- seizure (Shinoda et 
al., 2003) 
Future studies would 1) increase the enrollment, gender diversity, and subjects with a 
positive pre-admission history of seizure 2) examine bcl-2 genotypes and bcl-2 protein with 
neuropsychological outcomes after TBI. Based on the literature and the SNP’s of interest in this 
study, the hypothesis would be that the SNP’s with low bcl-2 concentrations would be associated 
with poor outcomes 3) re-examine the relationship with protein concentrations and gender and 
pre-admission seizures, and related those findings to the neuropsychological outcomes. 
5.3.2 Neurometabolites 
The neurometabolite findings are clustered into two groups: lactate and LP ratio results 
vs pyruvate and LP ratio results.  
SNP’s rs8083946 homozygous wild type (GG) was associated with a decrease in lactate 
concentrations and a decrease in LP ratios. SNP’s rs3810027 homozygous wild type (CC) was 
associated with a decrease in lactate concentrations alone. (See figures 5-8 and 5-10). The lactate 
acid analyses were under powered (rs3810027, power= 0.397; rs8083946, power=0.441). The LP 
ratio analyses for rs8083946, were underpowered as well (power=0.397).The SNP’s of interest in 
the lactate acid analyses, SNP’s rs3810027 and rs8083946 are neighboring SNP’s with 1943 base 
pairs separating the two. The correlation of the LD between the two SNP’s is r2=0.505. They 
share 6 of 7 surrogate SNP’s with r2>0.6 [rs7243091 (for rs8083946 only); rs1165975; 
rs1296167; rs9630855; rs7231914; rs4987768; rs7240326].  
SNP’s rs17759659 homozygous wild type (GG) and rs1801018 homozygous wild type 
(AA) were significant for a decrease in pyruvate concentrations and increase in LP ratios. SNP 
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 rs949037 homozygous wild type (TT) was significant for a decrease in pyruvate concentrations 
alone. (See figures 5-9 and 5-10). There is substantial LD for rs1801018 with rs17759659 
(r2=.634) and rs949037 (r2=.687). SNP rs1801018 and rs949037 share 3 surrogates SNP’s 
(rs1462129, rs1893806, and rs2051423). rs1801018 correlated with each of the 3 surrogates at 
r2= 0.737 and rs949037 correlates with the surrogates at r2=0.932. The LD correlation with 
rs949037 with rs17759659 is unknown. The analyses for the pyruvate data were adequately 
powered [rs17759659, power= 0.96659; rs1801018, power=0.756; rs949037, power=0.963] as 
well as the LP ratio data [rs17759659, power= 0.856; rs1801018, power=0.727] given the 
exploratory nature of the analyses. SNP rs4941185 homozygous wild type (AA) was marginally 
significant for an increase in pyruvate concentrations. HapMap does not contain any known 
























































































D: P= 0.0791 
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G= Genotype                             † = decrease (good) 







Figure 5-8: Lactate and BCL-2 Tagging SNP's 




















































































Pyruvate: Tagging SNP’s BCL-2
= statistically significant
= marginally significant
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LP Ratio: Tagging SNP’s BCL-2
= statistically significant
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G= Genotype                             † = decrease (good) 
D= Dichotomized Genotype       ‡ = increase (poor) 
ES= Effect size
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Figure 5-10: LP Ratio and BCL-2 Tagging SNP's 
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 The covariates of interest in the neurometabolite analyses were time (for lactate, 
pyruvate, and LP ratio) and gender (for lactate and LP ratio). Time is consistent with the 
literature that lactate concentrations and LP ratio were significantly higher days 1 and 2 post 
injury in relation to day 5 (Pyruvate was only significantly higher on day 1 than day 5). Females 
in this study were found to have significant higher lactate concentrations and LP ratios.  This is 
in contrast to the literature and theoretical underpinnings that suggests that females have lower 
lactate and LP ratio due to the neuroprotective effects of estrogens (Wagner et al., 2004; Wagner, 
2005; Mclean & Nunez, 2008). The one mechanism by which the female hormones, estrogen, is 
neuroprotective is receptor –dependent and receptor independent modulation of increased bcl-2 
expression (Dubal, Shughrue, Wilson, Merchenthaler, & Wise, 1999; Mclean & Nunez, 2008; 
Singer, Rogers, & Dorsa, 1998; Stoltzner, Berchtold, Cotman, & Pike, 2001; Zhao, Wu, Brinton, 
2005). 
Until this study there have been no studies that examine the relationship between BCL-2 
genotypes and lactate, pyruvate or L/P ratio after TBI. Lactate, pyruvate, and lactate/pyruvate 
ratio (L/P) are important because they are energy- related metabolites and biochemical indicators 
of brain injury and cerebral anoxia (Kerr et al., 2003; Wagner et al., 2004; Wagner et al., 2005; 
Yu et al., 2005). As a consequence of TBI, brain metabolism increases as well as energy 
demands and glycolysis (Chen, T. et al, 2000). This increase need for energy occurs 
simultaneously with the ischemia like changes that increase lactic acid due to the anaerobic 
glycolysis which deplete energy (Kerr et al., 2003; Wagner et al., 2004; Wagner et al., 2005; 
Werner & Engelhard, 2007; Yu et al., 2005). The anaerobic metabolism depletes the 
mitochondria ATP-stores as well as impairs membrane permeability that is dependent on energy. 
These events are coupled with additional secondary injury events (terminal membrane 
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 depolarization and the excessive release of excitatory neurotransmitters, depolarization of Ca2+ 
and Na+ channels) that lead to the activation of capsize cascades and ultimately necrosis or 
apoptosis (Werner & Engelhard, 2007). In this study the SNP’s (rs8083946 and rs3810027) that 
were indicated as having significantly decreased lactate and/ or LP ratios, would hypothetically 
be indicative of better outcomes because of the increase in energy within the mitochondria of the 
cells. The literature asserts that elevated lactate is related to poor outcomes, diminished cerebral 
blood flow, elevated intracranial pressure, and ischemia (Goodman, Valaka, Gopinath, Uzura, & 
Robertson, 1999; Kerr et al., 2003; Wagner et al., 2004; Wagner et al., 2005; Yu et al., 2005). 
Future studies would need to further explore this hypothesis.  
Lactate and pyruvate are often considered in ratio because they are antagonistic to each 
other (Kerr et al., 2003; Wagner et al., 2004; Wagner et al., 2005). Pyruvate is an intermediate in 
the metabolism of glucose. It is a potent ROS scavenger. Pyruvate is protective against ROS in 
neuronal tissue (Kerr et al., 2003; Wagner et al., 2004; Wagner et al., 2005; Yu et al., 2005). 
Increased pyruvate is associated with decreased cerebral ischemia (Yu et al., 2005). The 
relationship with pyruvate and bcl-2 is more clear in that it is known that pyruvate can act on the 
caspase independent cascade and inhibit the transport and activation on p53, thus increasing the 
expression of bcl-2 (Lee Y., 2003; Lee, Y. 2004). Based on the findings of this study the 
hypothesis could be made that SNP’s rs17759659, rs1801018, and rs949037, because they were 
associated with a decrease in pyruvate concentrations and/ or increase in LP ratios, would be 
associated with poor outcomes. Future studies would need to further explore this hypothesis. 
Limitations to this sub-study include the small sample size and small sample 
representation of females. In addition, this sub-study was conducted on 36 Caucasian subjects 
due to the lack of variability in the race covariate. 
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 5.3.3 Cerebral Blood Flow 
In the global CBF analyses the findings reveal that of the 14 SNP’s in the primary (full 
model) analyses there were 10 SNP’s with statistical or trending significance. Of the 10 SNP’s 8 
were associated with a decrease in global CBF [rs1026825 homozygous variant (AA) and 
homozygous wild type (GG); rs1381548 homozygous variant (GG); rs1481031 homozygous 
wild type (AA); rs17756073 dichotomized analysis  homozygous variant (GG); rs1801018 
homozygous wild type (AA) and homozygous variant (GG); rs4456611 in the dichotomized 
analysis homozygous wild type (TT);  rs899968 homozygous wild type (CC); rs949037 
homozygous variant (CC) and homozygous wild type (TT)]. The remaining two SNP’s 
rs4941185 homozygous wild type (GG) and rs7236090: homozygous variant (TT) were 
associated with an increase in global CBF. (See figure 5-11). 
Covariates of interest in these analyses were time and gender. Overall, time day one had 
the highest CBF compared to day 5, which is supported in the literature. Gender, the findings 
suggest that males have lower CBF than females which is consistent with the literature. The 
female sex hormones of progesterone and estrogen are believed to have neuroprotective and anti-
apoptotic effects which contribute to the maintenance of CBF after TBI and stroke (Pettus, 
Wright Stein & Hoffman, 2005; Roof & Hall, 2000a; Roof & Hall, 2000b; Roof, Hoffman, & 
Stein, 1997; Stein & Hoffman, 2003). However, of the 17 subjects in the study 4 were female, 
which may have some degree of biased the data due to low cell count.  
The analyses of the CBF data were exploratory in nature. Sample size is a significant 
limitation of what can be elucidated from the findings. The ES for these analyses was quite large, 
however, power was not able to be calculated due to the inability at calculate the rho (estimate R 
correlation [autocorrelation] secondary to the small sample size).  The clustering of the 
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 significant SNP’s suggest that global CBF is sensitive to both bcl-2 coding in exon 2 (rs949037, 
rs1801018), as well as, mRNA stability (all of these SNP’s are positioned in the intro region 
between exon 2 and exon 3 and have no know surrogates that are in LD with any of the exons: 




















































































Xe/CT Global CBF: Tagging SNP’s BCL-2
= statistically significant
= marginally significant
G: P= 0.0255 †
D: P= 0.0797
ES= 0.985
G: P= 0.0218 †
D: P= 0.0055
ES= 1.001
G: P= 0.0608 ‡
D: P= 0.0143
ES= -1.789
G: P= 0.003 ‡
D: P= 0.0292
ES= 1.009
G: P= 0.068 ‡
D: P= 0.2528
ES= 0.511
G: P= 0.0604 †
D: P= 0.0177 (GG)
ES= 1.559 (GG)
G: P= 0.0221 ‡
D: P= 0.0075
ES= -1.352
G: P= 0.0156 †
D: P= 0.0287
ES= 0.935
G= Genotype                             † = increase (good) 
D= Dichotomized Genotype       ‡ = decrease (poor) 
ES= Effect size
G: P= 0.0273 †
D: P= 0.0068
ES= 1.25
G: P= 0.1238 †
D: P= 0.03061 (TT)
ES= 0.9333 (TT)
3’ 5’
Exon 3 Exon 2
Exon 1
 
Figure 5-11: Global CBF and BCL-2 Tagging SNP's 
Cerebral ischemia, a consequence of secondary brain injury, is related to the reduction or 
complete loss of CBF (McLaughlin & Marion, 1996). Ischemic changes result in the release of 
cytochrome c leading to apoptosis occurs (Zhao, Steinberg, & Sapolsky, 2007).  In bcl-2 
knockout mice, homozygous knockout mice have significantly larger infarct area more severe 
reduction in CBF (Hata, Gillardon, Michaelidis,  & Hossmann, 1999). Seven of 17 subjects in 
this study were enrolled in a hypothermia protocol. Our study found that 1 SNP, rs1381548 
homozygous variant (GG), had a trending relationship with decreased CBF.  The literature 
asserts that the conflicting of evidence in the literature that hypothermia can increase bcl-2 
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 protein expression after global ischemia (Zhang, Z. et al., 2001) versus hypothermia only 
inhibiting bax expression 4 hours after ischemia but having no effect on other proteins 
(Eberspacher et al., 2003). The inconsistencies in the literature maybe related to differences in 
the effect of hypothermia on apoptosis in focal versus global ischemia (Yenari, et al., 2002; Zhao 
et al., 2005).  
5.4 COVARIATES 
5.4.1 Hypothermia 
This dissertation study found that hypothermia was related to DRS, mortality, Trails A 
and Trails B. The subjects who did not receive the hypothermia intervention had lower DRS 
scores; and lower mortality; good outcomes. For both Trails A and Trails B, the subjects who did 
not receive the hypothermia intervention had higher scores, which indicated poor outcome. The 
inconsistent findings maybe reflective of multiple analyses, small sample sizes, or the literature.  
The literature debates the efficacy of the hypothermia intervention in the treatment of secondary 
injury after severe TBI. The use of hypothermia as an intervention for the treatment and 
management of severe TBI is controversial. The inconsistent results are shrouded in the 
operational definition of hypothermia; deep hypothermia vs. mild hypothermia (Jermitsky, 
Omert, Dunham, Protetch, & Rodriguez, 2003; Jiang et al, 2002).  
Hypothermia as in intervention in TBI is believed to decreases neurotransmitter release, 
reduces metabolic requirements for oxygen and glucose, normalizes pH, decreases inflammatory 
precursors, and preserves brain tissue and blood brain barrier (Mcilvoy, 2005).  From the CBF 
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 literature there is conflicting evidence that hypothermia can increase bcl-2 protein expression 
after global ischemia (Zhang, Z. et al., 2001) versus hypothermia only inhibiting bax expression 
4 hours after ischemia but having no effect on other proteins (Eberspacher et al., 2003). The 
inconsistencies in the literature maybe related to differences in the effect of hypothermia on 
apoptosis in focal versus global ischemia (Yenari, et al., 2002; Zhao et al., 2005).  
The action of mild hypothermia on the mitochondria was found to be related to the 
reduction in the number of morphologically apoptotic neurons by nearly half in 48 hours 
compared to normothermic models (Xu, Yenari , Steinberg, & Giffard, 2002).  Along with this 
caspase-3, -8, and -9 activity was significantly decreased and cytochrome c translocation was 
reduced (Xu et al, 2002).  However, in this study there was a significant reduction in cJun N-
terminal kinase activation but not change in bcl-2 protein concentrations; however it is clear that 
hypothermia is an intervention for apoptosis (Xu et al, 2002).  Other studies have found that 
BCL-2 is upregulated in the presence of hypothermia (Yenari et al., 2003). One murine stroke 
model study used a gene therapy used a neurotropic herpes simplex viral vector system 
containing bipromoter vectors to transfer BCL-2  genes to neurons found that BCL-2 improved 
neuron survival was protective against stroke in a normothermic environment. In the 
hypothermic intervention significant neuroprotection was associated with BCL-2 upregulation 
suppressing cytochrome c release, caspase activation, and DNA fragmentation (Yenari et al., 
2003). The results of this dissertation support that hypothermia is implicated in both 
neuropsychological outcomes after TBI. The cell size for hypothermia throughout all of the 
analyses fluctuated, and particularly for specific aims 2, the low cell count may have influenced 
the findings. 
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 5.4.2 APOEє4 
While APOEε4 was indicated as a covariate because the literature suggests that there may 
be a synergistic relationship between APOEε4 and BCL-2 as a representative of apoptosis 
(Belton et al., 2003; Moulder et al., 1999; Ong et al., 2003; Shimohamma et al., 2001; Wei et al., 
1999) APOEε4 did not meet the a priori cut-off significance of p<0.2 for any of the analyses.  
APOEε4 was therefore omitted from all of the primary (full model) analyses. In future studies 
the potential synergistic relationship between BCL-2 and APOE/APOEε4 can be further 
explored by including APOEε4 in the model regardless of preliminary statistics as well as assess 
for an interaction of the variables. 
5.5 LIMITATIONS 
There are several limitations to these series of studies conducted for this dissertation. 
Sample size was a challenge given the subjects available with sub analyses data. The sample 
sizes fluctuate greatly in the primary models from 17 to 141 subjects.  However, the fixed effects 
estimates were robust for some of the exploratory studies and adequate post hoc power was 
noted. Missing data, especially for the covariates of hypotension, hypoxia, and seizure were 
problematic.  
While the demographics of the over all sample were representative of TBI in the greater 
Pittsburgh area, the generalizability of the data is limited due to the lack of racial and gender 
diversity in the sample. Multicenter study or a match case control design may help address these 
issues. 
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 The global functional outcomes data over the 24 months outcome periods were biased 
towards death as an outcome (GOS, DRS, and mortality).  Death carries over and crosses time, 
so that if a patient dies prior to the 3 month outcome, the death outcome was recorded for the 
remainder of the outcome points regardless if the 24 months post injury time point arrived.  Time 
was biased/ weighted towards the representation of death. A prime example of this bias was the 
mortality data 3 months [n=51 (25.4% of 230 subjects with 1.5% missing data)] versus 24 
months [n=58 (28.9% of 230 subjects with 41.3% missing data)].  
5.6 CONCLUSIONS 
The results of this study show that BCL-2 genotypes are associated with global functional 
outcomes and neurobehavioral outcomes after severe TBI. The global functional outcomes may 
be related to the coding region of exon 2. The cognitive behavioral outcomes, which were not 
analyzed directly with neurometabolite and CBF data, share significant SNP’s of interest and 
potential mechanisms of action by which cognitive behavioral outcomes are mediated by the 
underlying neurometabolite and CBF biological functioning. This study also asserts that there is 
a significant relationship between BCL-2 genotypes and bcl-2 protein concentrations, 
neurometabolite concentrations, and CBF after severe TBI.  The relationship between BCL-2 
proteins and bcl-2 protein concentrations was significant, this was to be expected because genes 
ultimately code for protein, however, what was not expected is that the SNP’s of interest were 
not associated with mRNA transcription thus protein synthesis. While our SNP’s had a 
significant relationship with bcl-2 protein concentrations and mechanism by which our SNP’s are 
functioning, even in the surrogate role as a tagging SNP, has yet to be fully elucidated; mRNA 
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 stability maybe one function. The neurometabolites of lactate, pyruvate and LP ratio were 
empirically associated with BCL-2 genotypes. On the biological level we would expect this 
because bcl-2 and these neurometabolites reside in the mitochondria, and that the 
neurometabolites which are associated with the metabolism of the organelle and is effected by 
Ca2+ , that the energy balance of ATP/ ADP and Ca2+  influx also effects the functioning of bcl-
2. Cerebral ischemia, a consequence of secondary brain injury, is related to the reduction or 
complete loss of CBF (McLaughlin & Marion, 1996). The literature asserts that for bcl-2 
knockout mice, homozygous knockout mice have significantly larger infarct area more severe 
reduction in CBF (Hata et al., 1999). After brain injury, ischemic changes result in the release of 
cytochrome c leading to apoptosis (Zhao, Steinberg, & Sapolsky, 2007). The CBF analyses 
findings support that BCL-2 genotypes are significantly associated with CBF.  
A pattern of significant SNP’s was revealed in the globals function outcomes, 
neurometabolite and CBD studies. The pieces of the BCL-2 gene coded for by the blocks of 
DNA tagged by the significant SNP’s at the 5’ end (rs17759659, rs949037, and rs1801018) may 
act as surrogates for exon 2. The initiation codon sires are in the exon 2 region at amino acids -31 
and  -58  which are associated with the structural flexible loop domain which is associated with 
phosporylation (Bruckheimer, Cho, Sarkiss, Herrmann & McDonnell, 1998;  Reed, 1997). 
Phosporylation in the loop is required for bcl-2’s to function in an anti-apoptotic manner at its 
full capacity (Ruvolo, Deng, & May, 2001). 
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5.7 FUTURE DIRECTIONS   
This study was a first step in exploring BCL-2 genotypes and how they affect both acute 
care biological/ clinical outcomes and long term neuropsychological outcomes after severe TBI 
in adults.  Future directions in original research studies or secondary analyses should assess:  
1. interaction of SNP’s and covariates 
 2. analyzing the SNP with biological/ clinical marker and an outcome measure (i.e. SNP/ 
Bcl-2 protein concentration/GOS) 
3. exploring gene/gene interaction of anti- versus pro-apoptosis genes (i.e., BCL-2 versus 
BAX). 
4. amino acid sequence versus the genomic sequence to further elucidate the surrogate 
function of the tagging SNP 
5. additional tagging SNP’s should be considered in the analyses, as the 17 SNP’s used in 
this study only covered the surrogate function of 1 of the 3 known exons: exon 2 
6. the hypothesis that the SNP’s, which are positioned in the intron region and cover 
surrogate function of other SNP’s in the intron region, are related to mRNA instability 
needs to be explored empirically 
7. additional clinical dependent variables should be examined (i.e. intracranial pressure, 
cerebral perfusion pressure, admission pupillary reaction) 
8. this study should be expanded to other  TBI populations, (i.e. pediatrics) and to other 
neurotrauma conditions (i.e. traumatic spinal cord injury) 
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 APPENDIX C 
EXAMPLE OF TAQMAN® PLOT 
 
   256
 APPENDIX D 
GLASGOW OUTCOME SCALE (GOS) 
Glasgow Outcome Scale 
1 DEAD 
2 VEGETATIVE STATE  
Unable to interact with environment;    
unresponsive 
3 SEVERE DISABILITY 
Able to follow commands/ unable to live 
independently   
4 MODERATE DISABILITY 
    Able to live independently; unable to return 
to work or school   
5 GOOD RECOVERY 
Able to return to work or school 
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 APPENDIX E 
DISABILITY RATING SCALE (DRS)
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 APPENDIX G 
TRAILS B 
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 APPENDIX H 
GLASGOW COMA SCALE (GCS) 
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 APPENDIX I 
EXAMPLE OF APOE GENOTYPE COLLECTION 
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DV: APOE GENOTYPES
Restriction Fragment Length Polymorphism (RFLP)
 
   262
 BIBLIOGRAPHY 
Acker, M.B. & Davies, J.R. (1989). Psychology test scores associated with late outcome in head 
injury. Neuropsychology, 3, 1-10. 
 
Adams, J.M. & Cory, S. (2007). The bcl-2 apoptotic switch in cancer development and therapy. 
Oncogene, 26, 1324-1337. 
 
Adrain, C., Creagh, E.M., & Martin, S.J. (2001). Apoptosis-associated release of Smac/DIABLO 
from mitochondria requires active caspases and is blocked by Bcl-2. EMBO Journal, 
20(23), 6627-36.  
 
Akgul, C., Moulding, D.A., & Edwards, S.W. (2004). Alternative splicing of Bcl-2 realted genes: 
functional consequences and potential therapeutic applications. Cellular and Molecular 
Life Science, 61, 2189-2199.  
 
Allsopp, T.E., Wyatt, S., Paterson, H.F., & Davies, A.M. (1993). The proto-oncogene bcl-2 can 
selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell, 73, 295-
307. 
 
Amemiya, S.,  Kamiya, T., Nito, C., Inaba, T., Kato, K., Ueda, M., Shimazaki, K., & Katayama, 
Y. (2005). Anti-apoptotic and neuroprotective effects of edaravone following focal 
transient focal ischemia in rats. European Journal of Pharmacology, 516, 125-130. 
 
Bahr, M. (2000). Live r let die-retinal ganglion cell death and survival during development and 
in the lesioned adult CNS. Trends Neuroscience, 23, 483-490. 
 
Baliga, B., & Kumar, S. (2003). Apaf-1/cytochrome c apoptosome: an essential initiator of 
caspase activation or just a sideshow? Cell death and Differentiation, 10, 16-18. 
 
Basso, M., Bornstein, R.A., & Lang, J.M. (1999). Practice effects on commonly used 
 measures of executive function across 12 months. The Clinical Neuropsychologist, 
13, 283-292. 
 
Bederson, J.B., Pitts, L.H., Tsuji, M., Nishimura, M.C., Davis, R.L., & Bartkowski, H. (1986). 
Rat middle cerebral artery occlusion: evaluation of the model and development of a 
neurologic examination. Stroke, 17(3), 472-6. 
 
   263
 Beffert, U., Danik, M., Krzywkowski, P., Ramassamy, C., Berrada, F., & Poirier, J. (1998). The 
neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. 
Brain Research - Brain Research Reviews, 27(2),119-42. 
 
Behl, C. & Manthey, D. (2000). Neuroprotective activities of estrogen: An update. Journal of 
Neurocytology, 29, 351-359. 
 
Belton, O., Duffy, A., Toomey, S., & Fitzgerald, D. (2003). Cyclooxygenase isoforms and 
platelet vessel wall interactions in the apolipoprotein E knockout mouse model of 
atherosclerosis. Circulation, 108(24), 3017-23. 
 
Bendel, R.B. & Afifi, A.A. (1977). Comparison of stopping rules in forward regression. Journal 
of the American Statistical Association, 72, 46-53. 
 
Bittigau, P., Sifringer, M., Pohl, D., Stadthaus, D., Ishimaru, M., Shimizu, H., Ikeda, M., Lang, 
D., Speer, A., Olney, J.W., & Ikonomidou, C. (1999). Apoptotic neurodegeneration 
following trauma is markedly enhanced in the immature brain. Annals of Neurology, 
45(6),724-35. 
 
Boehning, D., Patterson, R.L., Sedaghat, L., Glebova, N.O., Kurosaki, T., & Synder, S.H. 
(2003). Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying 
calcium-dependent apoptosis. Nature Cell Biology, 5(12), 1051-1061. 
 
Brain Injury Association of America (BIAA). (2007). What is Brain Injury? Retrieved, June 25, 
2008, from http://www.biausa.org/Pages/what_is_brain_injury.html 
 
Breckenridge, D.G., & Xue, D. (2004). Regulation of mitochondrial membrane permeabilization 
by BCL-2 family proteins and caspases. Current Opinion in Cell Biology, 16(6), 647-652. 
 
Bredesen, D.E. (2000). Apoptosis: Overview and signal transduction pathways. Journal of 
Neurotrauma, 17(10), 801-810. 
 
Bruckheimer, E.M., Cho, S.H.,  Sarkiss, M.,  Herrmann, J., & McDonnell, T.J. ( 1998). The  
Bcl-2 gene family and apoptosis. In T. Scheper (Ed.). Advances in biochemical 
engineering/biotechnology: Vol. 62 (pp. 75-105). Heidelberg, Berlin: Springer-Verlag. 
 
Bullock, R., Chestnut, R.M., Clifton, G., Chajar, J., Marion, D.W., Narayan, R.K., Newell, D.W., 
Pitts, L.H., Rosner, M.J., & Wilberger, J.W.  (1996). Guidelines for the management of 
severe head injury. European Journal of Emergency Medicine, 2, 109-127. 
 
Cai, J., Yang, J. & Jones, D.P. (1998). Mitochondrial control of apoptosis: the tole of cytochrome 
c. Biochimica et Biophysica Acta, 1366, 139-149. 
 
Cernak, I., Chapman, S.M., Hamlin, G.P., & Vink, R. (2002). Temporal characterization of pro- 
and anti-apoptotic mechanisms following diffuse traumatic brain injury in rats. Journal of 
Neuroscience, 9(5), 565-75-2. 
   264
  
Chen, C.C., Heinemann, A.W., Bode, R.K., Granger, C.V., & Mallinson T. (2004). Impact of 
pediatric rehabilitation services on children's functional outcomes. American Journal of 
Occupational Therapy, 58(1), 44-53. 
 
Chen, D.F., Schneider, G.E., Martinou, J.C., & Tonegawa, S. (1997). Bcl-2 promotes 
regeneration of severed axons in mammalian CNS. Nature, 385(6615), 434-9. 
 
Chen, Q.M., Gong, B., & Almasan, A. (2000). Distinct stages of cytochrome c release from 
mitochondria: Evidence for a feedback amplification loop linking caspase activation to 
mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death and 
Differentiation, 7, 227-233. 
 
Chen, T., Quian, Y., Rice, A., Zhu, J., Di, X., & Bullock, R. (2000). Brain lactate uptake 
increases at the site of impact after traumatic brain injury. Brain Research, 861, 281-287. 
 
Chiang, M., Chang, J., & Hu, C. (2003). Association between apolipoprotein E genotype and 
outcome of traumatic brain injury. Acta neurochir, 145, 649-654. 
 
Chittenden, T., Flemington, C., Houghton, A.B., Ebb, R.G., Gallo, G.J., Elangovan, B., 
Chinnadurai, G., & Lutz, R.J. (1995). A conserved domain in Bak, distinct from BH1 and 
BH2, mediates cell death and protein binding functions. EMBO Journal, 14(22), 5589-96. 
 
Cicerone, K.D., Mott, T.,  Azulay, J., & Friel, J.C. (2004). Community integration and 
satisfaction with functioning after intensive cognitive rehabilitiation for traumatic brain 
injury. Archives of Physical Medicial Rehabilitation, 85, 943-950. 
 
Cifu, D., Kreutzer, J., Marwitz, J., Rosenthal, M., Englander, J., & High, W. (1996a). Functional 
outcomes of older adults with traumatic brain injury: a prospective, multicenter analysis.  
Archives of Physical Medicine & Rehabilitation, 77(9),883-8. 
 
Cifu, D., Kaelin, D. & Wall, B. (1996b). Deep venous thrombosis: incidence on admission to a 
brain injury rehabilitation program. Archives of Physical Medicine & Rehabilitation, 
77(11),1182-5. 
 
Clark, R., Chen, J., Watkins, S., Kochanek, P., Chen, M., Stetler, R., Loeffert, J., & Graham, 
S.H. (1997). Apoptosis-suppressor gene bcl-2 expression after traumatic brain injury in 
rats. Journal of Neuroscience, 17(23), 9172-82. 
 
Clark, R., Kochanek, P., Chen, M., Watkins, S.,  Marion, D., Chen, J., Hamilton, R., Loffert, J., 
& Graham, S.(1999). Increase in bcl-2 and cleavage of caspase-1 and caspase-3 in human 




   265
 Clark, R., Kochanek, P., Adelson, P.D., Bell, M.,  Carcillo, J., Chen, M.,  Wisniewski, S.,  
Janesko, K., Whalen, M., & Graham, S. (2000). Increase in bcl-2 protein in cerebrospinal 
fluid and evidence for programmed cell death in infants and children after severe 
traumatic brain injury. The Journal of Pediatrics, 137(2), 197-20. 
 
Corrigan, J.D., Whiteneck, G., & Mellick, D. (2004). Perceived needs following traumatic brain 
injury. Journal of Head Trauma Rehabilitation, 19(3), 205-216. 
 
Cuende, E., Ales-Martinez, J.E., Ding, L., Gonzalez-Garcia, M., Martinez-A, C., & Nunez, G. 
(1993). Programmmed cell death by bcl-2-dependent and independent mechanisms in B 
lymphoma cells. The EMBO Journal, 12(4), 1555-1560. 
 
Davies, A.D. (1968). The influence of age on Trail Making Test Performance. Journal of 
Clinical Psychology, 24, 96-98. 
 
DeGiorgi, F., Lartigue, L., Bauer, M.K.A., Schubert, A., Grimm, S., Hanson, G.T., Remington, 
S.J., Youle, R.J., & Ichas, F. (2002). The permeability transition pore signals apoptosis 
by directing Bax translocation and multimerization [Electronic version]. The FASEB 
Journal, Published on-line February 25, 2005. 
 
Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T.,  Zhou, Q., Srinivasula, S.M.,  
Alnemri, E.S., Salvesen, G.S., &. Reed, J.C. (1998). IAPs block apoptotic events induced 
by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO 
Journal, 17, 2215–2223. 
 
Dong, G.X., Singh, D.K., Dendle, P. & Prasad, R.M. (2001). Regional expression of Bcl-2 
mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat. 
Brain Research, 903, 45-52.  
 
Eberspacher, E., Werner, C., Engelhard, K., Monika, P., Gelb, A., Hutzler, P., Henke, J., & 
Kochs, E. (2003). The effects of hypothermia on expression of the apoptosis- regulating 
protein Bax after incomplete cerebral ischemia and reperfusion in rats. Journal of 
Neurosurgical Anesthesiology, 15(3), 200-208.  
 
Eldaddah, B.A., & Faden, A.I. (2000). Caspase pathways, neuronal apoptosis, and CNS injury. 
Journal of Neurotrauma, 17(10), 811-829. 
 
Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratton, D.L., & Henson, P.M. (1992). 
Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific 
recognition and removal by macrophages. Journal of Immunology, 148(7), 2207-16. 
 
Felderhoff-Mueser, U., Sifringer, M., Pesditschek, S., Kuckuck, H., Moysich, A., Bittigau, P., & 
Ikonomidou, C. (2002). Pathways leading to apoptotic neurodegeneration following 
trauma to the developing rat brain. Neurobiology of Disease, 11(2),231-45. 
 
   266
 Finklestein, S., & Ropper, A. (1979). The diagnosis of coma: Its pitfalls and limitations. Heart & 
Lung, 8, 1059-1064.  
 
Fiskum, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Bratoon, D.L., & Henson, P.M. 
(2000). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers 
specific recognition and removal by macrophages. The Journal of Immunology, 148(7), 
2207-2216. 
 
Fullerton, H.J., Wu, Y.W., Zhao, S., &  Johnston, S.C. (2003). The risk of stroke in children: 
ethnic and gender disparities. Neurology, 61(2), 189-94. 
 
Garcia, I., Martinou, I., Tsujimoto, Y., & Martinou, J.C. (1992). Prevention of programmed cell 
death of sympathetic neurons by bcl-2 proto-oncogene. Science, 258, 302-304. 
 
Genecards. (2007). B-cell CLL/lymphoma 2. Retrieved June 21, 2007, from 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=BCL2&search=bcl-2 
Gennarelli, T.A. (1983). Head injury in man and experimental animals: Clinical aspects. Acta 
Neurochirurgica (Suppl.32), 1-13. 
 
Gennarelli, T.A., Thibault, L.E., & Graham, D.I. (1998). Diffuse axonal injury: An important 
form of traumatic brain injury. Neuroscientist, 4, 202-215. 
 
Girard D., Brown, J., Burnett-Stolnack, M., Hashimoto, N., Hier-Wellmer, S., Perlman, O. & 
Seigerman, C. (1996).The relationship of neuropsychological status and productive 
outcomes following traumatic brain injury. Brain Injury, 10(9), 663-76.  
 
Goodman, J.C., Valadka, A.B., Gopinath, S.P., Uzura, M., & Robertson, C.S. (1999). 
Extracellular lactate and glucose alterations in the brain after head injury measured by 
microdialysis. Critical Care Medicine, 27(9), 1965-73. 
 
Gouvier, W.D., Blanton, P.D., LaPorte, K.K., & Nepomuceno, C. (1987). Reliability and validity 
of the Disability Rating Scale and the Levels of Cognitive Functioning Scale in 
monitoring recovery from severe head injury. Archives of Physical Medicine & 
Rehabilitation, 68(2), 94-7. 
 
Graham, S.H., Chen, J., & Clark, R.S. (2000). Bcl-2 family gene products in cerebral ischemia 
and traumatic brain injury. Journal of Neurotrauma, 17(10), 831-841. 
 
Gur, D., Good, W.F., Wolfson, S.K., Jr., Yonas, H., & Shabason, L. (1982). In vivo mapping of 
local cerebral blood flow by xenon-enhanced computed tomography. Science, 215(4537), 
1267-1268.  
 
Hall, K.A., Cope, D.N., & Rappaport, M. (1985). Glasgow Outcome Scale and Disability Rating 
Scale: comparative usefulness in following recovery in traumatic head injury. Archives of 
Physical Medicine & Rehabilitation, 66, 35-7. 
 
   267
 Harris, M.H., & Thompson, C.B.  (2000). The role of Bcl-2 family in the regulation of outer 
mitochondrial membrane permeability. Cell Death and Differentiation, 7, 1182-191. 
 
Hata, R., Gillardon, F.,  Michaelidis, T. M., & Hossmann, K.A. (1999). Targeted disruption of 
bcl-2 gene in mice exacerbates focal ischemia brain injury. Metabolic Brain Disease, 14 
(2), 117-124. 
 
Hayashi, H., Igbavboa, U., Hamanaka, H., Kobayashi, M., Fujita, S.C., Wood, W.G., & 
Yanagisawa, K. (2002). Cholesterol is increased in the exofacial leaflet of synaptic 
plasma membranes of human apolipoprotein E4 knock-in mice. NeuroReport, 13(4), 383-
6. 
 
Hellmich, H.L., Garcia, J.M., Shimamura, M., Shah, S.A., Avila, M.A., Uchida, T., Parsley, 
M.A., Capra, B.A., Eidson, K.A., Kennedy, D.R., Winston, J.H., DeWitt, D.S., & Prough, 
D.S. (2005). Traumatic brain injury and hemorrhagic hypotension suppress 
neuroprotective gene expression in injured hippocampal neurons. Anesthesiology, 102(4), 
806-14. 
 
Henshall, D.C. (2007). Apoptosis signalling pathways in seizure-induced neuronal death and 
epilepsy. Biochemistry Society Transactions, 35(2), 421-423. 
 
Henshall, D.C., & Simon, R.P. (2005). Epilepsy and apoptosis pathways. Journal of Cerebral 
Blood Flow, 25, 1557-1572. 
 
Hockenbery, D., Nunez, G., milliman, C., Schreiber, R.D., & Korsmeyer, S. (1990). Bcl-2 is an 
inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348, 
334-348. 
 
Hosmer, D.W., & Lemeshow, S. (2000). Applied logistic regression (2nd ed.).  
 NY: John Wiley and Sons, Inc.  
 
Ignatius, M.J., Gebicke-Harter, P.J., Skene, J.H., Schilling, J.W., Weisgraber, K.H., Mahley, 
R.W., & Shooter, E.M. (1986). Expression of apolipoprotein E during nerve degeneration 
and regeneration. Proceedings of the National Academy of Sciences of the United States 
of America, 83(4), 1125-9. 
  
Itoh, N., Yonehara, S., Ishii, A., Yonohara, M., Mizushima, S.I., Sameshima, M., Hase, A., Seto, 
Y., & Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell surface 
antigen Fas can mediate apoptosis. Cell, 66, 233-243. 
 
Jennett, B. (1976). Outcome after severe head injury: definitions and predictions. Medical 
Journal of Australia, 2(13), 475-7. 
 
Jennett, B., & Bond M. (1975). Assessment of outcome after severe brain damage: A practical 
side. Lancet,1, 480-84. 
 
   268
 Jennett, B., Teasdale, G., Braakman, R., Minderhoud, J., & Knill-Jones, R. (1976). Predicting 
outcomes in individual patients after sever head injury. Lancet, 1, 1031-1034. 
 
Jermitsky, E., Omert, L., Dunham, M., Protetch, J., & Rodriguez, A. (2003). Harbingers of poor 
outcome the day after sever brain injury: Hypothermia, hypoxia, and hypoperfusion.  
Journal of Trauma Injury, Infection and Critical Care, 54(2), 312-319. 
 
Jiang, J., Gao, G., Li, W, Yu, M., & Zhu, C. (2002). Early indicators of prognosis in 846 cases of 
severe traumatic brain injury. Journal of Neurotrauma, 19(7), 869-874. 
 
Jordan, B.D., Relkin, N.R., Ravdin, L.D., Jacobs, A.R., Bennett, A., & Gandy, S. (1997). 
Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. 
Journal of the American Medical Association, 278(2), 136-40. 
 
Jurgensmeier, J.M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., & Reed, J.C. (1998). Bax 
directly induces release of cytochrome c from isolate mitochondria. Proc. Natl. Acad. 
Sci.,  95, 4997-5002. 
 
Kalmar, K., Novack, T.A., Nakase-Richardson, R., Sherer, M., Frol, A.B., Gordon, W.A., Hanks, 
R.A., Giacino, J.T., & Ricker, J.H. (2008). Feasibility of brief neuropsychologic test 
battery during acute inpatient rehabilitation after traumatic brain injury. Archives of 
Physical Medicial Rehabilitation, 89, 942-949. 
 
Kane, D.J., Sarafian, T.A., Anton, R., Hahn, H., Gralla, E.B., Valentine, J.S., Ord, T., & 
Bredesen, D.E. (1993). Science, 262, 1274-1277. 
 
Kerr, M., Kamboh, I., Yookyung, K., Kraus, M., Puccio, A., Dekosky, S., & Marion, D. (2003). 
Relationship between apoE4 allele and excitatory amino acid levels after traumatic brain 
injury. Critical Care Medicine, 31(9), 2371-2379. 
 
Kim, R. (2005). Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochemical and 
Biophysical Research Communications, 333, 336-343. 
 
King, J.T., Carlier, P.M.,  & Marion, D.W. (2005). Early Glasgow Outcome Scale scores predict 
long-term functional outcome in patients with severe traumatic brain injury. Journal of 
Neurotrauma, 22(9), 947-954. 
 
Kluck, R.M., Bossy-Wetzel, E., Green, D.R., & Newmeyer, D.D. (1997). The release of 
cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. 
Science, 275, 1132-1136. 
 
Kotapka, M.J., Graham, D.I., Adams, J.H., & Gennarelli, T.A. (1992). Hippocampal pathology 
in fatal non-missile human head injury. Acta Neuropathologica, 83(5),530-4.  
 
Kroemer, G. (2003). Mitochondrial control of apoptosis: an introduction [Electronic version]. 
Biochemical and Biophysical Research Communications, 304(3), 433-435. 
   269
  
Kroemer, G., & Reed, J.C. (2000). Mitochondrial control of cell death. Nature Medicine, 6(5), 
513-519. 
 
Labi, M., Brentjens, M., Coad, M., Flynn, W., & Zielezny, M. (2003). Development of a 
longitudinal study of complications and functional outcomes after traumatic brain injury. 
Brain Injury, 17(4), 265-78. 
 
LaDu, M.J., Falduto, M.T., Manelli, A.M., Reardon, C.A., Getz, G.S., & Frail, D.E. (1994). 
Isoform-specific binding of apolipoprotein E to Beta-amyloid. Journal of Biological 
Chemistry, 269, 23404-23406. 
 
LaDu, M.J., Pederson, T.M., Frail, D.E., Reardon, C.A., Getz, G.S., & Falduto, M.T. (1995). 
Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. 
Journal of Biological Chemistry, 270(16), 9039-42. 
 
Langlios, J.A.,  Rutland- Brown, W., &  Thomas, K.E. (2006). Traumatic brain injury in the 
Unites States: Emergency department visits, hospitalizations, and deaths. Atlanta: Centers 
of Disease Control and Prevention, National Center for Injury Prevention and Control. 
 
Larner, S.F., Hayes, R.L., McKinsey, D.M., Pike, B.P., & Wang, K.K.W. (2004). Increase 
expression and processing of caspase-12 after traumatic brain injury in rats. Journal of 
Neurochemistry, 88(1), 78-90. 
 
Lee, J.H., Jeon, M.H., Seo, Y.J., Lee, Y.J., Ko, J.H., Tsujimoto, Y., & Lee, J.H. (2004). CA 
repeats in the 3'-untranslated region of bcl-2 mRNA mediate constitutive decay of bcl-2 
mRNA. Journal of Biological Chemistry, 279(41),42758-64.  
 
Lee, Y., Kang, I., Bunger, R., & Kang, Y. (2003). Mechanism of pyruvate inhibition of oxidant-
induced apoptosis in human endothelial cells [Electronic version]. Microvascular 
Research, 66(2), 91-101. 
 
Lee, Y., Kang, I., Bunger, R., & Kang, Y. (2004). Enhanced survival effect of pyruvate 
correlates MAPK and NF-kappaB activation in hydrogen peroxide-treated human 
endothelial cells. Journal of Applied Physiology, 96(2), 793-801. 
 
Leininger, B.E., Gramling, S.E., Farrell, A.D., Kreutzer, J.S., & Peck, E.A. 3rd. (1990). 
Neuropsychological deficits in symptomatic minor head injury patients after concussion 
and mild concussion. Journal of Neurology, Neurosurgery & Psychiatry, 53(4), 293-6. 
 
Leppert, G. (2006). Apoptosis: Principles and methods. Bethesda, MD: Foundation for Advanced 




   270
 Levin, H.S., Gary, H.E. Jr., Eisenberg, H.M., Ruff, R.M., Barth, J.T., Kreutzer, J., High, W.M. 
Jr., Portman, S., Foulkes, M.A., Jane, J.A. et al., (1990). Neurobehavioral outcome 1 year 
after severe head injury. Experience of the Traumatic Coma Data Bank. Journal of 
Neurosurgery, 73(5), 699-709. 
 
Lezek, M.D.,  Howieson, D.B., & Loring, D.W. (2004). Neuropsychological assessment (4th ed.). 
Oxford Univeristy Press: New York. 
 
Li, H., Zhu, H., Xu, C., & Yuan, J. (1998). Cleavage of BID by capsease-8 medicates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.  
 
Li, L.Y., Luo, X., & Wang, X. (2001). Endonuclease G is an apoptotic DNase when released 
from mitochondria. Nature, 412(6842), 95-9.  
 
Liao, Z.B.,  Zhi, X.G., Shi, Q.H., & He, Z.H. (2008). Recombinant human erythropoietin 
administration protects cortical neurons from traumatic brain injury in rats. European 
Journal of Neurology, 15, 140-49. 
 
Liaquat, I., Dunn, L.T., Nicoll, J.A., Teasdale, G.M., &  Norrie, J.D. (2002). Effect of 
apolipoprotein E genotype on hematoma volume after trauma. Journal of Neurosurgery, 
96(1), 90-6. 
 
Liberman, J.N., Stewart, W.F., Wesnes, K., & Troncoso, J. (2002). Apolipoprotein E [epsilon]4 
and short-term recovery from predominantly mild brain injury. Neurology, 58(7),1038-
1044. 
 
Lippert-Gruner, M., Kuchta, J., Hellmich, M., & Klug, N. (2006). Neurobehavioural deficits 
after severe traumatic brain injury (TBI). Brain Injury, 20(6), 569-74.  
 
Lithgow, T., van Driel, R., Bertram, J.F., & Strasser, A. (1994). The protein product of the 
oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and 
the outer mitochondrial membrane. Cell Growth and Differentiation, 5, 411-417. 
 
Liu, X., Kim, C.N., Yang, J., Jemmerson, R., & Wang, X. (1996). Induction of apoptotic 
program in cell-free extracts: Requirement for dATP and cytochrome c. Cell, 86, 147-
157. 
 
Lou, J., Lenke, L., Xu, F., & O’brien, M. (1998). In vivo BCL-2 onocogene neuronal expression 
in the rat spinal cord. Spine, 23(5), 517-523. 
 
Lovasik,D., Kerr, M., & Alexander, S. (2001). Traumatic brain injury research: A review of 
clinical studies. Critical Care Nursing Quarterly, 23, 24-41. 
 
Lu, J., Ashwell, K., & Waite, P. (2000). Advances in secondary spinal cord injury. Spine, 25(14), 
1859-1866.  
 
   271
 Lu, J., Moochhala, S., Kaur, C., & Ling, E.A. (2000). Changes in apoptosis-related protein (p53, 
Bax, Bcl-2 and FOS) expression with DNA fragmentationin the central neverous system 
in rats after closed head injury. Neuroscience Letters, 290(2000), 89-92. 
 
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998). Bid, a Bcl-2 interacting 
protein, mediates cytochrome c release from mitochondria in response to activation of 
cell surface death receptors. Cell, 94, 481-490. 
 
Lynch, J.R., Pineda, J.A., Morgan, D., Zhang, L., Warner, D.S., Benveniste, H., & Laskowitz, 
D.T. (2002). Apolipoprotein E affects the central nervous system response to injury and 
the development of cerebral edema. Annals of Neurology, 51(1), 113-7. 
 
Maas, A.I., Braakman, R., Schouten, H.J., et al. (1983). Agreement between physicians on 
assessment of outcome following severe head injury. Journal of Neurosurgery, 58(3), 
321-5.  
 
Mah, S.P., Zhong, L.T., Liu, Y., Roghani, A., Edwards, R.H., & Bredesen, D.E. (1993). The 
protooncogene bcl-2 inhibits apoptosis in PC12 cells. Journal of Neurochemistry, 60, 
1183-1186. 
 
Mahley, R. W. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in 
cell biology. Science, 240(4852),622-30. 
 
Mannella, C.A. (1992). The 'ins' and 'outs' of mitochondrial membrane channels. Trends in 
Biochemical Sciences, 17(8), 315-20.  
 
Marion, D. (2001). Head Injuries: Current Principles of Triage and Acute Care. Unpublished, 
University of Pittsburgh Medical Center.  
 
Marques, M.A., Tolar, M., Harmony, J.A., & Crutcher, K.A. (1996). A thrombin cleavage 
fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. NeuroReport, 7, 
2529-32.  
 
Martins, L.M. (2002). The serine protease Omi/HtrA2: a second mammalian protein with a 
Reaper-like function. Cell Death and Differentiation, 9(7), 699-701. 
 
Mauch, D.H., Nagler, K., Schumacher, S., Goritz, C., Muller, E.C., Otto, A., & Pfrieger, F.W. 
(2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science, 294(5545), 
1354-7. 
 
Mclean, J., & Nunez, J.L. (2008). 17α Estradiol is neuroprotective in male and female rats in a 
model of early brain injury. Experimental Neurology, 210, 41-50. 
 
McCullers, D.L., Sullivan, P.G., Scheff, S.W., & Herman, J.P. (2002). Mifepristone protects 
CA1 hippocampal neurons following traumatic brain injury in rat. Neuroscience, 109(2), 
219-30. 
   272
  
Mcilvoy, L.H. (2005). The effect of hypothermia and hyperthermia on acute brain injury. AACN 
Clinical Issues, 16(4), 488-500. 
 
McLaughlin, M.R., & Marion, D.W. (1996).Cerebral blood flow and vasoresponsivity within 
and around cerebral contusions. Journal of Neurosurgery, 85, 871-876. 
 
Meaney, D.F., Smith, D.H., Shreiber, D.I., Bain, A.C., Miller, R.T., Ross, D.T., & Gennarelli, 
T.A. (1995). Biomechanical analysis of experimental diffuse axonal injury. Journal of 
Neurotrauma, 12(4), 689-94. 
 
Michikawa, M., &. Yanagisawa, K. (1998). Apolipoprotein E4 induces neuronal cell death under 
conditions of suppressed de novo cholesterol synthesis. Journal of Neuroscience 
Research, 54(1), 58-67. 
 
Millar, K., Nicoll, J.A., Thornhill, S., Murray, G.D., & Teasdale, G.M. (2003). Long term 
neuropsychological outcome after head injury: relation to APOE genotype. Journal of 
Neurology, Neurosurgery & Psychiatry, 74(8), 1047-52.  
 
Minambres, E., Ballesteros, M.A., Mayorga, M., Marin, M.J., Munoz, P., Figols, J., & Lopez-
Hoyos, M. (2008). Cerebral apoptosis in severe traumatic brain injury patients; An in 
vitro, in vivo, and postmortem study. Journal of Neurotrauma, 25, 581-91. 
 
Miyashita, T., Harigai, M., Hanada, M., & Reed, J.C. (1994). Identification of a p53-dependent 
negative response element in the bcl-2 gene. Cancer Research, 54(12), 3131-5. 
 
Miyashita, T., & Reed, J.C. (1995). Tumor suppressor p53 is a direct transcriptional activator of 
the human bax gene. Cell, 80, 293-299. 
 
Mohamad, N., Gutierrez, A., Nunez, M., Cocca, C., Martin, G., Cricco, G., Medina, V., Rivera, 
E., & Bergoc, R. (2005). Mitochondrial apoptotic pathways. Biocell, 29(2), 149-61. 
 
Morrison, B., Eberwine, J.H., Meaney, D.F., & McIntosh, T.K. (2000). Traumatic injury induces 
differential expression of cell death genes in organotypic brain slice cultures determined 
by complementary DNA array hybridization. Neurosciences, 96(1), 131-139. 
 
Moulder, K.,  Narita, M., Chang, L., Bu, G., & Johnson, E. (1999). Anaylsis of a novel 
mechanism of neuronal toxicity produced by an apolipoprotein E- derived peptide. 
Journal of Neurochemistry, 72(3), 1069-1080. 
 
Muchmore, S.W., Sattler, M., Liang, H., Meadows, R.P., Harlan, J.E., Yoon, H.S., Nettesheim, 
D., Chang, B.S., Thompson, C.B., Wong, S.L., Ng, S.C., & Fesik, S.W. (1996). X-ray 
and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature, 
381, 335-341.  
 
   273
 Muller, W., Meske, V., Berlin, K., Scharnagl, H., Marz, W., & Ohm, T.G. (1998). 
Apolipoprotein E isoforms increase intracellular Ca2+ differentially through a omega-
agatoxin IVa-sensitive Ca2+-channel. Brain Pathology, 8(4), 641-53. 
 
Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O’Rourke, K., Shevchenko, A., Ni, J., Scaffidi, 
C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., & Dixit, 
V.M. (1996). FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited 
to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85, 817-827. 
 
Myers, K.M., Fiskum, G., Liu, Y., Simmens, S.J., Bredesen, D.E., & Murphy, A.N. (1995). Bcl-
2 protects neural cells from cyanide/aglycemia-induced lipid oxidation, mitochondrial 
injury, and loss of viability. Journal of Neurochemistry, 65(6), 2432-40.  
 
Nabors, N., Seacat, J., & Rosenthal, M. (2002). Predictors of caregiver burden following 
traumatic brain injury. Brain Injury, 16(12), 1039-1050. 
 
Nakamura, M., Raghupathi, R., Merry, D.E., Scherbel, U., Saatman, K.E., & McIntosh, T.K. 
(1999). Overexpression of Bcl-2 is neuroprotective after experimental brain injury in 
transgenic mice. The Journal of Comparative Neurology, 412, 681-92. 
 
Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991). Apolipoprotein E 
immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's 
disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Research, 
541(1),163-6. 
 
Nathan, B.P., Bellosta, S., Sanan, D.A., Weisgraber, K.H., Mahley, R.W., &  Pitas, R.E. (1994). 
Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science, 
264(5160), 850-2. 
 
National Institute of Health Consensus Development Panel on Rehabilitation of Persons with 
Traumatic Brain Injury, (1999). Rehabilitation of persons with traumatic brain injury. 
JAMA, 282(10), 974-983. 
 
National Institute of Neurological Disorders and Stroke (NINDS). (2008). Traumatic brain 
injury: Hope through research (Publication No. 02-158.). Retrieved June 23, 2008, from 
http://www.ninds.nih.gov/disorders/tbi/detail_tbi.htm  
 
Nathoo, N., Narotam, P.,  Agrawal, D., Connolly, C., Van Dellen, J., Barnett, G., & Chetty, R. 
(2004). Influence of apoptosis on neurosurgical outcome following traumatic cerebral 
contusion. Journal of Neurosurgery, 101, 233-240. 
 
National Center for Biotechnology Information [NCBI] (2007). Bcl-2 : Humans. Retrived June 
21, 2007, from http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd =Show 
DetailView&TermToSearch=596&ordinalpos=1&itool=EntrezSystem2.PEntrez.Gene.Ge
ne_ResultsPanel.Gene_RVDocSum 
   274
 Nicoll, J., Roberts, G., & Graham, D. (1995). Apolipoprotien E. 4 allele is associated with 
deposition of amyloid B-Protein following head injury. Nature Medicine, 7, 135-137. 
 
Ng, I., Yeo, T., Tang, W., Soong, R., Ng, P., & Smith, D. (2000). Apoptosis occurs after cerebral 
contusions in humans [Electronic version]. Neurosurgery On-line, 46, 949-956.  
 
Nolan, S. (2005). Traumatic brain injury: a review. Critical Care Nursing Quarterly, 28(2), 188-
94. 
 
Nunez, G., London, L., Hockenberry, D., Alexander, M., McKearn, J.P., & Korsmeyer, S.J. 
(1990). Deregulated Bcl-2 gene expression selectively prolongs survival of growth 
factor-deprived hemopoietic cell lines. The Journal of Immunology, 144(9), 3602-3610. 
 
Ong, J.M.., Zorapapel, N., Aoki, A., Brown, D., Nesburn, A., Rich, K., & Kenney, C. (2003). 
Impaired electroretinogram (ERG) response in apolipoprotein E-deficient mice. Current 
Eye Research, 27(1), 15-24. 
 
Overall, J.E., & Gorham, D.R. (1962). The brief psychiatric rating scale. Psychological Reports, 
10, 799-812. 
 
Panizzon, K.L., Shin, D., Frautschy, S., & Wallis, R.A. (1998). Neuroprotection with Bcl-2(20-
34) peptide against trauma. Neuroreport, 9(18),4131-6.  
 
Pettus, E.H., Wright, D.W., Stein, D.G., & Hoffman, S.W. (2005). Progesterone treatment 
inhibits the inflammatory agents that accompany traumatic brain injury. Brain Research, 
1049(1), 112-9. 
 
Pillai, S., Kolluri, V. & Prharaj, S. (2003). Outcome prediction model for severe diffuse brain 
injuries; Development and evaluation. Neurology India, 51(3), 345- 349.  
 
Poirier, J., Baccichet, A., Dea, D., & Gauthier, S. (1993). Cholesterol synthesis and lipoprotein 
reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience, 55, 81-
90. 
 
Poirier, J., Hess, M., May, P.C., & Finch, C.E. (1991). Astrocytic apolipoprotein E mRNA and 
GFAP mRNA in hippocampus after entorhinal cortex lesioning. Molecular Brain 
Research, 11(2), 97-106. 
 
Povlishock, J.T. (Ed.). (2007). Guidelines for the management of severe TBI [Special Issue]. 
Journal of Neurotrauma, 24 suppl, s1-106. 
 
Proskuryakov, S.Y., Konoplyannikov, A.G., & Gabai, V.L. (2003). Necrosis: a specific form of 
programmed cell death?.  Experimental Cell Research, 283(1), 1-16. 
 
 
   275
 Raghupathi, R., Fernandez, S.C., Murai, H., Trusko, S.P., Scott, R.W., Nishioka, W.K., & 
McIntosh, T.K. (1998). Bcl-2 over expression attenuates cortial cell loss after traumatic 




Raghupathi, R., Conti, A.C., Graham, D.I., Krajewski, S., Reed, J.C., Grady, M.S., 
Traojanowski, J.Q., & McIntosh, T.K. (2002). Mild traumatic brain injury induces 
apoptotic cell death in cortex that is preceded by decreases in cellular Bcl-2 
immunoreactivity. Neuroscience, 110(4), 605-16. 
 
Raghupathi, R., Strauss, K.I., Zhang, C., Krajewski, S., Reed, J.C., & McIntosh, T.K. (2003). 
Temporal alterations in cellular Bax:Bcl-2 ratio following traumatic brain injury in the 
rat. Journal of Neurotrauma, 20(5), 421-35. 
 
Raghupathi, R. (2004). Cell death mechanisms following traumatic brain injury. Brain Pathol, 
14, 215-222. 
 
Rappaport, M., Hall, K.M., Hopkins, K., Belleza, T., & Cope, D.N. (1982). Disability Rating 
Scale for severe head trauma: Coma to community. Archives of Physical Medicine and 
Rehabilitation, 63, 118-123. 
 
Raudenbush S. (1997). Statistical analysis and optimal design for cluster randomized trials. 
Psychological Methods, 2, 173-185. 
 
Raudenbush, S.W., &  Bryk, A.S.(2001). Hierarchical Linear Models. Thousand Oaks, CA: 
Sage Publications, Inc. 
 
Reed, J.C. (1997).  Double identity for proteins of the Bcl-2 family. Nature, 387, 773-776. 
 
Reitan R. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. 
Perceptual and Motor Skills, 8, 271-276. 
 
Reitan,  R.M., & Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test Battery. 
Tucson: Neuropsychology Press. 
 
Reyland, M.E., & Williams, D.L. (1991). Suppression of cAMP-mediated signal transduction in 
mouse adrenocortical cells which express apolipoprotein E. Journal of Biological 
Chemistry, 266(31), 21099-104. 
 
Roof, R.L., & Hall, E.D. (2000a). Gender differences in acute CNS trauma and stroke: 
neuroprotective effects of estrogen and progesterone. Journal of Neurotrauma, 17(5), 
367-88. 
 
   276
 Roof, R.L. & Hall, E.D.(2000b). Estrogen-related gender difference in survival rate and cortical 
blood flow after impact-acceleration head injury in rats. Journal of Neurotrauma, 
17(12),1155-69. 
Roof, R.L., Hoffman, S.W., & Stein, D.G. (1997).  Progesterone protects against lipid 
peroxidation following traumatic brain injury in rats. Molecular & Chemical 
Neuropathology, 31(1), 1-11. 
 
Rosomoff, H.L., Kochanek, P.M., Clark, R., DeKosky, S.T., Uwe, E., Grenvik, A.N.A., Marion, 
D.W., Obrsit, W., Palmer, A.M., Safar, P., & White, R.J. (1996). Resuscitation from 
severe brain trauma [Electronic version]. Critical Care Medicine, 24(2), 48S-56S. 
 
Rostovtseva, T., & Colombini, M. (1996). ATP flux is controlled by a voltage-gated channel 
from the mitochondrial outer membrane. The Journal of Biological Chemistry, 271(45), 
28006-08. 
 
Ruvolo, P.P, Deng, X., & May, W.S. ( 2001). Phosphorylation of Bcl-2 and regulation of 
apoptosis. Leukemia, 15, 515-522. 
 
Ryan,  C.M., & Geckle, M.O. (2000). Circumscribed cognitive dysfunction in middle-aged 
adults with type 2 diabetes. Diabetes Care, 23, 1486-93. 
 
Salvesen, G.S.,  & Dixit, V.M. (1997). Caspases: Intracellular signaling by proteolysis. Cell, 91, 
443-446. 
 
Shimamura, M., Garcia, J.M., Prough, D.S., Dewirr, D.S., Uchida, T., Shah, S.A., Avila, 
M.A.A., & Hellmich, H.L. (2005). Analysis of longterm gene expression in neurons of 
hippocampal subfields following traumatic brain injury in rats. Neuroscience, 131, 87-97. 
 
Shimizu, S., Ide, T., Yanagida, T., & Tsujimoto, Y. (2000). Electrophysiological study of a novel 
large pore formed by Bax and the voltage-dependent anion channel that is permeable to 
cytochrome c. The Journal of Biological Chemistry, 275(16), 12321-25. 
 
Shimohamma, S., &  Kikara, T. (2001). Nicotinic receptor-mediated protection against ß-
amyloid neurotoxicity. Biological Psychiatry, 49, 233-239. 
 
Shinoda, S., Skradski, S.L., Araki, T., Schindler, C.K., Meller, R., Lan, J.Q., Taki, W., Simon, 
R.P., & Henshall, D.C. (2003). Formation of a tumour necrosis factor receptor 1 
molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 
during seizure-induced neuronal death. European Journal of Neuroscience, 17(10), 2065-
76. 
 
Singer, C.A., Rogers, K.L., & Dorsa, D.M. (1998). Modulation of Bcl-2 expression: a potential 
component of estrogen protection in NT2 neurons. Neuroreport, 9(11), 2565-8.  
 
   277
 Skulachev, V.P. (1998). Cytochrome c in the apoptotic and antioxidant cascades. FEBS Letters, 
423, 275-280. 
 
Soustiel, J.F., Palzur, E., Nevo, O., Thaler, I., & Vlodavsky E. (2005). Neuroprotective anti-
apoptosis effect of estrogens in traumatic brain injury. Journal of Neurotrauma, 22(3), 
345-52. 
 
Spikman, J.M., Deelman, B.G., & van Zomeren, A.H. (2000). Executive functioning, attention 
and frontal lesions in patients with chronic CHI. Journal of the International 
Neuropsychological Society, 22(3), 325-38. 
Spreen, O., & Strauss, E. (1998). A compendium of neuropsychological tests (2nd ed.). New 
York: Ox ford University Press. 
Stein, D.G., &  Hoffman, S.W. (2003). Estrogen and progesterone as neuroprotective agents in 
the treatment of acute brain injuries. Pediatric Rehabilitation, 6(1), 13-22. 
 
Stoltzner, S.E., Berchtold, N.C., Cotman, C.W., & Pike, C.J. (2001). Estrogen regulates bcl-x 
expression in rat hippocampus. Neuroreport, 12(13), 2797-800. 
 
Strauss, K.J., Narayan, R.K., & Raghupathi, R. (2004). Common patterns of Bcl-2 family gene 
expression in two traumatic brain injury models. Neurtoxicity, 6(4), 333-42. 
 
Susin, S.A., Zamzamim N., & Kroemer, G. (1998). Mitochondria as regulators of apoptosis-
doubt no more. Biochim. Biophys. Acta, 1366, 151-165. 
 
Tanaka, S., Takehashi, M., Iida, S., Kitajima, T., Kamanaka, Y., Stedeford, T., Banasik, M., & 
Ueda, K. (2005). Mitochondrial impairment induced by poly(ADP-ribose) polymerase-1 
activation in cortical neurons after oxygen and glucose deprivation. Journal of 
Neurochemistry, 95, 179-190. 
 
Teasdale, G., & Jennett, B. (1974). Assessment of coma and impaired consciousness. A practical 
scale. Lancet, 2(7872), 81-4. 
 
Teasdale, G., Knill-Jones, R., & Jennett, B. (1974). Assessing and recording “conscious level”. 
Journal of Neurology, Neurosurgery and Psychiatry, 37, 1286.  
 
Teasdale, G.M., Nicoll, J.A., Murray, G., & Fiddes, M. (1997). Association of apolipoprotein E 
polymorphism with outcome after head injury. Lancet, 350(9084),1069-71.  
 
Tehranian, R., Rose, M.E., Vagni, V., Griffith, R.P., Wu, S., Maits, S., Zhang, X., Clark, R.S., 
Dixon, C.E., Kochanek, P.M., Bernard, O., & Graham, S.H. (2006). Transgenic mice that 
overexpress the anti-apoptotic Bcl-2 protein have improved histological outcome but 
unchanged behavioral outcome after traumatic brain injury. Brain Research, 1101(1), 
126-35.  
 
   278
 Thomenius, M.J., & Distelhorst, C.W. (2003). Bcl-2 on the endoplasmic reticulum: protecting 
the mitochondria from a distance. Journal of Cell Science, 116, 4493-4499. 
 
Thornberry, N.A., & Lazebnik, Y. (1998). Caspases: Enemies within. Science, 281, 1312-1316. 
 
Thurman, D., Alverson, C., Dunn, K., Guerrero, J., & Sniezek, J. (1999). Traumatic brain injury 
the United States: A public health perspective. Journal of Head Trauma Rehabilitation, 
14(6), 602-615. 
 
Tolar, M., Keller, J.N., Chan, S., Mattson, M.P., Marques, M.A., & Crutcher, K.A. (1999). 
Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may 
mediate ApoE neurotoxicity. The Journal of Neuroscience, 19(16), 7100-7110. 
 
Tsujimoto, Y. (1984). Cloning of the chromosome breakpoint of neoplastic B cells with the 
t(14;18) chromosome translocation. Science, 226, 1097-1099. 
 
UCSC Genome Bioinformatics. (2006, March). Bcl-2 chr18:58,941,559-59,137,593. Retrieved 
June 18, 2007, from http://genome.ucsc.edu/cgi-bin/hgTracks?position=chr18:58941559-
59137593&hgsid=109413598&knownGene=pack&hgFind.matches=uc002lit.1 
Uzan, M., Erman, H., Tanriverdi, T., Sanus, G.Z., Kafadar, A., & Uzun, H. (2006). Evaluation of 
apoptosis in cerebrospinal fluid of patients with severe head injury. Acta Neurochir, 148, 
1157-1164. 
 
Vander Heiden, M.G., & Thompson, C.B. (1999). Bcl-2 proteins: regulators of apoptosis or of 
mitochondrial homeostasis?. Nature Cell Biology, 1(8), E209-16.  
 
Vander Heiden, M.G., Chandel, N.S., Li, X.X., Schumacker, P.T., Colombini, M., & Thompson, 
C.B. (2000). Outer mitochondrial membrane permeability can regulate coupled 
respiration and cell survival. Proceedings of the National Academy of Sciences of the 
United States of America, 97(9), 4666-71. 
 
Vanhaesebroeck, B., Reed, J.C., DeValck, D., Grooten, J., Miyashita, T., Tanaka, S., Beyaert, R., 
Van Roy, F., & Fiers, W.  (1993). Effect of bcl-2 proto-oncogene expression on cellular 
sensitivity to tumor necrosis factor-mediates cytotoxicity. Oncogene, 8, 1075-1081. 
 
Vanier, M., Mazaux, J.M., Lambert, J., Dassa, C., & Levin, H. (2000). Assessment of 
neuropsychologic impairments after head injury: Interrater reliability and factorial and 
criterion validity of the Neurobehavioral Rating Scale- Revised. Archives of Physical 
Medical Rehabilitiation, 81, 796-806. 
 
Vaux, D.L., Aguila, H.L., & Weissman, I.L. (1992). Bcl-2 prevents death of factor-deprived cells 
but fails to prevent apoptosis in targets of cell mediated killing. International 
Immunology, 4(7), 821-4. 
 
   279
 Veinbergs, I., Everson, A., Sagara, Y., & Masliah, E. (2002). Neurotoxic effects of 
apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. Journal of 
Neuroscience Research, 67(3), 379-87. 
 
Vincent, J., & Berre, J. (2005). Primer on medical management of severe brain injury. Critical 
Care Medicine, 33(6), 1392-1399. 
 
Vlodavsky, E., Palzur, E., Feinsod, M., & Soustiel, J.F. (2005). Evalution of the apoptosis-
related proteins of BCL-2 family in the traumatic penumbra area of the rat model of 
cerebral contusion, treated by hyperbaric oxygen therapy: a quantitative 
immunohistochemical study. Acta Neuropathol, 110, 120-126. 
 
Wagner, A., Bayir, H., Ren, D., Puccio, A., Zafonte, R. & Kochanek, P. (2004). Relationship 
between cerebrospinal fluid markers of excitotoxicity, ischemia, and oxidative damage 
after severe TBI: The impact of gender, age and hypothermia. Journal of Neurotrauma, 
21(2), 125-136. 
 
Wagner, A., Fabio, A., Puccio, A., Hirschberg, R., Li, W., Zafonte, R., & Marion, D. (2005). 
Gender association with cerebrospinal fluid glutamate and lactate/pyruvate levels after 
severe traumatic brain injury. Critical Care Medicine, 33(2), 407-413.  
 
Wang, X., Zhang, J., Kim, H.P., Wang, Y., Choi, A.M.K., & Ryter, S.W. (2004). Bcl-XL disrupts 
death-inducing signal complex formation in plasma membrane induced by 
hypoxia/reoxygenation. FASEB Journal, 18, 1826-1833. 
 
Wei, X.,  Zhang, Y. & Zhou, J. (1999). Alzheimer’s disease-related gene expression in the brain 
of senescence accelerated mouse. Neuroscience Letters, 268, 139-142. 
 
Weisgraber, K.H., Roses, A.D., & Strittmatter, W.J. (1994). The role of apolipoprotein E in the 
nervous system. Current Opinion in Lipidology, 5(2),110-6. 
 
Wennersten, A., Holmin, S., & Mathiesen, T. (2003). Characterization of Bax and Bcl-2 in 
apoptosis after experiemental traumatic brain injury in the rat. Acta Neuropathol, 105, 
281-288. 
 
Werner, C., & Engelhard, K. (2007). Pathophysiology of traumatic brain injury. British Journal 
of Anaesthesia, 99(1), 4-9. 
 
Wilson, I., & Cleary, P. (1995). Linking clinical variables with health related quality of life: A 
conceptual model of patient outcomes. JAMA, 273(1), 59-65. 
 
Wilson,  J.T., Pettigrew, L.E., & Teasdale, G.M.(1998). Structured interviews for the Glasgow 
Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. 
Journal of  Neurotrauma, 15(8),573-85. 
 
   280
 Wise, P., Dubal, D., Wilson, M. & Rau, S. (2000). Estradiol is neuroprotective factor in invivo 
and in vitro models of brain injury. Journal of Neurocytology, 29, 401-410.  
 
Xiong ,Y., Lin, H., Chen, B.D., Peterson, P.L., & Lee, C.P. (2001). Appearance of shortened 
Bcl-2 and Bax proteins and lack of evidence for apoptosis in rat forebrain after severe 
experimental traumatic brain injury. Biochemical & Biophysical Research 
Communications, 286(2),401-5. 
 
Xu, L., Yenari, M.A., Steinberg, G.K., & Giffard, R.G. (2002). Mild hypothermia reduces 
apoptosis of mouse neurons in vitro early in the cascade. Journal of Cerebral Blood Flow 
& Metabolism, 22(1), 21-8. 
 
Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P., & Wang, 
X. (1997). Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria 
blocked. Science, 275, 1129-1132. 
 
Yang, S.Y., & Xue, L. (2004). Human neuronal apoptosis secondary to traumatic brain injury 
and the regulative role of apoptosis-related genes. Chinese Journal of Traumatology, 
7(3), 159-164. 
 
Yang, X., Khosravi-Far, R., Chang, H.Y., & Baltimore, D. (1997). Daxx, a novel Fas-binding 
protein that activates JNK and apoptosis. Cell, 89(7), 1067-76.  
 
Yang, X.F., Zheng, X.S., Liu, W.G., & Feng, J,F. (2006). Bcl-2 gene therapy for apoptosis 
following traumatic brain injury. Chinese Journal of Traumatology, 9(5), 276-81.  
 
Yenari, M.A., Iwayama, S., Cheng, D., Sun, G.H., Fujimura, M., Morita-Fujimura, Y., Chan, 
P.H., & Steinberg, G.K. (2002). Mild hypothermia attenuates cytochrome c release but 
does not alter Bcl-2 expression or caspase activation after experimental stroke. Journal of 
Cerebral Blood Flow, 22, 29-38. 
 
Yenari, M.A., Zhao, H., Giffard, R.G., Sobel, R.A., Sapolsky, R.M., & Steinberg, G.K. (2003). 
Gene therapy and hypothermia for stroke treatment [Electronic version]. Annals of the 
New York Academy of Sciences, 993, 54-68. 
 
Yonas, H., Linskey, M., Johnson, D.W., Horton, J.A., Janecka, I.P., Witt, J.P., Jungreis, C., 
Hirsch, W.L., & Sekhar, L.N. (1992). Internal carotid balloon test occlusion does require 
quantitative CBF. American Journal of Neuroradiology, 13(4), 1147-52. 
 
Yu, S.W., Wang, H., Poitras, M.F., Coombs, C., Bowers, W.J., Federoff, H.J., Poirier, G.G., 
Dawson, T.M., & Dawson, V.L. (2002). Mediation of poly(ADP-ribose) polymerase-1-




   281
 Yu, S.W., Andrabi, SA., Wang, H., Kim, N.S., Poirier, G.G., Dawson, T.M., & Dawson, V.L. 
(2006). Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced 
cell death. Proceedings of the National Academy of Sciences of the United States of 
America, 103(48), 18314-9.  
 
Yu, Y., Kim, J., Lee, K., Kim, S., Han, P., & Lee, J. (2005). Inhibition of the cerebral ischemic 
injury by ethyl pyruvate with a wide therapeutic window. Stroke, 36, 2238-2243. 
 
Zha, H., Aime-Sempe, C., Sato, T., & Reed, J.C. (1996). Proapoptotic protein Bax 
heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) 
distinct from BH1 and BH2. Journal of Biological Chemistry, 271(13), 7440-4.  
 
Zhang, L., Nair, A., Krady, K., Corpe, C., Bonneau, R.H., Simpson, I.A., & Vannucci, S.J. 
(2004). Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in 
normoglycemic but not diabetic female mice. Journal of Clinical Investigation, 113(1), 
85-95.  
 
Zhang, X., Chen, Y., Jenkins, L.W., Kochanek, P.M., & Clark, R.S.B. (2005). Bench –to-bedside 
review: Apoptosis/ programmed cell death triggered by traumatic brain injury. Critical 
Care, 9(1), 66-75. 
 
Zhang, Z., Sobel, R.A., Cheng, D., Steinberg, G.K., & Yenari, M.A. (2001). Mild hypothermia 
increases Bcl-2 protein expression following global cerebral ischemia. Brain Research. 
Molecular Brain Research, 95, 75-85. 
 
Zhao, H., Yenari, M.A., Cheng, D., Sapolsky, R.M., & Steinberg, G.K. (2005). Biphasic 
cytochrome c release after transient global ischemia and its inhibition by hypothermia. 
Journal of Cerebral Blood Flow, 25, 1119-29. 
 
Zhao, H., Steinberg, G.K., & Sapolsky, R.M. (2007). General versus specific actions of mild-
moderate hypothermia in attenuating cerebral ischemic damage. Journal of Cerebral 
Blood Flow & Metabolism, 27(12), 1879-94.   
 
Zhong, L.T., Sarafian, T., Kane, D.J., Charles, A.C., Mah, S.P., Edwards, R.H., & Bredesen, 
D.E. (1993). Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc. 
Natl. Acad. Sci., 90, 4533-37. 
 
   282
